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Background. Worldwide, clinical guidelines recommend the reduction of 
glucose levels in people with type 2 diabetes mellitus (T2DM) as necessary 
in order to reduce risk of complications. In Scotland, the national guidelines 
suggest a target of glycated haemoglobin (HbA1c) of 53 mmol/mol (7.0%) 
and recommend an individualised treatment approach that may include 
lifestyle and/or pharmacological interventions. For most patients, the initial 
treatment is recommended to be lifestyle changes: diet and physical activity. 
However, when glycaemic targets are not achieved by lifestyle changes, 
pharmacological treatment should be added, drug choices should be based 
on patient characteristics and preferences.  
The literature review showed that the period after diagnosis is one of the 
critical points for optimal management for T2DM. However, it also showed 
that there is a lack of studies, which have focused on the initiation of 
pharmacological treatment in people with newly diagnosed T2DM. Thus, this 
study aimed to describe factors associated with the initiation of glucose-
lowering medication (GLM) in people with newly diagnosed T2DM and the 
underlying reasons for starting pharmacological treatment in a Scottish 
primary healthcare context. 
Methods. This study employed a convergent parallel mixed-methods design, 
comprising two strands: one quantitative and one qualitative. The quantitative 
strand comprised a retrospective cohort study design; participants were 
drawn from an extract of the SCI-Diabetes dataset, which included people 
who had been diagnosed with T2DM in Scotland between 2004 and 2012 
and were followed up for at least two years after diagnosis. This strand 
explored factors associated with time to initiation of GLM amongst people 
with newly diagnosed T2DM. For the qualitative strand, interviews were 
undertaken with 16 healthcare professionals (HCPs) recruited from 12 
practices in Scotland to identify and explore factors and considerations that 
might influence clinical decision-making in relation to initiation of GLM in 
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people with T2DM in a Scottish primary healthcare context, data were 
analysed thematically. 
Results. The cohort, for the quantitative strand, consisted of 154,660 people 
with newly diagnosed T2DM. More than half of people (54.9%) received GLM 
prescription within two years after T2DM diagnosis. The results indicated that 
increased age, male sex, the least deprived Scottish Index of Multiple 
Deprivation (SIMD) quintiles and receiving antihypertensive medication were 
associated with longer time to drug treatment. Conversely, HbA1c >53 
mmol/mol, body mass index (BMI) >30 Kg/m2 and receiving antihypertensive 
medication were associated with shorter time to drug treatment. The findings 
from the qualitative strand revealed that a variety of interwoven factors and 
considerations influenced HCPs’ decision-making about initiating medication 
to lower blood glucose. These fell into three main categories: individual-
patient related considerations, HCP-patient related factors, and contextual 
factors. Individual patient-related considerations included physiological 
aspects such as patient’s age and HbA1c, and psychological aspects, for 
instance, whether they were perceived to be motivated, their needs and 
expectations and cultural/ethnic background. HCP-patient related factors 
included historical contact with patients and, negotiation with patients. 
Contextual factors included time resources, division of labour within their 
practices, clinical guidelines (including the recent decommissioning of the 
Quality and Outcomes Framework; QOF), and HCPs’ perceptions of how 
their own roles fitted in with those of other colleagues involved in delivering 
diabetes care. 
Conclusions. The cohort showed that patients’ baseline HbA1c, age, sex, 
and SIMD quintile were among the factors associated with the timing of GLM 
initiation in Scotland from 2004 to 2012. However, the interviews with HCPs 
highlighted the complex factors, which can influence and inform HCPs’ 
decision-making. Thus, offering important insights into why prescription 
patterns for treatment of early type 2 diabetes vary across patients, practices 
and over time. 
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Lay Summary 
The main aim of this study was to describe factors related to the initiation of 
medication to control type 2 diabetes and, the reasons behind starting this 
treatment. I particularly focused on people who had been recently diagnosed 
with type 2 diabetes in Scotland. In other words, I wanted to know if there 
were differences between people who received and did not receive 
medication to lower their glucose levels. Also, I was interested in knowing 
why some people received a drug prescription sooner than others. 
To answer these queries, I analysed information on the people diagnosed 
with type 2 diabetes in Scotland between 2004 and 2012. Besides this, I also 
interviewed doctors and nurses working in different medical practices in 
Scotland. I found that just over half of people received a prescription for 
medication to control their diabetes after two years of being diagnosed with 
type 2 diabetes. People who were younger, had higher blood glucose, were 
obese and, lived in the most deprived areas (according to the Scottish Index 
of Multiple Deprivation) received a prescription for medication to control their 
diabetes sooner than those people with different circumstances. 
The doctors and nurses who took part in the study described several factors, 
which influenced their decision to prescribe medication. Among others, 
doctors and nurses mentioned that the principal aspect they took into 
consideration when prescribing medication to control type 2 diabetes was 
their patient’s characteristics such as age, blood glucose and, overall health 
condition. Yet, some other aspects like consultation length and staff shortage 
made their ability to focus on patients’ circumstances rather challenging. 
This study provides knowledge about the differences in prescription of 
medication to control type 2 diabetes. Although this study helps to explain 
why the prescription of medication to control type 2 diabetes varies, I 
recognise that more studies, which use more recent patients’ information, 
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Introduction and Background  1 
Chapter 1 Introduction and Background 
1.1 Introduction 
This thesis describes the factors associated with glucose-lowering 
medication (GLM) initiation in people with type 2 diabetes (T2DM) and, views 
of healthcare professionals (HCPs) working in primary care in Scotland about 
when to initiate GLM in people with T2DM. A mixed-methods research design 
was adopted, which means that a quantitative and a qualitative component 
were included. 
Diabetes is a public health concern; the World Health Organization (WHO) 
estimated that in 2014, 8.5% of the global adult population had diabetes 
(World Health Organization, 2016a). T2DM is the most common type of 
diabetes, elevated levels of glucose in people with T2DM can lead to life-
changing complications such as retinopathy, neuropathy, foot ulcers and 
amputation, kidney failure, heart disease, and stroke. These complications 
can have significant economic consequences for both health systems and, 
individuals and their families (American Diabetes Association, 2019a, World 
Health Organization, 2016a, World Health Organization, 2018a). 
According to clinical guidelines, early diagnosis and optimal control of blood 
glucose levels can delay the long–term complications of T2DM and reduce 
related costs (International Diabetes Federation, 2017a, American Diabetes 
Association, 2019a). Treatment for T2DM includes a healthy lifestyle, which 
encompasses a healthy diet and physical activity in order to attempt to 
achieve or maintain a healthy weight1. However, when clinically 
recommended levels of glucose are not achieved by following a healthy 
lifestyle, oral medication is usually required (International Diabetes 
Federation, 2017a). 
                                            
1 Healthy weight to reduce risk of T2DM is defined by the WHO as a BMI in the range of 
18.5-24.9 Kg/m2 WORLD HEALTH ORGANIZATION 2019a. Body mass index - BMI. A healthy lifestyle. Denmark: WHO Regional 
Office for Europe, WORLD HEALTH ORGANIZATION 2019c. Mean Body Mass Index (BMI). Global Health Observatory (GHO) data. 
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By conducting a retrospective cohort study looking at factors associated with 
the initiation of GLM within two years of T2DM diagnosis that are recorded in 
routine clinical care of people with T2DM, and interviewing HCPs about their 
reasons for starting (or not) GLM, this mixed-methods research seeks to 
provide a deeper understanding of factors associated with GLM initiation and 
clinical decision-making. 
This thesis is divided into six chapters plus appendices, and is structured as 
follows: 
 Chapter 1. Sets the scene for the thesis by providing general information 
about T2DM and its management, including the provision of healthcare in 
Scotland. 
 Chapter 2. Reviews the literature on GLM prescription patterns, time to 
pharmacological treatment initiation, and glycaemic control in people with 
a recent diagnosis of T2DM. It also includes a review of qualitative 
research focused on HCPs’ perspectives and experiences in diabetes 
care, particularly about factors influencing clinical decision-making. 
 Chapter 3. Provides an introduction to mixed-methods research, and 
describes the mixed-method design chosen and the rationale for this 
research. In addition, the specific methods followed for each strand of the 
study (quantitative and qualitative) are presented. 
 Chapter 4. Presents the results of the quantitative strand of the study, 
which consisted of a retrospective cohort study based on secondary 
analysis of diabetes register data from 2004 to 2012. 
 Chapter 5. Presents the findings from interviews undertaken with HCPs 
about factors and aspects they take into consideration to decide when to 
initiate GLM in people with T2DM. 
 Chapter 6. Provides a summary of the main findings and the overall 
discussion. In this chapter the study strengths and limitations are 
discussed, as well as the implications of the work and directions for future 
research.  
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1.2 Diabetes and non-communicable diseases 
Non-communicable diseases (NCDs) are usually those of long duration and 
slow progression (World Health Organization, 2018b). The most common 
types of NCDs include cardiovascular diseases (CVDs), cancer, chronic 
respiratory diseases and diabetes; these diseases have modifiable risk 
factors in common such as physical inactivity, unhealthy diet, tobacco use 
and the harmful use of alcohol, and are estimated to be responsible for 80% 
of premature NCD deaths (World Health Organization, 2018b, World Health 
Organization, 2019e). Premature NCD death is described by the WHO as the 
death occurred from 30 to under 70 years from a major NCD (World Health 
Organization, 2019d, World Health Organization, 2020b). 
In the United Kingdom (UK), NCDs are estimated to account for 89% of total 
deaths (World Health Organization, 2018d). Furthermore, in the UK, NCDs 
are important causes of years lived with disability (YLDs). However, diabetes 
is the only NCD, that in ten years (2007 to 2017) the ranking has increased, 
from 8th to 5th most common estimated cause of YLDs (Institute for Health 
Metrics and Evaluation, 2019b). Diabetes is also listed as one of the top 25 
causes of disability-adjusted life years (DALYs) in the world. 
YLDs are a measure of the burden of a disease; the term is used to refer to 
the number of years lived in less than optimal health. YLDs are calculated by 
multiplying the prevalence of a disease by the disability weight associated 
with that disease. The WHO defines DALYs as the sum of years of potential 
life lost due to premature mortality and the years of productive life lost due to 
disability: one DALY equals one lost year of healthy life. These units permit 
the estimation of the total number of years lost due to specific causes and 
risk factors and the comparison of health conditions over time and across 
different populations. Thus, in the UK, diabetes has been identified as one of 
the conditions that causes the most disability after lower back pain, headache 
disorders, depressive disorders and neck pain (Institute for Health Metrics 
and Evaluation, 2019b, Institute for Health Metrics and Evaluation, 2019a, 
World Health Organization, 2019b, National Institute of Mental Health, 2019).  
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Diabetes is a metabolic disorder that occurs when the pancreas does not 
produce insulin, the production is insufficient or when the body is not able to 
use the insulin produced effectively (World Health Organization, 2018a). 
Globally, diabetes is an important cause of premature mortality and disability 
(World Health Organization, 2016a, World Health Organization, 2014). 
Recently, the prevalence of T2DM has increased, and this increase is driven 
by ageing of the population and modifiable risk factors, such as lack of 
physical activity resulting in increasing prevalence of overweight and obesity; 
which are key risk factors (World Health Organization, 2014, World Health 
Organization, 2018a).  
Diabetes has two main forms: type 1 or type 2, with the latter form of 
diabetes resulting from the body’s ineffective use of insulin and accounting 
for 90-95% of all cases and is characterised by a progressive loss of insulin 
secretion with simultaneous insulin resistance (American Diabetes 
Association, 2019a, World Health Organization, 2016a, World Health 
Organization, 2018a). As the focus of this research is on people with T2DM, 
the following sections and sub-sections are concerned with this type of 
diabetes. 
1.3 Type 2 diabetes  
T2DM was previously referred to as “adult-onset” or “non-insulin dependent” 
diabetes. However, these terms are not accurate as nowadays T2DM is 
increasingly occurring in young adults, adolescents and children. 
Furthermore, insulin is often used in the management of T2DM (International 
Diabetes Federation, 2017a, American Diabetes Association, 2019a, World 
Health Organization, 2018a). In the following four sub-sections, I will describe 
the aetiology and epidemiology, diagnosis, monitoring of glycaemic control, 
and complications T2DM. 
1.3.1 Aetiology and epidemiology 
Although the aetiology of T2DM are complex, two key risk factors are age 
and being overweight or obese, increased percentage of body fat, principally 
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in the abdominal region is an important contributor to the risk of developing 
T2DM (Shanik et al., 2008, American Diabetes Association, 2019a, 
International Diabetes Federation, 2017a). Ethnic differences exist but 
populations with a high prevalence of obesity generally also have the highest 
prevalence of diabetes and, conversely, populations with a low prevalence of 
obesity have a low prevalence of diabetes (Shaw and Sicree, 2008). In 
addition, factors such as increasing urbanisation, and economic development 
have been associated with increased prevalence of T2DM at the population 
level (Shaw and Sicree, 2008, American Diabetes Association, 2019a).  
In order to implement actions to reduce their risk, it is important to identify 
people who might be at risk of developing T2DM such as those who have a 
first-degree relative with T2DM, who are overweight or obese, not physically 
active, smokers, with previous history of gestational diabetes, and those 
previously identified as having glucose intolerance (Ghosh S. and Collier A., 
2012, World Health Organization, 2018a, World Health Organization, 2016a, 
International Diabetes Federation, 2012). 
In 2016, the WHO estimated an overall prevalence of diabetes in the UK of 
7.7% for people over 30 years of age. However, men had a higher age-
standardised prevalence (8.4%) than females (6.9%) (World Health 
Organization, 2016b). The 2018 Scottish Diabetes Survey reported a crude 
prevalence of T2DM of 4.9%. Furthermore, it was reported that 81.7% of 
people with T2DM had a record of their body mass index (BMI), of whom 
31.8% were overweight (BMI 25 – 29.9 Kg/m2) and 55.2% were obese (BMI 
>30 Kg/m2) (Scottish Diabetes Data Group, 2018). 
1.3.2 Diagnosis 
Usually, the presence of symptoms such as polyuria, polydipsia and lack of 
energy leads to the screening and diagnosis of T2DM. However, as generally 
the onset of T2DM is slow, some people with T2DM can live for years without 
developing symptoms and the diagnosis may be made as an incidental 
finding (Scottish Intercollegiate Guidelines Network (SIGN), 2017a, 
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International Diabetes Federation, 2017a). The diagnosis of T2DM may be 
based on plasma glucose or by measuring glycated haemoglobin (HbA1c). 
According to the WHO (World Health Organization, 2018a), T2DM is 
diagnosed when one or more of the following criteria are met on two separate 
occasions among people without symptoms: 
1. Fasting venous plasma glucose (FPG) >7.0 mmol/l (126mg/dl) 
2. Oral glucose tolerance test (OGTT): Glucose two hours after a 75g of 
oral glucose load >11.0 mmol/l (200mg/dl)  
3. HbA1c ≥ 48 mmol/mol (6.5%) 
 
However, it is important to consider that, as research conducted in the United 
States (US) suggests, the validity of HbA1c as a diagnostic tool can vary with 
ethnicity, particularly among African American populations. The evidence 
suggests that African Americans tend to have higher levels of HbA1c than 
non-Hispanic whites. Likewise, conditions such as sickle cell disease, 
pregnancy, and HIV among others, can alter the relationship between HbA1c 
and glycaemia. Similarly, some conditions such as diet, gastrointestinal 
disorders, stress, and medications can produce abnormal results of an OGTT 
(American Diabetes Association, 2019a, World Health Organization, 2016a, 
Ghosh S. and Collier A., 2012). Thus, these aspects and considerations need 
to be taken into account in the diagnosis of T2DM and monitoring of glucose 
levels. 
In general, health outcomes are more likely to be unfavourable the longer a 
person lives with untreated T2DM. The implementation of universal screening 
for diabetes is not currently encouraged or recommended due to the lack of 
evidence that it is cost-effective. In the UK, the National Screening 
Committee recently reviewed the evidence on the effectiveness of screening 
for T2DM. The review showed a scarcity of high quality randomised 
controlled trials (RCTs) that have studied screening programmes’ effect on 
mortality or morbidity. Hence, there is currently no evidence that strongly 
supports the benefit of universal screening compared to the current 
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opportunistic approach to diagnosis (UK National Screening Committee, 
2019). However, England has introduced screening through the Health 
Check and NHS Diabetes prevention programme (NHS DPP). The NHS 
health check is for people in England aged 40 to 74 and who do not have 
pre-existing health conditions such as heart disease, high blood pressure or 
chronic kidney disease (NHS, 2019). The NHS DPP is a programme jointly 
developed by NHS England, Public Health England and Diabetes UK in 
which people who are at risk of developing T2DM are referred to a face-to-
face programme where they receive tailored education about a healthy 
lifestyle (NHS England, 2019). Moreover, the IDF recommends the provision 
of advice on a healthy lifestyle to people who are at risk of developing T2DM 
(International Diabetes Federation, 2012). 
1.3.3 Monitoring glycaemic control 
Currently, the preferred method for assessing glycaemic control among 
people with a diagnosis is by measuring HbA1c which reflects the average 
plasma glucose over the previous 8 to 12 weeks (World Health Organization, 
2011). This test requires a blood sample, and the patient does not need to be 
in a fasting state (World Health Organization, 2016a). HbA1c levels are 
reported either as a value in mmol/mol or as percentage depending on 
whether the International Federation of Clinical Chemists (IFCC) or the 
Diabetes Control and Complications Trial (DCCT) standards are used. In 
Scotland, HbA1c is now reported in mmol/mol since 2012 (Scottish Diabetes 
Group, 2009, Scottish Clinical Biochemistry Managed Diagnostic Network, 
2012). 
1.3.4 Complications  
The development and progression of several complications related to T2DM 
are strongly associated with raised levels of glucose. There is evidence to 
show that early interventions to lower glucose levels can slow the 
progression of complications. Over time, elevated levels of blood glucose in 
people with T2DM can lead to life-changing complications. People with T2DM 
can suffer damage to their eyes, kidneys, nerves, blood vessels and heart as 
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a consequence of microvascular disease. People with T2DM also have an 
increased risk, among other health problems, of having a heart attack or a 
stroke. The risk of macrovascular disease in people with T2DM, according to 
the WHO is two-to three-fold times increased compared to a person without 
T2DM. Furthermore, T2DM is one of the leading causes of kidney failure and 
lower limb amputation (World Health Organization, 2016a, World Health 
Organization, 2018a, International Diabetes Federation, 2017a).  
The effect of high blood glucose has been studied previously in the UK. For 
instance, Evans et al. (2015) studied cardiovascular mortality among adults 
with impaired glucose regulation in Tayside, Scotland. By using record-linked 
data from 2003 to 2008, the authors compared two groups of patients 
depending on their impaired glucose regulation (IGR) status: Non-IGR and 
IGR. The non-IGR group included people for whom there was a record of 
blood glucose testing during the studied period that was not diagnosed as 
IGR. The IGR group included those for whom a record of blood glucose 
testing during the studied period that was diagnosed as IGR. The mean age 
of patients was 63 years for the IGR group and 54 years for the non-IGR 
group. The regression analysis showed that the diagnosis of IGR was 
associated with an increased risk of mortality compared with people without 
diagnosis of IGR. The youngest group of patients had the strongest risk, 
thus, people <45 years in the IGR group had twice the risk than those <45 
years in the non-IGR (HR: 2.20; CI: 1.12–4.33).  
Moreover, Data from a Scottish Care Information – Diabetes Collaboration 
(SCI-Diabetes) cohort from 2001–2007 in Scotland showed that 
cardiovascular mortality risk was greater among people with T2DM compared 
to people without diabetes (Jackson et al., 2012). Further analysis of the SCI-
Diabetes database have showed that T2DM conferred an excess risk of 
death compared to people without T2DM (Read et al., 2016). Similarly, a 
study conducted by Gordon-Dseagu et al. (2014) analysed UK data from the 
Scottish Health Survey and the Health Survey for England and reported an 
increased risk of mortality from all-cause and cause-specific such as CVD, 
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cancer, and respiratory disease among people with diabetes. However, it is 
important to note that the study included people with both types of diabetes. 
Overall, complications of T2DM can have significant economic consequences 
on both health systems and individuals and their families (International 
Diabetes Federation, 2017a, World Health Organization, 2018a, World 
Health Organization, 2016a). In order to reduce the risk of complications, 
people with T2DM require comprehensive medical care, which should include 
regular monitoring of glucose levels, education about a healthy lifestyle, 
screening for complications as well as access to and correct use of 
medications (International Diabetes Federation, 2017a, World Health 
Organization, 2018a).  
1.4 Clinical guidelines for diabetes management 
According to clinical guidelines, in people who are at risk of developing 
T2DM, early diagnosis and optimal control of blood glucose levels, can delay 
the long–term complications of T2DM and reduce the related costs 
(American Diabetes Association, 2019c, International Diabetes Federation, 
2017a). In this sub-section, I will provide an overview of clinical guidelines as 
well as their recommended glycaemic targets for the prevention of 
complications. The comparison of clinical guidelines is important because 
their differences could provide insight into potential variations in the approach 
to diabetes management. 
Clinical guidelines suggest that when glycaemic targets are not achieved by 
lifestyle changes, pharmacological treatment should be added. Optimal 
treatment for people with T2DM must be based on patients’ characteristics 
(i.e. age, HbA1c) some people may be treated with oral medication whereas 
others may require insulin or a combination of both oral medication and 
insulin (American Diabetes Association, 2019c, Inzucchi et al., 2015, World 
Health Organization, 2016a). 
International organisations such as WHO and the International Diabetes 
Federation (IDF) have encouraged the development and implementation of 
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national measures for surveillance, prevention and control of T2DM. The 
development of evidence-based guidelines and protocols are important to 
define standards of care and to guide HCPs in the achievement of quality of 
care of individuals (World Health Organization, 2018a, International Diabetes 
Federation, 2017a). According to the WHO, worldwide 71% of countries have 
guidelines for diabetes care and management, which are either fully or 
partially implemented. These evidence-based guidelines, protocols and 
standards of care for diabetes are essential tools in T2DM management 
(World Health Organization, 2016a).  
A list of guidelines which includes the global guideline developed by the IDF, 
and those from the US, and the UK are provided in table 1 (International 
Diabetes Federation, 2012, American Diabetes Association, 2019f, Garber et 
al., 2019, National Institute for Health and Care Excellence, 2019, Scottish 
Intercollegiate Guidelines Network (SIGN), 2017b, Scottish Intercollegiate 
Guidelines Network (SIGN), 2017a). As can be seen in this table, all 
guidelines have incorporated specific aspects relating to glycaemic control. 
These aspects are related to glycaemic goals, recommendations on the 
frequency of glycaemic tests, and algorithms for glycaemic management. 
Table 1. Publication date and features related to glycaemic control 
included in current guidelines from the IDF global guideline, the US, 
and the UK.  













Globally IDF 2012       
US ADA 2019       
AACE/ACE 2019       
UK England + Wales NICE 2019       
Scotland SIGN 2017       
IDF= International Diabetes Federation, ADA=American Diabetes Association, 
AACE/ACE=American Association of Clinical Endocrinologists and American College of 
Endocrinologists, NICE= The National Institute for health and care excellence, SIGN= The Scottish 
Intercollegiate Guidelines Network 
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However, it is important to take into consideration that, although they cover 
similar aspects related to glycaemic management and control, the approach 
recommended by different guidelines might vary. Similarly, diversity in 
healthcare systems and the constant development of clinical guidelines can 
lead to variation in implementation and patients’ outcomes across different 
countries (Barth et al., 2016, Chastain et al., 2014). Even within one country, 
the use of guidelines has been shown to vary. For instance, in the US, many 
physicians revealed that their decisions about glycaemic management were 
influenced more by medication costs than algorithms and guidelines (Grant et 
al., 2007). Likewise, another survey conducted in the US indicated that less 
than half (43%) of the physicians followed the American Association of 
Clinical Endocrinologists and American College of Endocrinologists 
(AACE/ACE) guidelines, and 13% did not use guidelines to inform their 
decisions (Qiu et al., 2015). According to Barth et al. (2016), guideline non-
adherence is a rational process that encompasses structural, physician and 
patient factors where occasional deviation from clinical guidelines is 
considered appropriate depending on who the patient is and what their 
personal circumstances are. 
In 2013, the IDF published a global guideline, which sought to complement 
their existing one published in 2012. The guideline “managing older people 
with type 2 diabetes” was released in order to improve the quality of care 
provided to older people, and emphasised the lack of studies on cost-
effective diabetes care for older people (International Diabetes Federation, 
2013). Following the IDF publication, in recent years, some guidelines have 
included a section on the management of T2DM for older adults. The ADA 
included a specific section for the management in older individuals with 
T2DM in their 2019 standards of care (American Diabetes Association, 
2019e). Similarly, specific recommendations for older adults have been 
included in the NICE guideline NG28 (National Institute for Health and Care 
Excellence, 2019). 
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1.4.1 Glycaemic targets 
As observed in table 2, there are slight variations in glycaemic targets 
depending on the guideline used. For instance, The IDF, the ADA and the 
Scottish Intercollegiate Guidelines Network (SIGN) guidelines have 
established 53 mmol/mol (7%) HbA1c as a general goal, while the 
AACE/ACE has a more stringent goal. However, all agree in following an 
individualised approach to targets and treatments that may include lifestyle 
and/or pharmacological interventions (International Diabetes Federation, 
2012, International Diabetes Federation, 2013, American Diabetes 
Association, 2019c, American Diabetes Association, 2019e, National Institute 
for Health and Care Excellence, 2019, Scottish Intercollegiate Guidelines 
Network (SIGN), 2017b). 
Table 2. HbA1c goals and recommended frequency of glycaemic 
test in current guidelines from the IDF global guideline, the US, and 
the UK. 
Coverage Publisher HbA1c goal(s) Frequency of glycaemic 
tests 
Globally IDF  General goal of: <53 mmol/mol 
(7%) 
 Adults using multiple 
medications including glucose-
lowering drugs: 58-64 mmol/mol 
(7.5-8.0%) 
 Functionally independent older 
people: 53-59 mmol/mol (7.0-
7.5%) 
 Functionally dependent older 
people: 53-64 mmol/mol (7.0-
8.0%) 
 End of life care: the goal is to 
avoid symptomatic 
hyperglycaemia 
 Recommends individualization 
 Every 2-6 months 
depending on blood 
glucose control and 
changes in therapy. 
US ADA  General goal for non-pregnant 
individuals: <53 mmol/mol (7%) 
 Patients with lifestyle or 
metformin only stringent goal 
<48 mmol/mol (6.5%) 
 Patients with hypoglycaemia 
history, with short life 
 At least twice a year 
in patients with 
optimal control 
 4 times a year in 
those with changing 
therapy or not 
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expectancy or advanced 
complications less stringent goal 
<64 mmol/mol (8%) 
 Older adults with few coexisting 
chronic illnesses: <58 mmol/mol 
(7.5%) 
 Older adults with multiple 
coexisting chronic illnesses, 
cognitive impairment, or 
functional dependence <64-69 
mmol/mol (8.0-8.5%) 
 Recommends individualization 
meeting glycaemic 
goals 
 The frequency will 




AACE/ACE  <48 mmol/mol (6.5%) for 
patients without serious 
comorbidities and low risk of 
hypoglycaemia 
 >48 mmol/mol (6.5%) for 
patients with serious 
comorbidities and at risk of 
hypoglycaemic 
 Recommends individualization 
 Every 3 months until 
glycaemic levels are 
stable 
UK  NICE  <48 mmol/mol (6.5%) for 
patients with lifestyle 
modifications only 
 <53 mmol/mol (7%) for patients 
on drug treatment 
 <58 mmol/mol (7.5%) for 
patients on drug treatment with 
sub-optimal glycaemic control 
 Recommends individualization 
 Every 3 to 6 months 
intervals. 
 6-months interval 
once the HbA1c and 
glucose-lowering 
therapy are stable. 
 Tailored to individual 
needs. 
Scotland SIGN  <48 mmol/mol (6.5%) at 
diagnosis 
 General goal of <53 mmol/mol 
(7%) 
 Every 3 to 6 months 
intervals 
IDF= International Diabetes Federation, ADA=American Diabetes Association, 
AACE/ACE=American Association of Clinical Endocrinologists and American College of 
Endocrinologists, NICE= The National Institute for health and care excellence, SIGN= The Scottish 
Intercollegiate Guidelines Network 
 
In Scotland, an HbA1c >86 mmol/mol (10%) is classified as sub-optimal 
glycaemic control, maintaining such levels of HbA1c are described as having 
health consequences that have been described in section 1.3.4 (Scottish 
Intercollegiate Guidelines Network (SIGN), 2017a). Thus, attaining and 
maintaining glycaemic targets is important in the prevention of complications.  
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1.5 Management of T2DM 
As described in the previous section, lifestyle changes, pharmacological 
treatment, or a combination of both are usual approaches to glycaemic 
management. Since it is important to understand the reasons why these are 
recommended and prescribed, the following section summarises current 
evidence about lifestyle changes and pharmacological treatment for glucose 
control in people with recently diagnosed T2DM. Moreover, a sub-section 
about other interventions is also included. 
As it will be described through this section, the period after diagnosis is one 
of the critical points in the management of T2DM. Recent studies have 
shown the importance of the first years after the diagnosis of T2DM by 
showing that weight loss during these first years is achievable and can lead 
to T2DM remission (National Institute for Health Research, 2019). 
1.5.1 Lifestyle management  
Lifestyle interventions are a key component of management of T2DM. 
Recommended lifestyle changes include the adoption of a healthy diet and 
engagement in physical activity (Johnston et al., 2014, Kellow and Khalil, 
2013). However, lifestyle management is not only limited to diet and physical 
activity, it also includes self-management education, diabetes self-
management support, counselling for smoking cessation, and psychological 
care (American Diabetes Association, 2019b).The ADA has described four 
critical time-points for lifestyle management revision for people with T2DM. 
These are: at diagnosis, at annual assessments, when complicating 
emotional, physical or health factors arise, and when transitions in care occur 
(American Diabetes Association, 2019b). Similarly, the NICE guideline NG28 
highlights that at and around the time of diagnosis, structured education 
should be offered to people with T2DM. Patient education must include 
individualised advice which emphasises healthy balance eating, increasing 
physical activity, losing weight and other aspects of lifestyle modification 
(National Institute for Health and Care Excellence, 2019). 
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The effectiveness of lifestyle management has been subject to research. For 
instance, the recently completed Diabetes Remission Clinical Trial (DiRECT) 
conducted at 49 primary care practices in Scotland and England (Tyneside 
region) studied the effects of intensive weight management in people with 
T2DM (Leslie et al., 2016). While there were no specific criteria to be met by 
the practices, eligible participants had to: be aged 20-65 years, diagnosed 
with T2DM within the previous 6 years, have a BMI of 27-45 Kg/m2, and an 
HbA1c <108 mmol/mol (12.0%). Practices were randomised to provide an 
evidence-based weight management programme (intervention) or diabetes 
care by guidelines (control). People in the intervention group were asked to 
discontinue all oral and antihypertensive medication and follow the weight 
management programme with the aim of achieving and maintaining at least 
15 kg weight loss induced by a low energy formula diet. This diet consisted of 
an 825-853 kcal/day for three months, followed by structured food 
reintroduction of 2-8 weeks, and an ongoing structured programme. One of 
the primary outcomes of the trial was remission of diabetes which was 
defined as HbA1c <48 mmol/mol (6.5%) after at least two months off all 
antidiabetic medications, from baseline to 12 months of follow-up (Leslie et 
al., 2016, Lean et al., 2018). After 12 months of follow-up, remission was 
achieved in some members of both groups, 68 (46%) in the intervention 
group and six (4%) in the control group. (Lean et al., 2018). At 24 months of 
follow-up, 53 people (36%) in the intervention group and five (3%) in the 
control group were in diabetes remission; OR 25.82 [95% CI 8.25–80.84, 
p<0.0001] adjusted for study centre, practice size list and random effect for 
practice. The maintenance of remission status at 24 months was associated, 
among other factors, with weight loss from baseline and weight change from 
12 to 24 months (Lean et al., 2019).  
Research on weight loss among people with newly diagnosed T2DM by non-
intensive interventions has also been conducted in the UK. The ADDITION-
Cambridge trial aimed to quantify the association between behaviour change 
and weight loss after diagnosis of T2DM, and the likelihood of remission of 
diabetes at 5-year follow-up. A parallel group cluster RCT was conducted 
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among 49 practices in England. People aged 40-69 years without a diagnosis 
of T2DM who had a Cambridge Diabetes Risk Score >0.17 were invited to 
attend a stepwise screening programme for T2DM. People who were 
identified as having T2DM by this screening programme (n=867) were 
randomised into either multifactorial treatment (intervention group) or routine 
care (control group). Multifactorial treatment consisted of more frequent 
consultations, 30-minutes annual review, three 10-minutes consultation with 
a GP and nurse, provision of educational materials and guidelines, practice-
based academic detailing sessions, and encouraging earlier use of 
medication to improve control of risk factors. For the routine care group, 
practices were advised to follow current UK guidelines. Measures were taken 
at baseline, one- and five-year follow-up, remission was defined as an HbA1c 
<48 mmol/mol in the absence of any diabetes medication or bariatric surgery. 
At the end of the 5 years of follow-up, 84% (n=867) participants had weight 
and HbA1c measured and were included in the analysis. The mean age of 
participants was 61 +7 years and 61% were men. At the end of the follow-up 
period, 55% had initiated GLMs. People who lost >10% body weight in the 
first year after diagnosis of T2MD were significantly more likely to achieve 
remission at 5 years compared with those who increased or maintained their 
body weight; RR:1.77, [CI: 1.32-2.38] adjusted for baseline weight, follow-up 
period, age, sex, ethnicity, socioeconomic group, education level, occupation, 
trial group, clustering of practices and date of diabetes diagnosis (Dambha-
Miller et al., 2020). 
Moreover, the Look AHEAD trial was conducted to examine the effects of 
weight loss on CVD morbidity and mortality, and to compare an intensive 
multi-component lifestyle intervention with diabetes support and education. 
Participants were randomised to receive either intensive lifestyle intervention 
(ILI) or diabetes support and education (DSE). ILI consisted of an 
intervention designed to induce weight loss by calorie-intake reduction, 
increased physical activity and, several individuals and group sessions. DSE 
consisted of annual group sessions on diet, physical activity and social 
support. There was not a specific criteria about duration of T2DM, 47.4% and 
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44.6% of people in the ILI and DSE groups, respectively, were <5 years from 
diagnosis of T2DM (Look AHEAD Research Group, 2014). In this trial, people 
with T2DM receiving lifestyle interventions experienced significant 
improvement in their glycaemic control and reduced their cardiovascular risk 
factors by reducing their blood pressure and cholesterol levels. Furthermore, 
high remission rates of T2DM among newly diagnosed patients, those 
without insulin prescription and with lower initial levels of HbA1c were 
observed (Johnston et al., 2014). However, it is important to take into 
account the large amount of support provided to patients in the ILI treatment 
arm. 
Although research which focused on lifestyle interventions amongst people 
with newly diagnosed T2DM have shown promising results, in a real-life 
scenario lifestyle changes have shown to be very difficult to achieve. 
Qualitative research has provided insight into the challenges that patients 
may experience in adhering to lifestyle recommendations. The literature 
which has focused on patients’ perspectives is vast, and hence only a brief 
overview will be provided here. 
Thoolen et al. (2008) conducted a systematic review to examine how recently 
diagnosed patients adjust to living with T2DM during the first year of their 
disease and to investigate variations in patient’s psychological adjustment, 
particularly on factors surrounding diagnosis, which could influence patients’ 
subsequent reactions. The search was conducted in four databases, articles 
in English published between 1993 and 2008 which focused on T2DM and 
their outcomes during the first year after diagnosis were included. A total of 
32 articles were included; these articles reported the findings from 24 
different studies (qualitative and quantitative). Overall, the authors reported 
that very few people with newly diagnosed T2DM successfully achieved 
lifestyle changes. A major factor that seemed to influence patient’s 
adjustments to T2DM was the presence, or absence, of symptoms and 
whether they experience their symptoms as such. Thus, patients who did not 
experience symptoms or did not feel “ill” felt that they could continue with 
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their unhealthy lifestyles. Moreover, the authors described that many patients 
did not fully understand the impact of having T2DM, however, they were 
interested in receiving information about changes they could integrate to their 
lifestyle. The authors concluded that successful adjustment in the first year 
after diagnosis was not necessarily related to lack of emotional distress, and 
emphasised the role of HCPs and the need for looking beyond emotional 
reactions and consider patients’ perceptions of their disease and how they 
adapt and engage in self-care activities (Thoolen et al., 2008).  
Furthermore, Frost et al. (2014) conducted a qualitative synthesis of T2DM 
self-management strategies for long term medical outcomes and quality of 
life in the UK. The synthesis included 22 articles published between 2000 
and 2013 which described four different studies. After analysing the articles, 
the authors stated that, for people with T2DM, the emphasis of treatment on 
biomarkers was often perceived as unachievable and burdensome and 
recommended to rather place emphasis on small patient-centred goals (i.e. 
portion control, weight loss) that patients perceive as achievable. The authors 
highlighted the need to facilitate ongoing open dialogue in usual practice in 
order to achieve sustainable changes (Frost et al., 2014). 
1.5.2 Pharmacological treatment  
Non-insulin glucose-lowering drugs are the most frequent pharmaceutical 
treatment for T2DM and may be used as monotherapy, in combination or 
with insulin (Higgins et al., 2016b, Mata-Cases et al., 2016). There are 
several classes of medications for T2DM treatment. In this sub-section I will 
present the main mode of action of first-line pharmacological agents for 
glucose control included in the SIGN guideline 154, and which are the most 
frequently prescribed to people with newly diagnosed T2DM (Scottish 
Intercollegiate Guidelines Network (SIGN), 2017b). Furthermore, a brief 
account on second- and third-line drugs for glucose control will be presented. 
1.5.2.1 First-line glucose lowering medication 
In the UK, first-line medication for T2DM has changed in recent years, 
shifting from sulfonylureas to metformin (Hamada and Gulliford, 2015). 
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Sharma et al. (2016) reported that overall, in people with T2DM who received 
GLM, metformin prescription increased from 55.4% in 2000 to 83.6% in 2013 
and sulfonylureas decreased from 64.8% to 41.4% in 2000 and 2013, 
respectively. Initial treatment in people recently diagnosed with T2DM 
followed a similar pattern. In 2000, 51.1% were prescribed sulfonylureas as 
the initial drug, and 45.1% were prescribed metformin as first-line drug 
therapy, whereas by 2013 91% of people with a recent diagnosis of T2DM 
who received drug therapy were started on metformin and 6.3% with 
sulfonylurea. However, the study did not consider differences in prescribing 
patterns according to patients’ characteristics such as age or comorbidities. 
Moreover, treatment choices seemed to be in accordance with UK guidelines 
that, from 2000, recommended metformin as first-line drug treatment 
(Sharma et al., 2016). 
1.5.2.1.1 Metformin 
Metformin is one of the most effective and safe drugs and is recommended 
as an initial pharmacological agent when it is not contraindicated, or the 
patient can tolerate taking it (American Diabetes Association, 2019d, 
International Diabetes Federation, 2017a, Scottish Intercollegiate Guidelines 
Network (SIGN), 2017b).  
Metformin has been used as a GLM for approximately 60 years (it was 
introduced as GLM in 1959) and it is the only available biguanide currently in 
clinical use (White, 2014, Schernthaner and Schernthaner, 2007). The major 
action of metformin is to decrease hepatic glucose output by decreasing 
gluconeogenesis and, to a lesser extent, by increasing glucose uptake by 
skeletal muscles. Hence, metformin helps in reducing hepatic glucose 
production and gastrointestinal absorption of glucose and improves 
peripheral sensitivity to insulin. However, the insulin-sensitising effect is 
reported as smaller compared with other agents such as thiazolidinediones, 
which will be described below (Scottish Intercollegiate Guidelines Network 
(SIGN), 2017b, Schernthaner and Schernthaner, 2007, Manolopoulos and 
Ragia, 2014). 
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In general, metformin has a high level of acceptance and relatively low cost, 
it does not produce weight gain, which is a benefit for overweight patients. 
However, there is no strong evidence about benefits for cardiovascular 
morbidity and mortality. The side-effects more frequently reported are 
gastrointestinal, such as diarrhoea and abdominal discomfort and its use is 
not recommended in people with renal impairment (Schernthaner and 
Schernthaner, 2007, Scottish Intercollegiate Guidelines Network (SIGN), 
2017b, Bianchi et al., 2018). 
1.5.2.1.2 Sulfonylureas 
The introduction of sulfonylureas to the market dates from the 1950s when 
the first-generation became available for glycaemic control (White, 2014). 
Currently, sulfonylureas are an alternative approach to metformin in the 
presence of osmotic symptoms or intolerance to metformin and should also 
be considered as add-on second-line treatment. First-generation 
sulfonylureas such as tolbutamide and chlorpropamide are now rarely used. 
Second-generation like glibenclamide, glipizide, gliquidone, glimepiride and 
gliclazide are currently used more frequently (Stingl and Schernthaner, 2007, 
American Diabetes Association, 2019d, Scottish Intercollegiate Guidelines 
Network (SIGN), 2017b). 
Sulfonylureas help to reduce blood glucose levels by increasing the 
endogenous release of insulin from -cells in the pancreas. Although these 
drugs have high efficacy and are available at low cost, their use is associated 
with weight gain and hypoglycaemia. Thus, sulfonylureas should be used 
with caution (Scottish Intercollegiate Guidelines Network (SIGN), 2017b, 
Bianchi et al., 2018). 
When metformin and sulfonylureas are not tolerated, the following are also 
accepted by the Scottish Medicine Consortium for first-line use: sodium-
glucose co-transporter-2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) 
inhibitors, and thiazolidinediones (Scottish Intercollegiate Guidelines Network 
(SIGN), 2017b). An overview of these drugs will be provided in the following 
sub-sections. 
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1.5.2.1.3 SGLT2 inhibitors  
SGLT2 inhibitors are a novel and recent group of agents, these work by 
reducing renal glucose re-absorption from the tubular lumen in the kidney, 
which results in increased glucose excretion (Bailey and Krentz, 2017, White, 
2014). Currently, there are three drugs licensed in this class: canagliflozin, 
dapagliflozin, and empagliflozin. The SIGN guideline 154 recommends 
SGLT2 inhibitors as monotherapy when metformin is contraindicated, not 
tolerated and when diet and exercise alone are not sufficient to control 
glucose levels, and only if a DPP-4 inhibitor would otherwise be prescribed, 
and a sulfonylurea or pioglitazone is not appropriate (Scottish Intercollegiate 
Guidelines Network (SIGN), 2017b). 
Empagliflozin and canagliflozin have proven cardiovascular benefit, thus, in 
people with T2DM and CVD, the use of SGLT2 inhibitors should be 
considered. Moreover, the use of SGLT2 inhibitors has been associated with 
other benefits such as weight loss, blood pressure reduction, uric acid 
reduction, and low risk of hypoglycaemia. However, since SGLT2 inhibitors 
efficacy depends on plasma glucose levels and rate of glomerular filtration, in 
people with moderate renal impairment the efficacy is reduced. Moreover, 
some adverse-effects like genital mycotic infections, diabetes ketoacidosis, 
bone fracture, and lower-limb amputation have been reported (Bianchi et al., 
2018, Scottish Intercollegiate Guidelines Network (SIGN), 2017b). 
1.5.2.1.4 DPP-4 inhibitors 
Research into DPP-4 inhibitors began in the 1990s, however, the introduction 
of the specific inhibitors to the market was not until the late 2000s with the 
introduction of sitagliptin in 2007 (Bailey and Krentz, 2017). These drugs 
inhibit DPP-4 enzyme hence resulting in prolonged active incretin levels with 
consequent increased insulin synthesis and release, and decreased 
glucagon secretion. There are four DPP-4 inhibitors currently available: 
alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin. However, only 
linagliptin, sitagliptin and vildagliptin are accepted for use as monotherapy by 
the Scottish Medicine Consortium and should be considered for people for 
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whom both metformin and sulphonylureas are inappropriate due to 
contraindications or intolerance (Scottish Intercollegiate Guidelines Network 
(SIGN), 2017b). 
Overall, DPP-4 inhibitors are considered to have a good safety profile. These 
drugs are associated with low risk of hypoglycaemia and are also reported to 
be weight neutral and can be used, with a dose adjustment, in people with 
kidney impairment. However, their use is contraindicated in people with 
previous pancreatitis. Research about DPP-4 inhibitors on cardiovascular 
safety has shown that, with the exception of saxagliptin and alogliptin, they 
do not increase cardiovascular events (Scottish Intercollegiate Guidelines 
Network (SIGN), 2017b, Bianchi et al., 2018). 
1.5.2.1.5 Thiazolidinediones 
The glucose-lowering effect of thiazolidinediones was reported in the early 
1980s, the first agent troglitazone was available in the UK only for a few 
weeks in 1997 and was withdrawn for being associated with hepatoxicity. 
Two other agents, rosiglitazone and pioglitazone were introduced in Europe 
in 2000. However, after data indicating an increased risk of heart failure, 
rosiglitazone was withdrawn (Bailey and Krentz, 2017).  
Thiazolidinediones increase adipose and muscle insulin sensitivity by 
activating nuclear receptors and promoting esterification and storage of free 
fatty acids in subcutaneous adipose tissue. The only drug in this class 
authorised in the UK is pioglitazone (Scottish Intercollegiate Guidelines 
Network (SIGN), 2017b, Bianchi et al., 2018). However, the use of 
pioglitazone as monotherapy is restricted for people who have experienced 
hypoglycaemia or in whom metformin and sulfonylureas are contraindicated 
or not tolerated (Scottish Intercollegiate Guidelines Network (SIGN), 2017b). 
There is currently lack of evidence to draw conclusions on its effect on 
cardiovascular outcomes. However, the use of pioglitazone has been 
associated with weight gain, peripheral oedema, bone fracture, heart failure, 
and bladder cancer. Thus, its use should not be considered in people with 
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heart failure, and should be considered usually as dual or triple therapy 
(Scottish Intercollegiate Guidelines Network (SIGN), 2017b).  
1.5.2.2 Second-line and third-line drugs 
As previously stated, guidelines vary in relation to HbA1c targets. However, 
all recommend that when HbA1c targets are not achieved with metformin 
monotherapy, HCPs should consider a combination of metformin and one of 
the following treatment options: sulfonylurea, thiazolidinedione, DPP-4 
inhibitors, SGLT2 inhibitors, glucagon-like peptide 1 (GLP-1) receptors 
agonists, or basal insulin (American Diabetes Association, 2019d, Garber et 
al., 2019, National Institute for Health and Care Excellence, 2019, Scottish 
Intercollegiate Guidelines Network (SIGN), 2017b). Furthermore, as a result 
of the progressive nature of the disease, it is recognised that many people 
with T2DM will eventually require insulin therapy (American Diabetes 
Association, 2019d). 
1.5.3 Other interventions 
Obese adults with T2DM should be offered individualised interventions to 
encourage weight loss such lifestyle interventions and, in some cases, 
bariatric surgery (Scottish Intercollegiate Guidelines Network (SIGN), 2017a). 
In this sub-section I will address surgery to improve metabolic control and 
provide a summary on the evidence related to intensive glycaemic control. 
1.5.3.1 Bariatric surgery 
The weight loss after a bariatric surgery has also reported as being 
associated with T2DM remission. In the UK, the clinical guideline CG189 for 
obesity indicates that people with less than 10 years of T2DM diagnosis and 
with a BMI of >35 Kg/m2 should be considered for bariatric surgery, as long 
as they are receiving or will receive assessment in a tier three service 
(specialist service) (National Institute for Health and Care Excellence, 2014). 
A meta-analysis conducted by Yan et al. (2014) analysed data derived from 
eight studies of people with T2DM (N= 1,247) who underwent bariatric 
surgery. The authors reported a positively significant association between % 
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excess weight loss and T2DM remission (random model weighted mean 
differences = 9.73, 95 % CI: 4.73–14.74, p < 0.01). Remission was defined as 
the cessation of GLM and different glycaemic thresholds, which ranged from 
HbA1c of <5–6, 6.5, or 7% and FPG of <100 or <124 mg dL depending on 
the study. (Yan et al., 2014).  
Moreover, Sheng et al. (2017) conducted a systematic review and meta-
analysis with the aim to evaluate the long-term (> 5 years) outcomes of 
bariatric surgery on diabetes remission, microvascular and macrovascular 
events, and mortality among people with T2DM. The authors reported the 
results from ten articles, one RCT and nine cohorts. However, the pooled 
estimates only included the nine cohort studies. The selection criteria 
included articles that either targeted or had a subgroup analysis of people 
with T2DM, reported at least one of the outcomes of interest, and were 
followed-up for at least five years. All the studies included men and women, 
and the comparison group consisted of people who were given non-surgical 
treatments for T2DM (i.e. GLM and/or lifestyle modifications). One study 
included only people with BMI < 35 Kg/m2, two studies included people with 
BMI <35 Kg/m2, and six included only people with BMI > 35 Kg/m2. The 
meta-analysis showed that people in the surgery group had higher rate of 
diabetes remission compared with those in the non-surgical treatment group 
(RR = 5.90; 95% CI = 3.75–9.27). Furthermore, the authors reported no 
significant heterogeneity across studies (Q = 0.04, I 2 = 0%), and no 
publication bias as suggested by the funnel plots and Egger’s test (P = 0.36). 
For the RCT, the authors reported that at year five the surgery group 
(intervention) had 50% remission rate while the non-surgical group (control) 
had 0%.  
Thus, the evidence provided by such studies shows that weight loss has the 
potential to improve glycaemic control among people with T2DM. As 
mentioned above, bariatric surgery is available on the NHS for people with 
T2DM who meet certain criteria such as having a BMI >35, have attempted 
and struggle to lose weight with diet and exercise and agree to the long-term 
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follow-up after the surgery (NHS, 2017). However, bariatric surgery may have 
side effects such as malnutrition, gallstones, among others (NHS, 2017).  
1.5.3.2 Intensive glycaemic control  
This section will discuss some studies that have looked at the effects of 
intensive glycaemic control for people with T2DM. The definition of intensive 
glycaemic control was different depending on the study; however, it generally 
relates to the prescription of pharmacotherapy and the achievement and/or 
maintenance of HbA1c levels <42 mmol/mol (6%). I will focus on briefly 
describe results from ad-hoc selected RCTs conducted in people with newly 
diagnosed T2DM carried out to determine the effect of tight or intensive 
glycaemic control on -cell function and glycaemia and/or cardiovascular risk 
and reduction of complications. I will also summarise the outcomes of other 
studies such as the Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation (ADVANCE), and the 
Action to Control Cardiovascular Risk in Diabetes (ACCORD) and describe 
two meta-analyses of RCTs on the effects of intensive glycaemic control 
effects. These did not focus on people with newly diagnosed T2DM however, 
results from such research are presented here because of the role that they 
have had in informing clinical guidelines for the management of diabetes 
(American Diabetes Association, 2019c, Scottish Intercollegiate Guidelines 
Network (SIGN), 2017a, Scottish Intercollegiate Guidelines Network (SIGN), 
2017b), and to provide an overview of benefits and potential harms of an 
intensive approach to glycaemic control. 
The KIIT trial, conducted in Korea, aimed to determine the effects of early 
intensive glycaemic control; with intensive insulin treatment (IIT) or initial 
combined oral antidiabetic drug (COAD) therapy; on long-term glycaemic 
control and the preservation of -cell function in people with newly diagnosed 
T2DM. Participants were included if aged 25 to 70 years, diagnosed with 
T2DM within the previous 12 months and whose HbA1c levels were between 
64mmol/mol and 108 mmol/mol. People with contraindication to insulin, oral 
agents, retinopathy, chronic liver disease, renal dysfunction, heart disease, 
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pregnant women and chronic conditions requiring long-term use of 
glucocorticoid treatment were excluded. A total of 112 individuals were 
randomised to either the IIT group or the COAD group. For a maximum of 12 
weeks, participants in the IIT group had their insulin titrated every three days 
or two weeks based on the results of self-monitoring of blood glucose, FPG 
and HbA1c levels, while participants in the COAD group received standard 
doses of glimepiride and metformin which were titrated every two weeks 
based on glucose levels. After this period, participants with HbA1c <64 
mmol/mol were instructed to change their treatment to lifestyle modification 
alone for four weeks. Then, if after these four weeks, their HbA1c was <53 
mmol/mol lifestyle modifications were continued; otherwise, GLMs (COAD 
group schedule) was introduced. Participants’ mean age and duration of 
T2DM were 46.9+10.1 years and 0.8+2.1 months, and 48.4+10.4 years and 
0.6+1.6 months for the IIT and the COAD groups, respectively. After the 
intervention period, participants were followed-up for up to 104 weeks. The 
authors reported that 53.3% of participants in the IIT group and 18.8% in the 
COAD group were drug-free and considered in remission. The Cox 
regression analysis showed that the initial intensive treatment method was an 
independent attributable factor drug-free glycaemic remission. However, 
these results must be interpreted with caution because, in both groups, the 
mean BMI at baseline was relatively low, 26.9+7.3 and 25.1+3.3 Kg/m2 for 
the IIT and COAD groups, respectively (Chon et al., 2018). 
Similar studies have been conducted in other countries. For instance, a RCT 
conducted in the US aimed to assess the efficacy of early intensive diabetes 
therapy with either insulin plus metformin (INS) or triple oral therapy (TOT) 
with metformin, glyburide, and pioglitazone on glycaemic control and -cell 
function. People with newly diagnosed T2DM (in the previous two months) 
who were drug-naïve and were aged 21 to 70 years were recruited. All 
participants (n=63) were randomised to either INS or TOT and followed-up 
for six years, completion rates were 66% and 55% for the INS and the TOT 
group, respectively. The mean age of participants was 44.9+10.1 years, 36% 
were female. At 6 years, 63.2% in the INS and 68.8% in the TOT had HbA1c 
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<53 mmol/mol. -cell function remained stable for both groups, insulin 
sensitivity decreased in both groups, no significant change in total 
cholesterol, LDL or triglycerides were reported. Moreover, the authors 
reported an overall low rate of mild hypoglycaemia and 24% of treatment 
failure (HbA1c >64 mmol/mol). The authors concluded that early intervention 
after diagnosis has the potential to stabilise -cell function (Harrison et al., 
2014). 
The ADVANCE trial was designed to assess the effects on major vascular 
outcomes of lowering the HbA1c to a target of 6.5% or less in people with 
T2DM. The trial started in 2001 and counted with centres in Asia, Europe, 
North America, and Australasia. Participants were eligible if they had a 
diagnosis of T2DM at 30 years or older, an age of at least 55, and a history of 
major macrovascular or microvascular disease or at least one other risk 
factor for CVD. A total of 11,140 participants were randomly assigned to 
receive therapy with either perindopril and indapamide or matching placebo 
and to undergo either a strategy of intensive glycaemic control (intervention) 
or standard glucose control (control). Mean age for both groups was 66+6 
years, mean duration of diabetes and HbA1c was 7.9+6.3 years and 7.51%, 
and 8+6.4 years and 7.52% for the intervention and control groups, 
respectively. Participants in the intervention group (n=5,571) were given 
gliclazide and required to discontinue any other sulfonylurea, those in the 
control group (n=5,569) who were using gliclazide were required to substitute 
it with another sulfonylurea. Follow-up was at week two, and months one, 
two, three, four and six, and every three months thereafter for the 
intervention group. For the control group follow-up was at three, four, and six 
months, and every six months thereafter; the median duration of follow-up 
was five years. After the follow-up period, the intervention group had a mean 
HbA1c of 6.5%, the control group a mean of 7.3%. Moreover, mean systolic 
blood pressure was lower in the intervention group (135.5 vs 137.9 mmHg), 
mean body weight was greater in the intervention group by 0.7 Kg. Major 
macrovascular or microvascular events were 18.1% in the intervention group 
and 20% in the control group; compared with the control group, there was a 
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statistically significant reduction of major microvascular events in the 
intervention group (HR: 0.86, CI: 0.77-0.97) but not in the incidence of major 
macrovascular events. Moreover, as compared with the control group, there 
was a significant reduction in renal events in the intervention group (HR:0.79; 
CI: 0.66-0.93) and new-onset microalbuminuria (HR:0.91; CI: 0.85-0.98). 
However, more people in the intervention group than in the control group 
were hospitalised for any cause (44.9% vs 42.8%), with some of the excess 
of hospitalisations due to severe hypoglycaemia (OR:1.52; CI:1.01-2.28). 
Severe hypoglycaemia occurred more frequently in the intervention group 
than in the control group (The ADVANCE Collaborative Group, 2008). 
The ACCORD trial in North America studied the effects of strict and standard 
glycaemic control on cardiovascular events. In this study, people with T2DM 
were recruited if they were (a) aged 40–79 years and had CVD or if were 
aged 55–79 years and there was evidence of atherosclerosis, albuminuria, 
ventricular hypertrophy or two risk factors for CVD, (b) had HbA1c >58 
mmol/mol (7.0%) and, (c) their BMI was <45 Kg/m2. A total of 10,251 were 
included; mean age was 62.2 years, mean HbA1c 67 mmol/mol and mean 
BMI 32.2 Kg/m2. Participants were randomised to either strict glycaemic 
control (intervention) with a target HbA1c of 47.5 mmol/mol (<6.5%) or a 
standard (control) HbA1c goal of 53-62.8 mmol/mol (7-7.9%). Those 
assigned to intensive glycaemic control had a greater frequency of 
hypoglycaemia and relative increased mortality of 22% as compared to 
standard therapy (The Action to Control Cardiovascular Risk in Diabetes 
Study Group, 2008). Post-trial analyses revealed that patients who had high 
HbA1c levels had higher mortality (Punthakee et al., 2014). Further analysis 
adjusted by selected baseline patient characteristics and treatment received 
showed that a greater decrease of HbA1c was associated with a lower risk of 
death, where 1% of HbA1c increase was associated with 22% increased risk 
of death (Riddle et al., 2010). Furthermore, patients who were randomised to 
receive strict glycaemic control and had a pre-transition (the last measure on 
or before treatment relaxation) HbA1c <6.5% were more likely to maintain 
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lower HbA1c levels after one year of treatment relaxation (Punthakee et al., 
2014). 
The UKPDS was a RCT conducted which aimed to determine the effect of 
intensive glycaemic control on the incidence of complications in people with 
T2DM (King et al., 1999). People with newly diagnosed T2DM (n= 3,867; 
58% male) were recruited from 23 hospitals between 1977 and 1991. 
Participants were eligible if aged 25-65 years (mean age: 54; IQR 48-60 
years) and had FPG >6 mmol/L on two mornings, 1–3 weeks apart. Mean 
FPG was 8.0 mmol/L (7.1–9.7), HbA1c 53.9 mmol/mol (SD +8.6). 
Participants were randomised to either receive conventional treatment 
(control) or intensive treatment (intervention). People in the control group 
were initially on diet only (dietician advice every three months) with the aim of 
maintaining FPG <15 mmol/L. However, if hyperglycaemia or symptoms 
occurred, people were initiated on sulfonylurea, metformin or insulin. People 
in the intervention group were treated with GLM (sulfonylureas or insulin) to 
maintain FPG <6 mmol/L and received dietary advice. After following-up the 
cohort for 10 years, a lower median HbA1c was reported in the intensive 
treatment group (treated with pharmacological treatment) than in the 
conventional group (initial treatment with diet). Moreover, people assigned to 
intensive treatment had a 25% risk reduction in microvascular disease 
compared to people in the conventional group. However, hypoglycaemic 
episodes were more frequent among people in the intensive treatment arm, 
particularly amongst those who received insulin therapy (UK Prospective 
Diabetes Study (UKPDS) Group, 1998).  
Additionally, post-trial analysis of the UKPDS cohort showed beneficial 
effects of intensive glycaemic control. The reduction in the relative risk of 
microvascular disease continued during the post-trial period for patients in 
the sulfonylurea-insulin group. Similarly, patients in the metformin group, as 
compared with conventional therapy, had a reduction in the relative risk of 
myocardial infarction and death from any cause. This reduction was 
maintained throughout the post-trial follow-up period (Holman et al., 2008). It 
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is important to note that the diagnostic criteria for T2DM used in the UKPDS 
trials were different (FPG >7.8 mmol/L) than the criteria now used (World 
Health Organization, 1985). Moreover, the inclusion criteria in the UKPDS 
and other RCTs such as the ACCORD and ADVANCE have limited external 
validity as it does not reflect the contemporary British population with T2DM 
(Saunders et al., 2013). Saunders et al. (2013) described the proportion of 
people with T2DM living in Scotland who met the eligibility criteria of such 
RCTs. In relation to the UKPDS trial, the authors reported that a maximum of 
51% of people with newly diagnosed T2DM in the Scottish population were 
eligible for inclusion in the trial. Patients’ data in Scotland were drawn from 
the SCI-Diabetes – start of 2008 extract.  
Further analyses of these trials and similar RCTs have been conducted in 
order to evaluate both treatment approaches. For instance, a meta-analysis 
by Hemmingsen et al. (2011) reported no significant difference between 
intensive and standard glycaemic therapy for all-cause and cardiovascular 
mortality but a reduction of non-fatal myocardial infarction, retinopathy and 
microvascular (as composite outcome) in the intensive therapy group. 
However, there was a 30% increase in relative risk of severe hypoglycaemia 
for the intensive therapy group compared to the standard treatment group. 
The length of follow-up of the studies included ranged from four months to 12 
years; median follow-up time was not provided by the authors. 
Likewise, Sardar et al. (2015) conducted a meta-analysis from 17 RCTs, 
which set out to examine regional variations in the efficacy and safety of 
intensive glycaemic control treatment in people with T2DM. Mean duration of 
follow-up was 5.1 years in North America and 4.1 years in the rest of the 
world. The authors reported no significant differences between intensive or 
standard glucose therapy for all-cause mortality and cardiovascular mortality. 
However, an interaction, depending on the region where the RCTs were 
conducted, was found. While RCTs in North America resulted in a 
significantly higher all-cause mortality and cardiovascular mortality for 
patients in the intensive than standard therapy arm, RCTs from the rest of the 
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world showed a non-significant difference. However, further analysis of data 
from the post-trial period showed significantly lower all-cause mortality for the 
intensive therapy patients (Sardar et al., 2015). Thus, country-specific factors 
may play a role in patients’ outcomes following intensive glycaemic control. 
Overall, RCTs studying the effects of intensive vs standard glycaemic control 
for people with T2DM have reported lower HbA1c levels for people receiving 
intensive treatment, even during the post-trial period; however, results for 
mortality have been inconsistent. Therefore, the benefits of intensive 
glycaemic control are not conclusive and may not outweigh the potential 
harms to patients. As a consequence, intensive glycaemic therapy to reach 
tight HbA1c targets in diabetes care is not supported by the evidence 
(American Diabetes Association, 2019c, Hemmingsen et al., 2011, Sardar et 
al., 2015). 
1.6 Diabetes care in Scotland  
As stated in section 1.4, the development of guidelines and approaches to 
T2DM care can differ depending on the country and may contribute to 
variation in diabetes outcomes (International Diabetes Federation, 2017b, 
Sardar et al., 2015). Therefore, in the following sub-sections, I will focus on 
the provision of T2DM care in Scotland, as this is the location where the data 
from this study originated and was collected.  
People with T2DM are recommended to receive at least annual monitoring; in 
Scotland, this work is now mostly done outside hospitals in primary care 
(Scottish Intercollegiate Guidelines Network (SIGN), 2017a). Primary care 
includes services provided in the community commonly by HCPs such as 
GPs or nurses, or allied healthcare professionals such as pharmacists, 
physiotherapists, midwives and occupational therapists (ISD Scotland, 2010, 
Scottish Government, 2018). Most care for people with T2DM is performed 
by GPs and nurses working in primary care. The majority of general practices 
are independent contractors constituted of GPs, practice-employed nurses, 
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that vary in size and composition of their workforce (Murrels et al., 2013, ISD 
Scotland, 2018b).  
1.6.1 Healthcare professionals’ role in diabetes care 
HCPs are in regular contact with a large proportion of the population, which 
place them in an ideal position to provide lifestyle counselling and advice for 
prevention of T2DM and its complications (Geense et al., 2013, Pikala et al., 
2011, Rubio-Valera et al., 2014). Every HCP contributes to the healthcare 
team with the relative contributions of nurses and doctors varying in different 
settings. Physicians are often responsible for prescribing, and traditionally 
their role has been recognised as a coordinator of care for people with 
T2DM, particularly for patients with comorbidities (Lo et al., 2016, Zenzano et 
al., 2011) 
However, some countries, such as the UK have provided nurses with the 
legal authority to prescribe. The number of nurses prescribing varies 
considerably across health boards within the UK (Courtenay, 2018). In 
Scotland, the “Primary Care Workforce Survey Scotland 2017” reported that 
12% of nurses were Nurse Practitioners who have completed additional 
education and have been enabled to prescribe (ISD Scotland, 2018b). 
Overall, nurses have had increasing participation in primary care in Scotland, 
whereas in 2013, it was reported that total GP consultations decreased by 
1.4% while practice nurses’ consultations rose by 31% compared to 2012. 
Furthermore, diabetes ranked as the sixth most common reason to consult a 
GP or a practice nurse; the majority of the consultations were with a nurse 
rather than a GP (National Statistics Scotland, 2013)  
1.6.2 Structured education programmes 
In the UK, structured education programmes for people with T2DM are 
available to support self-management. Currently, there are some courses 
available such as “Diabetes Education and Self-Management for Ongoing 
and Newly Diagnosed Type 2 diabetes” (DESMOND), X-PERT, Freedom 4 
life, and Hypo Program. However, some programmes such as Freedom 4 life 
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are offered only in specific areas (Wiltshire) or are focused on particular 
aspects of diabetes, such as Hypo Awareness Program, which aims to 
improve people’s knowledge of hypoglycaemia symptoms, particularly those 
who take insulin, sulfonylureas or glinides (Diabetes.co.uk, 2019a, 
Diabetes.co.uk, 2019b, Diabetes.co.uk, 2019c).  
In Scotland, the SIGN guideline 116 indicates that adults with T2DM should 
have access to structured education programmes (Scottish Intercollegiate 
Guidelines Network (SIGN), 2017a). The DESMOND programme started as 
a RCT in 2008 and was rolled out country-wide after achieving positive 
outcomes such as greater improvements in weight loss, smoking cessation 
and increasing understanding of diabetes in the intervention as compared to 
the usual care arm (Davies et al., 2008). DESMOND is available in some 
health boards in Scotland for people with T2DM, and usually, practices refer 
people with newly diagnosed T2DM directly to a DESMOND coordinator. 
Currently, the programme offers nine sessions monthly across Edinburgh, 
East, Mid and West Lothian and can be attended in either one full day or two 
half days (DESMOND Project, 2019). 
1.6.3 Quality and Outcome Framework 
As will be described in Chapter 3, the cohort analysis included data from 
2004 to 2012, a period in which the Quality and Outcome Framework (QOF) 
was operating. Therefore, here I briefly introduce the QOF and the approach 
that has replaced it. The QOF was a pay-for-performance scheme introduced 
in April 2004 across the UK. It measured achievement of indicators, with 
points and payments awarded to the general practices depending on their 
level of achievement.  
In Scotland, QOF was decommissioned in April 2016 (ISD Scotland, 2016c, 
Roland and Guthrie, 2016). The removal of QOF was seen as an opportunity 
to focus on disease prevention and increase shared decision-making and a 
personalised approach. Thus, increased patient involvement is sought by 
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focusing on their needs and preferences (Royal College of General 
Practitioners, 2016, Royal College of General Practitioners, 2019). 
The QOF indicators covered four domains which were clinical, public health, 
quality and safety, and medicines management. Clinical indicators related to 
processes and outcomes of health conditions such as diabetes and other 
chronic diseases. Public health included indicators such as blood pressure 
and smoking. Quality and safety consisted of indicators related to outpatient 
referrals. Medicines management included indicators on meetings with NHS 
Board prescribing advisers and medication review for patients. Concerning 
diabetes, the last list of QOF indicators in 2015/2016 for Scotland included, 
among the clinical indicators, the proportion of patients on the register who 
had HbA1c levels under certain targets. The achievement of a range 
threshold for each target awarded points to practices for payment (ISD 
Scotland, 2016d). For HbA1c, targets were <59 mmol/mol (7.5%), <64 
mmol/mol (8.0%), <75 mmol/mol (9.0%), and the corresponding points and 
range threshold for each were 17, 8, 10 points and 40-50%, 45-70%, and 50-
90%, respectively. Likewise, practices received a maximum of 11 points if 40-
90% of people with newly diagnosed diabetes had been referred to a 
structured education programme within nine months after entry to the register 
(ISD Scotland, 2016b). 
In comparison to prior years, QOF’s first year of implementation showed a 
considerable improvement in the quality of diabetes care, and in its last year, 
the average achievement for diabetes indicators was 98.1% (Guthrie and 
Tang, 2016, National Statistics Scotland, 2016). However, despite the 
positive changes which included diversification of nurses’ role and teamwork, 
the incentives to adhere to guidelines was one of the major criticisms of the 
QOF. The financial incentives, which were calculated based on the number 
of points achieved by the practice, were judged as a potential drawback in 
person-focused care by becoming less personal, ‘tick-box’ medicine. (Gillam, 
2010, Guthrie and Tang, 2016).  
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NHS Scotland’s new approach to improving the quality of care after the 
discontinuation of QOF is by forming GP clusters. A GP cluster typically 
comprises five to eight GP practices, which are in similar geographical areas. 
The purpose of this approach is to ‘encourage GPs to take part in quality 
improvement activity with their peers and contribute to the oversight and 
development of their local healthcare system’ (ISD Scotland, 2016a). Thus, 
led by GPs, clusters of practices are meant to collaborate in order to prioritize 
relevant areas for planning, quality control and quality improvement (Royal 
College of General Practitioners, 2016, Roland and Guthrie, 2016). However, 
the effect of this new approach on quality of care and outcomes for people 
with T2DM is not clear. This change in policy, and the current variability 
between GPs prescribing rates; reasons for which are not yet clear (Royal 
College of General Practitioners, 2016); offer opportunities for research to 
describe and explore the effect diabetes management and treatment 
decisions both before and after the new policy was introduced.  
1.7 Summary  
Sub-optimal glycaemic control leads to an increased risk of microvascular 
and macrovascular complications. Although optimal glycaemic control helps 
reduce the risk of complications, intensive glycaemic control can be unsafe 
for some people and targets should be tailored to each patient (International 
Diabetes Federation, 2012).  
As indicated in section 1.5, the time of diagnosis and of the annual 
assessments have been recognised by the ADA as two of four critical time 
points for optimal management of T2DM; the other two time points being 
when new complications develop, and when transitions in care occur. At 
diagnosis, people with T2DM usually experience the challenge of integrating 
diabetes management into their daily lives. Thus, this time point provides an 
opportunity for HCPs to assess barriers to treatment and to establish 
glycaemic targets; although these targets must be individualised (American 
Diabetes Association, 2019b, American Diabetes Association, 2019c, 
Thoolen et al., 2008, Frost et al., 2014).  
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After diagnosis of T2DM, guidelines recommend that lifestyle modifications 
should be the first step to take for glycaemic management and treatment 
modifications such as drug treatment initiation or intensification should be 
based on HbA1c levels (International Diabetes Federation, 2012). Currently, 
clinical guidelines recommend a higher HbA1c target for certain clinical 
groups and older people with T2DM. Most guidelines, including the Scottish 
SIGN guidelines, have established a general HbA1c goal of 53 mmol/mol 
(7%) (International Diabetes Federation, 2017b, Inzucchi et al., 2015, 
Scottish Intercollegiate Guidelines Network (SIGN), 2017b) 
In Scotland, most of diabetes care is done in primary care by HCPs such as 
GPs or nurses (Murrels et al., 2013, ISD Scotland, 2018b). Nurses’ 
participation in diabetes care in primary care has increased over the years, 
the activities that nurses currently perform range from provision of education 
to prescription of pharmacological therapy (National Statistics Scotland, 
2013). Furthermore, in Scotland, some people with T2DM have the 
opportunity to receive additional education via structured education 
programmes such as DESMOND (DESMOND Project, 2019). 
From 2004 to 2016, the QOF operated in Scotland. During this, practices 
were financially rewarded, in a point-system scheme, for the achievement of 
clinical indicators (ISD Scotland, 2016d). One of the major criticism of the 
QOF was the perceived lack of person-centred care (Guthrie and Tang, 
2016, Roland and Guthrie, 2016). After QOF’s decommission, “GP clusters” 
are responsible for reviewing and improving quality of care in Scotland (ISD 
Scotland, 2016a).  
The study of people with T2DM represents an opportunity to improve T2DM 
management and inform practice using real-world data (RWD), which is 
defined as data generated during routine clinical practice rather than 
collected in the context of a RCT (Berger et al., 2017). The use of RWD, 
which generates real-world evidence, has been recognised as playing an 
important role in the evaluation of epidemiology, treatment patterns, 
compliance, and health outcomes of different treatments (Mahajan R., 2015, 
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Berger et al., 2017, McDonald et al., 2017). Studies using RWD may have a 
wide range of outcomes. However, the evidence generated by RWD 
traditionally comprise clinical and demographic information which lack the 
perspectives and experiences of patients and HCPs (McDonald et al., 2019).  
Thus, in the next chapter, I will describe the findings from my review of the 
literature, which included quantitative and qualitative studies, and focused on 
two main broad areas: (1) prescription patterns of GLM and time to drug 
treatment initiation in people recently diagnosed with T2DM, and (2) HCPs’ 
perspectives and experiences in providing care to people with T2DM, 
particularly about factors influencing clinical decision-making. The decision to 
focus the literature search on GLM initiation in people with newly diagnosed 
T2DM was based on the sensitive period that the time after diagnosis 
represents in patients’ lives and the future of their treatment. As described in 
this chapter, the period soon after diagnosis is recognised as crucial for 
optimal management of T2DM. Actions taken at this point may affect the 
person’s quality of life in the long-term, and attempts at improving the 
glycaemic control of people with T2DM must be prioritised (International 
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Chapter 2 Literature Review: management of 
T2DM 
2.1 Introduction 
In this chapter, I will present the findings of a literature review focused on the 
management of T2DM with a particular focus on GLM initiation in people with 
T2DM. As described in the previous chapter, the first approach to managing 
T2DM varies between guidelines, and there is no international consensus on 
whether to start management of T2DM with lifestyle changes alone or in 
combination with GLM.  
However, clinical guidelines highlight that the adoption of a healthy lifestyle is 
central to effective diabetes management and should be emphasised in the 
initial comprehensive medical evaluation after diagnosis. Attaining and 
maintaining clinically recommended levels of blood glucose at an early stage 
is crucial for the prevention of T2DM complications. Moreover, clinical 
guidelines recommend that targets and therapies should be adapted to meet 
patients’ circumstances and needs (International Diabetes Federation, 
2017b, American Diabetes Association, 2019b). 
2.1.1 Aims  
The purpose of this literature review is to identify, critically appraise and 
synthesise the relevant published quantitative and qualitative research 
relevant to GLM initiation in people with T2DM. The specific aims are as 
follows: 
1. To describe glucose-lowering prescriptions patterns, identify 
factors associated with glucose-lowering treatment initiation in 
people with T2DM, and describe clinical inertia in the context of 
T2DM. 
2. To explore and describe HCPs’ reasons for their choice of 
treatment (lifestyle interventions and/or pharmacological therapy) 
following the diagnosis of T2DM. 
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These aims cover broad themes that are important to understand GLM 
initiation in people with T2DM. However, the reason for having such broad 
aims is because the initial scoping review showed insufficient literature 
focusing on glucose-lowering initiation in people recently diagnosed with 
T2DM and studies focused on reasons for initiating GLM in those newly 
diagnosed.  
2.1.2 Overview of methods  
At my first-year PhD review, after discussion with the panel and supervisors 
and, considering the scope and timescale of the PhD research, I decided to 
conduct a systematic search and literature review instead of a systematic 
review in recognition that I would not be able to draw upon time and human 
resources (a second reviewer) to conduct two full systematic reviews.  
Grant and Booth (2009) have identified and characterised 14 different types 
of reviews commonly used. The authors indicate that although both 
systematic reviews and systematic search and reviews aim for an exhaustive 
comprehensive searching, there are some differences between them. 
Therefore, before moving onto the two main sections of this chapter it is 
important to address these differences. 
In a systematic review, research evidence is systematically searched for, 
appraised and synthesised, it often adheres to guidelines on the conduct of a 
review and includes a quality assessment which determines the inclusion and 
exclusion of articles. A systematic search and review usually addresses 
broad questions and seeks to identify the most significant items in the field, 
and although it demonstrates an extensively researched literature, it may or 
may not include quality assessment. The strengths of this latter type of 
review are the incorporation of multiple study types to provide a more 
complete picture of the research topic. However, the major limitation or 
criticism of this type of review is related to the fact that the articles included 
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are assessed and valued without a standardised tool or checklist (Grant and 
Booth, 2009). 
The process of conducting a systematic search and review commenced in 
2016 and was updated in 2019. Given the different nature and scope of the 
literature aims (one quantitative and one qualitative) two different search 
strategies were built. Thus, to respond to aim one, the methods followed are 
presented in sub-section 2.2.1, and to respond to aim two, in sub-section 
2.3.1. 
Findings from the reviews are presented in a narrative form in two main 
sections; sub-sections were organised according to the themes identified 
after reading the articles retrieved during the search. The first section relates 
to the first aim and focuses on quantitative research. It covers aspects 
related to prescription patterns and time to treatment initiation and clinical 
inertia. The second part aims to describe clinical decision-making from HCPs’ 
perspective, which included qualitative studies. Although tables with a 
summary of the articles are presented in each section, a narrative or textual 
approach of the findings from the studies included was adopted because it 
offers an effective way of synthesising findings from multiple studies designs, 
such as qualitative and quantitative (Popay et al., 2006).  
2.2 Section 1: prescription patterns and time to drug 
initiation in people with T2DM 
The aim of this component of the literature review was to describe 
prescription patterns of first-line GLM in people with T2DM, the 
characteristics of those receiving such prescriptions and time to GLM 
initiation to understand how T2DM is managed in real-world practice. The 
existing literature on treatment patterns is extensive and has been the focus 
of study in several countries. However, there is a relatively small body of 
literature about time to initial drug initiation and predictors of treatment 
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initiation. A detailed account of these studies is presented in the following 
sub-sections.  
First, I will describe the methods utilised. Then, I will present the results of 
the database search and screening process. Next, I will move onto the first 
sub-section (2.2.2.1), in which I will describe the changing patterns of GLM in 
the US, Europe and the UK. The introduction of new medications and the 
constant monitoring of their secondary effects shape prescription patterns. 
For instance, an early study on the use of metformin for glucose control by 
Gottlieb and Auld (1962) described its benefits, particularly when a patient 
was intolerant to sulfonylureas and tolbutamide. However, its use did not 
increase until decades later. Similarly, in 2010, ten years after its approval, 
the drug rosiglitazone was suspended and withdrawn from the market. This 
was the result of research indicating that it may increase the risk of 
myocardial infarction (Cohen, 2010). As it will be described in section 2.2.2.1, 
trends in the use of GLM have changed over time.  
Next, in sub-section 2.2.2.2 I will introduce the concept of “clinical inertia”. In 
the study of pharmacological therapies, when healthcare providers are 
considered to not initiate or intensify treatment for diagnosed patients 
appropriately, such behaviour is termed “clinical inertia”. The term was first 
coined by Philips et al., who identified this behaviour in the management for 
hypertension, dyslipidaemia, and diabetes (Phillips et al., 2001). 
Finally, in sub-section 2.2.2.2 I will present the outcomes of the studies, 
which specifically focused on time to treatment initiation and predictors of 
GLM prescription. 
2.2.1 Methods 
A priori eligibility criteria were established. These criteria were determined 
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2.2.1.1 Eligibility criteria  
2.2.1.1.1 Inclusion criteria 
1. Observational studies (cross-sectional, cohort, survey, or case-control). 
Since the aim is to describe real-world practice, RCTs were not 
considered. 
2. Articles reporting proportions of patients with and without pharmacological 
treatment after T2DM diagnosis and/or prescribing patterns after 
diagnosis in the US and Europe. This criterion was established after the 
initial scoping review showed a sheer number of articles describing 
patterns worldwide. Although with some differences2, GLMs for T2DM 
available in the US and Europe are similar (Davies et al., 2018). 
3. Articles describing clinical inertia in people with T2DM in the UK. 
4. Articles reporting time to drug treatment initiation in people with newly 
diagnosed T2DM, no geographical limitations. 
5. Only articles published in English and available as full-text (if the same 
results were published in more than one article, only the most recent and 
complete was included). 
2.2.1.1.2 Exclusion Criteria 
1. Studies that do not provide new empirical data such as reviews, editorial 
letters or others will be excluded, as well as those not available as full 
text.  
2. Articles focused only on hypothetical reasons for treatment choice were 
excluded. 
3. Articles describing prescription patterns in newly diagnosed not in Europe 
nor the US were excluded. 
4. Articles describing clinical inertia outside the UK were not included. 
                                            
2 Not licensed in the US: vildagliptin, gliclazide. Not licensed in Europe: rosiglitazone, 
colesvelam, quick-release bromocriptine, human insulin inhalation powder, pramlintide 
DAVIES, M. J., D’ALESSIO, D. A., FRADKIN, J., KERNAN, W. N., MATHIEU, C., 
MINGRONE, G., ROSSING, P., TSAPAS, A., WEXLER, D. J. & BUSE, J. B. 2018. 
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the 
American Diabetes Association (ADA) and the European Association for the Study of 
Diabetes (EASD). Diabetes Care, 41, 2669.. 
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5. Articles focused on describing patterns of use of specific medications (i.e. 
metformin only) were not considered. 
6. Studies describing time to drug treatment initiation not focused on newly 
diagnosed patients or which data are not stratified and therefore not 
possible to analyse, were excluded. 
2.2.1.2 Information sources and search strategy 
The literature search was conducted in three electronic databases: Excerpta 
Medica Database (EMBASE), Medline via PubMed and Scopus. The 
complete list of the search terms employed for each database is available in 
appendix 1A.  
2.2.1.3 Selection process  
The software EndNote X9 was used to manage records and identify duplicate 
studies. The selection process was performed, according to the a priori 
inclusion and exclusion criteria, in three main stages: 1) all retrieved articles 
were screened by their study title. 2) abstracts from all selected articles in the 
first stage were read to determine their relevance. 3) full-text of all those 
articles considered potentially eligible were read to determine their relevance 
according to the inclusion criteria. Moreover, references from selected 
studies were manually scanned for additional relevant studies. 
In figure 1 is presented the review process concerning this section of the 
literature review. Specific details of full-text articles which were evaluated and 
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Records identified from database searching: 
 PubMed (n= 507)** 
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 Scopus (n=1,367) 
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2.2.2 Results 
A total of 27 articles were included in this section of the literature review. 
Articles were concerned with prescription patterns, clinical inertia, and time to 
treatment initiation in people with newly diagnosed T2DM. The narrative 
review of the articles included is presented as follows: 
 Sub-section 2.2.2.1 presents studies that described prescription patterns 
of glucose-lowering medication, which includes those for the US, 
mainland Europe and the UK. 
 Sub-section 2.2.2.2 is concerned with studies focused on clinical inertia in 
the UK, and  
 Sub-section 2.2.2.3 presents the articles focused on time to treatment 
initiation in people with newly diagnosed T2DM. 
 
Assessment of study quality 
Although this type of review does not strictly require a quality assessment of 
the studies included (Grant and Booth, 2009), the appraisal was conducted in 
order to give the reader a context of the overall quality of the literature 
presented. Quality of the included studies was assessed using the Newcastle 
– Ottawa quality assessment scale (NOS) (Wells et al.) for cohort studies and 
the Joanna Briggs Institute (JBI) (Moola et al., 2017) critical appraisal 
checklist for analytical cross-sectional studies. The NOS assesses three 
perspectives: the selection of the study groups, the comparability of the 
groups, and the ascertainment of either the exposure or outcome of interest. 
The scale includes eight questions (see appendix 3), each question can be 
awarded a maximum of one star with exception of question five which is 
concerned with comparability and can be awarded a maximum of two stars. 
Thus, the maximum score for this scale is nine (Wells et al.). The JNB 
includes eight questions (see appendix 3), where the answer for each one 
can be either yes, no, unclear and, not applicable. In the current study, 
articles assessed using the JBI were given a star if the answer was yes or 
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not applicable, otherwise if the answer was no or unclear the field was left 
empty. Hence, articles assessed using the JBI could have a maximum of 
eight stars (Moola et al., 2017).  
Currently, official threshold scores for the assessment tools used have not 
been determined (Wells et al.). However, in order to provide an overview of 
the quality of the studies included in the review, discretionary cut-off points 
were created to classify articles as high, medium or low quality; high-quality 
articles were those with at least 8 stars, medium those with 5–7, and low 
quality those with <4 stars. Below, table 3 presents a summary of the 
assessment, the table includes the scale used and the score of each article. 
Overall, 37% of the articles were of high-quality and the remaining 63% of 
medium quality. 
Table 3. Quality appraisal summary  
No. First author  Year Scale Score Quality  
1 Boyc 2007 NOS 7/9 Medium  
2 Brown  1999 NOS 7/9 Medium 
3 Chung  2015 NOS 9/9 High  
4 Desai 2012 NOS 7/9 Medium 
5 Fillion  2009 NOS 8/9 High 
6 Grimes 2014 NOS 8/9 High  
7 Hamada 2015 NOS 8/9 High  
8 Hamada 2016 NOS 7/9 Medium 
9 Hazel-Fernandez 2015 NOS 8/9 High  
10 Heald 2018 NOS 8/9 High  
11 Hippisley-cox 2004 JBI 7/8 Medium  
12 Kennedy 1988 NOS 5/9 Medium  
13 Khunti 2013 NOS 7/9 Medium  
14 Khunti 2016 NOS 7/9 Medium  
15 Kostev 2018 JBI 6/8 Medium  
16 Lopez-Sepulveda  2017 NOS 7/9 Medium  
17 Lunger 2017 NOS 6/9 Medium  
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18 Mauricio 2017 NOS 8/9 High 
19 Mor 2015 NOS 9/9 Medium  
20 Pani 2008 NOS 7/9 Medium  
21 Sharma 2016 JBI 7/8 Medium  
22 Sinclair 2012 NOS 8/9 High 
23 Spoelstra  2004 NOS 9/9 High 
24 Sun 2013 NOS 7/9 Medium  
25 Wysowski 2003 JBI 6/8 Medium  
26 Zhang 2012 NOS 8/9 High 
27 Zografou 2014 NOS 7/9 Medium 
 
2.2.2.1 Prescription patterns of glucose-lowering medication  
In this sub-section, I will present evidence from the US and Europe; then, I 
will focus on what is currently known from data in the UK. In table 4 is 
presented a summary of the articles found in the search which were included 
in this section.  
Table 4. Articles focused on prescription patterns of glucose-








Data obtained from the IMS Disease Analyzer–
Mediplus France Database. Includes 
approximately 840 practices. 
N= 14,281 participants (2001 cohort: 4,672, 
2002 cohort: 8,060, 2003 cohort: 10,724) 
Mean age was 64.14 years (2001), 64.09 years 
(2002), and 64.24 years (2003). 
Metformin monotherapy 
2001:17.38%, 2002: 19.51%, 2003: 21.31% 
Sulfonylurea monotherapy: 




Participants were drawn from a diabetes 
registry which covered 20% of the population in 
Portland, Oregon. 
N= 6,318 of incident T2DM cases. 
79.2% were prescribed sulfonylurea monotherapy in 
1988, the proportion dropped to 20.5% in 1997. 
Metformin monotherapy was introduced in 1995. In 
1996 accounted for 7% of prescriptions and in 1997 
increased to 9.8%.  
No drug therapy (diet and exercise) declined, from 




Data were obtained from claims data from a 
pharmacy benefit manager. People were 
included in the analysis if aged 18 to 100 years, 
Participants mean age was 58 years. In 2006: 51% 
were started on metformin, 26.2% were started on a 
sulfonylurea, 20.1% were started on a 
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newly initiated on GLM between 2006 and 
2008.  
N= 254,973 patients. 
thiazolidinedione. In 2008: 65% were started on 
metformin, 18.1% were started on a sulfonylurea, 




Data were drawn from GPRD which links over 
400 practices. The cohort consisted of patients 
(N=67,981) with T2DM from 2000 to 2006.  
Prescription rates per patient-year were 9.6 in 2000 
and 14.8 in 2006. Metformin prescription increased 
across the years, and in 2002 surpassed 
sulfonylureas as the most prescribed. Sulfonylureas 





The cohort (N=20,947) was drawn from two 
primary care reimbursement services pharmacy 
claims database (the general medical services 
scheme and the long-term illness scheme) and 
included people with newly treated (initiated on 
monotherapy, excepting insulin) T2DM aged 40 
years or older from 2008 to 2009. 
The majority of the cohort were male (57.9%).  
Overall, 76% were initiated on metformin, 22% on 





Population-based cohort (N=12,881) from the 
UKCPRD database. People were included if: 
diagnosed with T2DM between 1990 and 2013, 
aged 80 years or older, were prescribed GLM. 
Mean age at diagnosis for the cohort was 83 years. 
The majority were female (61%). Prescription of 
sulfonylureas changed from 94% in the early 1990s to 
29% in 2010s. Prescription of metformin changed 




Cohort (N=5,324) from the UKCPRD database. 
People with T2DM who died between 2011 and 
2013 were sampled.  
The median age was 86 years, 50% female.  
Most patients (78%) received GLM during the last 
year of their life. Metformin and sulfonylureas were the 





Cohort (N=17,527) from Medicare Advantage 
Prescription Drug plan members of Humana 
Inc. health insurance plan. Pharmacy claims 
data of metformin from 2007 to 2012 of people 
aged 18-89 years who were diagnosed with 
T2DM were used. 
Mean age was 69.6 years, 51% were female.  
Most patients (59.4%) had not changed in their 
treatment in 12 months after initiating with metformin. 
One third (33.3%) discontinued, 4.9% added and 




Analysis at GP practice level. Data were drawn 
from the National Diabetes Audit and QOF. 
Overall, the use of metformin increased by 4.4% from 
2015/2016 to 2016/2017. Use of sulfonylureas 
declined 2% for the same period but remained the 
most common treatment (overall) with 62% people 




GLM data were drawn from three databases 
from IMS America: 1) the National Prescription 
Audit, 2) the National Disease and Therapeutic 
Index, and 3) the U.S. Pharmaceutical Market-
Drugstores. 
Tolbutamide: in 1964 accounted for 75% of the 
market. In 1986 10%. 
Chlorpropamide: in 1986 accounted for 33% 
Glyburide: in 1986 29% of prescriptions 




Data from the Disease Analyzer database 
(QuintilesIMS). 
Patients with an initial diagnosis of T2DM  
and available HbA1c values between 2011 and 
2015 were included.  
N= 9,850 
Mean age was 80.7 years, 31.2% were men.  
Prescription patterns differed significantly between 
nursing home and home care settings for metformin 
(46.6% vs 60.5%), insulin (57.9% vs 41.1%), 
sulfonylurea (24.9% vs 34.2%), DPP4 inhibitors 
(13.4% vs 19.8%), and other antihyperglycemic drugs 
(7.8% vs 12.1%). 
 
 






Data of drug utilisation was obtained from 
public healthcare system databases for the 
period 2001-2014. 
Overall, the use of GLM increased by 20.1% in the 
study period. Sulfonylureas use decreased by 45.5%. 
The use of metformin increased and in 2014 




Cohort (N=7,760) from the diabetes registry 
Tyrol. People were analysed if they attended 
one visit (outpatient or inpatient) between 2012 
and 2015. 
Mean age was 65.2 years, 58% were female. 
Metformin was the drug most prescribed; 
monotherapy was used in 16.6% of all patients. 
However, proportions varied according to age. People 
over 60 years of age had fewer prescriptions for 




Data obtained from THIN database which 
includes data from 550 practices throughout the 
UK. Overall, 406 344 people with T2DM were 
included; 203,639 of these were newly 
diagnosed between 2000 and 2013.  
62.6% of people with newly diagnosed T2DM were 
prescribed GLM.  
Prescription of metformin increased from 45.1% in 
2000 to 91% in 2013. Use of sulfonylureas decreased 




Data about oral antidiabetic drugs from 1990 to 
2001 derived from two pharmaceutical 
marketing research databases from IMS Health 
and National Disease and Therapeutic Index. 
Dispensed outpatient prescriptions changed over 
time. Metformin was marketed in 1995 and in 2001 
accounted for 32.7% of prescriptions. 
Sulfonylureas dominated the market in 1990, glipizide 
and glyburide accounted for 77% of prescriptions, and 
by 2001 these accounted for 35.5% of prescriptions.  
 
2.2.2.1.1 Research in the US  
In the US, the study of prescription patterns dates from the 1960s. In that 
decade, tolbutamide was the most frequent medication used. By the 1970s, 
its use had decreased, and in 1986, it accounted for 10% of prescriptions 
while chlorpropamide (a first-generation sulfonylurea) was reported as the 
most frequently used drug for treating what was known as non-insulin 
dependent diabetes at the time. However, the use of second-generation 
sulfonylureas (glyburide and glipizide) was increasing, and by 1990s these 
were the most commonly prescribed medications for glucose control for 
people with T2DM in the US (Kennedy et al., 1988, Wysowski et al., 2003). 
However, it was not until mid-1990s that metformin’s use started to make an 
important contribution to the treatment of T2DM in the US (Brown et al., 
1999), and by 2001 it was estimated to account for almost 33% of 
prescriptions, forming only a slightly smaller proportion than second-
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generation sulfonylureas which had 35.5% of the market (Wysowski et al., 
2003). 
More recent studies have also looked at treatment patterns for people with 
T2DM. Desai et al. (2012) evaluated the use of specific drugs for the initial 
management of T2DM in a cohort of 254,973 patients (of 18 to 100 years of 
age) who initiated oral hypoglycaemic monotherapy between 2006 and 2008. 
They reported that metformin was the most prescribed drug during the study 
period, accounting for 51% to 56% of initial prescriptions in 2006 and 2008 
respectively. However, as they relied on pharmacy claims, it is not possible to 
know why specific medications were prescribed to individual patients. 
Hazel-Fernandez et al. (2015) conducted a historical cohort analysis among 
people aged 18-89 years covered by the US government-sponsored health 
insurance Medicare who were diagnosed with T2DM and initiating metformin 
between 2008 and 2011. A total of 17,527 people were included, the majority 
(59.4%) remained without changes in their drug prescription after 12 months 
of follow-up, it was also reported that increased age, Black race3, and pill 
burden were associated with a decreased hazard of addition of a further 
diabetes treatment. Furthermore, after analysing by prescriber, it was found 
that people were more frequently prescribed metformin in primary care or by 
an internal medicine physician than by an endocrinologist; however, no more 
information about prescribers’ characteristics was provided. 
2.2.2.1.2 Research in Europe 
In Europe, trends in medication use have been studied in countries such as 
Spain, Germany, France, Ireland, and Austria. Here, I will present a summary 
of the main findings of such studies.  
                                            
3 People who participated in Hazel-Fernandez et al’s study were categorised in White, Black and 
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Boyc et al. (2007) examined prescribing trends for GLM from 2001 to 2003 
using a database from the IMS Diseases Analyzer-Mediplus, which contains 
information about patient characteristics, diagnoses, and prescribed 
medication in France. People were included if they were categorised as 
having T2DM, were > 20 years old, and had received at least two 
prescriptions for an oral GLM, a total of 14,281 unique individuals were 
analysed. There was a prescribing trend shifting from sulfonylureas (34.9% to 
29.4%) to metformin monotherapy (17.3% to 21.3%). However, older 
individuals were more likely to receive sulfonylurea monotherapy instead of 
metformin monotherapy.  
Similarly, a retrospective cohort study conducted in Ireland sought to 
describe the utilisation patterns of GLM in people receiving their first 
medication for T2DM; however, no data about disease duration was 
presented. It was reported that 76% started treatment with metformin, and 
22% with a sulfonylurea. Older age was associated with a higher likelihood of 
being prescribed sulfonylurea (Grimes et al., 2014). Lunger et al. (2017) 
reported similar trends in Tyrol, Austria. They described that 85% of people 
with T2DM between 2012 and 2015 received at least one GLM. In general, 
metformin was the most commonly prescribed medication, except for older 
patients (> 60 years). Likewise, a study conducted in the Andalusian region 
in Spain showed that, during 2001-2014, the use of sulfonylureas decreased 
while metformin usage increased (López-Sepúlveda et al., 2017). 
In Germany, Kostev et al. (2018) analysed prescription patterns in people 
with T2DM living in nursing homes and home care settings. Hence, the 
participants were older adults, mean age was 80.7 and 74.8 years old in a 
nursing home and home care, respectively. They reported that, although 
there was no significant difference in the proportions of people with HbA1c 
>58 mmol/mol (7.0%), prescription patterns differed significantly between 
settings. In nursing home settings, insulin was the most common therapy 
(57.9%) while in people living at home, metformin formed the most common 
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treatment (60.5%). Thus, these findings suggest that factors other than 
HbA1c may influence treatment decisions.  
2.2.2.1.3 Studies in the UK 
In the UK, first-line T2DM drug treatment choices have changed over time. 
Similar to what has been reported in the US and other European countries, 
there has been an overall shift from sulfonylureas to metformin. Filion et al. 
(2009) analysed trends in the prescription of GLM among people with T2DM. 
They analysed data for people with T2DM from 2000 to 2006 from the 
General Practice Research Database (GPRD), which was linked to around 
400 general practices in the UK. They selected people with a diagnosis of 
T2DM who were at least 30 years of age at diagnosis; their cohort included 
30,234 people. In general, it was reported that from the year 2000 to 2006 
prescription rates of GLM increased from 9.6 prescriptions/patient-year to 
14.8 prescriptions/patient-year. The absolute increase was greatest for the 
prescription of metformin, which in 2002 surpassed sulfonylureas and 
became the most commonly prescribed GLM.  
A similar study was conducted by Sharma et al. (2016), who investigated 
trends in incident and prevalent diagnoses of T2DM and its pharmacological 
treatment between 2000 and 2013. The cohort consisted of 406,344 people 
with T2DM (> 35 years at the time of diagnosis); data were obtained from 
The Health Improvement Network (THIN) primary care database. The THIN 
database contains medical records from more than 550 general practices in 
the UK. The overall proportion of people receiving a prescription for 
metformin increased markedly from 55.4% in 2000 to 83.6% in 2013, 
whereas the proportion of people receiving a prescription for sulfonylureas 
decreased from 64.8% to 41.4% in 2000 and 2013, respectively. Moreover, a 
sub-cohort analysis, which included 203,639 people with newly diagnosed 
T2DM, showed that the use of metformin increased annually, and in 2013, 
91% of newly diagnosed patients were prescribed metformin as first-line 
treatment. The rapid increase in the prescription of metformin was attributed 
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to HCPs’ adherence to clinical guidelines, although information about choice 
of treatment was not available; likewise, there was no information about 
whether treatment patterns differed between subgroups of patients. 
A more recent study, which looked at the pattern of prescribing of GLMs for 
T2DM in England in 2016/2017, showed that metformin was taken by 51% of 
people with T2DM. The analysis also demonstrated that, as monotherapy or 
combined with other drugs, the proportion of metformin users grew by 4.4% 
compared with 2015/2016. Heald et al. (2018) also noted that the use of 
sulfonylureas declined by 2% between these years. Furthermore, the 
proportions of people prescribed other agents such as SGLT-2 inhibitors and 
the Degludec/Liraglutide combination grew strongly at 70% and 80% per 
annum, respectively. Notably, some older medications such as tolbutamide 
and glibenclamide were still being prescribed in some practices. However, no 
potential explanations for these patterns were provided by the authors (Heald 
et al., 2018). 
So far, these studies have provided insight into prescribing pattens in the UK. 
However, it is worth to note that the duration of T2DM has not been 
considered in the analysis. Hence, it is not possible to know if patterns differ 
among people with newly diagnosed T2DM. 
2.2.2.1.4 Glucose lowering medication for older people with T2DM 
Two studies of GLM prescription, which focused exclusively on older people 
with T2DM, in the UK, were found. Both studies reported the lack of studies 
which could inform treatment decisions for elderly people with T2DM. In 
2015, a population-based cohort was conducted using the UK Clinical 
Practice Research Datalink (CPRD) with the aim to evaluate trends in GLM 
utilisation for people with T2DM diagnosed over 80 years of age. Overall, 
26,230 people with T2DM aged 80 years or older at diagnosis were identified 
between 1990 and 2013. It was reported that 51% did not receive a GLM 
prescription and that people who remained without medication were slightly 
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older than those who received a prescription (median age 84 vs 83 years). 
Moreover, there was a higher proportion of patients with coronary heart 
disease among those who remained without drug prescription than among 
those who received a prescription (32% vs 28%, P<0.001). Among people 
who received GLM prescription from 1990 to 2013, the main drug therapy 
changed from sulfonylureas (94% in the early 1990s to 29% in 2010) to 
metformin (22% to 86%). However, sulfonylureas were more likely to be 
prescribed than metformin to people over 90 years of age. While data for the 
group who did not receive GLM were not analysed, the authors recognised 
that important insights could be obtained from a comparison of people who 
received GLM prescription and those who did not (Hamada and Gulliford, 
2015).  
A UK CPRD study evaluated primary care drug utilisation by people with 
T2DM (>80 years), in their last year of their life, who died between 2011 and 
2013. The selection criteria included people with T2DM who visited their GP 
at least once every three months in the last year of their life. A total of 5,324 
patients were included, with a median age of 86 years and median T2DM 
duration of 10 years. The majority (78%) of people were treated with GLM 
during the last year of their life. Overall, metformin and sulfonylureas were 
the drugs most commonly prescribed. However, in people with decreased 
renal function, metformin was less frequently prescribed. Large proportions of 
people were receiving other drugs such as antihypertensives (76%), and 
statins (62%). This study showed that during their last year of life, older 
people with T2DM received intense pharmacological treatment. However, the 
authors believed that their care might not have been considered as being for 
the end-of-life and acknowledged the need for more research in this field 
(Hamada and Gulliford, 2017).  
The previous sections reviewed prescription patterns and showed that non-
insulin GLM are the most frequent pharmaceutical treatment for diabetes, as 
monotherapy, or in combination alone or with insulin (Boyc et al., 2007, 
 
 
56  Introduction and Background 
 
Sharma et al., 2016, Heald et al., 2018). Moreover, it showed that among the 
elderly, who also often have other health conditions, prescription patterns 
might slightly differ from the ones for younger people with T2DM (Hamada 
and Gulliford, 2015, Hamada and Gulliford, 2017, Kostev et al., 2018). As 
indicated in the aims section of this chapter, due to the lack of research on 
initiation of GLM in people with newly diagnosed T2DM, I broadened the 
search and found an increasing body of literature focusing on clinical inertia. 
This topic, which I present in the following section, provides insights into the 
timing of GLM initiation and factors related to it. 
2.2.2.2 Clinical Inertia 
In recent years, there has been increased interest in clinical inertia in relation 
to T2DM. In the context of T2DM, Strain et al. (2014) defined it as: “a failure 
to initiate or intensify treatment in a timely manner in people with diabetes 
whose health is likely to improve with this intensification”. Thus, clinical inertia 
can occur in people with a recent diagnosis of T2DM due to failure to start 
pharmacological treatment at an appropriate time. For those already 
receiving pharmacological treatment the term relates to lack of treatment 
escalation, either by increasing doses or addition of further drugs (tablets 
and/or insulin) (Strain et al., 2014). However, Khunti and Davies (2017) have 
recently argued that inertia can relate not only to initiating or increasing 
treatment but also to decreasing or halting pharmacological treatment when it 
would be appropriate to do so. They have suggested that clinical inertia 
should be reserved for the lack of adherence to guidelines and introduced a 
new term “therapeutic inertia”, which should be used to describe “failure to 
advance therapy or to de-intensify therapy when appropriate to do so”.  
Most of the studies on clinical inertia in relation to T2DM, both quantitative 
and qualitative, have focused on treatment intensification or initiation of 
insulin for people with T2DM who are already receiving GLM rather than 
initiation among people with recently diagnosed diabetes. Furthermore, it is 
worth noting that many of the studies on clinical inertia have been funded by 
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large pharmaceuticals companies (McEwen et al., 2009, Ruiz-Negrón et al., 
2019, Zhang et al., 2011, Patel et al., 2012, Sinclair et al., 2012, Strain et al., 
2014, Qiu et al., 2015) and that the main focus of such studies are reasons 
and barriers to drug prescription or treatment intensification. Thus, there is a 
lack of evidence about initiation of first-line GLM in newly diagnosed people 
with T2DM. Only four studies were found which focused on clinical inertia in 
the UK, these are presented in table 5. 





Population of study 
Definitions and 
Endpoint 




analysis from the 
CPRD database 
covering the period 
from 2004 to 2006 
with follow up to 
2011 (maximum 
follow up time was 
7.3 years). 
People with T1DM, 
treated with diet only, 
or insulin only were 




points: 1) HbA1c > 
53mmol/mol 2) 





Time between being 
in poor control and 
treatment 
intensification 
Mean baseline HbA1c was 68 mmol/mol, 73 
mmol/mol, and 75 mmol/mol in people taking 
one, two, or three GLMs, respectively.  
Mean age at diagnosis was 62.6 years, 61.5 
years and 59 years for people taking one, 
two, or three GLMs, respectively. 
In people with HbA1c >53 mmol/mol taking 
one agent, median time to intensification with 
an additional oral agent was 2.9 years, 
median time to intensification with insulin 
was .7.2 years. Median time to insulin 
intensification in people with HbA1c >53 
mmol/mol taking two or three OADs was 7.2 
and .7.1 years, respectively 
2 Khunti, 
2016 
Cohort (N=11,696) of 
people >18 years 
with T2DM. data 
were extracted from 
the UKCPRD. 
Participants were 
included if they had 
started basal insulin 
between 2004 and 
2011, with follow up 
on 2013. 
Poor glycaemic 
control was defined 
as a recording of 
HbA1c ≥58 











Mean age was 65.5 years, 55.7% were men. 
Mean duration of T2DM was 8.2 years. For 
those who received treatment intensification 
mean age was 61.3 years, mean duration of 
diabetes 7.7 years. 
From all patients, 36.5% had their treatment 
intensified. Median time from initiation of 
basal insulin to intensification with either 
bolus or premix insulin or GLP-1 was 4.3 
years regardless of HbA1c. 
Increasing age and duration of T2DM were 
associated with longer time to intensification. 
Increasing BMI was associated with shorter 
time to intensification. 30.9% of people with 
poor glycaemic control had their treatment 
intensified. The median time was 3.7 years. 
 
 








data from the UK, 
France, Germany, 
Italy, Spain, and the 
US). 
Data of people with 
T2DM (N=40,627) 
initiating basal insulin 
with or without oral 
GLM from 2008 to 
2012, aged 30 years 
or older were 
included in the 
analysis 
Target achievement 








and risk of 
hypoglycaemia. 
Mean age was 63.3 years.  
More than half (62.9%) of patients in the UK 
initiated basal insulin with very high HbA1c 
(>75 mmol/mol). 
 
Overall, compared with those who achieved 
an HbA1c <53 mmol/mol three months after 
starting basal insulin, people with HbA1c >53 
mmol/mol three months after basal insulin 
initiation were more likely to not reach the 









2002 and 2011. 
Data derived from 
SCI-diabetes.  
Poor glycaemic 
control by three cut-
off points: >7%, 
>8% and >9% 
HbA1c. 
Endpoint: time from 
diagnosis to insulin 
prescription and 
time with poor 
glycaemic control. 
Median age at time of insulin prescription 
was 63 years. Median time to insulin 
prescription was 73 months after diagnosis, 
HbA1c at prescription was 10%. Moreover, 
median time until insulin prescription with 
sub-optimal HbA1c was: 49 months for 
HbA1c >7%, 25 months for HbA1c >8%, and 
10 months for HbA1c >9%. 
 
Overall, studies focusing on treatment intensification or escalation have 
reported evidence of delays in treatment intensification for people with T2DM 
with sub-optimal glycaemic control (Khunti et al., 2013, Mauricio et al., 2016, 
Zografou et al., 2014, Khunti et al., 2016). Mauricio et al. (2016) analysed 
electronic medical records in France, Germany, Italy, Spain, the UK, and the 
US in insulin naïve people >30 years of age with T2DM initiating basal insulin 
analogues (insulin preparation that mimics physiological insulin) with or 
without oral glucose-lowering drugs. They reported that most patients started 
basal insulin when they had very high HbA1c levels >75 mmol/mol (9%). 
Mean HbA1c at the time of basal insulin initiation range from 69 mmol/mol in 
Germany to 85 mmol/mol (9.9%) in the UK (Mauricio et al., 2016). 
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Similarly, research conducted in the UK by Khunti et al. (2013) showed a 
delay in treatment intensification in people with T2DM with sub-optimal 
glycaemic control. Patients who received treatment intensification, by 
addition of further oral antidiabetic drugs or insulin initiation, had a mean 
HbA1c of 9.4 +2.3%. However, it is important to note that this study did not 
take patients’ clinical characteristics into account and based their analysis 
mainly on HbA1c levels. Hence, the analysis carried out did not include 
important covariates such as age, BMI or comorbidities that may have 
influenced decisions about treatment intensification (Khunti et al., 2013). 
Although treatment intensification is out of the scope of this PhD, the 
literature about clinical and therapeutic inertia provided insight about aspects 
related to prescription of GLM in people with T2DM, and highlighted the need 
for considering variables other than HbA1c.  
2.2.2.3 Management for newly diagnosed people with T2DM 
As previously mentioned, a large proportion of research identified from the 
literature search has focused mainly on treatment trends and intensification 
of treatment among people already receiving monotherapy for the treatment 
of T2DM. However, some studies (see table 6) have been carried out which 
have looked at treatment initiation in people with newly diagnosed T2DM. 
These studies will be summarised in this sub-section. 
Table 6. Articles found in the search which focused on newly 





Population of study Main outcome of interest 
1 Chung,  
2015 
US 
Data extracted from EpicCare group 
practice with approximately 100 
physicians in northern California. 
People (N=2,258) were included in the 
analysis if were diagnosed with T2DM, 
aged 35 years or older, not having a 
record of being diagnosed as T1DM, 
not pregnant during 2007-2010. People 
Mean age was 56.9 years, 57% were male. 
Mean baseline HbA1c was 7.3%. 
55% of patients were treated with either GLM 
or education/counselling during the first year of 
follow up. Amongst those who initiated 
treatment, 46% did it in the first week, 68% in 
the first month of diagnosis. 
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without a diagnosis but who had 
evidence of having received GLM were 
not included as well as those with 
active cancer of serious kidney or liver 
disease. 
Metformin was prescribed to 87% of those who 
received GLM prescription. 
Compared with people who did not receive 
treatment, those who did were more likely to be 
young, obese, have higher levels of glucose, 




Cross-sectional study of 7,870 people 
with diabetes in 2003 across 42 
practices in the Trent region.  
65.7% were treated with GLM, and 34.3% 
(2,700) did not have recorded drug 
prescription. Compared with those who 
received a prescription, people treated by diet 
only were significantly less likely to have as 
many records of measurements of HbA1c, 
cholesterol, blood pressure, BMI, and other 




Cohort of people with newly diagnosed 
T2DM (N=1,158) between 2009 and 
2014 and who were followed up for 365 
days. Data extracted from a nationwide 
DD2 cohort. 
Overall, 57% were men, 66% enrolled from 
hospital outpatient clinics. 26% did not receive 
GLM during the first year after diagnosis, 62% 
received monotherapy, and 12% combination 





Participants data (N=5,804) were 
obtained from 12 outpatient practices in 
Massachusetts from the period 
between 2005 and 2006 
Disease progression was defined as HbA1c 
>7% or treatment initiation. 
The multivariate analysis showed that baseline 
HbA1c and younger age were the major 
independent predictors of disease progression. 
Each decade of age reduced the risk of 




The cohort was drawn from the IMS 
MediPlus database. People >30 years 
with newly diagnosed T2DM during the 
period of 2003 to 2005 and who were 
followed up for at least two years were 
included in the analysis.  
Mean age was 62.4 years, 54% were men. 
36%, 42%, and 51% of participants initiated 





Data were drawn from 17 GP practices 
in a middle-sized town. People with 
newly diagnosed T2DM from 1994 to 
2000 were included in the analysis 
(N=603). 
Mean age was 62 years, 43.4% were men.  
Overall, 53% started GLM in the first month 
after diagnosis. Three years after diagnosis 




Cohort study used the GE Healthcare’s 
Clinical Data Services electronic 
medical record dataset. People with 
newly diagnosed T2DM between 2004 
and 2005 were included in the analysis 
(N=2,254) 
Mean age was 58 years, 58% were men. 
Over two years of follow up, 66.1% initiated 
oral GLM. The median time to treatment 
initiation was three months. 





The cohort was drawn from the GE 
Healthcare’s Clinical Data Services 
electronic medical record. 
Mean age at diagnosis was 52 years for people 
<65 years, and 73 for those >65 years of age.  
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People with newly diagnosed T2DM 
between 2003 and 2005, of at least 30 
years of age, whose data was available 
two years before and after diagnosis 
were included in the study (N=10,743). 
Time to treatment initiation was longer for older 
patients compared with younger patients (HR: 
0.82; CI: 0.75-0.90). 
 
A study conducted in The Netherlands by Spoelstra et al. (2004) aimed to 
investigate which factors determined the initiation of GLM in people with 
T2DM in general practice. In total, 603 people with T2DM diagnosed from 
1994 to 2000 were included in the analysis, 53% were prescribed GLM at 
diagnosis; after three years of follow-up, 81% had received drug prescription. 
The Kaplan-Meier curves showed a tendency for men to start treatment 
sooner after diagnosis than women; however, this difference was not 
statistically significant. The initiation of GLM was strongly related to baseline 
glucose levels. However, this study has the limitation that only 66% of 
participants had recorded blood glucose values. Furthermore, the authors 
stated that GPs’ reasons for prescribing or following guidelines is unclear 
(Spoelstra et al., 2004), which highlights the need for research to focus on 
clinical decision-making. 
In Denmark, Mor et al. (2015) conducted a cohort study with the aim to 
examine prescribing practices and predictors of glucose-lowering therapy 
within the first year following diagnosis of T2DM. Participants were selected if 
they had been recently diagnosed with T2DM and followed up for 365 days. 
Data from 1,158 people recently diagnosed with T2DM were included. 
Overall, 57% (659) of the patients were men. During the first year of 
diagnosis, 26% (302) did not receive GLM, 62% (723) received monotherapy 
and 12% (133) received combination therapy. The likelihood of receiving 
GLM was higher for people <40 years old (adjusted RR: 1.29; CI:1.16-1.44) 
and those aged 40-59 years old (adjusted RR: 1.16; CI:1.08-1.24) compared 
with those >60 years. Similarly, patients who had a high baseline blood 
glucose were more likely to receive GLM (>59 mmol/mol, adjusted RR: 1.25; 
CI: 1.10-1.42), compared with those <48 mmol/mol. An important observation 
 
 
62  Introduction and Background 
 
is that 66% of participants had been enrolled from hospital outpatient clinics 
which may indicate more advanced T2DM. 
A similar study was conducted in the UK by Hippisley-Cox and Pringle 
(2004). In 2003, a cross-sectional study was conducted in order to establish 
the proportion of patients with T2DM treated by diet only and the inter-
practice variation in the use of medications. Data were provided by 42 
practices in the Trent region. People registered as having T2DM and who 
were at least 35 years old were included in the study. Overall, 7,870 patients 
with T2DM were identified, 65.7% (5,170) were treated with GLM, and 34.3% 
(2,700) who did not have recorded drug prescription were assumed to be 
treated with “diet only”. Compared to those receiving medication, people 
treated by diet only were reported to be significantly less likely to have as 
many records of measurements of HbA1c, cholesterol, blood pressure, BMI, 
and other clinical care data. These results remained significant after 
adjustment for age, sex, deprivation, and the general practice where they 
were registered. Similarly, people treated with diet only were less likely to be 
referred to a dietician, a podiatrist or chiropodist than those who received a 
drug prescription (Hippisley-Cox and Pringle, 2004). The authors concluded 
that there was substantial variation between practices in the management of 
T2DM and that routine surveillance could be improved. The author’s 
emphasis on variation between clinicians is in line with Spoelstra et al’s 
conclusion, thus this study also emphasises the need for studying clinical 
decision-making. However, it must be considered that this study was 
conducted before the implementation of QOF, which sought to improve the 
quality of diabetes care and that prescribing patterns may have changed after 
the study was conducted. 
In order to assess the association between patient age and initiation of GLM 
initiation following the diagnosis of T2DM, Sinclair et al. (2012) conducted a 
cohort analysis using the Intercontinental Medical Statistics MediPlus 
database in the UK. Participants were included if they were newly diagnosed 
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and at least 30 years old. The status of “newly diagnosed” was defined as no 
prior diagnosis of T2DM, no prescription for GLM in the previous 12 months 
before diagnosis and follow-up for two years after diagnosis. Between 2003 
and 2005, 11,543 people were identified as newly diagnosed with T2DM, 
mean age was 62.4 years, and 54% were male. Overall, 36%, 42%, and 51% 
of participants initiated GLM within 180 days, one year, and 2 years of 
diagnosis. Metformin was the drug most commonly prescribed as first 
treatment (76%), followed by sulfonylureas (19%), and insulin (4%). In 
addition, differences were found in time to drug treatment initiation and the 
choice of the first-line drug. In this instance, the use of metformin decreased 
with increasing age, and the use of sulfonylureas increased with a patient’s 
age. Similarly, the proportion of people with GLM prescription was lower 
among older than younger people, though, the effect of age was reduced in 
people with higher baseline HbA1c. However, it is worth noting that HbA1c 
measurements were only available for 55% of the cohort and that further 
patients’ characteristics such as BMI and socioeconomic data were not 
included in the analysis (Sinclair et al., 2012). Similar to previous studies in 
this section, the need to conduct further research to better understand the 
differences in prescription patterns, particularly among young and old people 
with newly diagnosed T2DM, was identified. 
Some similar studies have been conducted in the US. A cohort analysis, 
including people diagnosed with T2DM in 2004/2005 who were at least 18 
years old, and who were followed-up for one year reported clinical predictors 
of GLM initiation after one year. After adjusting for race, sex, and weight 
change, the likelihood of drug initiation decreased by 40% with every decade 
of age (Pani et al., 2008). Likewise, Sun et al. (2013) carried out a cohort 
analysis of people with T2DM diagnosed in 2004-2005 who were followed-up 
for at least 2 years and who were eligible for statin therapy based on ADA 
recommendations in 2008. Data for 2,254 patients were analysed; after two 
years, 66.1% were initiated on GLM, the median time to drug treatment 
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initiation was three months (Sun et al., 2013). Similarly, results from Zhang et 
al. (2012) who conducted a retrospective cohort study of people with newly 
diagnosed T2DM of at least 30 years of age, and who were followed-up for at 
least two years, revealed variations in time to drug prescription. Overall, 
10,743 people were included; however, data on baseline HbA1c were 
available for only 5,600 (52.1%). Older patients had longer time to GLM 
initiation than younger patients did. Moreover, at diagnosis, 25% of patients 
<65 years initiated drug treatment while only 15% of people > 65 years did. In 
general, the proportions of people initiating GLM increased as HbA1c 
increased, other factors associated with increased likelihood of initiating drug 
therapy included higher BMI, and the use of lipid-lowering medication. 
Moreover, the authors explained that reasons for not prescribing were not 
included in their database (Zhang et al., 2012).  
In addition, Chung et al. (2015) examined patterns and predictors of initiation 
of treatment for incident diabetes in an ambulatory care setting in the US 
from 2007 to 2010. Data from 2,258 people of at least 35 years old, with 
newly diagnosed T2DM were analysed. Mean age was 56.9 years and 57% 
were male. Most patients (55.1%, n=1,244) had recorded treatment in the 
first 12 months of diagnosis; 20% received medication only, 19.8% received 
medication and education/ counselling and 15.3% received education/ 
counselling only. The Kaplan-Meier cumulative hazard estimates showed that 
among those who received treatment of any kind, it occurred quickly. 
Amongst those who received treatment 46% (570) did so in the first week, 
and within the first month, 68% (840) had already initiated treatment. 
Moreover, the majority of those who received medication, the prescription 
was metformin (87%). The bivariate analysis of people with and without 
treatment showed that those who received treatment of any kind were 
younger (53.9+12.2 years vs, 60.6+15.0 years, p <0.001), less likely to be 
female (39.6% vs 47.5), more likely to be categorised as obese (45% vs 
33.3%, p <0.001), more likely to have higher HbA1c levels (7.9% +2.0 vs. 
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6.4% +0.6, p <0.001). An important aspect to take into consideration is that 
people were considered to have received education/counselling based on 
attendance data and not solely on physician referral thus data may not reflect 
the real proportions of counselling/education prescriptions (Chung et al., 
2015). 
2.2.3 Section summary  
This sub-section has provided a summary of the literature relating to glucose-
lowering prescriptions patterns and the factors associated with glucose-
lowering treatment initiation in people with T2DM. Sub-section 2.2.2.1 has 
shown that over the years, there has been a general shift from sulfonylureas 
to metformin as first-line GLM in both older and younger populations. The 
studies presented provided interesting findings; however, few studies 
investigated patient characteristics that may influence prescription patterns. 
Sub-section 2.2.2.2 presented two relatively new concepts, clinical inertia 
and therapeutic inertia, both of which relate to pharmacological management. 
The studies have found that overall, there is a delay in treatment 
intensification; however, treatment initiation and the analysis of clinical 
variables other than HbA1c need to be considered. Sub-section, 2.2.2.3, 
provided insights about disease management in people with newly diagnosed 
T2DM. The studies presented in this sub-section demonstrated that although 
HbA1c was an important factor for the initiation of GLM, other aspects such 
as age played a role. However, it is important to consider that most of the 
studies reported high proportions of missing data and the need for studying 
clinical decision-making in people with newly diagnosed T2DM.  
Thus, metformin is currently the medication most commonly prescribed as 
fist-line agent and, time to prescription differs according to patients’ 
characteristics. In the UK, the study which most recently looked at time to 
drug prescription used the period of 2003 to 2005 (Sinclair et al., 2012); it is 
not clear whether the introduction of QOF may have influenced time to first 
GLM after diagnosis of T2DM. Moreover, as reported by the studies 
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presented in the last sub-section, HCPs reasons when deciding when to 
prescribe and the factors that they consider when prescribing remain unclear. 
Hence, I conducted a literature review of studies of early treatment of T2DM 
from the HCPs’ perspectives. However, due to the dearth of qualitative 
literature on initiation of GLM I will provide a broader review of the literature. 
A summary of the studies identified is presented in the following sections. 
2.3 Section 2: HCPs’ perspectives and experiences in 
the management of T2DM and clinical decision-
making. 
By conducting an additional search, I sought to gather information about 
qualitative research, which had looked at HCPs’ experiences, views and 
attitudes with regards to diabetes care, particularly on clinical decision-
making regarding the initiation of GLM in people with T2DM. However, there 
was no qualitative literature which specifically focused on this topic. 
Therefore, I broadened the search to include literature that looked at 
treatment decision-making amongst HCPs in primary care for people with 
T2DM more generally. 
Hence, the qualitative literature review included aspects that HCPs’ consider 
and take into account to inform their decisions; for instance, their perceptions 
about patients, organisational factors such as workforce, time constraints, 
and HCPs’ experiences and views on clinical guidelines. These aspects led 
me to include a sub-section on patient-centred care because, as I will 
describe later, HCPs’ sometimes perceived that organisational factors 
conflicted with tailored care. Furthermore, this review also helped me to 
develop a topic guide and refine the research questions for this PhD. 
2.3.1 Methods 
In a similar way to the previous section 2.2, a priori eligibility criteria were 
established, these criteria were determined after an initial review which 
explored the topic. 
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2.3.1.1 Eligibility criteria  
2.3.1.1.1 Inclusion criteria 
1. Qualitative articles which focused on the management of T2DM from 
HCPs’ perspectives, no geographical limitation. 
2. Qualitative articles focused on HCPs’ views on clinical guidelines for 
T2DM, or on guidelines in a general way (not focused on any disease 
or condition). 
2.3.1.1.2 Exclusion Criteria 
1. Quantitative studies that surveyed HCPs on hypothetical cases. 
2. Articles that focused on medication adherence and compliance. 
3. Articles that focused on guidelines for specific diseases other than 
T2DM. 
4. Articles not available full-text 
5. Articles not published in English. 
2.3.1.2 Information sources and search strategy 
The literature search was conducted in three electronic databases: Excerpta 
Medica Database (EMBASE), Medline via PubMed and Scopus. The 
complete list of the search terms employed for each database is available in 
appendix 1B.  
2.3.1.3 Selection process  
The software EndNote X9 was used to manage records and identify duplicate 
studies. The selection process was performed, according to the a priori 
inclusion and exclusion criteria, in three main stages: 1) all retrieved articles 
were screened by their study title. 2) abstracts from all selected articles in the 
first stage were read to determine their relevance. 3) full-text of all those 
articles considered potentially eligible were read to determine their relevance 
according to the inclusion criteria. In figure 2 is presented the review process 
concerning this section of the literature review. Specific details of full-text 
articles which were evaluated and not considered for this review are 
presented in appendix 2B. 
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2.3.2 Findings 
A total of 28 articles were included in this section of the literature review. The 
narrative review of the articles included is presented as follows: 
 Sub-section 2.3.2.1 Management of type 2 diabetes in primary care: 
HCPS’ perspectives 
 Sub-section 2.3.2.2 Attitudes, experiences and views on clinical 
guidelines which include patient-centred care which and pay for 
performance schemes. 
All the above themes were intertwined and many of the articles found 
covered various sub-themes. Contrary to the quantitative review where a 
summary of the studies included was presented in a table format, the 
qualitative review will only provide, through the two main sub-sections, a 
narrative summary of the papers. 
Assessment of study quality 
Even when studies are not to be excluded based on quality, assessment of 
the methodological strengths and limitations is important. For qualitative 
studies, the focus of the appraisal should be the study methodological rigour 
rather than the risk of bias (Noyes et al., 2019). The Cochrane handbook 
states that more than 100 appraisal tools for qualitative studies are available 
(Noyes et al., 2019). However, it recognises that many do not focus on the 
study rigour. One tool that it is recognised and recommended is the CASP 
tool for qualitative research (Noyes et al., 2019, Critical Appraisal Skills 
Programme, 2018). Therefore, articles selected were appraised using the 
CASP checklist for qualitative research. This tool includes 10 questions (see 
appendix 3B); however, the first two questions are considered screening 
questions which, if answered yes to both, indicate that it is worth proceeding 
with the remaining eight. Each question can be answered with a ‘yes’, ‘no’, or 
‘can’t tell’, for this review, if the answer to a question was ‘yes’ one point was 
added to their score; thus, 10 is the maximum score possible for any article. 
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Below, table 7 presents a summary of the score of each article included in 
the qualitative review.  
Table 7. Summary of quality appraisal of qualitative studies 
No First author Year Score No First author Year Score 
1 Al-Alawi 2019 9/10 15 Luijks 2015 8/10 
2 Alexander 2016 8/10 16 Mayer 1999 7/10 
3 Aujoulat 2015 8/10 17 McDonald 2008 10/10 
4 Baynouna 2018 6/10 18 McDonald 2007 9/10 
5 Brown  2002 5/10 19 Milos 2014 8/10 
6 Carlsen  2008 8/10 20 Noor Abdulhadi 2013 9/10 
7 Daniels 2001 5/10 21 Patel 2012 8/10 
8 Gabbay and May 2004 9/10 22 Pather 2019 9/10 
9 Hunt 2012 7/10 23 Pooley 2001 7/10 
10 Ingemansson 2014 7/10 24 Proser and Walley 2007 8/10 
11 Kinnuen-Amoroso 2013 7/10 25 Radwan 2018 9/10 
12 Lawton  2016 9/10 26 Sola 2014 8/10 
13 Le  2015 8/10 27 Tracy 2003 7/10 
14 Lee 2012 9/10 28 Zafar 2015 8/10 
 
2.3.2.1 Management of type 2 diabetes in primary care: HCPS’ 
perspectives 
As described in the previous chapter, most T2DM care and management in 
Scotland and the rest of the UK is now done in primary care. Therefore, 
HCPs working in these settings play an important role in T2DM management; 
they are responsible for pharmacological treatment choices and time to 
initiation for most people with T2DM (Saudek, 2002). However, as I will 
describe in this section which explores HCPs’ views about and experiences 
of managing people with T2DM, clinical decision-making is the result of at 
least three interrelated or intertwined dimensions: patients, HCPs and the 
healthcare system itself. 
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2.3.2.1.1 HCPs’ perspectives on the influence of patient-related factors on 
treatment choices 
Based on 26 semi-structured interviews, which explored the experiences of 
doctors and nurses, who worked in diabetes care at primary healthcare 
centres in Oman, of their encounters with patients with T2DM, Noor 
Abdulhadi et al. (2013) argued that patients’ attitudes and characteristics 
appeared to have an important influence on treatment approaches and 
outcomes. The HCPs who participated in this study regarded the elderly and 
people with low educational levels as amongst the most “difficult” patients. In 
general, these patients were perceived as having generalised difficulty in 
modifying lifestyle habits. Likewise, religious patients who believed that 
diseases came from God who decided their fate were perceived to be less 
likely to want or be able to change their lifestyle and follow medical advice 
and thus, were considered less likely to manage their disease effectively. 
Barriers to optimal diabetes care, from the HCPs’ perspectives, were mostly 
related to attitudes generated by patients’ behaviour. HCPs expressed 
frustration due to unsuccessful efforts to improve patients’ health, 
discussions with some patients were considered useless, and thus they 
preferred to only focus on the disease by acting as disease-oriented doctors 
and avoiding asking personal details “No, I did not ask about any personal 
details, what is the use of that. She never follows any instructions. I focused 
only on her medical condition and that it is.”(Noor Abdulhadi et al., 2013, p. 
263). However, the authors also found that some HCPs could not speak 
Arabic, which is the language most commonly spoken by their patients who 
often cannot speak English. HCPs’ inability to speak their patients’ language 
made necessary the assistance of other HCP or family members. This 
situation led HCPs to focus only on their medical condition and clinical 
information and to avoid deep discussions with their patients (Noor Abdulhadi 
et al., 2013).  
Similarly, Al-Alawi et al. (2019) conducted semi-structured interviews with 
HCPs responsible for providing diabetes care at primary healthcare centres 
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in Oman. HCPs perceived the cultural beliefs and traditions of people with 
T2DM as influencing their behaviour regarding T2DM management. For 
instance, HCPs suggested that their patients followed other people’s advice, 
such as family and friends, instead of their own. This situation was described 
as causing patients to not attend their appointments to monitor their diabetes 
and generating disbelief about the information HCPs provided. Likewise, 
Brown et al. (2002) conducted focus groups with 36 physicians in Canada to 
explore issues and perceptions regarding the management of people with 
T2DM. The authors reported that patient’s attitudes such as passivity or 
unrealistic perspectives were seen as barriers to optimal T2DM 
management. Conversely, the ability to assume responsibility for their 
diabetes was described as a facilitator. However, it was pointed out that 
sometimes the motivation to change was frequently triggered by major health 
events such as the fear of receiving insulin. 
Furthermore, Pooley et al. (2001) interviewed people with T2DM and HCPs 
who delivered diabetes care in England to explore the issues they perceived 
as central to effective management of diabetes in primary care. The authors 
reported that, although in general patients’ and HCPs’ concerns were similar, 
HCPs who participated in their study were more concerned about patients’ 
compliance with recommendations than with establishing a management 
plan in collaboration with the patient. However, HCPs identified time 
constraints as a barrier to delivering patient-centred consultations, 
particularly when they were not familiar with the patient due to lack of 
continuity of care. Nevertheless, it is important to consider that this study was 
conducted several years ago and since then changes in the healthcare 
system have occurred. 
Aujoulat et al. (2015), who conducted group interviews with GPs in Belgium 
to elucidate beliefs about clinical inertia and to identify modifiable provider-
related factors associated with clinical inertia, reported that from the HCPs’ 
perspective, patients’ attitudes such as perceived aggressiveness, poor 
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adherence to treatment recommendations, refusal of pharmacological 
treatment (i.e. insulin) or denying their medical needs created a general 
feeling of dissatisfaction and powerlessness amongst them. These perceived 
feelings were reported by the authors as being related to the delay of 
pharmacological treatment initiation and clinical inertia (Aujoulat et al., 2015). 
While the study focused on experiences with insulin, these findings highlight 
the fact that HCPs’ perceptions of patients’ attitudes may influence their 
decisions about T2DM management. However, it must be acknowledged that 
no individual interviews were conducted, thus, the results reported might not 
fully reflect the experiences of all GPs who participated in the study. 
As mentioned above, no studies were identified that focused on treatment 
initiation in people with newly diagnosed T2DM. In contrast, insulin initiation 
has received more attention. However, since insulin initiation relates to 
clinical decision-making, the most relevant literature is presented in this 
section. In this respect, HCPs have generally expressed the view that 
decisions about insulin initiation are strongly influenced by patient-related 
factors. For instance, Lee et al. (2012) conducted semi-structured interviews 
and focus groups with HCPs who provided diabetes care in Malaysia with the 
aim of identifying barriers to insulin initiation from HCPs’ perspectives. HCPs 
reported that a common perception among patients was that insulin is the 
cause of severe complications, and some patients considered insulin 
initiation as a punishment, which increased patients’ fear of starting on 
insulin. Thus, HCPs’ perceptions of patients’ beliefs may hinder optimal 
diabetes treatment; in this instance, by delaying timely initiation of insulin 
therapy. 
Similar findings were reported in a qualitative study carried out in the UK by 
Patel et al. (2012). The authors sought to explore barriers to prescribing of 
insulin, particularly delays to initiation, from the perspective of HCPs involved 
in managing T2DM in a multi-ethnic setting. Semi-structured interviews were 
conducted with HCPs from primary and secondary care. Overall, most 
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barriers were attributed to patients, with “psychological insulin resistance” 
being regarded as very common, regardless of ethnicity. Moreover, there 
was a perception that South Asian patients were more likely to be negatively 
influenced and feel stigmatised of having diabetes by other people’s 
comments. The stigma of having T2DM usually led patients to avoid or wish 
to discontinue certain treatments such as insulin therapy “One person’s 
neighbour comes: ‘Oh why are you taking insulin, I’m fine with my tablets, my 
doctor gave me new tablets’. They’ll come back: ‘Doctor, I don’t want insulin, 
my neighbour is taking this’. There are a lot of such issues”. (Patel et al., 
2012, p1313). However, the study was conducted in an area in the UK with a 
high number of people from South Asia, hence the findings might not reflect 
the experience of HCPs in Scotland.  
In general, these studies recognise the complexity of treatment decision-
making in people with T2DM. For instance, Pooley et al. (2001) highlighted 
that patients’ attitudes and behaviour influence HCPs’ decisions and may 
delay treatment initiation. Similarly, Noor Abdulhadi et al. (2013) observed 
that other patient-related aspects, such as the perceptions of patients’ health 
literacy may influence HCPs decisions about treatment decision-making as 
such patients were often perceived as less likely to follow medical advice. 
Moreover, HCPs recognised the need for a patient-centred holistic approach, 
however, they acknowledged that such approach requires extensive 
communication and time (Al-Alawi et al., 2019, Pooley et al., 2001, Noor 
Abdulhadi et al., 2013).  
The aspects reported so far, related to patients, are not the only ones 
reported as influencing clinical decision-making, as I will describe in the 
following sections, HCPs-related and organisational factors were perceived 
as also influencing HCPs clinical decision-making about treatment for T2DM.  
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2.3.2.1.2 Healthcare professional-related factors 
HCPs in the study by Noor Abdulhadi et al. (2013) indicated that sometimes 
their own attitudes could influence patients’ views and feelings about 
medication to control their diabetes. For instance, some HCPs acknowledged 
aggression towards non-adherent patients and referred to, sometimes having 
attempted to frighten them with the threat of potential complications if they 
continued to be non-adherent. However, some mentioned that using a 
friendly approach with patients was a better strategy as it helped create trust 
and confidence. Therefore, a lack of good communication skills was seen by 
HCPs as a barrier to optimal diabetes care. In addition, some HCPs reported 
that avoiding deep discussions or social talk with patients and focusing only 
on the current medical condition was a result of the lack of good 
communication skills (Noor Abdulhadi et al., 2013). Likewise, additional 
research conducted in Oman by Al-Alawi et al. (2019) described different 
perspectives and experiences from HCPs in relation to the challenges and 
opportunities for service improvement in diabetes care in primary care. The 
study included observations of their daily practice and interviews with 
physicians, nurses, dieticians, health educators, pharmacists, a psychologist 
and a medical orderly. While these HCPs also described being frustrated by 
their patients’ attitudes and behaviours, they indicated that good 
communication with patients is necessary to achieve optimal care (Al-Alawi 
et al., 2019). 
Similarly, Lee et al. (2012), interviewed HCPs working in government clinics, 
university-based primary care clinics and hospital and private GP clinics and 
hospitals in Malaysia, and reported HCP-related barriers to insulin initiation. 
These barriers included HCPs’ perceptions of patients’ negative attitudes and 
their perceived lack of motivation. However, according to participants, these 
negative attitudes were the result of patients’ unwillingness to modify their 
habits or adhere to treatment. Furthermore, lack of confidence was 
mentioned by some HCPs who considered themselves to be unfamiliar with 
some aspects of insulin treatment and who considered that insulin initiation 
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should be done in hospitals or specialised clinics. Likewise, HCPs in Brown 
et al. (2002) study pointed out the need for ongoing medical education in 
order to develop the skillset that would allow them to manage people T2DM 
comfortably. 
The non-specialist role of HCPs was also pointed out by Zafar et al. (2015), 
who interviewed HCPs (19 GPs and one nurse) working in primary care in 
the UK. All interviewees were reported as having a leading role in diabetes 
management at their practices. Some of the HCPs interviewed reported that 
their limited expertise in T2DM management could contribute to clinical 
inertia. HCPs’ suggested that the lack of expertise was caused by the shift in 
diabetes management from secondary to primary care (Zafar et al., 2015). 
This leads us to the next important component influencing treatment 
decision-making: organisational factors. 
2.3.2.1.3 Organisational factors 
These factors relate to the healthcare system and the organisation of 
healthcare; primarily to time constraints and the nature of the workforce. In 
the study conducted by Noor Abdulhadi et al. (2013), which was described 
above, HCPs (doctors and nurses) considered counselling patients to be a 
fundamental but time-consuming task, which HCPs often reported to be 
hindered by their high workload and lack of time. For instance, some HCPs 
suggested that their workload was a barrier to providing optimal diabetes 
care and that short consultation length affected their interactions with 
patients. Furthermore, some HCPs believed that a shortage of well-trained or 
qualified personnel increased their already high workloads (Noor Abdulhadi 
et al., 2013).  
Pooley et al. (2001) reported that a common view held by HCPs working in 
primary care in England was that lack of time underpinned many issues. For 
instance, lack of time during consultations was perceived as limiting the 
exchange of complex information, and the delivery of a patient-centred 
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approach “Diabetic patients do need time, and that’s the hard thing really- 
fitting them in anywhere… people don’t understand how much time we 
actually spend with patients.”(Pooley et al., 2001, p.321). Since the 
experience of living with diabetes is highly variable for each patient, HCPs 
recognised the need for tailored care; however, lack of time and resources 
was described as restricting them from doing this. Likewise, high-quality 
consultations were seen as difficult to achieve due to time constraints, which 
challenged good communication with patients, as HCPs lacked time to give 
information to patients or to answer their questions. Many HCPs identified a 
constant conflict between the service they would like to be able to provide 
and the care that was possible to give. Hence, a patient-centred approach 
was considered the area most difficult to deliver as it required lengthy and 
repeated consultations (Pooley et al., 2001). 
Alongside consultation length, lack of staff continuity has been highlighted by 
HCPs as a barrier to good communication with patients which may lead to 
inadequate consultations with HCPs feeling unable to address patients’ 
needs. Lack of continuity has been reported by HCPs as potentially affecting 
the initiation of certain treatments, such as insulin, because they perceive 
that not being able to maintain follow-up of their patients makes more difficult 
for them to assess effectively patients’ needs, concerns and circumstances 
(Lee et al., 2012, Pooley et al., 2001). Lack of continuity of care was also 
described as creating communication problems as it becomes difficult to be 
familiar with patients’ circumstances and to deal with patients’ concerns 
effectively (Pooley et al., 2001). Equally, Lee et al. (2012) reported that 
physicians in their study believed that they were unable to maintain the 
follow-up of their patients due to lack of continuity of care. However, HCPs 
also described that sometimes the inability to provide continuity of care 
relates to other healthcare system-related barriers, such as lack of personnel 
(Lee et al., 2012). 
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In addition, limited availability of educational materials, and language barriers 
among people from different ethnic and linguistic backgrounds have been 
described as factors affecting effective communication with patients and 
optimal disease management (Daniels et al., 2001, Lee et al., 2012, Al-Alawi 
et al., 2019). Milos et al. (2014) conducted focus groups with GPs in primary 
care in Sweden and reported that some GPs considered that educational 
materials with patient-adapted information about guidelines would benefit the 
patient-doctor relationship by creating a dialogue about the treatment 
approach. Thus, evidence-based information written in a way that is easily 
understandable by patients was believed to be a good alternative that could 
help patients to better understand HCPs’ suggestions and approach to 
treatment, and foster discussion.  
2.3.2.2 Attitudes, experiences and views on clinical guidelines 
In this sub-section, I will draw upon HCPs’ attitudes and experiences in 
relation to evidence-based clinical guidelines. Studies that have looked at 
HCPs’ experiences of clinical guidelines for the management of T2DM were 
scarce. Hence, in order to better understand how HCPs use clinical 
guidelines to inform their decisions, I reviewed a broader literature and 
included studies that looked at clinical guidelines in a more general way. 
Therefore, this sub-section is not included under the organisational factors. 
Some studies have shown that clinical outcomes improve when HCPs 
adhere to clinical guidelines recommendations. However, quantitative studies 
have reported a generalised lack of adherence to guidelines (Barth et al., 
2016, Qiu et al., 2015). For the management of T2DM, guidelines are 
considered essential tools for the improvement and standardisation of patient 
care (Barth et al., 2016). As described in chapter 1, guidelines have included 
algorithms to help health professionals decide on when to start GLM. In this 
section, I will discuss HCPs’ attitudes towards guidelines, the ways in which 
HCPs such as GPs and nurses follow them, and the possible reasons behind 
differences in how they approach and implement these guidelines. 
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Healthcare professionals’ perceived quality and usefulness of clinical 
guidelines. 
Overall, studies which have explored HCPs’ perceptions and attitudes have 
found that guidelines are seen as useful tools, which help support evidence-
based decision-making and improve quality in the general practice by 
standardising healthcare and guiding practice to optimal care (Alexander et 
al., 2016, Hunt et al., 2012, Ingemansson et al., 2014, Luijks et al., 2015, 
Solà et al., 2014). However, some studies have also reported ambivalent 
feelings amongst some HCPs. In a study conducted by Radwan et al. (2018), 
who interviewed 20 senior doctors and nurses managing chronic diseases in 
Palestine, HCPs praised the existence of clinical guidelines; however, some 
revealed that they questioned the quality of the evidence informing them as 
they considered it outdated. Similarly, Baynouna Al Ketbi and Zein Al Deen 
(2018) conducted focus groups with 25 physicians in the United Arab 
Emirates. The authors reported that although recommendations in guidelines 
were valued by participants, HCPs reported being concerned that some 
recommendations might not apply to all patients. Likewise, Alexander et al. 
(2016) interviewed physicians in Canada and reported that overall guidelines 
were seen as useful, however, some participants expressed reservations and 
concerns about the quality of the evidence used during guideline 
development as, according to them, guidelines were not developed by 
primary care doctors. However, a note of caution is due here since this study 
reported findings based on 10 interviews. The authors stated that most 
physicians reported having time constraints and been too busy to participate, 
which reflects some of the challenges of interviewing HCPs.  
Moreover, many physicians reported that guidelines were not as explicit as 
they would have liked and lacked clarity with regard to the recommendations 
(Alexander et al., 2016). Similarly, Carlsen and Norheim (2008) reported from 
their focus groups with HCPs in Norway that transparency in the 
development of guidelines and the inclusion of insights from GPs, or a 
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multidisciplinary group, would provide them with a sense that these are not 
developed by economic motivation and may take into account the complexity 
of general practice. In the same way, Luijks et al. (2015) reported that GPs in 
the Netherlands expressed a need for more detailed guidelines, particularly 
for patients with multimorbidities because single disease guidelines can 
sometimes be conflicting and unclear. Some HCPs considered that 
guidelines sometimes are more focused on cost-efficiency rather than 
patients’ individual needs, and in the case of some complex diseases, such 
as diabetes and hypertension, HCPs from South Africa and Sweden, have 
suggested that guidelines might have limited applicability (Daniels et al., 
2001, Milos et al., 2014).  
Adherence to guidelines 
Qiu et al. (2015) concluded from their surveys with physicians in the US that 
one of the main impediments to diabetes guideline adherence may be related 
to the complexity and uniqueness of each patient. In the same way, GPs in 
Sweden interviewed by Ingemansson et al. (2014) expressed that the use of 
clinical guidelines depended on each patient’s situation since it is common 
that many people who they see in primary care have multiple health 
problems. This aspect entails two elements to consider. Firstly, that HCPs 
may often perceive that clinical guidelines reduce patients to “simple figures” 
(Aujoulat et al., 2015, p. 3), and secondly, narrowing HCPs’ role by not 
allowing them to exercise their own clinical judgement (Aujoulat et al., 2015, 
Ingemansson et al., 2014). This is exemplified in the work undertaken by Le 
et al. (2015) who interviewed GPs working in primary care in Denmark, and 
reported that guidelines may be implemented in different ways depending on 
the practice’s structure and internal organisation as some had organised 
collective activities to discuss and implement guidelines. Furthermore, in this 
study, GPs mentioned that guidelines were something from which to find 
inspiration, compare ideas or to have an opinion about but not something to 
which they have to adhere to strictly (Le et al., 2015).  
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Other studies have also reported that HCPs often refer to their own 
knowledge and clinical experience to assess whether the recommendation 
should apply to particular patients with particular health conditions because 
the main factor influencing their decisions is patients’ safety. For instance, 
HCPs might deviate from a guideline’s recommendations whenever they 
consider it necessary, and overall, recommendations seemed most likely to 
be followed in the case of younger and relatively healthier patients than for 
elderly or more complex patients with multiple diseases (Luijks et al., 2015).  
Moreover, research on HCPs’ views on guidelines for people with 
multimorbidities or chronic illness (Luijks et al., 2015, Hunt et al., 2012), and 
diabetes (Alexander et al., 2016) have reported that HCPs’ decisions also 
varied depending on the patient’s circumstances, which included the patient’s 
life expectancy or stage of the disease. According to the HCPs, some of the 
guidelines’ recommendations were not often applicable to all patients, and 
sometimes guidelines lacked clear solutions, which led them to adapt their 
decisions to patients’ characteristics and specific situations (Alexander et al., 
2016, Luijks et al., 2015, Hunt et al., 2012). Similarly, GPs in the Netherlands 
who participated in focus groups conducted by Luijks et al. (2015) expressed 
that although useful, the applicability of clinical guidelines is limited for people 
with multimorbidities, GPs particularly expressed the need for better support 
in diagnosing, treating and managing priorities in people with 
multimorbidities. 
Furthermore, HCPs’ have reported that high workload, high demand for 
efficiency in their work, and time constraints increased stress among them 
and hindered the optimal use of guidelines. For instance, some HCPs 
reported that, given their lack of time, the omission of some 
recommendations, such as lifestyle advice, might have happened due to their 
high workload and limited consultation length (Daniels et al., 2001, 
Ingemansson et al., 2014). Despite the views mentioned above, clinical 
guidelines were valued and considered fundamental as an aid when initiating 
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or intensifying pharmacological treatment. In general, when making decisions 
on pharmacological treatment, Milos et al. (2014) reported from their 
interviews with Swedish GPs that a key motivating factor for guideline 
adherence was time saved as GPs often lacked time to self-inform about new 
drugs and treatments. Thus, having the evidence-based information 
synthesised in a guideline was seen as useful, and when the need arose, 
HCPs based their decisions about drug prescription on guidelines’ algorithms 
which need to be constantly updated and discussed, especially when new 
drugs became available (Milos et al., 2014). However, constant changes or 
updates of guidelines made it more difficult for HCPs to adhere to them, 
especially if the guideline’s topic was not of their own interest (Le et al., 
2015). 
Some studies have reported that HCPs repeatedly expressed their dislike of 
long guidelines, with a lot of facts. Long guidelines were regarded as difficult 
to scan through and use and, together with time-constrains in primary care, 
length was believed to have become a hurdle to the application of guidelines 
(Ingemansson et al., 2014, Kinnunen-Amoroso, 2013). Tracy et al. (2003) 
reported from their interviews with family physicians in Canada that heavy 
workloads was one of the barriers most commonly reported by participants to 
the use of guidelines. In a similar way, some participants in the study 
conducted by Alexander et al. (2016) described being concerned about 
guidelines’ length, especially because there are several guidelines for 
different diseases and consulting all of them is a highly time-consuming task. 
Furthermore, Solà et al. (2014) who conducted focus groups with 46 
physicians in Spain, reported that many physicians suggested that the format 
and presentation of clinical guidelines could be enhanced by using plain 
simple language, with no ambiguities, in an electronic format and a 
summarised version available with the most important recommendations for 
clinical practice (Solà et al., 2014).  
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HCPs’ perceptions of their own role may be an important factor in guideline 
adherence. For instance, Tracy et al. (2003) described that Canadian 
physicians reported to use guidelines as a starting point but favour their 
intuition and clinical experience when making decisions. This view is 
supported by Ingemansson et al’s study where it was reported that some 
GPs saw guidelines as a set of instructions to be followed and thus, felt 
controlled and disrespected in their role as healthcare provider, as by 
following guidelines they felt they would have little input into what and little 
chance of learning from their own experiences (Ingemansson et al., 2014). 
Equally, GPs interviewed by Aujoulat et al. (2015) reported that treating to 
target narrowed their role of health promoter by not allowing them to provide 
the health care that they considered their patients to need and, also, reducing 
patients to simple figures “A patient cannot be reduced to figures! Figures 
alone cannot reflect the complexity of clinical cases. Every situation is 
unique! We do have targets for our patients, but targets need to be adapted 
to every patient’s individual situation” (Aujoulat et al., 2015, p.3). Hence, 
HCPs want to exercise their own clinical judgement when treating their 
patients. Likewise, Mayer and Piterman (1999) conducted focus groups with 
GPs in Australia. The authors reported that GPs often described to exercise 
their own clinical judgement based on their experience and taking into 
account their patients’ context and their issues rather than following 
guidelines strictly. In this instance, Pather and Mash (2019) reported from 
their interviews with family physicians in South Africa that these HCPs 
described a need for contextualising guidelines for the local use and the user 
(i.e. physician, nurse). 
Variation in clinical guidelines adherence and implementation 
HCPs’ role within the healthcare team (i.e. nurse, doctor) might have an 
influence on whether and to what extent guidelines are used. Kinnunen-
Amoroso (2013) carried out qualitative semi-structured interviews with 
doctors and nurses to explore their attitudes towards evidence-based 
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guidelines and the barriers and facilitators to using and implementing them. It 
was reported that, in general, doctors were more familiar with the guidelines 
than nurses. However, nurses reported greater adherence to guidelines than 
physicians; the author described that while doctors were more proactive in 
the search of new information, nurses considered themselves as “obedient” 
(Kinnunen-Amoroso, 2013, p.614) and use the information that was provided 
to them by their employers. Regarding differences in HCPs’ role, Daniels et 
al. (2001) who undertook interviews and focus groups with doctors and 
nurses involved in diabetes care in South Africa, reported that nurses 
considered guidelines especially useful for understanding physicians’ 
decisions on treatment (Daniels et al., 2000). However, the authors did not 
provide any insight about this finding. 
Moreover, Lawton et al. (2016), and Gabbay and May (2004) reported from 
their interviews with HCPs in the UK that GPs usually felt more autonomous 
and were able to deviate from procedures to tailor patient care, and often 
they only would look through guidelines to reassure themselves that there 
was nothing major that needed changing, and if it was, it would be discussed 
with other colleagues. Conversely, nurses were generally more stringent and 
followed procedures and policies. This might be related to that they feel more 
pressured than GPs to achieve targets; however it is also reported that 
nurses would turn to guidelines when faced with an unfamiliar problem, and 
once they were familiar with the procedure they would rarely if ever look at 
the guideline again. Gabbay and May (2004) reported, from their 
ethnographic study in two primary care practices in England, that clinicians 
privileged experience over any other form of knowledge and usually acquired 
what they thought was the best evidence from their professional networks. 
This was particularly true for GPs who, compared to nurses, had more 
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The work undertaken by Ingemansson et al. (2014) and Le et al. (2015) have 
shown that the implementation of guidelines varies between practices. For 
instance, GPs interviewed by Ingemansson et al. (2014) reported that when 
new guidelines arrived, they reviewed them through structured group-
dialogues in their primary healthcare centres. In these group-dialogues, GPs 
expressed they had a great opportunity for exchanging knowledge, receiving 
feedback and being socially and intellectually stimulated.  
In the same manner, Le et al. (2015) reported that GPs in Denmark 
implemented guidelines in different ways. While some informally discussed 
new clinical guidelines, others did so in formalised meetings and made 
informal oral agreements to make changes, based on guidelines, in their 
practices. Furthermore, some prepared protocols for the practice’s staff 
modifying clinical guidelines according to their practice’s needs (Le et al., 
2015). However, this study is limited by its sample size since the authors only 
interviewed seven GPs. 
2.3.2.2.1 Patient-centred care 
Having discussed HCPs’ attitudes to and implementation of clinical 
guidelines, I will now move on to discuss their views and perceptions of 
patient-centred T2DM care. As argued previously, HCPs perceived 
adherence to guidelines as sometimes conflicting with tailored care as, with 
the former, specific patients’ characteristics are not taken into account. For 
example, some Swedish GPs expressed that they felt free to deviate from 
guidelines as, according to them, the aims of guidelines are not always in 
alignment with patients’ needs and mostly were concerned with drug costs 
(Milos et al., 2014). Thus, having a holistic view of patients when making 
patient-centred decisions may often result in deviation from guidelines or 
omission of some recommendations (Lawton et al., 2016, Luijks et al., 2015). 
However, before describing the literature on patient-centred care, I would like 
to refer to a term commonly used in the literature on patient-centred care: 
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shared decision-making. In a recent publication by the Scottish Government 
entitled “What works to support and promote shared decision making: a 
synthesis of recent evidence”, shared decision-making is described as 
encompassing the assurance that the people are completely aware of risks 
and benefits to better inform the consent process, and that it is incorporated 
the person’s values and preferences, when making clinical decisions, to 
enable a person-centred approach. Moreover, decisions should be made by 
utilising the expertise of the clinician and the knowledge of the patient and 
what matters to them. The benefits of shared decision-making are the 
recognition of the patient’s right to be involved in their healthcare decisions 
and the focus on treatments and options with more beneficial outcomes to 
the patients. In Scotland, it has been recognised that conducting realistic 
medicine by recognising patient’s preferences may bring greater benefits to 
the healthcare system and its users (The Scottish Government, 2019).  
In relation to T2DM, Alexander et al. (2016) reported from their interviews 
with physicians in Canada that these individuals often reported having a 
similar approach to treatment for diabetes, regardless of disease duration. 
Thus, they described that when managing patients with long-term T2DM or 
with a recent diagnosis they sought to provide education, guidance and 
shared decision-making. HCPs pointed out that each patient is different; they 
often have different expectations of their treatment and have different levels 
of commitment and adherence to their disease management. Therefore, 
given the uniqueness of each patient, treatment would usually encompass 
shared decision-making (Alexander et al., 2016). However, the authors only 
conducted 10 interviews, and participants were purposively sampled, 
participants were excluded if they reported not using clinical guidelines 
routinely; hence, findings may not be generalisable due to the small number 
of interviews and the HCPs expressed use of clinical guidelines, which may 
have particular perceptions of patient-centred care. 
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Similarly, Aujoulat et al. (2015) reported that GPs in Belgium, who 
participated in group interviews to elucidate their beliefs about clinical inertia, 
described involving patients in their decision-making. Thus, they based their 
treatment approach on patients’ goals, possibilities and preferences. GPs 
also mentioned that sometimes not treating could be the result of complex 
clinical reasoning and not necessarily failure to initiate GLM in a timely 
manner. Additionally, GPs believed that patients should have an active role in 
the consultation and clinical decision-making (Aujoulat et al., 2015). 
2.3.2.2.2 Pay for performance schemes 
So far, the evidence suggests that generally, treatment decisions made by 
HCPs are the result of a complex interaction between patients’ 
characteristics, time resources and clinical guidelines. However, HCPs also 
have to act in accordance with national frameworks, such as pay for 
performance schemes implemented by the healthcare system. This following 
section seeks to examine HCPs’ interpretation and approach to pay for 
performance schemes, which may bring greater insight into clinical decision-
making in the pharmacological management of people with T2DM. 
As previously mentioned, guidelines for diabetes care and management 
usually include, among other things, targets for glycaemic control. 
Compliance with these targets is, to some extent, monitored by frameworks; 
such as QOF, although, as described in the previous chapter, this has now 
been decommissioned in Scotland. These frameworks are commonly 
developed as pay-for-performance schemes that measure achievement of 
indicators related to processes and outcomes of health conditions (ISD 
Scotland, 2016c, Roland and Guthrie, 2016). 
The literature search yielded five studies which looked at pay-for-
performance schemes. A narrative account of the studies focused on such 
schemes is presented in this last sub-section. Given that in Scotland the 
QOF was recently decommissioned, it is important to include studies which 
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may bring insights on the impact that this scheme potentially had on the 
management of some diseases.  
Moreover, these schemes can shape the relationship between HCPs and 
their patients and between HCPs. This has been exemplified in the work 
undertaken by Lawton et al. (2016) who interviewed GPs, nurses and 
practice managers in the UK, many of the participants considered that, for 
effective implementation and achievement of indicators, it was important to 
have effective communication between HCPs and their patients, between 
colleagues and between primary and secondary care. However, GPs also 
reported that trying to reach targets imposed by frameworks could negatively 
influence consultations by adding an extra pressure that may affect their 
rapport with patients, and that some targets might be inappropriate for some 
patients, such as the elderly and those on multiple medications. 
Furthermore, the implementation of new policies requires reorganisation of 
HCPs’ roles. In relation to QOF, McDonald (2008) conducted an in-depth 
qualitative case study in two general practices in England to investigate 
mechanisms and perceptions of control of their autonomy following the 
implementation of the pay-for-performance contract in general practices. The 
practices observed varied in size. The largest practice had an individual lead 
staff member for each of the QOF target areas who was free to decide how 
to organise their workload in order to achieve the required performance 
levels. GPs in this practice adopted a surveillance and feedback approach 
and considered QOF implementation as something positive. However, they 
also expressed that QOF resulted in only small changes to their existing 
practices. In contrast, the medium size practice had one GP responsible for 
overseeing and leading the whole process. Nurses had a particular 
perspective on the framework; they described feeling demotivated by the 
constant criticism of their performance by the GP responsible for monitoring 
the processes. Nurses also expressed concerns about the targets and their 
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potentially negative consequences for patient-centred care (McDonald, 
2008).  
In a similar study conducted by McDonald et al. (2007) in which they sought 
to explore the impact of financial incentives for quality of care on practice 
organisation, clinical autonomy, and internal motivation of doctors and nurses 
working in primary care. HCPs from two general practices in England 
expressed the view that they were concerned about the need to collect 
information, which they thought could affect the quality of consultations, and 
that the desire to reach targets would lead to patients be treated as 
conditions and not as people. This view was again more prevalent among 
nurses than doctors (McDonald et al., 2007). Overall, most HCPs expressed 
support for the scheme. However, a small number of doctors complained 
about surveillance by colleagues, and some respondents described potential 
distortions of clinical practice through neglect of non-incentivised aspects of 
care, although they described these as occurring in other practices, not their 
own (McDonald et al., 2007). 
In the study by McDonald (2008), HCPs from both practices expressed 
dissatisfaction about financial rewards associated with QOF. However, 
McDonald et al. (2007) also reported that sometimes the quality incentive 
scheme was a source of professional motivation, especially for nurses who 
were assigned responsibility for monitoring one or more target areas. 
Conversely, GPs who were not clinical leads sometimes waited until they 
were found out by the lead partner responsible for the surveillance, rather 
than proactively pursuing targets. However, there was no evidence that QOF 
implementation was a threat to internal motivation or HCPs’ core values 
(McDonald et al., 2007). 
Pay-for-performance schemes are not always considered as positively by 
HCPs. For instance, qualitative interviews conducted with clinicians in the US 
by Hunt et al. (2012) suggested that pay-for-performance programs may 
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further contribute to polypharmacy. One interviewee reported, “I wouldn’t 
really like to admit it, but the insurance companies making a financial carrot is 
probably one impetus for really cracking down on my diabetics to get them 
7.0% or less.”(Hunt et al., 2012, p.456). Moreover, Hunt et al. (2012) reported 
that patients with chronic diseases managed in primary care usually were 
started on GLM after having moderately elevated test results. According to 
the authors, this may be because HbA1c threshold levels changed just 
before the study was conducted (Hunt et al., 2012).  
Overall, GPs expressed a professional ideology that defended patients’ 
needs over clinical goals. Moreover, some GPs suggested that financial 
incentives might shift the focus from the patient’s benefit to the immediate 
financial reward. Some GPs were concerned that incentives could lead to 
perverse consequences arguing that it is unethical for prescribing targets to 
be dependent upon remuneration since effective prescribing should be a 
professional responsibility. Furthermore, GPs also suggested that the 
financial return was too little for the increased workload demanded (Prosser 
and Walley, 2007).  
2.3.3 Section summary 
This section has discussed HCPs’ experiences of views about T2DM care 
and management. Moreover, HCPs attitudes towards clinical guidelines and 
frameworks were presented. Although there is a relatively large body of 
literature which has looked at HCPs’ attitudes and perspectives about clinical 
guidelines, few studies have looked at these issues in the context of T2DM.  
Most of T2DM care and management is conducted by HCPs working in 
primary care. Although HCPs are responsible for treatment choices, clinical 
decision-making is a complex process that involves the HCP, the patient and 
the healthcare system. In the studies presented above, HCPs reported 
informing their decisions by considering patients’ characteristics and 
attitudes. However, studies conducted by Lee et al. (2012) and Zafar et al. 
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(2015) showed that HCPs’ approach to managing T2DM may vary depending 
on clinicians’ expertise and special interest in T2DM.  
HCPs also described their views and attitudes towards clinical guidelines. 
Overall, HCPs had different approaches to guidelines depending on their 
professional role and their responsibilities in their implementation. Moreover, 
HCPs reported a need for more transparency in the development of 
guidelines’ recommendations; particularly clinicians who expressed a need 
for including input from primary care colleagues. This plea for transparency is 
of great importance as, in order for strategies to be implemented, it is 
essential that those executing them to believe in their value. Otherwise, 
guidelines’ development might be interpreted by some HCPs as a failure to 
appreciate the complexity of medical practice, and perceived as a mere 
intention of standardising prescribing practices. Furthermore, to be 
considered as a reliable source of information and provide feelings of trust, 
guidelines need to be constantly updated. It is important noting that most of 
the studies presented about clinical guidelines did not particularly focus on 
T2DM. 
Patient-centred care, which was considered fundamental by HCPs, entails 
knowing the patient’s characteristics and conditions. However, the lack of 
continuity of care and time constraints were described as sometimes making 
difficult for HCPs to familiarise themselves with particular patients. 
Furthermore, HCPs had diverse views on pay for performance schemes, 
while some considered them as a professional motivator, others believed it 
was a drawback in person-centred care. 
The scope of this section was limited to qualitative evidence where the 
researchers recruited participants from specific geographical locations and 
time. Thus, the findings here summarised might not be representative of the 
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2.4 Summary  
This chapter has attempted to summarise all relevant literature about GLM 
initiation, particularly among people with newly diagnosed T2DM. However, 
as I identified in the literature search, little attention has been paid to the 
period soon after diagnosis, in both quantitative and qualitative research.  
Patterns of drug prescriptions for people with T2DM have previously been 
studied in the UK (Gallagher et al., 2015, Hamada and Gulliford, 2015, 
Higgins et al., 2016a, Sharma et al., 2016, Sinclair et al., 2012). However, 
most of these studies have focused on treatment intensification rather than 
treatment initiation and factors associated with it. Similarly, the literature 
review made evident the dearth of studies on HCPs’ reasons for initially 
prescribing GLM in people with recently diagnosed T2DM.  
Furthermore, this review highlights the complex variety of factors, which may 
affect approaches to the management of diabetes. These factors include 
HCPs’ characteristics, their approach and views about clinical guidelines and 
patients’ characteristics. Additionally, in relation to GLM prescription in 
people with newly diagnosed T2DM, the review of the literature made evident 
some research gaps. For instance, there was a lack of information about the 
differences between people who received drug prescription and those who 
did not. Likewise, most studies about treatment initiation have focused on 
HbA1c levels but there is a need for more information on other clinical 
aspects that might be related to drug treatment initiation, and to know to what 
extent HCPs take into account patients’ opinions when deciding to initiate 
GLM. Moreover, few studies have looked at potential differences according to 
HCPs’ professional role (GPs vs nurses) and the use of clinical guidelines for 
T2DM. Lastly, it still remains to be known the perceived impact on diabetes 
care after QOF’s decommissioning in Scotland. 
The literature here presented served as the foundation of this PhD, this 
chapter highlighted a gap in knowledge regarding GLM in people with newly 
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diagnosed T2DM. Very few studies have described the factors associated 
with time to GLM initiation in people recently diagnosed with T2DM. 
Moreover, there is a need to gather more up-to-date data, and to include a 
qualitative research component in order to understand the reasons 
underlying and informing treatment patterns and decision-making about when 
to initiate medication. Thus, based on these gaps and the results from the 
literature review I informed the design and conduct of a mixed-methods study 
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Chapter 3 Research Design 
3.1 Introduction 
This chapter describes the mixed-methods research design used to address 
the research questions. The aims, objectives and research questions are 
presented as well as the rationale for the decision to use a mixed-methods 
design. In addition, the specific methods for each strand of the study 
(quantitative and qualitative) are presented. Finally, an overall summary of 
the chapter is given. 
3.2 Aims and objectives 
This study aimed to describe factors associated with the initiation of GLM in 
people with newly diagnosed T2DM and the underlying reasons for starting 
pharmacological treatment in a Scottish primary healthcare context. The 
purpose of this convergent parallel mixed-methods study was to combine 
quantitative and qualitative data to allow a deeper insight into GLM initiation 
in people with T2DM. Thus, the study was formed by two strands: one 
quantitative and one qualitative.  
The quantitative strand comprised a retrospective cohort study design, which 
was used to generate data describing GLM prescription patterns, specifically 
exploring factors associated with time to initiation of GLM amongst people 
with newly diagnosed T2DM. For the qualitative strand, interviews with HCPs 
working in primary care were undertaken. The interviews were used to 
identify and explore factors and considerations that might influence clinical 
decision-making in relation to initiation of GLM in people with T2DM in a 
Scottish primary healthcare context. Combining two different and 
complementary kinds of data can produce valuable information. The data 
generated can inform policymakers about factors that HCPs take into 
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3.3 Research questions 
The overarching research question that this study attempted to answer is the 
following: 
What leads to the initiation of glucose-lowering medication in people with 
newly diagnosed T2DM in primary care in Scotland? 
However, in order to provide a sense to what each method can 
contribute to answering, a mixed-methods research question 
following Creswell and Plano Clark’s approach was developed. This 
mixed-methods research question is the following:  
What factors are associated with GLM initiation, and what 
are the views and experiences of healthcare professionals 
working in primary care about when to initiate GLM? 
In order to answer the research question, sub-questions associated with 
each strand of the study were developed. Thus, drawing upon two strands of 
research into GLM initiation amongst people with T2DM, the sub-questions 
that this study sought to answer are: 
For the quantitative strand:  
1. What is the proportion of people with T2DM who have and who have 
not received prescriptions for GLM within two years after diagnosis, 
and how do characteristics differ between people who have and who 
have not received a prescription for GLM within two years after 
diagnosis of T2DM? 
2. What is the proportion of people with T2DM and sub-optimal 
glycaemic control without a GLM prescription two years after 
diagnosis?  
3. What factors are associated with time to GLM prescription for people 
with T2DM within two years of diagnosis? 
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In addition, for the qualitative strand: 
4. What are HCPs’ reasons for starting GLM in people with recently 
diagnosed T2DM? 
5. What factors and considerations HCPs take into account when starting 
individuals recently diagnosed with T2DM on GLM? 
6. How and in what ways do HCPs use clinical guidelines to inform their 
decision-making in relation to initiating GLM? 
3.4 Methodological approach: mixed-methods 
A mixed-methods approach was identified as the best approach to address 
the research questions. Mixed-methods research combines qualitative and 
quantitative approaches in the context of one study. Collecting diverse types 
of data provides a wider and deeper understanding than the two 
methodologies are capable of providing independently (Kroll and Neri, 2009, 
Plano Clark and Ivankova, 2016, Tashakkori et al., 2015).  
Mixed-methods designs require decisions to be made about the level of 
interaction between the two strands, the priority and timing of each strand, 
and the procedures for mixing the strands (Creswell and Plano Clark, 2011, 
Curry and Nunez-Smith, 2015c). This study adopted a convergent parallel 
mixed-methods design as described by Creswell and Plano Clark (2011) as 
its characteristics (see 3.4.2) allow to complement and expand findings from 
both components to answer the overarching research question. 
In the following sub-sections, I will provide an overview of the major mixed-
methods designs. Then, I will describe the characteristics of the mixed-
methods design I chose for my study. Subsequently, the priority, timing and 
links between strands will be explained. 
3.4.1 Mixed-methods designs 
Creswell and Plano Clark (2011) have described six major mixed-methods 
designs: (1) the convergent parallel, (2) the explanatory sequential, (3) the 
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exploratory sequential, (4) the embedded design, (5) the transformative 
design, and (6) the multiphase design. A summary of the characteristics of 
each of these mixed-methods designs is presented in Table 8.  
Table 8. Characteristics of the major mixed-methods designs by 
Creswell and Plano Clark (2011) 
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Most mixed-methods designs, such as the sequential ones, require the same 
group of people to be studied. Although different samples size are required 
for each strand, they involve the recruitment of the same group in order to 
explain quantitative results (explanatory sequential) or to generalise 
qualitative findings (exploratory sequential). Consequently, these designs 
were not suitable for this research (Plano Clark and Ivankova, 2016, Creswell 
and Plano Clark, 2011, Kroll and Neri, 2009, Padgett, 2012c). 
In an embedded design, mixing occurs at the design level; in other words, 
one study informs the other. Consequently, collection of additional, or a 
second set of data for both strands is usually necessary (Creswell and Plano 
Clark, 2011, Watkins and Gioia, 2015). However, this design is used in 
combination with a clinical trial. Therefore, this design was not suitable for 
answering the overarching research question. 
Likewise, the other two designs, the transformative and multiphase design 
were not aligned to the research questions of this study. The transformative 
design is commonly used in disciplines such as social work as it seeks to 
identify social injustices in order to generate social change. In this design, the 
subjects of study are marginalised and underrepresented populations. 
Therefore, the characteristics of this design were not suitable for this 
research. Likewise, the multiphase design is used to address a large 
objective by answering a set of incremental questions. In other words, an 
initial sequential design is implemented, and then a new study is built based 
on what was learned from the previous one. This design requires not only 
time available to conduct the different phases of the study but also for the 
researchers to have experience in large-scale research, sufficient resources 
and funding (Creswell and Plano Clark, 2011, Kroll and Neri, 2009, Watkins 
and Gioia, 2015). 
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Thus, the convergent parallel mixed-methods design was the most 
appropriate for this study. The characteristics and reasons for the choice of 
this design are covered in detail in the next sub-section. 
3.4.2 The Convergent Parallel Design 
In table 8 presented in the previous section, I provided a summary of the 
main mixed-methods design that showed that each design is useful for 
different purposes. The convergent parallel design was chosen as its 
characteristics matched the research question. This is one of the most well-
known and widely used approaches; the purpose of this design is to obtain 
different but complementary data on a topic. The aim is to balance the 
strengths and limitations of each method to triangulate the data by comparing 
and contrasting qualitative findings with quantitative results for corroboration 
or validation purposes and also to develop a more complete understanding of 
a phenomenon, which in this study is the initiation of glucose-lowering 
medication in people with newly diagnosed T2DM (Creswell and Plano Clark, 
2011, Curry and Nunez-Smith, 2015c).  
For this design, data collection can either derive from different samples or 
study participants, or one strand might be limited to a sub-sample from the 
other strand. Therefore, this design allowed the use of two different sources 
of information: a dataset with clinical data from people with T2DM, and 
interviews with HCPs. The use of data from different samples has the 
purpose of maximising the yield of distinct potentially complementary sources 
of evidence (Curry and Nunez-Smith, 2015b). 
Furthermore, during the progression of the research, the researcher may 
work between the components by switching the focus from one strand onto 
the other iteratively, depending on the logistics of conducting the study (Curry 
and Nunez-Smith, 2015c, O'Cathain, 2009, Tashakkori et al., 2015). One of 
the key differentiators of this design is that the outcomes of each strand are 
independent of each other. Thus, the timing and order of each strand depend 
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on the logistics of each study (Tashakkori et al., 2015). The flexibility of this 
design was a useful aspect that allowed me to conduct the research without 
pauses during the process. For instance, while waiting for ethical approval to 
conduct the interviews I was able to select the variables of interest for the 
quantitative strand; I will further explain the process later on in this chapter. 
Moreover, since both strands can be conducted simultaneously this is a time-
efficient design. Therefore, the convergent parallel approach is used when 
there is limited time to collect the data or when only limited quantitative and 
qualitative data can be collected (Creswell and Plano Clark, 2011). However, 
the differences in qualitative and quantitative paradigms imply that there is no 
specific set of standards to ensure validation in mixed-methods research. In 
order to obtain reliable and valid findings, it is important for the researcher to 
adhere to standards of rigour, which in mixed-methods requires the 
researcher to be consistent with the theoretical assumptions underpinning 
the paradigm of the mixed-methods study design chosen (Giddings and 
Grant, 2009). 
Hence, the characteristics of this design are in line with the overarching 
research question and it offers a practical way of answering the research 
questions. The overarching research sought to provide a thorough 
understanding about the initiation of GLM. The mixed-methods research 
question posed two different types of queries, the first query was about 
“factors associated with GLM initiation”, which looked for relationships 
between variables, and thus required use of quantitative methods. The 
second query related to “views and experiences of HCPs”, thus qualitative 
methods were needed in order to capture the experiences and perspectives 
of HCPs. Since the data generated by each method was considered 
complementary, each method was given equal value. 
For this study, data about factors associated with GLM initiation were drawn 
from patients’ clinical data. These data allowed testing for associations 
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between patients’ characteristics and prescription initiation. In addition, as 
they are responsible for prescribing GLM, HCPs were interviewed in order to 
understand their experiences and rationale when prescribing GLM. 
Therefore, two different samples were used to generate a more 
comprehensive understating of the initiation of GLM in people with newly 
diagnosed T2DM and answer the overarching research question. Further 
details on the rationale behind interviewing HCPs are presented in section 
3.6.3. 
3.4.2.1 Research paradigm  
In this section, I describe the paradigm that informed the mixed-methods 
design. This paradigm should not be confused with the theoretical stance 
adopted for the qualitative study, which will be described in section 3.6.2. 
The convergent parallel mixed-methods research bases its knowledge on 
pragmatic grounds. Therefore, pragmatism is the philosophical foundation or 
“worldview” of this study. Paradigmatic assumptions guide the choice of 
methodology and methods of the research and the nature of the research-
researcher relationship (Giddings and Grant, 2009).  
Pragmatism is based on the assumption that all methods have different 
research paradigms with their own virtues and limitations, it enhances utility 
over ideology or philosophy and acknowledges the fallibility of knowledge 
development. It allows the adoption of a pluralistic stance to gather all types 
of data to best answer the research questions (Padgett, 2012d, Creswell and 
Plano Clark, 2011). Thus, a pragmatic approach is problem-centred and 
oriented towards real-world practice. Given that the priority is to answer the 
research questions, this viewpoint allows the selection of appropriate 
methods to best answer them, which in this study comprised a qualitative 
strand and a quantitative strand (Hesse-Biber et al., 2016). 
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3.4.2.2 Level of interaction and stage of integration 
Mixed-methods study designs have different typologies relating to timing, 
mixing, and priority (Tashakkori et al., 2015). The level of interaction refers to 
the extent to which each strand of the study is independent or interacts with 
the other. Accordingly, Creswell and Plano Clark (2011) recognise two 
different levels, namely independent or interactive. The stage of integration 
refers to the combination or merging of the strands. This can occur at 
different stages and typically depends on the major design that is followed. 
The mixing can occur: (1) during interpretation, (2) during data analysis, (3) 
during data collection, or (4) at the level of design (Creswell and Plano Clark, 
2011).  
As previously mentioned, this study used a convergent parallel design which 
is characterised by adopting an independent level of interaction, meaning 
that each strand is independent of the other. In other words, research 
questions, data collection, and analysis are separated, and the strands are 
only mixed during the conclusions and overall interpretation of the study 
(Creswell and Plano Clark, 2011). However, Creswell and Plano Clark (2011) 
hold the view that the options for and combinations of the level of integration, 
priority, timing and mixing of a mixed-methods research design are limitless 
and depend on the research question (Creswell and Plano Clark, 2011). 
Other authors such as Bazeley (2009) have recognised that the purpose and 
questions of the study should be the main driver for the approach to 
integration. Equally, Plano Clark and Ivankova (2016) acknowledge that an 
effective integration requires a “conversation” between the strands. Thus, by 
informing and enhancing one another, a more comprehensive set of insights 
can be produced. Hence, for this study, an adaptation to the level of 
interaction was conducted. While research questions were kept separated for 
each strand, data collection and analysis followed an interactive process as 
they were seen as complementary. 
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As presented in figure 3, the strands of this study interacted during data 
collection and analysis; yet, the main stage of integration occurred in the 
discussion. In this manner, each strand was improved by informing the other. 
For instance, as shown in the yellow boxes, I conducted a preliminary 
analysis of the cohort, which informed the topic guide that was developed for 
the interviews with HCPs. In the preliminary analysis I found that HbA1c was 
one of the main factors associated with initiation of GLM within two years of 
T2DM diagnosis; however, I also found that non-clinical factors such as age 
were associated with longer time to drug treatment initiation. These results 
together with findings from the literature review about factors that inform 
HCPs’ decision-making led me to include in the topic guide a question about 
other factors besides HbA1c that HCPs consider when choosing a treatment 
for glucose control.  
Similarly, when analysing the interviews and after discussion with the panel 
during my second-year review, I realised that I needed to include and 
analyse variables on blood pressure, cholesterol and prescription of other 
drugs which were not included previously (blue boxes). Then, results from 
both strands were revised to look for convergency (orange boxes). Although I 
had found that age was an important aspect, to this point, I had not formally 
tested or stratified the analysis in relation to this variable. Hence, the green 
boxes show these further analyses stratified by age. Further variables which 
were of interest such as the presence of chronic kidney disease or 
information about prescriber were not possible to be added. Thus, as it has 
been exemplified in the figure, I sought to enhance each study with findings 
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3.4.2.3 Priority and timing of each strand 
Another key decision that is necessary to make is about the timing and 
priority that is given to each strand. For this study, equal priority was given to 
both strands as they were considered to enhance each other and to increase 
the potential to understand the phenomenon studied. Therefore, both were 
considered to have an equally important role in addressing the research 
question (Creswell and Plano Clark, 2011).  
The collection of data in mixed-methods research usually requires more time 
due to the use of different procedures, and some designs require more time 
than others. Therefore, the timing of each strand needs to be established, but 
this is determined by the relationship between them (Curry and Nunez-Smith, 
Quantitative Qualitative 
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2015c, Halcomb and Andrew, 2009). In mixed-methods studies, timing refers 
to the completion of the entire strand (i.e. qualitative strand or quantitative 
strand) and not only to the stage of data collection. Accordingly, a study’s 
timing can be concurrent, sequential, or multiphase (Creswell and Plano 
Clark, 2011). 
Although the major design of this study was convergent parallel, I worked on 
each strand intermittently. Thus, the timing of each strand was multiphase. 
As illustrated above in figure 3, I alternated between studies depending on 
the resources available at the time. For instance, while waiting for ethical 
approval to conduct the interviews, I was able to work on the quantitative 
strand by selecting variables of interest. Then, as described above, after 
conducting and analysing the initial interviews, I added new variables to the 
dataset.  
The use of a multiphase combination timing allowed me to make the greatest 
use of the time available for the PhD. This timing enabled me to work 
continually on the research and provided me with the opportunity to enhance 
each study with preliminary findings from the other. 
3.4.3 Time frame  
Here the times and procedures in collecting and analysing qualitative and 
quantitative data are summarised. Further details of each strand are 
presented later in the sections concerned with quantitative and qualitative 
methods.  
3.4.3.1 Data collection 
The elements included in data collection are sampling procedures, obtaining 
permissions, and collecting information/recording data. Following the general 
structure of convergent parallel designs, both strands commenced at roughly 
the same time. However, there was a cyclical fluctuation between strands as 
can be seen in Table 9. Overall, data collection for both strands was 
conducted over an 18-month period, from March 2017 to September 2018. 
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Table 9. Overview of data collection procedures and time frames 
Element Quantitative strand Qualitative strand 
Time frame Procedure Time frame Procedure 
Sampling March – April 
2017 
 
 Identification of 
the cohort for 
the study 
July 2017  Identification of 
participants for 
the study 










by the MRC 















 Selection of 
variables of 
interest 
 Obtaining final 
database+ 







 Selection of 
method to 
collect data 




+ An initial dataset was obtained at the end of the year 2017. However, the identification of new variables 
of interest led to the creation of a new and final dataset, which was obtained in 2018. * Interviews were 
conducted after obtaining ethical approval.  
3.4.3.2 Data analysis and interpretation  
After obtaining access to the quantitative dataset and completing the 
interviews with the participants, the next steps were (1) to prepare and 
explore the quantitative and qualitative data, and (2) to analyse and interpret 
the quantitative and qualitative data. These steps were implemented 
simultaneously and iteratively; findings from the quantitative strand required 
me to go back to the interview transcripts, and findings from the qualitative 
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strand suggested the inclusion of additional variables. Furthermore, in the 
qualitative strand, the themes identified were intertwined, and the writing 
process was iterative in order to find the most suitable way to present them. 
The time frame for the procedures associated with data analysis and 
interpretation are summarised in table 10 
Table 10. Summary of procedures conducted for each strand 
Element Quantitative strand Qualitative strand 





 Clean the dataset 
 Recode and or 
compute 
variables 














April 2019  Inspection of the 
data visually 





 Read through 
data 
 Identifying and 
developing 
themes to code 
data 
Data analysis  April – June 
2019 


















 Writing up results  
 Elaboration of 
tables and figures 






 Writing up 
results in themes 
 
 
Research Design  109 
3.4.4 Ethical considerations  
In order to collect data, permission needs to be sought from the individuals 
who will provide the information (or their guardians/representatives) and 
sometimes from the sites where the study is conducted (Creswell and Plano 
Clark, 2011). 
With the purpose of obtaining permission to access to the quantitative 
dataset, I completed the e-learning course assessment for Scotland on 
“Research Data and Confidentiality”. This course is offered by the Medical 
Research Council and covered the following topics:  
1. The concept of confidentiality and how to work within the law 
2. Some principles of the Data Protection Act 
3. Consent and the issues in accessing data for research without 
consent 
4. Appropriate disclosure and routes for access without consents 
5. Accessing data from the Office for National Statistics and the NHS, 
and  
6. Archiving and sharing research data.  
After successful completion of this course in March 2017, Professor Sarah 
Wild and Dr Jeremy Walker – on behalf of the Scottish Diabetes Research 
Network Epidemiology Group, provided me with access to the dataset. For 
the qualitative strand of this study, ethical considerations are presented in 
section 3.6.4.3. 
Having defined the key decisions of the study design and described the 
general procedures of data collection, analysis and interpretation of the 
strands, I will now move on to describe the challenges of reporting mixed-
methods research, which will help to understand the decision-making around 
the structure of the thesis. 
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3.4.5 Challenges of reporting mixed-methods research 
The mixed-methods approach offers the opportunity to develop a thorough 
understanding of the topic and flexibility. However, designing and conducting 
mixed-methods research requires careful consideration to be given to the 
principles and complexities of this approach. There are many challenges to 
using mixed-methods; these not only relate to the general approach but also 
to the design used and the ways to report the research (Andrew and 
Halcomb, 2009, Creswell and Plano Clark, 2011, Palinkas, 2011). Here I will 
describe two of the major challenges to reporting mixed-methods research 
described in the literature: (1) Style, language and voice, and (2) Structure of 
the presentation. 
First, there is often a challenge imposed by differences in jargon for 
quantitative and qualitative methodologies. Different voices are associated 
with each strand posing the dilemma of which to use. Researchers can adopt 
the language associated with each component. However, the paradigm will 
be relevant when deciding which voice to adopt. For this research, the 
approach adopted was pragmatism. This approach permits the use of 
whichever style suits different parts of the report (O'Cathain, 2009, Creswell 
and Plano Clark, 2011). Thus, in line with the paradigm of the convergent 
parallel mixed-methods design, a flexible approach to language was adopted 
for this thesis (Creswell and Plano Clark, 2011). For instance, the first person 
subjective voice is seldom used in the chapters on quantitative results, 
whereas for the quantitative sections, this voice was used more frequently. 
Second, when conducting mixed-methods research, decisions must be made 
in relation to the order of data collection, the size of the samples, and 
whether there will be one or two samples (Curry and Nunez-Smith, 2015a). In 
the same way, presenting the results poses the challenge of deciding the 
order of each component. Generally, there are two possible formats: a 
sequential format where methods and findings of one component are 
followed by the other component and an integrated format where both 
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components are incorporated together. While sequential formats are 
suggested for thesis writing, integrated writing is still preferred in the peer-
reviewed literature (O'Cathain, 2009). Table 11 presents the outline of both 
formats for a doctoral thesis.  
Table 11. Formats of report writing based on O'Cathain (2009) 




















Findings based on any or all 
components can be presented in 
several chapters (3-4) 
Discussion 
In convergent designs, the consequences of having different samples, 
different samples size and the integration of the findings in a meaningful way 
need to be considered. (Creswell and Plano Clark, 2011) Therefore, in this 
thesis, a segregated model B of report writing was considered to be most 
appropriate because it allowed the presentation of the information in 
accordance with the mixed-methods design chosen. Furthermore, given that 
each strand answered complementary research questions, and taking into 
account that each methodology produces a different type of findings, 
devoting a dedicated chapter to each strand’s findings was considered most 
suitable. 
3.5 Quantitative Methods  
This sub-section is concerned with the methods of the quantitative strand of 
the research. As previously stated, the quantitative strand sought to explore 
factors associated with time to pharmacological treatment amongst people 
with newly diagnosed T2DM. The research data for this strand was drawn 
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3.5.1 The SCI diabetes cohort 
First, I will describe the source of the data and the criteria used to build the 
cohort for this study. Then, I will list and define the variables of interest to this 
research as well as classifying them as dependent and independent 
variables. 
After RCTs, cohort studies are regarded as the most robust design for 
medical research. Cohort studies provide the opportunity to include a wide 
range of patients and to compare those exposed and unexposed; this is 
described as an observational study where the researcher observes the 
natural events without intervening (Mauricio Barria, 2018, Elwood, 2017). 
Either data collected as baseline (before an intervention or at the beginning 
of a study) or existing medical records can be used to identify risk factors for 
a particular outcome and can deliver findings that can help to understand the 
relationship between such risk factors and the occurrence of the outcome of 
interest (Mauricio Barria, 2018). 
For this study, the cohort was drawn from an extract of the SCI-Diabetes 
dataset. The SCI-Diabetes is a dynamic clinical management and information 
system in which HCPs enter patients’ data that is collected nightly from a 
variety of sources such as primary and secondary care across all 14 health 
board areas in Scotland (Diabetes in Scotland, 2015, INPS, 2013, Emslie-
Smith, 2010). All patients (unless the patient refuses from participation in the 
SCI-DC) with the following diabetes diagnosis codes are automatically 
included in the SCI-Diabetes extract: 1) C10% diabetes mellitus, 2) R102 [D] 
Glucose tolerance test abnormal, 3) R10D0 [D] Impaired fasting glycaemia, 
4) R10E [D] Impaired glucose tolerance, 5) L1809 Gestational diabetes 
mellitus, and 6) 44V2 Glucose tolerance test impaired. Patients records 
include a classification of their type of diabetes. Moreover, the data included 
in the SCI-Diabetes includes updated conditions relevant for diabetic 
monitoring, other data such as test results, blood pressure, height, weight, 
and updated demographic details to ensure an accurate record of people 
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actively receiving care. (INPS, 2013, Cunningham et al., 2011). The clinical 
database provides information to support the treatment of NHS Scotland 
patients (Diabetes in Scotland, 2015). Pseudonymised extracts of the 
database are available for research by people with approved data 
governance training with permission of the Scotland A multi-centre research 
ethics committee and the Privacy Advisory Committee of National Health 
Service Scotland (Cunningham et al., 2011).  
The dataset used in this study was created for me by Dr Jeremy Walker in 
2017 and updated with the addition of new variables in 2018. The initial 
dataset held information on 174,154 individuals diagnosed with any form of 
diabetes in Scotland between 01 January 2004 and 31 December 2012. The 
dataset included for each patient a unique SCI-Diabetes serial number, as 
well as demographics and clinical data which will be explained in detail in the 
next sub-section 3.5.2. In order to identify participants suitable for addressing 
the study aims, participants were selected according to predefined eligibility 
criteria, which are described in the following sub-section. Overall, based on 
the eligibility criteria and the addition of further variables of interest, the final 
dataset which was analysed included information on 154,660 patients 
diagnosed with diabetes between 2004 and 2012, the flow chart describing 
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3.5.1.1 Eligibility criteria  
To limit the possibility of including patients without T2DM and to provide data 
for follow-up, participants had to meet certain conditions. Primary inclusion 
criteria for the initial cohort were: 
1. Classified as having T2DM diagnosis 
2. > 30 years old at diagnosis of diabetes 
3. No record of prescription of GLM before the date of diagnosis of T2DM 
4. Were followed up and remained alive for at least two years after 
diagnosis. The inclusion of people who remained alive during the 
observed period was determined to make certain that prescription 
prospects were similar amongst participants. 
5. Diagnosed between 2004 – 2012  
The cut-off age was chosen in order to reduce the chance of selecting 
patients who may have had T1DM misclassified as T2DM. The requirement 
for at least two years of follow up after diagnosis is necessary to allow time 
for measurement of treatment patterns after diagnosis, and to compare the 
174,154 
155,158 
 8,426 registered as having type 1 diabetes or other 
 1,826 <30 years 
 8,195 had recorded date of death less than 2 years after 
T2DM diagnosis 
 549 had recorded GLM prescribed before date of T2DM 
diagnosis 
 1 without date of birth  
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results with previous research. The date of diagnosis was limited by the 
research data available at the time of data extract.  
3.5.2 Variables of interest  
The selection of variables for this strand was based on the literature review 
and findings from the qualitative interviews. The dependent or outcome 
variables are drug treatment, time-to-drug treatment initiation, and type of 
drug prescribed. The independent or exposure variables included 
demographic variables, metabolic factors such as blood pressure, glucose 
and cholesterol levels, and the prescription of other drugs such as 
antihypertensive and lipid-lowering medications. 
3.5.2.1 Operational variables definition 
A description of each variable of interest is presented in the following 
sections. First, the dependent variables are presented. Then, a description of 
the independent variables is provided, which for clarity were grouped into 
categories such as demographics and metabolic factors. 
3.5.2.2  Outcome/dependent variables 
A summary of the dependent variables of this study, which were drug 
treatment and time-to-drug treatment prescription initiation are presented 
below in table 12. 
Table 12. Summary of dependent variables included in the statistical 
analyses. 
Variable Type Definition 
Drug treatment  Categorical dichotomous 
variable (yes/no)  
The prescription of GLM for T2DM 
within two years from diagnosis. 
Time-to-drug treatment  
prescription initiation 
This variable was treated as a 
continuous numerical variable 
for survival analysis and as a 
categorical variable to allow 
data stratification as follows: 
This refers to the time expressed in 
days, months or years between the 
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a. 0 to 3 months: consisting 
of the period from the date 
of diagnosis to 90 days 
after diagnosis. 
b. 3 to 12 months: covering 
from 91 to 360 days after 
the date of diagnosis. 
c. 12 to 24 months: 
comprising of day 361 to 
day 730 after the date of 
diagnosis. 
These time frames were chosen in 
accordance to the SIGN guideline 154 
which suggests a review of treatment 
for glucose-control every 3–6 months 
when targets are not reached, the 
Scottish diabetes framework which 
states that people with T2DM are 
offered at least an annual review to 
monitor the progression of their 
condition. (Scottish Intercollegiate 
Guidelines Network (SIGN), 2017b, 
Scottish Government, 2006). 
Drug classification This variable was treated as 
categorical. It indicates the 
category of the first drug 
prescribed within the two years 
of follow-up. 
This was created by looking at 
the anatomical therapeutic 
chemical (ATC) code 
corresponding to the patient's 
first prescription for GLM   
Drugs were classified according to 




gliclazide, glimepiride, glipizide, 
tolbutamide, gliquidone, 
chlorpropamide  
Insulin: encompassing all insulin 
formulations. 
Others. Encompassing the following 
sub-categories:  
 Thiazolidinediones: rosiglitazone, 
pioglitazone 
 Prandial glucose regulator: 
repaglinide, nateglinide 
 GLP-1 analogues: liraglutide, 
exenatide 
 DPP-4 Inhibitors: sitagliptin, 
saxagliptin, linagliptin, vildagliptin 
 Alpha glucosidase inhibitor: 
acarbose 
 Herbal: Guar gum 
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3.5.2.3 Exposure/independent variables 
In chapter 2, the need to investigate the combined role of clinical and 
demographic factors in treatment decisions was highlighted. Hence, I 
included in the quantitative strand variables related to both, demographic and 
metabolic factors. 
Demographics: Including age at diagnosis of diabetes, ethnicity, sex, 
socioeconomic status at diagnosis and year of diagnosis. The definition of 
each variable is presented in table 13. 
Table 13. Summary of demographic variables included in the 
statistical analyses. 
Variable Type Definition 
Age Continuous numerical variable and 
categorical, by using the following 
age ranges: 30-44, 45-59, 60-75, 
and over 75 years of age. As well 
as a binary category: <65 and >65 
years of age. 
Represents patients’ age at the date of 
diagnosis. Age categories were selected 
to facilitate comparison with previous 
studies, such as Sinclair et al. (2012) 
Ethnicity Categorical in: (1) White 
Scottish/British, (2) Other and (3) 
Unknown. However, for the Cox 
regression analysis, this variable 
was used as categorical 
dichotomous: 
(1) White Scottish/British, and (2) 
other and unknown. 
This refers to the patient’s ethnic group. 
Sex Categorical dichotomous: male or 
female 
The person’s sex 
Socioeconomic 
status 
This variable was used as 
categorical (quintiles). 
 
Refers to the individual’s position within 
the SIMD condensed to quintiles where 
1= most deprived and 5= least deprived. 
The SIMD is an area-based measure, 
and it was made by splitting Scotland 
into small areas and by looking at each 
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area indicators such as pupil 
performance, crime, unemployment, 
and travel times to the GP among 
others. Thus, it can be used to find 
areas of greater need for support 
(Scottish Government, 2016a). 
Year of diagnosis Numerical Refers to the numerical variable 
indicating the year when the person was 
diagnosed with T2DM. This year was 
also regarded as the index year.  
Metabolic factors: As seen in table 14, these include systolic and diastolic 
blood pressure, cholesterol, CVD, and BMI, whether the individual was 
actively receiving a prescription for medication to lower lipids and blood 
pressure and glycaemic control.  
Table 14. Summary of metabolic variables included in the statistical 
analyses. 





Whether the individual was actively 
receiving antihypertensive medication 
at the date of T2DM diagnosis. 
Antihypertensive medications were 
included according to the ATC 
classification system of drugs. The 
following ATC drug classes were 
included: 
i. C02 – Antihypertensives  
ii. C03 – Diuretics  
iii. C07 – Beta-blockers  
iv. C08 – Calcium channel blockers 
v. C09A – Angiotensin-converting 
inhibitors 
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BMI Continuous numerical variable 
and, also as categorical 
variable based on the WHO’s 
classification of obesity as 
follows: 
a. Non-obese: <30.0 Kg/m2 
b. Obese: >30.0 Kg/m2 
Body Mass Index (Kg/m2). The 
individual’s average BMI at the closest 
date of diagnosis (180 days +/- date of 
diagnosis). 
Cholesterol Numerical and  
Categorical variable: (1) 
normal < 5 mmol/L and (2) 
High > 5 mmol/L. 
An individual’s average levels of 
cholesterol (mmol/L) at the closest 
date of T2DM diagnosis (180 days +/- 
date of diagnosis) 
CVD Categorical dichotomous 
(yes/no). 
Indicating whether an individual had a 
record of admission with a diagnosis of 
CVD at diagnosis (pre-existing) or 
during follow-up. The variable was built 
according to the International 
Classification of Disease (ICD-10; from 
i to iii ) and the Classification of 
Surgical Operation and Procedures 
(OPCS-4; from iv to xi) codes, CVD 
was identified as having one or more 
of the following:  
i. Coronary heart disease I20-I25 
ii. Cerebrovascular disease I60-I69, 
G45 
iii. Peripheral vascular disease 
I70.2, I73 
iv. Coronary artery bypass graft K40-
K46 (main A position only) 
v. Percutaneous coronary intervention 
K49, K50.1, K50.8, K75 
vi. Carotid revascularisation L29.4, 
L29.5, L31.1, L34.4 
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viii. Iliac and femoral 
bypass/endarterectomy/embolecto
my L50.-, L51.-, L52.-, L53.2, L58.-, 
L59.-, L60.1, .2, L62.2 
ix. Transluminal operations including 
angioplasty L26.1, .2, .3, .8, .9, 
L31.1, .8, .9 L39.1, .2, .3, .8, .9, 
L43.1, .2, .3, .8, .9 L47.1, .2, .8, .9, 
L54.1, .2, .8, .9 L63.1, .2, .3, .8, .9, 
L71.- 
x. Major amputation (of leg below, 
through or above knee) X09.3, 9.4, 
9.5 
xi. Minor amputation (foot or toe) 
X10.1, 10.8, 10.9; X11.1, 11.2, 
11.8, 11.9 
In this study, codes for amputation 
were included. Although trauma or 
infection it cannot be discarded as the 
cause of the amputation, peripheral 
arterial disease is a common cause 
(NHS, 2019a).  
Diastolic Blood  
Pressure (DBP) 
Numerical and categorical 
variable according to the SIGN 
guidelines in (1) Normal < 80 
mmHg and (2) High >80 mmHg 
The individual’s average diastolic 
blood pressure (mmHg) at the closest 
day of diagnosis (180 days +/- date of 
diagnosis). 
Glycaemic control  Continuous numerical variable, 
HbA1c levels were also 
classified by ranges (<53 
mmol/mol, 53-63 mmol/mol, 
64-74 mmol/mol, 75-85 
mmol/mol, and >85 mmol/mol). 
Also, according to the SIGN 
guidelines, HbA1c levels will 
be classified in optimal/sub-
optimal glycaemic control (<53 
mmol/mol or >53 mmol/mol). 
It is determined by HbA1c levels 
(mmol/mol). 
The SIGN guidelines general 
recommendation for HbA1c target is 
53 mmol/mol (7.0%) (Scottish 
Intercollegiate Guidelines Network 
(SIGN), 2017b). 
Baseline data reported the average 
HbA1c value in the period between 
180 days before the date of T2DM 
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Whether the individual was actively 
receiving lipid-lowering medication at 
the date of diabetes diagnosis 
For this study, lipid-lowering 
medications were included according 
to the ATC classification system of 
drugs. The C10 “Lipid modifying 
agents” ATC drug class was included. 
Systolic Blood Pressure 
(SBP)  
Numerical and categorical 
variable according to the SIGN 
guidelines in (1) Normal < 130 
mmHg and (2) High >130 
mmHg. 
The individual’s average systolic blood 
pressure (mmHg) at diagnosis (180 
days +/- date of diagnosis) 
3.5.3 Data cleaning  
This process was carried out in order to remove potentially inaccurate 
records from the database. The process was undertaken for the final cohort, 
including 154,660 patients and consisted of an examination for outliers. 
Ranges for plausible data were drawn from SCI-diabetes data quality audit in 
Read (2015) and are presented in table 15.  
Table 15. Cut-off points for continuous variables (Read, 2015) 
Variable  Lower Bound Upper Bound 
Age  30 105 
BMI Kg/m2 15 75 
SBP (mmHg) 80 400 
DBP (mmHg) 40 300 
HbA1c (mmol/mol) 20 304 
Total cholesterol (mmol/L) 1.0 15.0 
After this, entries outside the cut-off points were removed and treated as 
missing. Overall, a total of 57 entries were deleted and treated as missing. 
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Table 16. Implausible data removed from the original cohort. 
Variable Outliers 
BMI at diagnosis 18 
SBP at diagnosis 8 
DBP at diagnosis 3 
Cholesterol at diagnosis 28 
3.5.4 Missing Data 
After cleaning the data, the proportion of missing data for each of the 
variables of interest was calculated. The results are presented in table 17. 
Table 17. Frequencies and proportions of missing data for variables 
of interest 
Variable  Missing Values % of missing data 
HbA1c at diagnosis 17,756 11.5 
BMI at diagnosis 59,810 38.7 
SBP at diagnosis 10,295 6.7 
DBP at diagnosis 10,290 6.7 
Cholesterol at diagnosis 14,999 9.7 
Missing data are a common issue where a dataset has information missing 
for some variables for some cases. Statistical software packages commonly 
exclude cases with missing information from regression analyses, which can 
lead to the elimination of an important proportion of cases and biased 
estimates (Vittinghoff et al., 2012). Different methods to handle missing data 
have been developed; here, I will describe some of the most commonly used. 
3.5.4.1 Handling missing data 
There are many different reasons for incomplete data and the simplest 
method to handle it is by a strategy known as list-wise deletion or complete 
case analysis (CCA). A CCA is a dataset without missing data due to the 
exclusion from the analysis of cases with any missing data. As previously 
discussed, the use of cases with complete data can lead to a substantial 
reduction of the cases and the introduction of bias. (Allison, 2002, Vittinghoff 
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et al., 2012) In order to overcome the problem posed by a reduced dataset, it 
is possible to fill in the missing data to obtain a complete dataset by using 
standard methods for handling missing data. However, an important step to 
choosing the best approach is to establish the mechanisms of missing data 
(Vittinghoff et al., 2012). 
3.5.4.2 Mechanisms of missing data 
Briefly, data can be missing completely at random (MCAR) when the 
probability of the data being missing is not associated with any part of the 
data, thus missingness on a certain variable is not related to missingness on 
some other variable. Another mechanism for missing data is data missing at 
random (MAR), which implies a conditional probability of missing data where, 
for a case, the probability of missing data for a specific variable can depend 
on another variable related to that particular case but not vice versa. 
However, it is not possible to test whether the conditions of MAR are met 
(Allison, 2002, Vittinghoff et al., 2012). Finally, data can be missing not at 
random (MNAR) when the probability of missingness depends on 
unobserved quantities; therefore, it is not possible to verify or dismiss MNAR 
from the observed data. However, under suspicion of MNAR, a sensitivity 
analysis can be conducted, one way is by multiple imputation (Vittinghoff et 
al., 2012). 
Multiple imputation is often regarded as a reliable method for completing a 
dataset with missing values; this approach also incorporates random error in 
order to reflect the degree of uncertainty due to the missing data (Vittinghoff 
et al., 2012, Allison, 2002). As the name indicates, it is necessary to impute a 
dataset several numbers of times in order to get valid estimates. The 
specification of the imputation model requires building a probabilistic model 
to fill in the missing data, whenever variables are associated with one 
another, they should be included in the model (Vittinghoff et al., 2012). 
However, this approach usually requires time to conduct, and although it is 
recognised as a reliable method, it is not without limitations (Allison, 2002). 
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One of the most discussed issues is about reliability, which depends on the 
correct specification of the model (Longford, 2005). I will explain more about 
this aspect in the following imputation sub-section.  
3.5.4.3 Complete case analysis 
As previously described, a CCA or list-wise deletion is achieved by excluding 
all cases with incomplete data. The main advantage of this method is the 
attainment of a dataset where any kind of statistical analysis can be used. 
However, if the mechanism of missing data takes any form other than MCAR, 
the use of a CCA can lead to bias due to the probability of a missing data on 
an independent variable depending on the values of the dependent variable 
(Allison, 2002). 
3.5.4.4 Imputation 
There are different mechanisms of data imputation. In general, these 
methods imply substituting plausible data for each missing value in order to 
be able to use a dataset without missing values. Some of the most common 
mechanisms of imputation are conditional mean imputation, maximum 
likelihood and multiple imputation which is regarded as more a more efficient 
method than maximum likelihood and is particularly useful for estimation in a 
Cox proportional hazards model (Vittinghoff et al., 2012). 
Due to its accessibility for a wide range of analyses and availability in some 
of the main software packages, multiple imputation is becoming the approach 
preferred for managing partially observed datasets (Carpenter et al., 2012). 
However, when formulating the imputation model, it is necessary to ensure 
compatibility with the model of interest. Hence, all the variables in the model 
of interest should be included in the imputation model, including the response 
(Carpenter et al., 2012, Vittinghoff et al., 2012). 
After considering the different methods of missing data management, a CCA 
and multiple imputation were chosen for this strand. As previously 
mentioned, both methods have their limitations. However, their use was 
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considered necessary to investigate the potential introduction of bias by 
missing data. Furthermore, as both methods were used, results from the two 
datasets are presented, as is recommended when imputation is performed. 
However, as results from both were similar, in the results section it is only 
presented those for the imputed dataset. The results of the CCA are 
presented in the appendices. 
3.5.5 Complete case analysis 
For CCA patients were selected only if they had complete data for the 
variables of interest. Overall, a total of 66,890 participants had missing 
information for at least one variable of interest; these cases were deleted and 
resulted in a complete dataset with no missing data (n= 87,770). 
3.5.6 Multiple imputation  
Data from the full cohort were analysed to determine the pattern of missing 
data, e.g. Missing completely at random (MCAR), Missing at random (MAR). 
Data MCAR will yield a statistically non-significant result when performing a 
little MCAR test. The little MCAR test for the cohort used in this study was 
found to be statistically significant, thus failing to prove that data is 
completely randomly missing. Read (2015) studied the mechanisms of 
missing data in the SCI-diabetes dataset for people diagnosed with T2DM 
before 1995 and 2008 plus a sub-analysis of those diagnosed between 2004 
and 2008. It was reported that from 2004, once the QOF was introduced, 
MAR was the missing data mechanism more plausible for the SCI-Diabetes 
dataset. Moreover, multiple imputation by either predictive mean matching 
(PMM), multivariate normal (MVN) multiple imputation or multiple imputation 
using chained equations (MICE) were deemed to be suitable approaches to 
handling missing data in this dataset. Consequently, as the current study 
included people diagnosed with T2DM between 2004 and 2012, it was 
assumed that data is MAR. Here the general approach to handling missing 
data is described.  
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The approach to deal with missing data was by means of MICE using the 
mice package in R software. The imputation model comprised the following 
variables: age, sex, SIMD, ethnicity, BMI, SBP, DBP, HbA1c, cholesterol, 
CVD and time-to-drug prescription initiation. Non-normally distributed 
variables were log-transformed for the imputation process and transformed 
back for the analysis; this is described more in detail in the section ‘Testing 
assumption of normality’. Furthermore, following what is suggested by the 
literature, the number of imputed datasets depended on the extent of missing 
data. Overall, 56.75% of the cases had complete data. Thus a total of 45 
datasets were created, which took >48 hours to complete and required me to 
obtain access to greater computing capacity.  
3.5.7 Statistical methods  
3.5.7.1 Significance testing 
All statistical tests used a significance level of 0.05, and 95% confidence 
intervals are presented. All p-values were rounded to three decimal places 
with the exception of p-values that round to 0.0000, which are presented as 
<0.0001. Any p-value <0.05 was considered statistically significant. 
3.5.7.2 Data summarisation 
Summary statistics comprised descriptive statistics for the study variables. 
Percentages and number of responses in each category are described for 
dichotomous and categorical variables, and the mean and standard deviation 
are described for continuous variables. In addition, the median and 
interquartile range are presented when considered appropriate.  
All means and percentages were formatted to one decimal place; likewise, 
the standard deviation was formatted to one decimal place. All summary and 
comparison tables (e.g. people with and without a record of prescription) 
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3.5.7.3 Software 
RStudio and SPSS version 22 were the statistical software packages used to 
produce all summaries, listing, statistical analysis and graphs. However, 
Microsoft Excel was also used to generate some graphs. 
3.5.8 Statistical analysis  
People diagnosed with T2DM between 2004 and 2012 and who fulfil the 
inclusion criteria were the main analysis population. The primary outcome of 
this analysis was the proportion of patients who initiated drug treatment 
within two years following the diagnosis of T2DM. In addition, the association 
between patient factors and time to drug prescription was explored. 
3.5.8.1 Testing the assumption of normality 
Testing the assumption of normality is important for all research; a variable’s 
distribution will determine the appropriate summary statistic and type of 
analysis to be performed when making comparisons between groups 
(Sheard, 2018). Therefore, variables were checked for normality. The 
exploration involved a visual inspection for normality using histograms 
generated in SPSS.  
With the exception of HbA1c, which was positively skewed, the variables of 
interest followed a normal distribution. Since the multiple imputation method 
assumes that all quantitative variables follow a normal distribution, a log-
transformation of HbA1c was conducted prior to data imputation, and then 
data were back-transformed. For the subsequent analysis, since the 
variables had a normal distribution, parametric tests were conducted. 
3.5.8.2 Proportions of people with T2DM with and without GLM 
prescription and their characteristics 
Baseline characteristics were assessed using data recorded closest to time 
of diagnosis; descriptive statistics are presented in tables including 
demographic data, HbA1c and pre-existing conditions such as CVD. Chi-
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square tests and independent-samples t-test were used to examine 
differences between groups. 
The analysis of prescription patterns included only people who received GLM 
prescription within two years of diagnosis. Descriptive statistics were used to 
determine the proportion of people who after two years received a certain 
type of GLM. As previously mentioned, GLMs were classified into four main 
types: metformin, sulfonylurea, insulin and others. 
Further analyses were carried out using age as a continuous variable and 
stratified by age groups. The Kaplan-Meier estimator was used to show 
differences in time to drug prescription by age groups.  
3.5.8.3 Proportions of people with T2DM with sub-optimal glycaemic 
control  
Participants were categorised into different groups according to their HbA1c 
levels. The different categories have been previously defined. Descriptive 
statistics are presented in tables, including demographic data, pre-existing 
conditions, and whether if received or not a prescription for GLM. Chi-square 
tests and independent-samples t-test were used to examine differences 
between groups. 
3.5.8.4 Factors associated with time to GLM prescription  
For the analysis of the relation between time to drug prescription initiation 
and covariates, Cox regression models were used. Data were censored for 
patients who did not receive a GLM prescription during 730 days of follow-up.  
Cox proportional hazards models were used to test the association of 
possible covariates such as age, sex, HbA1c and CVD (both prevalent and 
incident during follow up) with time to treatment initiation. The Cox 
proportional hazard model for survival time is a regression analysis used to 
assess time to events, and there are various continuous or categorical 
explanatory variables, it is one of the most widely used models for analysis of 
survival (Vollmer, 2011). The model requires the data to meet the 
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proportional hazards assumption to be fit for this model; this means that 
hazard function ratios do not change with time (Vollmer, 2011, Nikulin and 
Wu, 2016). 
Therefore, data were analysed in order to determine their suitability to this 
model. Further information is presented below. 
Checking the assumption of proportional hazards 
For continuous variables, the tests to evaluate the proportional hazards 
assumption were based on the scaled Schoenfeld residuals and tests of non-
linearity by plotting the Martingale residuals. These residuals represent the 
difference between the observed and expected covariate given the risk set at 
that time, when the assumption is met, a plot of the residuals against 
individual covariates should be linear (scattered around zero). Overall, the 
proportional hazards assumption was considered violated when the 
Martingale residuals plot failed to show a linear relation and the test of the 
Schoenfeld residuals were statistically significant. Then, if the assumption 
was violated, the variable was stratified into groups. Thus, it was converted 
into a categorical variable (Xue and Schifano, 2017). 
Table 18 below shows the results of the Schoenfeld residuals. According to 
these results, it is not possible to assume a proportional hazard in most 
variables. BMI, SBP, HbA1c, and cholesterol showed a significant 
relationship which indicates that residuals are not close to zero, and thus 
refutes the proportional hazards. 
Table 18. Test for the proportional-hazards assumption based on the 
scaled Schoenfeld residuals 
Variable rho Chi-square p-value 
Age at diagnosis 0.003 0.496 0.481 
BMI 0.051 128.178 <0.0001 
SBP 0.019 18.290 <0.0001 
DBP -0.001 0.135 0.714 
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HbA1c 0.192 1390.122 <0.0001 
Cholesterol 0.037 68.632 <0.0001 
Figure 5 below presents the plots from the Martingale residuals which help to 
determine linearity. As indicated in table 18, patterns in BMI, SBP, HbA1c, 
and cholesterol plots suggest that these variables do not meet the 
assumption of linearity.  
Figure 5. Tests of non-linearity: Martingale residuals plots for age, BMI, 
SBP, DBP, HbA1c, and cholesterol 
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Given than nonlinearity was apparent in some variables such as BMI, SBP, 
HbA1c, and cholesterol, categories were created for these variables. 
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Moreover, although nonlinearity was not an issue for DBP, this variable was 
used as a categorical variable in order to be consistent with SBP. As 
described in tables 12-14 in section 3.5.2, the categorisation of the variables 
was made according to clinical cut-offs with testing of the potential hazards 
assumption for categorical variables as described below. 
For this analysis, age at diagnosis of diabetes was used as a continuous 
variable in order to estimate the change in the hazard (GLM prescription 
initiation) per each year of age. Furthermore, as seen in table 13 and 14, all 
of the other covariates included in the models were treated as categorical 
variables, such as sex, CVD at baseline, receiving lipid-lowering medication, 
receiving antihypertensive medication, cholesterol, BMI, HbA1c, SBP and 
DBP. 
The proportional hazard assumption for each categorical variable was 
checked using log minus log survival plots. For this purpose, the time to drug 
treatment variable was log converted, and survival curves were analysed. If 
the lines were parallel, then the assumption was considered not to be 
violated. The log minus log survival plots are presented in figure 6. The 
variables which were checked are sex, ethnicity, SIMD, HbA1c, BMI, 
cholesterol, CVD, antihypertensive medication and lipid-lowering medication. 
The proportional hazards assumption was considered to have been met for 
these variables.  
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Figure 6. Log minus log survival plots 












Further analysis stratified by age 
In order to check for a relation between age and HbA1c, a linear regression 
analysis was conducted to test the homoscedasticity between variables. 
Then, a Pearson correlation analysis was conducted. Subsequently, adjusted 
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3.6 Qualitative methods 
In this section, I will describe the qualitative strand of the study. As previously 
described, the qualitative strand of this PhD focused on HCPs’ 
understandings and views in order to develop a better understanding of the 
factors and considerations that might influence clinical decision-making in 
relation to initiation of pharmacological treatment in people with T2DM. Thus, 
this study sought to obtain information which would help to broaden the 
results of the quantitative analysis and provide greater understanding about 
clinical decision-making. Moreover, I sought to explore the reasons for 
differences in HCPs’ reported decision-making with regards to initiating GLM. 
The following sub-section provides the reasons why a qualitative approach 
was adopted. Then, I will go on to describe the theoretical framework which 
informed the study, followed by an account of the strengths and limitations of 
the method of data collection chosen. A subsequent section moves on to 
describe the recruitment process and sample selection. Finally, the approach 
to data analysis is presented. 
3.6.1 Rationale behind the qualitative study 
Qualitative studies seek to answer the “what” “how” and “why” of a 
phenomenon, they focus on understanding factors that may contribute to a 
phenomenon (Britten, 1995, Britten, 2011). Qualitative research uses non-
numerical techniques of data production and analysis, they relate to the use 
of textual data deriving from transcriptions of verbal or observational data, 
and the use of distinctive theoretical frameworks. Furthermore, qualitative 
research allows people to express their thoughts in their own terms, which 
can give rise to unanticipated or unexpected findings. Thus, the use of 
qualitative methods can allow a deeper understanding of a phenomenon 
(Holloway, 2005). 
Moreover, the scope of qualitative research has been shown to be of value in 
providing information about views and perceptions of healthcare 
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professionals on aspects related to healthcare (Britten, 1995). The outputs of 
qualitative research are valuable to the healthcare environment in different 
ways; their contributions include the development of conceptual definitions 
such as “shared decision-making” to the development of new theories 
(Britten, 2011). 
Providing explanations rather than mere descriptions is regarded as one of 
the most important contributions to healthcare literature (Britten, 2011). 
Although healthcare decisions have been traditionally based on statistically 
significant data, qualitative research is an approach that offers means to 
address important issues related to evidence-based practice and the 
complexities of organisation and reorganisation of healthcare (Collin, 2010, 
Caronna, 2010). A crucial way to improve evidence-based medicine is to 
understand how HCPs adapt elements such as guidelines, and how they 
perceive them in relation to their clinical autonomy and how they “translate” 
evidence-based medicine into practice. Thus, the use of qualitative methods 
in healthcare research helps to identify values and perceptions of various 
actors and to grasp the complexity of decision-making and structural changes 
in healthcare delivery (Collin, 2010). 
Qualitative research enhances the development and effective implementation 
of evidence-based policies and programmes. In diabetes research, the 
inclusion of qualitative research can contribute to understanding 
stakeholders’ needs and barriers to enhanced healthcare, resources, and 
processes, especially in areas that have not been widely studied (Hennink et 
al., 2017). As described in earlier chapters, to date, qualitative research has 
tended to focus mainly on patients’ experiences of diabetes and the services 
and support they receive, and lesser attention, by comparison, has been 
placed on HCPs’ perspectives (Hennink et al., 2017).  
Thus far, I have described how qualitative research provides means to gain 
insights into a phenomenon. Therefore, in order to answer the research 
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questions previously stated, a qualitative approach was considered most 
appropriate. In the next sub-section, I will present the theoretical framework 
chosen to inform this study. 
3.6.2 Theoretical stance  
The overall aim of this qualitative study was to elucidate clinical decision-
making around GLM initiation. Since this study focused on HCPs’ decisions 
and considerations as to when to start pharmacological treatment in people 
with diabetes, it is important to consider the theories that informed this strand 
of the research. Principles of the “Normalisation Process Theory” (henceforth 
NPT) and the basic principles of the social-ecological model (SEM) were 
adopted as a framework to understand HCPs’ reported decision-making and 
understandings (May and Finch, 2009). The decision to use NPT and SEM 
was partly the result of the literature review described in chapter 2, which 
showed the importance of contextual factors and organisational factors on 
clinical decision-making. Thus, together with findings from the literature 
review, these theories informed the development of the topic guide and the 
main themes which framed the data analysis.  
NPT theory is used to investigate the routine embedding of material practices 
and ideologies in their social contexts and is concerned with the social 
organisation of the work of implementation, which is operationalised through 
four mechanisms: coherence, cognitive participation, collective action and 
reflexive monitoring. This theory provides a framework to investigate 
processes that become components of everyday work such as the use of 
clinical guidelines or medical devices. For this study, the process relates to 
HCPs’ decisions about when to initiate GLM in people with recently 
diagnosed T2DM. It is presumed that HCPs have already a set of ideas 
about diabetes care that was learned, shared, and experienced in their own 
social contexts (coherence). Such practice is framed by their engagement to 
it, a shared belief that requires buying in the value of providing such care 
(cognitive participation) which is aimed at an institutional goal that requires a 
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collective investment of effort (collective action) and constant judgement 
about their utility and effectiveness (reflexive monitoring). The appraisal of 
the practice can either be collective or individual and can lead to a 
modification or reconstruction of the practice. Therefore, all that happens at a 
particular consultation within a practice will be influenced by contextual 
factors and individual judgements (May and Finch, 2009). Therefore, this 
study is underpinned by a theoretical perspective concerned with the 
processes that lead to the integration of a practice, taking into account the 
impact of a constantly changing social context. The development of the topic 
guide for the interviews was partly informed by the four mechanisms of the 
NPT, this is described in detail in section 3.6.4.2.  
In relation to the SEM, Bronfenbrenner developed this perspective for 
research in human development. In summary, it relates to the interaction of 
the environment and the development of a person. This model emphasises 
that an environment is a set of nested structures, each inside the next and 
that behaviours are shaped by these structures, which have also been 
referred to as multiple systems or levels of influences. Thus, the use of this 
model allows one to observe and detect a wide range of influences on an 
individual’s decision-making, such as community (macrosystem), 
organisational (exosystem), interpersonal (mesosystem) and individual 
(microsystem); therefore, indicating that an individual’s decision-making, will 
depend on certain characteristics of their context (Bronfenbrenner, 1979). 
Therefore, the SEM offers a mean to understanding clinical decision-making 
in a holistic way by considering the interplay between HCPs and their 
environment.  
In this study, the WHO approach of the SEM levels of influence was adapted 
to take into account the influence of factors such as protocols and resources 
on clinical decision-making (World Health Organization, 2020a, Dahlberg and 
Krug, 2002). In this way, the SEM informed the categorisation and deductive 
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construction of the initial themes and categories used during the data 
analysis process.  
The SEM sees the individual at the centre of a multilevel environment. Since 
HCPs’ clinical decision-making was the focus of this strand, the first theme 
constructed was HCPs’ role which relates to the first SEM level (individual). 
The second level is the interpersonal which relates to close relationships 
which may shape clinical decision-making, for this level, two themes were 
built: HCP-patient relationship and patient-related factors. The third level 
(organisational) is concerned with the social and physical environment, and 
the fourth level (community) relates to societal and cultural factors such as 
policies, healthcare system, and economy, among others (Dahlberg and 
Krug, 2002, World Health Organization, 2020a). As it will be described later 
in this chapter, these last two levels were joined to build one category named 
contextual factors. The list of themes and categories built based on the SEM 
is presented in section 3.6.5. 
The SEM has been previously applied to healthcare research; for instance, 
Misfeldt et al. (2017) used this model to understand issues influencing teams’ 
work in primary care in Canada. Likewise, Suter et al. (2017) studied how 
policies, regulation and legislations inform the design and implementation of 
team-based primary healthcare service delivery in three provinces in 
Canada. These studies found that in primary care settings “the context” 
refers to legislations, availability of human resources, protocols, 
organisational leadership and vision, and team leadership and vision, among 
other factors (Misfeldt et al., 2017, Suter et al., 2017). Thus, the design of this 
study is underpinned by the SEM and NPT theoretical perspectives, which 
seek to provide a framework to explain why things become routine 
components of everyday work and explore how a person’s context can 
influence and shape their decision-making. 
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Here, I have described the principles of the theories and how they informed 
this study. The next part of this section will focus on data collection. 
Accordingly, I will first describe the approach to data collection chosen for 
this study, interviews, and explain the reason why this was chosen.  
3.6.3 Interviews 
Qualitative interviews are conducted with the purpose of discovering the 
interviewee’s framework of meanings and understandings (Britten, 1995), 
which in this study are related to decision making around GLM initiation in the 
management of T2DM. For the qualitative strand of the research, one-to-one 
interviews were the method used for data collection. 
Interviewing is a method that gives participants the opportunity to describe 
their experiences in detail. Moreover, it is used to access the participants’ 
understandings of their world. Interviews capture a unique and subjective 
account and depend on the participant’s ability to recall, reflect on and 
articulate their experiences. Therefore, an interview is unique and cannot be 
replicated since it is a process that varies from participant to participant and 
is influenced by the participant’s experiences (Holloway, 2005). 
Furthermore, interviews are conducted in order to explore in detail the topic 
being discussed, to learn what is important from participants’ perspectives 
(Britten, 1995, Holloway, 2005). By conducting interviews is also possible to 
reveal how people view and explain their behaviour and experience their 
environments. Thus, interviews allow the researcher to explore and discuss 
past events (Holloway, 2005). The type of questions to be asked during a 
qualitative interview depend on the topic studied. However, in order to pursue 
an idea in more detail, less structured interviews with open-ended questions 
are preferred (Britten, 1995). 
3.6.4 Recruitment and sample 
In order to expand the results from the cohort analysis, I aimed to interview 
GPs and nurses, working in primary care because they are the HCPs 
 
 
Research Design  141 
responsible for prescribing GLM and managing T2DM. As described in 
chapter 1, although traditionally GPs are in charge of prescribing, in the UK, 
registered nurses who have completed additional courses are authorised to 
prescribe. Furthermore, general practice nurses are in charge of monitoring 
and managing chronic diseases in which diabetes is included (Scottish 
Government, 2016b, Scottish Executive Health Department, 2006). In this 
section, I will outline the recruitment process and the data collection process. 
The qualitative strand used a deductive-inductive approach, which is further 
explained in section 3.6.5. Data collection and analysis commenced 
simultaneously to find similarities and relationships between interviews and 
refine the analysis (Gray, 2004). This approach was chosen as it allows 
findings from early interviews to inform topics and questions asked in later 
ones. By using this approach, I was also able to inform my sampling, as I 
describe later on. 
3.6.4.1 Sample 
In contrast with quantitative research, qualitative studies do not require 
probabilistic sampling but a proper selection of participants. In other words, in 
qualitative research statistical representativity is not relevant, however, to 
involve and seek a sample which includes people with knowledge or life 
experience related to the research question is needed. Since qualitative 
research seeks to collect rich-data, participants’ ability to provide meaningful 
information on the topic is important (Namey and Trotter, 2015, Moen and 
Middelthon, 2015, Tolley et al., 2016). For this study, purposive sampling was 
used driven by the research questions; this means that respondents were 
deliberately chosen based on their ability to provide the information needed 
(Padgett, 2012b, Tracy, 2013). 
Initially, I considered interviewing only HCPs with a special interest in T2DM. 
However, after discussion with my supervisors and my first-year review panel 
members, I decided to broaden my focus to all GPs and nurses managing 
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people with T2DM regardless of their interest in T2DM. Overall, by including 
HCPs’ without interest in T2DM, I expected to gather a more diverse set of 
experiences and views, which would enrich the findings as they are also in 
charge of prescribing GLM.  
Furthermore, I considered it important to include individuals who do not have 
a special interest in T2DM but still manage people with this condition on a 
daily basis. First, not every practice has a specialist in T2DM to whom GPs or 
nurses can approach to discuss treatment options. Second, HCPs’ with and 
without a special interest in T2DM might inform their decisions on the 
management of T2DM differently. Third, the inclusion of a broader sample 
would be more likely to mirror the reality of primary care. Thus, I sought to 
adopt a maximum variation sampling methodology in order to capture 
heterogeneity across HCPs. However, for the reasons I will describe below, I 
anticipated that recruiting such a sample would be difficult. 
Recruitment represented a significant challenge to this research. There were 
several reasons to this, which I will now address. To begin with, as a non-
British non-medical PhD student, I lacked clinical contacts in Scotland. In 
addition, this study had very limited funding; thus, no financial or other kinds 
of incentives could be offered to potential participants. Lastly, the tight 
schedule of clinicians made this task challenging. The majority of HCPs I had 
contact with were extremely busy and could only allocate short time-slots to 
talk to me. Additionally, as mentioned by some HCPs, they were interested in 
participating; however, their intention to participate vanished in the face of 
other crucial tasks that they needed to perform. However, by using an initial 
convenience sample followed by snowballing recruitment, I gained access to 
the participants of this study. This two-step approach to recruiting participants 
will be described in more detail in the following paragraphs. 
First, a convenience sample was recruited. Convenience sampling is 
characterised by ease of access to participants, although is less rigorous 
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than other approaches to sampling, it is often used when the budget is limited 
and/or there is a short period to recruit participants (Tolley et al., 2016). I 
followed this approach due to the lack of initial clinical contacts in the UK. 
Although contacting HCPs directly by their emails is an approach commonly 
used, for the current study, the reasons to why this was not considered 
feasible were 1) writing to HCPs as an unknown individual was deemed as 
not beneficial and 2) it could be perceived as making excessive demands 
and a cold way to contact participants. These two aspects were considered 
as potentially causing my request to be ignored by HCPs and a less efficient 
way of recruiting participants. Thus, as a fist-step, I approached clinical 
colleagues working within the University of Edinburgh who had established 
networks and contacts in primary care. In this manner, I was able to gain 
access to an initial sample consisting of academic GPs and GPs working in 
diabetes care. 
Second, access to a convenience sample allowed me to locate further 
participants by using the snowball method of recruitment. The snowball 
recruitment method involves the recruitment of one or more, sometimes hard-
to-reach participants, and asking them to refer the researcher to other 
members of their group. Although HCPs are not essentially a hard-to-reach 
population, for the reasons I have described above, my access to them was 
limited. The snowballing strategy requires first finding an individual with the 
desired characteristics, then using the person’s social network to recruit 
similar individuals in a multistage process. After the initial person helps to 
recruit participants, the participants then will help to recruit others 
themselves. Therefore, the number of participants increases or “snowballs” 
as participants help to recruit others by referring them to the researcher 
(Padgett, 2012b, Sadler et al., 2010). 
Recruitment of participants by snowballing is particularly useful when the aim 
of the study is explorative, qualitative or descriptive. It serves as an 
alternative when other sampling methodologies are not feasible (Cohen and 
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Arieli, 2011). Even though this method has been widely used in research 
conducted in conflict areas, and among seriously ill, gangs and drug users, 
its use can be extended to other contexts, such as populations that are not 
hidden but are hard-to-reach for research purposes (Cohen and Arieli, 2011). 
Furthermore, snowballing is regarded as one of the most effective methods 
to obtain access to populations with the advantage of shortening the time and 
reducing costs (Cohen and Arieli, 2011, Sadler et al., 2010). However, one of 
the aspects that has received significant criticism is related to sample 
representativeness, although in qualitative research representativeness is not 
relevant, a wide and diverse range of people is desired to obtain complex, 
nuanced descriptions of a phenomenon (Cohen and Arieli, 2011, Moen and 
Middelthon, 2015). A convenience sampling supplemented by a snowballing 
approach helped ensure an adequate number of participants took part in the 
study to allow sufficient data to be collected 
Information about participants is presented in chapter 5. I tried to achieve a 
sample of HCPs working in different settings: rural and urban, small and 
large, with and without specialists in diabetes, in affluent and deprived areas. 
However, the sample was skewed towards GPs working in urban areas. This 
could be attributed to the recruitment methods employed, convenience and 
snowballing sampling. These have the limitation that the sampling depends 
on the referrals and on the willingness of them and their contacts to 
participate, which can lead to the exclusion of individuals who do not belong 
to the specific network being accessed and might cause unbalance in 
selected demographic characteristics. Furthermore, these recruitment 
methods can also lead to the inclusion of the more cooperative participants 
who are willing to participate in the study (Cohen and Arieli, 2011, Sadler et 
al., 2010, Tracy, 2013). 
Potential participants were provided with invitation packs consisting of a 
cover letter, participant information sheet and an ‘opt-in’ form. Participants 
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who opted-in were interviewed, and after interviewing them, I asked them to 
pass on an electronic invitation pack to colleagues they thought might be 
interested in participating. However, I informed them that this was not 
mandatory and would not affect their participation and that I did not need to 
know the names or personal details of their colleagues, unless they decided 
to participate. All information packs included my contact details and that of 
my supervisor, Professor Julia Lawton, to allow participants the opportunity to 
discuss the study and address any concerns or queries before agreeing to 
take part. After returning the opt-in form and having the chance to discuss the 
study, potential participants were sent out a consent form to review in 
advance of the interview taking place. Written consent was obtained from all 
participants. All participants were advised of their right to withdraw from the 
research at any time, without giving a reason, and without repercussions. 
Participants did not receive any incentives for their participation. 
After conducting and analysing the last interviews, I realised that the sample 
was heavily skewed towards GPs. I tried to interview more nurses; however, 
this task became very difficult as they were hard-to-reach. Towards the end 
of the data collection stage, the nurses I managed to get in contact with 
expressed their lack of time to talk to me. Some of the nurses that I 
interviewed confirmed this issue and described their time constraints and 
how they struggled to maintain training and skills in diabetes care in work 
hours.  
Although the initial plan was to interview 20 HCPs, data collection was 
stopped after 16 HCPs were interviewed. The decision to stop data collection 
at this point was made because of HCPs’ limited availability and lack of 
resources to incentivise them. Although a bigger sample would have been 
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3.6.4.2 Data collection 
As previously indicated, one-to-one interviews consisting of broad, open-
ended questions were used to enable the discussion to stay relevant to the 
study aims, while allowing HCPs to express additional information that they 
considered relevant to their decision-making in relation to initiation of GLM in 
people with T2DM.  
At the beginning of each interview, I introduced myself to the interviewee, 
discussed the study and answered any question they had. I emphasised that 
all information that could be used to identify them would be removed from the 
typed up interviews and that our talk was confidential. The preamble to the 
interview was essential as it allowed me to clarify my position as a non-
medical professional, which I considered vital to disclose in order to obtain 
more detailed and extended answers. Furthermore, disclosing my position 
was pointed out as relevant by some participants since after I mentioned my 
position of non-medical PhD student, they expressed that they would be 
more clear and explicit with their explanations and terminology.  
As indicated in sub-section 3.5.2, the NPT is one of the theories which 
underpinned this strand. The four mechanisms or principles of the NPT 
helped frame most of the questions included in the topic guide (see appendix 
4). Table 19 shows each mechanism of the NPT and the themes and 
questions that were included in the topic guide based on them. 








Example of questions 
included 
Coherence  Defines and organises a 
practice (prescription of 
GLMs), which has a meaning 
that is learned, shared, and 




Compared to other practices in 
the area, how big is this 
practice? 
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specific social context (HCPs 
in primary care). 
How many GPs and nurses 
work in the practice? 
Cognitive  
participation 
Practices are framed by 
human engagement (HCPs). 
Includes people implicated in 
the practice which joins and 
support it (task allocation) 
and requires buying into the 
practice (knowledge on the 
topic). 
Division of 
tasks and their 






How is diabetes care organised 
in the practice? Could you tell 
me a little bit about yourself 
and your role in your practice? 
How do you decide when is 
appropriate or necessary to 
prescribe pharmacological 
treatment for glucose control? 
Collective  
action  
Relates to confidence and 
trust in the process. Two 
important qualities 1) skill-set 
and 2) Incorporation within a 
social context. Requires 
collectively invested effort 
(inter and intra-professional 
communication). 
Development 






Do you have the opportunity to 
keep up to date? If so, how do 
you do this? 
How hard/easy is to keep 
updated with new 
policies/guidelines? 
Is there anyone else 
responsible for care of people 
with diabetes? How do you 
divide the workload? 
Reflexive  
monitoring 
Evaluation and monitoring of 
processes (Patients’ 
outcomes). Includes 
judgements about the 
practice utility and 
effectiveness which may lead 
to a reconfiguration 
Monitoring of 
patients.  
How frequently do you review 
patients?  
Are there any reasons about 
why your decisions about when 
to initiate pharma treatment 
might have changed over time? 
 
However, the development of the semi-structured guide was not only based 
on the four mechanisms of the NPT but also on findings from the literature 
review. Hence, other topics which were not considered in the questions 
informed by the NPT such as those related to QOF were included given their 
relevance to the research questions. The incorporation of these additional 
questions led to a transformation of the general structure of the topic guide 
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used to conduct the interviews, i.e. the order of the questions did not follow 
the NPT mechanisms but general key areas to be explored.  
In this way, three key areas were explored in the interviews with HCPs. First, 
since the literature review showed that the organisation, implementation and 
approach to guidelines and frameworks vary between practices, I enquired 
about their professional background and their practice structure. This 
included information about their professional training, whether they had taken 
any courses in diabetes or had an interest in it, information about their 
practice size and its location, and their patients’ socio-demographic 
backgrounds. The information from this section gave me a general idea of 
their context, which was useful to tailor some following questions and to 
identify topics to follow-up. In addition, I took the opportunity to ask about 
their role in a multidisciplinary team and the organisation of diabetes care. 
The second area was the management of T2DM. During this part of the 
interview, I asked participants about their patients’ pathways to diagnosis, 
initial consultations and I also asked them to give me examples whenever 
was possible. This area in the interview guide was informed by the results 
from previous studies which described that aspects such as consultation 
length, workload and continuity of care influence clinical decision-making. 
Furthermore, I let them know that I was aware of QOF and its recent 
decommissioning and asked them about their experiences and thoughts 
about guidelines’ usefulness as well as that of other resources available to 
help them manage T2DM. Some questions that I often asked during this part 
of interview were related to their perception about the way they prescribe and 
(if) why they thought it had changed over time, and if they considered the 
decommissioning of QOF as having an impact on the treatment and care 
given to patients with T2DM. Third, before closing the interview, I gave each 
participant the opportunity to add information that was not discussed 
previously, but which they considered important when deciding to initiate 
GLM in people with T2DM. 
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An example of the general topic guide is included in appendix 4. Overall, the 
topic guide was developed in light of what was found in the literature review, 
the preliminary findings of the quantitative strand, and taking into 
consideration the epistemological position, particularly the NPT which has 
been previously described. Furthermore, my supervisor Julia Lawton, helped 
me check that the topic was generating the information I needed to answer 
the research questions by looking at some of the initial interviews. This 
process also helped to refine the topic guide. In addition, as mentioned 
before, the inductive approach of this study allowed me to explore issues that 
early interviewees brought to the conversation. For instance, in light of 
findings emerging from the initial interviews, I included questions about the 
assessment of patients’ motivation, which were not initially included and not 
reported in the literature review in chapter 2. Similarly, one participant 
mentioned that they do things in a particular way, which they considered 
different from other clinical colleagues. Then, after this interview, I decided to 
ask every HCP if they thought they did anything different from their 
colleagues regarding when to prescribe GLM for people recently diagnosed 
with T2DM. Furthermore, each interview followed a unique structure as I was 
guided by specific things individuals volunteered and raised. 
Interviews were conducted either face-to-face or by telephone, depending on 
HCPs’ preferences; the majority of participants opted for a telephone call. 
The duration of the interviews varied from 30 to 56 minutes and were 
conducted between 27 March 2018 and 20 September 2018. All interviews 
were digitally recorded and subsequently transcribed in full. 
3.6.4.3 Ethical considerations 
Since the recruitment was through clinical colleagues and snowballing, and 
not through NHS resources, ethical approval was sought from the Usher 
Research Review Group (UREG). Approval from the University of Edinburgh, 
Usher institute’s review board, was obtained for the research project to 
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proceed; date of initial application: 14 December 2017, date of approval: 23 
March 2018. 
Participants were not asked to disclose patients’ data or patients’ private 
information during their interviews and were reminded that their input should 
be based on their personal opinions, views and experiences. Data generated 
from the research were kept securely, all hard-copies of data, including 
consent forms, were stored securely in secure filing cabinets within a locked 
office at Edinburgh University. Likewise, all audio recordings were 
downloaded and stored electronically in a private folder on a password-
protected computer within a locked office at Edinburgh University, and 
access to these data was only possible by myself, and my supervisors. The 
audios were transcribed by myself, and only two interviews were transcribed 
by a trusted employee of the University, with a confidentiality agreement in 
place. Transcripts were anonymised, participants were given a unique 
identifying number, and all identifiable personal information was stored 
separately. 
3.6.5 Data analysis 
Analysis of the data is an integral part of the research process, and it is to 
some extent a shaper of the research process, it helps us to understand 
“What does it all mean?” (Moen and Middelthon, 2015, Leavy, 2017). Data 
analysis was an iterative process, a deductive-inductive approach was 
adopted, and data analysis started as soon as data collection began. Once 
an interview was conducted, I transcribed it promptly and undertook an initial 
analysis to identify issues, which also informed subsequent interviews.  
The construction of categories in qualitative data analysis depends mostly on 
the research question and what is known about the subject or field. There are 
two different approaches to the development of categories: inductive and 
deductive. First, the construction of categories based on empirical data is 
referred to as an inductive approach where categories are built by 
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paraphrasing, generalising and abstracting the original data. Second, in a 
deductive approach the construction of categories is based on theories and 
hypothesis about the field studied. These two approaches are not 
contradictory and may be used combined for qualitative text analysis 
(Kuckartz, 2014). Thus, as a first step, from what I found in the literature 
review and based on the SEM, I develop main broad themes and categories, 
which served as a starting point or searching aid. Secondly, the sub-
categories were constructed inductively. For instance, one main category 
deductively constructed was “patient-related factors” as this was something 
that had emerged from the literature review as a main broad theme. 
However, sub-themes such as “psychological readiness” or “development 
and presence of symptoms” emerged from the analysis of the interviews’ 
transcriptions.  
According to the SEM, HCPs’ decisions about when to start GLM is the result 
of a dynamic interplay between individual, interpersonal, organisational and 
community environments. In table 20 is presented the list of themes and 
categories that were deductively constructed based on the literature and 
categorised into themes according to the SEM levels. These themes and 
categories were used as an initial aid but are not the final ones that will be 
presented in chapter 5. As it will be explained in the findings chapter, the list 
was modified by the inductive construction of categories (based on HCPs’ 
accounts).  
Table 20. Initial themes and categories deductively constructed as 
search aid for data analysis. 
SEM level Main theme Categories 
1. Individual HCPs’ role 
Experience, role, and qualifications 
Perceptions of own role 
2. Interpersonal 
HCP-patient relationship 
Historical contact with patients 
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3. Organisational 
Contextual factors 
Characteristics of the practice 





Data preparation and organisation consisted of transcribing the interviews. 
The software NVivo facilitated data retrieval and thematic coding. The initial 
immersion or exploration to the data took place during the transcription 
process. I transcribed most of the interviews myself, and I had the 
opportunity to construct initial sub-thematic codes during this process. 
Furthermore, I also engaged in an immersive reading and listening of the 
interviews that were transcribed by someone else. I did this to check the 
accuracy of the transcriptions, and to engage with their content in the same 
way as with the other interviews.  
Thus, the coding process in which I classified the data into general themes 
started at the same time as transcription and consisted of an iterative 
process that continued until the process of writing up the findings. After 
transcribing the interviews, I employed manual procedures such as colour-
coding, and the software NVivo for data coding, thematic development and 
data retrieval. Coding and thematic development are one of the most 
common procedures to analyse qualitative data and consists of searching for 
patterns and central ideas, and assigning names or labels to sections of data 
in order to develop themes (Holloway and Galvin, 2016, Padgett, 2012a).  
The data were analysed using the method of cross-comparison to identify 
common issues and experiences. Thus, the thematic categories, which 
emerged from the qualitative text analysis, refer to topics included in different 
passages within the interviews’ transcripts (Kuckartz, 2014). Thematic codes 
were developed through repeated close-readings of the interview transcripts, 
although deductively constructed categories were initially developed based 
on the literature, these were used as a general aid and not as a rigid set of 
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main themes. I developed an initial mental map to organise in a visual way 
the themes identified in the interviews. Then, after several meetings and 
discussions with my supervisor, three main themes were identified, which are 
presented in chapter 5. 
3.6.6 Reflexivity 
In this sub-section, I will provide insights emerging from my reflections on my 
role in the study. Reflexivity is a practice that researchers should pay 
attention to in order to reduce, or at least acknowledge the impact of personal 
bias. It requires the researcher to be conscious and to understand their role 
critically in the decisions that shape the data, and their approach to 
understanding it (Frattaroli S., 2012, Longhofer et al., 2012). 
I would like to address my position as a non-British, non-medical PhD student 
who speaks English as a second language. As I mentioned above, these 
aspects made the recruitment process very challenging as I aimed to conduct 
a study without having a network in the UK. However, once I gained access 
to initial participants, my position helped me to recruit further participants. 
Some HCPs seemed to sympathise with my position as a PhD student, and 
accepted to participate. Furthermore, the majority also agreed to pass on the 
invitation packs to their colleagues.  
Moreover, as mentioned above, during the interviews, I made the 
interviewees aware of my background. Thus, I informed them that I do not 
have a medical background and my accent made evident that I was a 
foreigner and non-native speaker of English. These characteristics, I consider 
worked in my favour because most of the participants tried to provide clear 
and explicit answers.  
3.7 Integration of quantitative and qualitative findings  
As previously mentioned, the research process was iterative, and while each 
strand was considered independent of the other, I used preliminary findings 
from the quantitative analysis to inform the topic guide. In addition, I used 
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themes emerging from the interviews to interpret quantitative data and 
considered the possibility of conducting further analysis that would have 
helped to provide greater insight. However, as I will describe in the 
discussion, further analyses of the dataset were not possible. In brief, the 
additional variables that I thought of including after analysing the interview 
data were not available for the cohort dataset. 
In order to convey the merged results, I used a combination of approaches to 
integrating them, such as comparison of convergent and contradictory 
findings, and triangulation in which I sought to extend and complement 
findings. The use of these approaches allowed me to bring findings together 
in order to enhance each other and to increase the potential to understand 
associations between the different kinds of data. 
For this study, triangulation refers to the examination of findings from two 
different viewpoints (quantitative and qualitative), which provide different 
angles of a topic. These different sources might produce a fuller and more 
complete picture of the phenomenon if brought together. Thus, by drawing 
findings from two different sources, triangulation was used to produce 
complementary data (Bergman, 2008).  
The overall interpretation of the findings is presented in chapter 6. In order to 
merge the two sets of results, I first identified areas or themes that were 
represented in both strands. Then, I compared and contrasted them. Finally, I 
synthesised the results in a discussion where I sought to explain to what 
extent and in what ways findings converged and related to each other. 
3.8 Summary  
This chapter has described the overall research aims, the mixed-methods 
approach used to address the overarching research question as well as the 
research questions related to each of the quantitative and qualitative strands. 
It has also provided detailed information about the mixed-methods study 
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design and methods and outlined the research process for both the 
quantitative and qualitative strands.  
For the quantitative strand, a retrospective cohort study was conducted; 
participants were drawn from a 2016 extract of the SCI-diabetes dataset. 
Participants were selected if they were diagnosed with T2DM between 2004 
and 2012 and survived for two years after diagnosis. The data cleaning sub-
section presented the methodology used to build the dataset for the analysis. 
However, given the proportion of missing values, methods of managing 
missing data were discussed. The analysis of the cohort resulted in the 
creation of two different datasets, a CCA and a multiple-imputed one. The 
key outcomes were the proportion of patients that initiated drug treatment 
within two years following diagnosis of T2DM and the association between 
patient factors and time to GLM prescription initiation. Descriptive statistics, 
Kaplan-Meier curves and Cox regression models were used. 
For the qualitative strand, interviews were conducted with HCPs working in 
primary care; the normalisation process theory and the social-ecological 
model informed the study. A deductive-inductive approach was used; thus, 
data collection and analysis started at the same time. A purposive sample 
was recruited and supplemented by a snowball method of recruitment. Data 
were transcribed and analysed using the method of cross-comparison.  
The next chapter presents the results of the quantitative strand. Then, 
chapter 5 reports the findings from the qualitative strand. The integration of 
both strands of the research is presented and discussed in chapter 6. 
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Chapter 4 Quantitative results  
4.1 Introduction 
As explained in the previous chapter in section 3.5.4.3, a CCA was 
performed initially, and then an imputed dataset was created and analysed. 
In the chapter that follows, I present only the results of the imputed dataset 
as it was considerably larger. The results from the CCA, which were similar 
to the imputed dataset, can be found in appendix 4. A comparison of the 
findings from the analyses of the imputed and CCA datasets is given at the 
end of this chapter. 
The first section of this chapter is concerned with the description of the 
characteristics of the people included in the cohort. Then, the differences 
according to glycaemic control (optimal vs sub-optimal) are provided. 
Subsequently, the results of the Kaplan-Meier survival analysis and the Cox-
regression analysis are presented. Lastly, a summary of the main findings is 
provided. 
4.2 Characteristics of the population  
In this section, I will describe the characteristics of the entire cohort, as well 
as characteristics stratified by age groups. Overall, as observed in table 21, 
men formed over half of the entire cohort and most age groups, with the 
exception of patients > 75 years of age in which there was a higher 
proportion of women than men. Furthermore, as seen in table 21 the majority 
of the participants (39.8%) were in the 60-74 years category. 
Demographic characteristics such as ethnicity were distributed similarly 
across all age groups, where the majority of the people were identified as 
white Scottish/British. Larger proportions of the population were in the most 
deprived quintile than in the least deprived quintile and this pattern was more 
marked in younger than older age groups.  
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Table 21. Baseline characteristics of people diagnosed with T2DM 
from 2004 to 2012 in Scotland included in the imputed dataset. 
Variable Entire Cohort 
(n= 154,660) 
Age Groups (years) 
30 to 44 
(n= 17,274) 
45 to 59 
(n= 53,927) 




Age, years (mean + SD) 61.0 + 12.5 39.6 + 3.9 53.2 + 4.2 67.0 +4.2 80.2 +4.1 
Gender, male (%, n) 55.9 (86,421) 60.6 (10,465) 60.5 (32,614) 55.0 (33,893) 43.2 (9,449) 
























SIMD quintiles (%, n) 



































4.3 Proportions of people with T2DM with and without 
glucose-lowering medication prescription during 
follow-up and their characteristics 
Demographic and metabolic factors such as HbA1c, cholesterol and pre-
existing CVD were compared between people with and without GLM 
prescription initiation at different time points.  
The proportions of people who received GLM prescription initiation by year of 
diagnosis are described first. Lastly, the baseline characteristics of people 
who received and did not receive medication prescription by two years after 
diagnosis are presented. 
4.3.1 Differences by year of diagnosis 
As shown in figure 7 below, from 2004 to 2012, more than half of the patients 
received a GLM prescription within two years from the diagnosis of T2DM. 
The index year with the highest proportion of people receiving a prescription 
was 2011 with 56.7% and the year with the lowest was 2012 with 52.8%. 
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Time to glucose-lowering initiation prescription was stratified into three 
different time-points after diagnosis in a) Diagnosis (0-90 days), b) from 3 to 
12 months and, 3) from 12 to 24 months after diagnosis. Overall, of those 
who received a prescription (n=84,997), 56.8% received it within 90 days 
after diagnosis, 25.1% between three and 12 months after diagnosis, and 
18.1% within 12 to 24 months after diagnosis. Figure 7 shows a clear trend of 
increasing proportions of people who received medication prescription at 
diagnosis (0 – 3 months) ranging from 25.6% in 2004 to up to 36.1% in 2012. 
Moreover, the lowest proportions of people who received GLM prescription 
for every index year was between 12 to 24 months after T2DM diagnosis.  
Figure 7. Proportions of patients in the imputed dataset cohort who 
received drug treatment, stratified by period of prescription. 
 
 
4.3.2 Baseline characteristics of people with T2DM who 
received GLM prescription vs people with T2DM who 
did not. 
In this section, a description of the differences among people with T2DM that 
received and did not receive GLM prescription within two years after 
diagnosis is presented. In order to ease the interpretation of the results, 
abbreviations for the groups of people who received and did not receive GLM 
prescription will be used in the following sections. Henceforth, the group of 
2004 2005 2006 2007 2008 2009 2010 2011 2012
12 to 24 months 12.0% 10.9% 11.0% 10.4% 11.1% 9.7% 9.7% 9.9% 5.0%
3 to 12 months 16.3% 16.1% 14.8% 14.0% 13.6% 13.2% 12.0% 12.6% 11.8%
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people who received GLM prescription within two years of diagnosis will be 
referred to as GLM-2Y, and the group of people who did not receive 
medication prescription within 2 years will be referred as NM-2Y. 
Overall, table 22 shows that GLM-2Y patients were significantly younger 
(58.9 years) compared to NM-2Y (63.5 years). Distributions of other 
demographic characteristics such as SIMD and ethnicity were also different. 
In general, the majority of people in the GLM-2Y group were from the most 
deprived SIMD quintiles.  
There was a significant difference in HbA1c, BMI, SBP, DBP, and cholesterol 
between the groups. Mean HbA1c was significantly higher in GLM-2Y than 
NM-2Y. After stratifying by levels of HbA1c, the analysis showed that a larger 
proportion of GLM-2Y had HbA1c >53 mmol/mol at baseline than NM-2Y. 
Likewise, GLM-2Y had a higher mean BMI, and also a larger proportion had 
a BMI >30 Kg/m2 than NM-2Y.  
Interestingly, mean SBP and the proportion of people with SBP >130 mmHg 
were observed to be significantly lower for GLM-2Y than for NM-2Y. 
Conversely, mean DBP (80.8 mmHg) and proportions of people with DBP 
>80 mmHg (49.6%) were higher for GLM-2Y than for NM-2Y.  
The bottom part of the table shows that almost half of GLM-2Y had baseline 
cholesterol >5 mmol/L (48.0%), which was statistically significantly higher 
than for NM-2Y (42.8%). In contrast, GLM-2Y included lower proportions of 
people with pre-existing CVD, people receiving lipid-lowering medication, and 
people receiving antihypertensive medication. However, since people in the 
NM-2Ygroup were older, some of the above associations could be 
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Table 22. Baseline characteristics of people diagnosed with T2DM in 
Scotland 2004 – 2012, classified whether they received 
pharmacological treatment by two years after diagnosis 
Variable Received medication  
prescription 
Yes (84,997) No (69,663) 
Age, years (mean + SD) 58.9 + 12.3 63.5 + 12.2 
Gender, male (%, n) 57.0 (48,419) 54.6 (38,002) 
























BMI Mean Kg/m2 + SD 32.6 + 6.9 31.5 + 6.3 
> 30 Kg/m2 (%, n) 61.5 (52,266) 54.9 (38,268) 
Systolic Blood 
Pressure  
Mean mmHg + SD 137.5 + 15.2 138.6 + 15.3 
> 130 mmHg (%, n) 67.6 (57,439) 71.1 (49,570) 
Diastolic Blood 
Pressure  
Mean mmHg + SD 80.8 + 8.7 79.6 + 19.3 
> 80 mmHg (%, n) 49.6 (42,207) 44.9 (31,308) 
HbA1c Mean mmol/mol + SD 68.2 + 19.5 49.3 + 11.1 
> 53 mmol/mol(%, n) 78.6 (66,811) 24.8 (17,251) 
Cholesterol Mean mmol/L + SD 5.1 + 1.2 4.9 + 1.1 
> 5 mmol/L (%, n) 48.0 (40,802) 42.8 (29,805) 
Pre-existing CVD (%, n) 17.4 (14,774) 21.3 (14,810) 
Receiving lipid-lowering medication (%, n) 31.2 (26,488) 38.9 (27,069) 
Receiving antihypertensive medication (%, n) 49.1 (41,757) 60.5 (42,179) 
Differences between groups were statistically significant for all variables presented in this 
table (p-value < 0.0001) 
4.3.3 Analysis by age groups 
In addition to the data presented in the previous section, it is important to 
describe in greater detail the differences between baseline characteristics of 
the GLM-2Y and NM-2Y groups stratified by age groups given the potential 
for confounding by age.  
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In general, mean HbA1c and the proportions of people with HbA1c >53 
mmol/mol were higher for GLM-2Y across all age groups (table 23). 
However, there were some characteristics which consistently changed 
across age groups. For instance, table 23 shows an inverse association 
between age and mean HbA1c. A similar inverse association was found 
between age and mean BMI. However, the comparison within groups 
showed that whether they received medication prescription or not, BMI was 
not significantly different for people in the 30-44 years group. In contrast, 
GLM-2Y from the 45 to 59 years, 60 to 74 years and >75 years sub-groups 
had significantly larger proportions of people with a BMI > 30 Kg/m2 than 
NM-2Y. The analysis of cholesterol levels showed similar trends to the ones 
for BMI, proportions of people with cholesterol >5mmol/mol were significantly 
larger for GLM-2Y than NM-2Y with the exception of the 30 to 44 years 
group, and an inverse association was found between age and cholesterol 
levels. Moreover, table 23 also shows an increasing pattern of higher SBP, 
higher proportions of people with pre-existing CVD, and higher proportions of 
people receiving lipid-lowering and antihypertensive medication at increased 
age regardless of whether they received GLM or not. These patterns suggest 
that age could be a potential confounder between the influence of patients’ 
clinical characteristics and GLM prescription. 
For 30-44 years old, mean SBP was significantly higher for NM-2Y, but the 
proportions of people with >130 mmHg were not statistically significantly 
different. Similar results were found for cholesterol where the mean was 
higher for GLM-2Y, but no difference was found in the proportions of people 
with cholesterol >5 mmol/L. In contrast, mean DBP was significantly lower for 
GLM-2Y. However, no difference was found in the proportions of people with 
DBP >80 mmHg. With regards to other medications, a lower proportion of 
GLM-2Y were receiving antihypertensive medication at baseline. 
Among people of 45 to 59 years of age, table 23 shows that GLM-2Y patients 
had higher mean BMI and also a higher proportion of people in the obese 
category. Moreover, mean HbA1c and the proportion of people with sub-
optimal glucose levels were higher for GLM-2Y. In contrast, mean SBP was 
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lower for GLM-2Y, and lower proportions of people were receiving lipid-
lowering medication and anti-hypertensive medication than NM-2Y. No 
differences were found for DBP, and people with pre-existing CVD. 
For people between 60 to 74 years of age at diagnosis of diabetes, table 23 
shows that the GLM-2Y group had significantly higher mean BMI, mean 
HbA1c, mean DBP, and mean cholesterol. Likewise, proportions of people 
with obesity, sub-optimal HbA1c, DBP > 80 mmHg, and cholesterol > 5 
mmol/L were higher amongst GLM-2Y. Contrarily, GLM-2Y had a significantly 
lower mean SBP and people with SBP >130 mmHg and also lower 
proportions of pre-existing CVD, people receiving lipid-lowering medication 
and people anti-hypertensive medication. 
For the oldest age group (>75 years), similar results to those found for the 
previous age group can be seen in table 23. Hence, GLM-2Y had 
significantly higher mean BMI, mean HbA1c, mean DBP, and mean 
cholesterol. Equally, proportions people with obesity, sub-optimal HbA1c, 
DBP > 80 mmHg, and cholesterol > 5 mmol/L were higher for GLM-2Y. 
Conversely, significantly lower proportions of people receiving lipid-lowering 
medication and anti-hypertensive medication were found for GLM-2Y.  
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4.3.4 Prescription patterns 
A sub-group analysis of people who received GLM prescription was 
conducted in order to determine patterns of prescription. The results in table 
24 show that overall, metformin was the first medication most commonly 
prescribed followed by sulfonylureas. Proportions of people prescribed 
metformin decreased across age groups, the opposite was found for 
sulfonylureas where proportions increased among older age groups.  
Moreover, the proportions of insulin prescription were low across all age 
groups, and there was a decreasing proportion across age groups. Thus, the 
30 to 44 age group had the highest proportion of insulin prescription, and the 
group of people >75 years had the lowest.  
Table 24. Patterns of first medication prescribed to people with 





Age groups (years) 
30 to 44 
n=11,953 
45 to 59 
n=33,115 
















































Differences between groups were statistically significant for all variables presented in this 
table (p-value < 0.0001) 
It is important to note that, among those who received GLM prescription, only 
92.9% (79,039) were recorded as being prescribed monotherapy. The 
remaining 7.1% were registered as having received two or more drugs for 
glucose-control. Hence, the numbers in table 24 do not add to 100 percent. 
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No further analysis was conducted in relation to prescription patterns as this 
was beyond the scope of this study. 
This section addressed the first research question what is the proportion of 
people with T2DM within two years after diagnosis who have and who have 
not received prescriptions for GLM within two years after diagnosis, and how 
do characteristics differ between people who have and who have not 
received a prescription for GLM within two years after diagnosis? The results 
from the analysis showed that: 
 Overall, 54.9% (n=84,997) of people diagnosed with T2DM between 
2004 and 2012 received GLM within two years after diagnosis. 
Moreover, from 2004 to 2012 there was a trend of increasing 
proportions of people receiving GLM within three months of diagnosis 
(25.6% in 2004 to 36.1% in 2012)  
 In general, age and HbA1c were higher for people who received a 
prescription by two years after diagnosis of T2DM. Moreover, amongst 
those who received a GLM prescription proportions of people 
receiving anti-hypertensive medication and lipid-lowering medication 
were significantly lower. 
 The analysis by age groups showed that regardless of their 
prescription status, people in the >75 years groups had lower BMI, 
lower HbA1c and cholesterol, but had higher SBP, proportion of pre-
existing CVD and were receiving lipid-lowering and antihypertensive 
medication in higher proportions.  
These findings suggest that some clinical factors and their association with 
prescription of GLM could be confounded by age. Furthermore, this section 
included a sub-group analysis of prescription patterns of people who received 
GLM within two years after diagnosis, which showed that the first GLM most 
commonly prescribed was metformin. The section that follows moves on to 
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describe in greater detail the glycaemic control of the studied population and 
the differences between groups according to their HbA1c.  
4.4 Glycaemic control and glucose-lowering 
medication prescription initiation 
Having explained the characteristics of people with T2DM by receipt of a 
GLM prescription within 2 years from diagnosis, I will now move on to 
address the second research question of this strand. In this section, I 
describe the role of both HbA1c at diagnosis of diabetes and the additional 
effect of age in influencing treatment choices 
4.4.1 Baseline HbA1c by age groups 
In table 25, mean, median and interquartile ranges of HbA1c closest to 
diagnosis for the cohort and for age groups are presented. Higher mean 
HbA1c was observed in younger than older groups. The fact that a large 
proportion of HbA1c values were below the cut-off point for T2DM diagnosis; 
presumably arises because the diagnosis was based on blood glucose rather 
than HbA1c. 
Table 25. HbA1c closest to diagnosis in the imputed dataset, 




30 to 44 
n= 17,274 
45 to 59 
n= 53,927 




Mean (SD),  
mmol/mol 
59.7 (18.9) 64.7 (20.5) 61.8 (19.5) 57.8 (17.6) 55.9 (16.4) 
Median (IQR),  
mmol/mol 
54 (47–68) 60 (50–77) 56 (48–72) 52.5 (46–65) 51.5 (45–61) 
4.4.2 Differences between people with optimal and sub-
optimal HbA1c 
People with T2DM were classified according to their HbA1c closest to 
diagnosis into optimal (< 53 mmol/mol) or sub-optimal (> 53 mmol/mol) 
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groups. The results of the analysis based on this classification are presented 
in this section.  
It can be seen from Table 26 below that people with HbA1c >53 mmol/mol in 
the cohort consisted of 58.2% (48,926) men. Overall, there was a larger 
proportion of white Scottish/British (70.2%) than other/unknown ethic groups, 
but proportions did not differ between those with optimal and sub-optimal 
HbA1c. Furthermore, there was a larger proportion of people from the most 
deprived SIMD quintiles (1 and 2) in the group with sub-optimal HbA1c. 
People with sub-optimal HbA1c were significantly younger than those with 
optimal HbA1c. 
Moreover, people with sub-optimal HbA1c had higher mean BMI and higher 
proportions with a BMI > 30 Kg/m2, than people with optimal HbA1c. 
Similarly, mean cholesterol and mean DBP were higher for people with sub-
optimal HbA1c. In contrast, people with optimal HbA1c included a statistically 
significantly larger proportions of people with SBP >130 mmHg. However, 
mean SBP was not significantly different between optimal and sub-optimal 
HbA1c. 
Compared to people with sub-optimal HbA1c people with optimal HbA1c 
were more likely to have pre-existing CVD, possibly due to the fact that this 
group included a larger proportion of older people who have lower HbA1c. 
Likewise, a higher proportion of people with optimal HbA1c were receiving 
lipid-lowering medication and antihypertensive medication. 
Table 26. Characteristics of people in the imputed dataset with 
recently diagnosed T2DM stratified by baseline HbA1c levels, <53 
mmol/mol and >53 mmol/mol 
Variable 
HbA1c  P values 
<53 mmol/mol >53 mmol/mol  
Age, years (mean + SD 62.9 (12.5) 59.4 (13.6) <0.0001 
Gender, male (%, n) 53.1 (37,495) 58.2 (48,926) <0.0001 
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Ethnicity, White Scottish/British (%, n) 70.2 (49,592) 70.2 (59,010) 0.349 

















Mean Kg/m2 + SD 31.8 (6.9) 32.3 (7.0) <0.0001 
> 30 Kg/m2 (%, n) 57.0 (40,245) 59.8 (50,289) <0.0001 
Systolic Blood  
Pressure  
Mean mmHg + SD 137.9 (15.4) 137.9 (15.7) 0.862 
> 130 mmHg (%, n) 70.0 (49,393) 68.5 (57,616) <0.0001 
Diastolic Blood  
Pressure  
Mean mmHg + SD 79.5 (9.0) 80.9 (9.3) <0.0001 
> 80 mmHg (%, n) 44.3 (31,266) 50.2 (42,249) <0.0001 
Cholesterol 
Mean mmol/L + SD 4.9 (1.1) 5.1 (1.2) <0.0001 
> 5 mmol/L (%, n) 41.1 (29,032) 49.4 (41,575) <0.0001 
Pre-existing CVD (%, n) 22.6 (13,930) 16.9 (12,702) <0.0001 
Receiving lipid-lowering  
medication (%, n) 
41.0 (28,972) 29.2 (24,585) <0.0001 
Receiving antihypertensive  
medication (%, n) 
62.8 (44,318) 47.1 (39,618) <0.0001 
4.4.3 Glucose-lowering medication prescription among 
people with optimal and sub-optimal HbA1c 
Figure 8 below compares the proportions of people with sub-optimal HbA1c 
with and without GLM prescription within two years of diagnosis. Overall, 
approximately one-third of people (25.8%) with optimal HbA1c received 
medication prescription by two years after diagnosis. Conversely, for those 
with sub-optimal HbA1c, the majority (79.5%) received a pharmacological 
prescription for glucose control within two years after T2DM diagnosis. 
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Figure 8. Proportions of people with T2DM in the imputed dataset, by 
pharmacological treatment status at 2 years after diagnosis. 
 
4.4.3.1 Proportions of people who received and did not receive 
glucose-lowering medication prescription stratified by different 
ranges of sub-optimal HbA1c 
The previous section showed a large difference in proportions of people who 
received medication prescription by two years after T2DM diagnosis by 
HbA1c category. As described in the previous section, compared with people 
with optimal HbA1c (<53 mmol/mol), a larger proportion of the people with 
HbA1c > 53 mmol/mol received medication prescription within 2 years after 
diagnosis of T2DM.  
The next section describes a sensitivity analysis using different cut-points for 
HbA1c. Figure 9 below illustrates the breakdown of people with and without 
GLM prescription stratified by different groups of sub-optimal HbA1c. In 
general, there is a clear trend of increasing proportions of people with 
medication prescription. Thus, a larger proportion (94.8%) of people with 
HbA1c >85 mmol/mol were prescribed GLM prescription by two years after 
diagnosis.  
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Overall, more than half received GLM prescription by two years after 
diagnosis; proportions ranged from 64.2% (23,263) for those with an HbA1c 
of 53 – 63 mmol/mol to 94.8% (14,960) for those with an HbA1c > 85 
mmol/mol. 
Figure 9. Proportions of people with T2DM in the imputed dataset by 
pharmacological treatment status at 2 years after diagnosis, 
stratified by ranges of HbA1c 
 
4.4.4 HbA1c distribution by age groups 
As previously described, 20.5% (17,251) of people with HbA1c > 53 
mmol/mol did not receive a GLM prescription by two years after diagnosis. 
Table 27 presents a comparison of the proportions of people with sub-optimal 
HbA1c according to age groups. 
Table 27 compares the breakdown of sub-optimal HbA1c categories 
according to age groups. Overall, higher HbA1c was associated with 
increased proportions of people receiving GLM in all age groups. In addition, 
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increased age group. Conversely, proportions for all other sub-optimal HbA1c 
groups decreased at increased age groups. Hence, people >75 years had 
lower proportions of people with the highest HbA1c ranges. 
Table 27. Proportions of patients in the imputed dataset with HbA1c 
>53 mmol/mol who did not receive pharmacological treatment by 






Age group (years) 
30 to 44 
n= 1,828 
45 to 59 
n= 5,763 












































This section addressed the second research question of this study, which is: 
what is the proportion of people with T2DM and sub-optimal glycaemic 
control without a GLM prescription two years after diagnosis? Taken 
together, the results of this section provide important insights into differences 
in prescription proportions according to different HbA1c categories.  
 Over half of the cohort (54.3%, n=84,062) had a baseline HbA1c >53 
mmol/mol. Among those who had HbA1c >53 mmol/mol, 79.5% 
(n=66,811) received GLM prescription within two years from 
diagnosis. The sensitivity analysis illustrated in figure 9 showed that 
the proportions of people who received GLM within two years from 
diagnosis increased at increasing HbA1c levels at baseline. 
 The analysis of HbA1c closest to diagnosis stratified by age groups 
presented in table 25 showed that mean and median HbA1c differed 
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by age group. Mean HbA1c decreased at increased age group. Thus, 
the 30 to 44 years group had the highest HbA1c mean, and the >75 
years group had the lowest.  
 The analysis of people with baseline HbA1c >53 mmol/mol by age and 
HbA1c ranges (table 25) showed that a larger proportion of people 
>75 years had HbA1c of 53–63 mmol/mol and the youngest group of 
people with 30–44 years had the lowest proportion. Conversely, the 
oldest group (>75 years) had lower proportions of people with HbA1c 
>63 mmol/mol whereas people of 30–44 years had the highest 
proportions of people with HbA1c >63mmol/mol. Furthermore, across 
the HbA1c classification groups, there was an increasing proportion of 
people with GLM by two years after diagnosis. 
4.5 Time to glucose-lowering medication prescription 
This section will explain the factors associated with time to GLM initiation by 
two years after diagnosis for people with T2DM diagnosed between the years 
2004 to 2012. 
The first part of this section uses Kaplan-Meier curves to describe differences 
in time to treatment after diagnosis of diabetes by age groups. Next, average 
days to medication prescription are presented and compared across age 
groups. Finally, the last part of this section presents the results of the Cox 
regression analysis. 
4.5.1 Time to glucose-lowering medication initiation by age 
group  
4.5.1.1 Kaplan Meier 
The results of the Kaplan-Meier survival analysis are presented in figure 10. 
Overall, proportions receiving a prescription for GLM were 31.2%, 45.0%, 
and 54.9% for 30 days, 1 year, and 2 years after diagnosis of T2DM. 
Furthermore, figure 10 shows that the proportion of patients who had 
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received drug treatment for T2DM within two years of diagnosis decreased 
with increasing age.  
Figure 10. Kaplan-Meier curves for time to glucose-lowering treatment 





















Table 28 below presents the comparison of proportions of people who 
received GLM prescription by two years after the diagnosis of T2DM and the 
median time to pharmacological prescription (25th, 75th percentile). Results 
are presented before and after stratifying by age groups. Overall, mean and 
median days to treatment were higher for the older age group and lower for 
the youngest group. Thus, proportions of people who received GLM 
prescription by two years after diagnosis were 69.3%, 61.4%, 50.3%, and 
40.9% for patients in the 30 to 44, 45 to 59, 60 to 74, and > 75 age groups, 
respectively (p<0.0001). 
It is apparent from the table that, within two years of T2DM diagnosis, 
younger people have shorter times to GLM initiation. Overall, the number of 
days to GLM prescription was positively skewed since median values were 
considerably fewer than mean number of days. Another interesting aspect of 
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this table is related to the eldest group (>75 years), although this group had 
the lowest proportion of people who received GLM prescription within two 
years after diagnosis. The median and mean days to medication prescription 
were lower than those for the two previous groups, 60–74 years and 45–59 
years. 
Table 28. Time to pharmacological treatment initiation by age group 
among patients over 30 years of age in Scotland 2004-2013 who 





Age Groups (years) 
30 to 44 
n=17,274 
45 to 59 
n=53,927 
60 to 74 
n=61,584 
> 75 years 
n=21,875 
Patients with drug  
treatment within 2 years  











Median number of days  
from diagnosis to  
treatment initiation (IQR) 
54 (7 – 258) 40  
(5 – 230) 
56  
(7 – 261) 
60  
(7 – 268) 
53  
(7 – 247) 
Mean days to time to  
treatment initiation  
155.8 142.9 156.8 160.6 152.7 
So far, differences in prescription and time to prescription across different 
groups have been shown. A more detailed account of the factors associated 
with time to GLM prescription is given in the following section. 
 
4.5.2 Factors associated with time to drug treatment initiation  
In this section, the results of the Cox regression analysis, the univariate and 
the four adjusted models are presented. Further details about variable 
selection and the examination of the assumptions of the model were 
presented in the previous chapter. 
Results are presented in table 29 where the first column “Univariate model” 
indicates the results from the model including the single variable described in 
the left column of the table. The following column “Adjusted model 1” 
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presents the results of the model adjusted by age, sex, ethnicity, and SIMD. 
Next, the column “Adjusted model 2” provides the results from the model, 
which adjusted for the characteristics included in model 1 plus baseline 
HbA1c. Then, the column “Adjusted model 3” presents results from the model 
included the variables in model 2 plus other metabolic factors such as BMI, 
SBP, DBP, cholesterol and pre-existing CVD. Finally, the last column 
“Adjusted model 4” provides the results of the model, including the variables 
in model 3 with the addition of use of other drugs such as lipid-lowering 
medication and antihypertensive medication.  
4.5.2.1 Hazard ratios for glucose-lowering medication prescription 
As expected from previous findings, the data in table 29 also show that older 
age was associated with longer time to drug treatment initiation. Conversely, 
HbA1c >53 mmol/mol and higher BMI were associated with shorter time to 
GLM prescription.  
Moreover, model 1 suggests that increased age, female sex, other/unknown 
ethnicity and lower deprivation were associated with longer time to GLM 
prescription. Results of model 2 were similar to model 1; however, female 
sex and HbA1c >53 mmol/mol were associated with shorter time to 
medication prescription. 
The table below shows that in the adjusted models 3 and 4 increased age, 
other/unknown ethnicity, and the least deprived SIMD quintiles were 
associated with longer time to medication prescription. Conversely, female 
sex, HbA1c >53 mmol/mol and BMI >30 Kg/m2 were associated with having 
shorter time to GLM prescription.  
With respect to other metabolic factors, model 3 shows that raised blood 
pressure; SBP >130 mmHg and DBP >80 mmHg was associated with longer 
time to medication prescription. Similarly, cholesterol >5 mmol/L was 
associated with longer time to GLM prescription; no significant association 
was found for pre-existing CVD. Moreover, model 4 shows that receiving 
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antihypertensive medication was associated with having longer time to 
medication prescription. However, receiving lipid-lowering medication was 
associated with shorter times to medication prescription; there was no 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   
   
   
   






































   
 
































   
   








































































































































































































































































































































































































































































































































































































































































































   



















   




































   
   
   
   
   
   





















   
   






















   
   









180  Quantitative Results 
4.5.2.2 Further analyses on factors associated with time to drug 
treatment initiation analyses in the imputed dataset, stratified by 
age 
As table 25 in sub-section 4.4.1 showed, there seemed to be a correlation 
between HbA1c and age. This was further inspected visually and by a formal 
test of interaction. As shown in figure 11, HbA1c decreased at increased age. 
The formal test of interaction corroborated this, the test between age and 
HbA1c showed that age and HbA1c were negatively correlated r= –0.161, p 
= <0.0001. In other words, a one-year increase on patient’s age is associated 
with a decrease of 0.161 mmol/mol on HbA1c. 
Thus, adjusted model 4 analyses (described in section 4.5.2), stratified by 
age were conducted and are shown in table 30. Although there was an effect 
on patients’ age, HbA1c >53 mmol/mol was associated with shorter time to 
GLM initiation across all age groups. Hazard ratios for time to treatment 
associated with the higher HbA1c category increased with age and people 
with T2DM in the oldest group (>75 years) with HbA1c >53 mmol/mol had 
six-fold times increased in risk of receiving GLM compared with people in the 
same age group with HbA1c <53 mmol/mol. 
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Moreover, patients’ sex and its association with time to GLM prescription 
differed depending on age groups. While there was no significant association 
between sexes for the oldest groups (60 to74 years, and >75 years), in the 
group of people aged 30 to 44 years females had shorter time to GLM 
initiation, and in those aged 45 to 59 years, males had shorter time to GLM 
initiation. Demographic characteristics such as ethnicity and SIMD showed 
similar results with previous analyses. Hence, other/unknown ethnicity and 
least deprived SIMD quintiles were associated with longer time to GLM 
initiation. 
Table 30. Adjusted hazard ratios for initiation of GLM for people with 
T2DM in the imputed dataset, stratified by age group 
Variable 
Age groups (years) 









Age 0.99 (0.98-0.99) 0.99 (0.98-0.99) 0.99 (0.98-0.99) 0.98 (0.97-0.98) 
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Antihypertensive 














Furthermore, in order to be able to compare my findings with the literature 
presented in chapter 2, a further analysis using binary categories for patients’ 
age was conducted. Table 31 shows the results of the adjusted model 4, 
which included all variables presented. As shown in table 31, and in 
accordance with previous analyses, people aged >65 years had longer time 
to GLM initiation than people aged <65 years. 
Table 31. Adjusted hazard ratios for initiation of GLM for people with 
T2DM in the imputed dataset using age in binary categories. 
Variable Adjusted model 4 p-value 
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In this section, the third research question: what factors are associated with 
time to GLM prescription for people with T2DM within two years of diagnosis, 
was addressed. The key points of the analyses presented in this section are: 
 The Kaplan-Meier curves showed that time to GLM after T2DM 
diagnosis increased at increased age group. Thus, in figure 10 it can 
be observed that the proportion of people who had received GLM by 2 
years after diagnosis was higher for the 30-44 years group (69.3%) 
and lower for the >75 years group (40.9%). 
 The Cox regression analysis presented in table 29 showed that 
increased age was associated with having longer time to drug 
prescription for glucose control. Moreover, HbA1c >53 mmol/mol and 
BMI >30 Kg/m2 were associated with having shorter time to GLM 
prescription. 
 As it was suggested in previous sections, there was a potential 
association between HbA1c and age. Therefore, an analysis of these 
variables was performed. Such analysis indicated a negative 
association (HbA1c decreased at increased age) and further analysis 
stratified by age groups were conducted.  
 However, despite the association between age and HbA1c the 
association between age and time to treatment persisted after 
adjustment for HbA1c. The stratified analysis by age in binary 
categories showed similar results. 
4.6 Imputed dataset vs CCA 
Here, I will present a brief comparison of the results from the imputed dataset 
presented in this chapter to the ones related to the CCA that are presented in 
more detail in the appendix. Although there were many similarities, 
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interesting differences were found between complete and imputed datasets, 
particularly with regard to factors associated with time to GLM prescription.  
People with complete data available had a higher mean age and slightly 
lower HbA1c levels than those with missing data. Moreover, one of the main 
differences between the datasets is that in the youngest age group the 
proportion of people with a BMI > 30 Kg/m2 was higher amongst the NM-2Y 
group in the CCA dataset, whereas for the imputed dataset, there was no 
difference between groups. Overall, for both datasets, HbA1c was higher for 
the GLM-2Y group. Furthermore, the proportions of people receiving anti-
hypertensive medication were significantly higher among NM-2Y across all 
age groups. Similarly, proportions of people receiving lipid-lowering 
medication were higher among NM-2Y for the 45 to 59 years, 60 to 79 years 
and > 75 years groups.  
Furthermore, the fully adjusted Cox regression analysis conducted for the 
CCA showed no statistically significance by receipt of prescription within two 
years for BMI, unlike the significant difference observed in the imputed 
dataset. BMI was the variable with the most missing values. This suggests 
that limiting the analysis to patients with complete data may bias the results. 
However, the role of chance cannot be eliminated given the smaller size of 
the CCA dataset. Thus, although results in general for both datasets showed 
similar figures, the deletion of cases with incomplete data introduced 
potential bias and results of the CCA should be interpreted with caution. 
4.7 Summary of findings 
Overall, the cohort consisted of a majority of men (55.9%), majority white 
Scottish/British (70.0%) and nearly a quarter were from the most deprived 
SIMD quintile (SIMD I). Furthermore, more than half of people received GLM 
prescription within two years after T2DM diagnosis, the majority of those who 
received medication were within three months of diagnosis of T2DM. The 
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proportions of people receiving GLM within 2 years after diagnosis increased 
over time. 
People who received medication prescription were younger at diagnosis of 
diabetes, had higher BMI, HbA1c, and cholesterol than those who did not. In 
addition, people who received GLM prescription included lower proportions of 
people with pre-existing CVD, receiving lipid-lowering medication and 
antihypertensive medication, with age differences potentially contributing to 
this pattern. Overall, metformin was the medication most commonly 
prescribed across all age groups. 
In general, HbA1c at diagnosis of diabetes was higher for the youngest age 
group (30 to 44 years) and showed a decreasing trend across age groups. 
Furthermore, there was a positive association between HbA1c at diagnosis 
and proportion of people who had been prescribed GLM within two years 
after diagnosis.  
Results of the fully adjusted Cox regression analysis of the imputed dataset 
showed that increased age, other/unknown ethnicity, the least deprived SIMD 
quintiles and receiving antihypertensive medication were associated with 
longer time to drug treatment. Conversely, female sex, HbA1c >53 mmol/mol, 
BMI >30 Kg/m2 and receiving lipid-lowering medication were associated with 
shorter time to drug treatment. After stratification by patients’ age, the fully 
adjusted model showed that although there was an association between 
older age and longer time to GLM initiation, people in the >75 years group 
with HbA1c >53 mmol/mol had shorter time to GLM prescription. 
In summary, older age and male sex were associated with longer time to 
GLM initiation. BMI and the use of other medications were also associated 
with shorter time to drug prescription for glucose control. The next chapter 




Qualitative Findings  187 
Chapter 5 Qualitative findings 
5.1 Introduction  
In this chapter, I will present the findings of the qualitative strand of the study, 
which complement and expand the results presented in the previous chapter, 
particularly about factors associated with longer time to pharmacological 
treatment initiation, however, other findings that were not quantitatively 
studied will also be presented. Thus, the findings in this chapter will provide 
additional insights and broaden the knowledge of the topic studied. First, I will 
provide an overview of the participants’ characteristics. Then, I will outline the 
three main themes, which elucidate the factors that influenced HCPs’ 
decision-making around medication prescription initiation; namely, individual 
patient-related considerations, HCP-patient related factors, and contextual 
factors. 
5.2 Participants and settings 
The quantitative strand focused on analysing patients’ data and did not 
include information related to the HCPs in charge of prescribing. In this 
section I present the characteristics of the HCPs who participated in the 
study, a brief description of the settings where they worked is also included. 
Overall, 16 HCPs were interviewed; 11 GPs and 5 Practice nurses. 
Participants were recruited from 12 different practices in Scotland; six in 
Edinburgh, two in East Lothian, two in West Lothian, one in Midlothian and 
one in Glasgow. 
The following table presents some of the main characteristics of the 
participants; it includes participants’ professional role (general practitioner or 
nurse), the location of their practice, which has a number appended to it; 
each number refers to a different practice within that specific region. 
Furthermore, it includes their years of clinical experience, which have been 
categorised into five groups (<5, 5-9, 10-14, 15-19, and >20 years) whether 
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they had a special interest in diabetes, and their sex4. Each HCP has been 
allocated a unique identifier which will be used throughout this chapter. 
Table 32. Characteristics of participants 
Name Professional role Practice 
 location 







GP1 General practitioner Edinburgh 1 >20  Yes Male 
GP2 General practitioner Edinburgh 2 5 – 9 No Male 
GP3 General practitioner Edinburgh 2 5 – 9 No Male 
GP4 General practitioner Edinburgh 3 < 5 No Male 
GP5 General practitioner West Lothian 1 >20 Yes Female 
GP6 General practitioner Edinburgh 4 15 –19 Yes Male 
GP7 General practitioner West Lothian 2 < 5 No Female 
GP8 General practitioner Glasgow 15 – 19 Yes Male 
GP9 General practitioner East Lothian 1 5 – 9 Yes Male 
GP10 General practitioner East Lothian 2 10 – 14 No Female 
GP11 General practitioner Midlothian 1 >20 No Male 
PN1 Practice Nurse Edinburgh 5 5 – 9 No Female 
PN2 Practice Nurse Edinburgh 6 5 – 9 No Female 
PN3 Practice Nurse West Lothian 1 15 – 19 Yes Female 
PN4 Practice Nurse East Lothian 2 10 – 14 Yes Female 
PN5 Practice Nurse East Lothian 2 >20 Yes Female 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
The information in this table shows a balance in the number of males and 
females who were interviewed. However, the sample was skewed to male 
GPs, an issue which has been noted in chapter 3. Furthermore, apart from 
one South-East Asian individual, all participants were White British. Years of 
                                            
4 In qualitative research, gender is the term commonly used. However, in order to be consistent 
with the terminology used in previous chapters “sex” is used instead through this chapter. 
5 Years of clinical experience was not all necessary in general practice, some might include 
experience in hospitals. 
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clinical experience ranged from two to forty. In addition, half of the 
interviewees did not have a particular interest in diabetes.  
Almost all HCPs provided additional information about their practices. Below, 
table 33 presents information about the size of the practice (number of 
patients listed), which have been categorised into three groups (<5,000, 
5,000–10,000, and >10,000), workforce, which refers to the number of GPs 
and nurses; workforce has been categorised as follows: three groups for the 
number of GPs (<5, 5–10, and >11) and two groups for the number of nurses 
(1–3 and >3). The table also includes other information that HCPs provided 
about the practice such as patients’ socioeconomic status (SES). Since some 
of the HCPs interviewed worked in the same practice, the information is 
presented is organised by the name of the practice which corresponds to 
practice location in table 32. 
In general, there was variation in terms of practice size and location; 
however, most practices reported to have patients with low- or mixed SES. 
Among practices in the cities of Edinburgh and Glasgow, most of them were 
large practices as they had registered more than ten thousand patients, only 
one practice was small (<5,000). Practices located in semi-rural areas were 
from average to large size. Overall, most of the practices (n=7) were reported 
to serve populations with mixed SES, three reported that most patients were 
from low SES, and only in one practice the HCP indicated that patients were 
from middle to high SES.  
Table 33. Characteristics of the practices 
Name of practice Practice size Workforce SES of patients/ other information 
Edinburgh 
Edinburgh 2 5,000 – 10,000 5 – 10 GPs 
1 – 3 nurses 
Low SES. 
Average patients’ age-wise. 
Edinburgh 3 > 10,000 5 – 10 GPs 
1 – 3 nurses 
Mostly low and mid-SES. 
Edinburgh 4 > 10,000 > 10 GPs 
> 3 nurses 
Mixed of high- and low-SES.  
An important proportion of elderly patients. 
Edinburgh 5 > 10,000 5 – 10 GPs Mixed SES. 
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1 – 3 nurses 
Edinburgh 6 5,000 – 10,000 5 – 10 GPs 
1 – 3 nurses 
Mixed SES.  
An important proportion of young patients. 
West Lothian 
West Lothian 1 > 10,000 > 10 GPs 
> 3 nurses 
Low-SES  
High proportion of elderly population. 
West Lothian 2 5,000 – 10,000 5 – 10 GPs 
1 – 3 nurses 
Mixed of mid- and low-SES. 
East Lothian 
East Lothian 1 5,000 – 10,000 5 – 10 GPs 
1 – 3 nurses 
Mixed SES 
Important proportion of elderly patients. 
East Lothian 2 > 10,000 > 10 GPs 
> 3 nurses 
Low SES 
Mixed age of patients. 
Midlothian 
Midlothian 1 > 10,000 > 10 GPs 
> 3 nurses 
Mixed SES 
Average age of patients 
Glasgow 
Glasgow < 5,000 < 5 GPs 
1 – 3 nurses 
Middle to high SES. 
 
5.2.1 Division of tasks in primary care 
None of the participants worked as locums; all were attached to their 
practices and the division of tasks in relation to diabetes depended on 
whether there was a specialist in the practice. For the practices where none 
of the GPs had a special interest in diabetes, all were expected to treat 
patients with T2DM. Typically, a patient was diagnosed by a GP and then 
referred to a nurse for follow-up and annual check-ups. 
How T2DM was managed in the practices where participants worked is 
another relevant aspect that needs to be considered before I proceed to 
describe the findings. Therefore, the next section moves on to describe the 
process of diagnosing T2DM in primary care and an overview of patients’ 
subsequent pathway once the diagnosis has been confirmed. Usually, these 
aspects were not influenced by HCPs but by standardised procedures within 
particular practice’s management and the wide healthcare system and 
included: registration to the practice’s diabetes register, the delivery of T2DM 
diagnosis, initial referrals and the arrangement of follow-up consultations. 
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5.2.2 Diagnosing T2DM in primary care 
Participants indicated that in the practices where they worked there were 
usually two routes to diagnosing T2DM. The first route involved conducting a 
blood test if a patient presented symptoms such as polyuria and polydipsia or 
if they were concerned about a particular patient; for instance, someone with 
previously impaired glucose, pre-diabetes or with other chronic diseases. The 
second route was by chance through a routine blood test. Regardless of the 
route to diagnosis, after diagnosis, patients became part of their diabetes 
register and recall system. As exemplified in the quote below by GP3, 
participants described that usually GPs were the HCP in charge of delivering 
the diagnosis to patients, who then referred patients to the practice nurse. 
This highlights the importance of both HCPs in the management of T2DM.  
“Diagnosis is usually done by the GP, and then we refer 
them onto our practice nurse, she can spend more time 
with them talking a wee bit more about diet and lifestyle 
and get them set up with that kind of monitoring 
system.” GP 3 
Furthermore, some GPs reported spending the first consultation explaining 
and discussing the diagnosis. Explaining the diagnosis was described by 
most HCPs as a time-consuming task, some further described needing to 
book a double appointment to do so.  
“And once the diagnosis has been confirmed, we will 
get an appointment with the doctor at the practice who 
will bring the news to the patient that has got type 2 
diabetes. We tend to get people on a double 
appointment so they have a bit more time so we can 
discuss the diagnosis, get them lifestyle advice, about 
diet, exercise if possible and some people are elderly 
and can’t do exercise and have limited mobility. We 
have to look after blood pressure, cholesterol, about 
past or actual smoking. So we try to address most of 
this on the first consultation and give them advice.” GP6 
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5.2.3 Patient’s pathway  
Once a patient was diagnosed, they were usually registered as “diabetic” and 
thereafter were included in the practice’s register of patients with diabetes. 
Then, a patient’s pathway usually continued through a referral to DESMOND; 
which as described in chapter 1, is a structured education programme for 
people newly diagnosed with T2DM. Patients also needed to attend their 
practices for check-ups to monitor their blood pressure, cholesterol levels, 
protein levels in urine, and assessment of cardiovascular risks. 
The frequency of consultations depended on several factors. Some practices 
had established a management system for diabetes where patients might be 
linked to a particular GP or nurse who was in charge of conducting routine 
check-ups at certain time-points after diagnosis; however, the regularity and 
the timing of consultations depended on patients’ individual characteristics. 
“Some people will get seen monthly if necessary, 
maybe not for the first year but certainly for the first 
seven, eight months just to make sure we’re on top of it 
and they're on top of it. Again, it depends on their age, 
depends on their HbA1c, depends whether they've 
been started on medication and what the medication is.” 
GP5 
Participants described how follow-up consultations were commonly 
undertaken at three and six months after diagnosis since HbA1c levels need 
three months to show any change. Reviews were recommended to be 
conducted at least every 15 months. Follow-up consultations were described 
as usually including education about diabetes.  
So far, I have presented information about the HCPs who participated in the 
study, including their clinical experience and interest in diabetes. I have also 
provided important information that sets the scene for understanding the 
general conditions and circumstances of HCPs and their practices. In the 
following section, I provide additional contextual information on HCPs’ 
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opinions and stance on when to start GLM before moving onto describe the 
findings. 
5.3 Prescribing glucose-lowering: the context 
The HCPs interviewed described T2DM as a progressive disease 
characterised by an inevitable reduction in insulin production over time. 
Therefore, they viewed GLM as something that would be necessary for 
almost all patients: 
“The natural history is that your insulin production will 
slow with time. So, there comes a point where you are 
diagnosed, but then the insulin production continues to 
drop so you need more and more tables, and 
eventually, you need insulin, that is the classic 
interpretation, but we know there’s considerable 
variation.” GP1 
HCPs viewed the reduction in risk of complications resulting from increased 
levels of glucose as the primary reason for prescribing GLM. 
“If we have well-controlled diabetes, then we are going 
to reduce the risk of complications, and that is in 
essence.” GP1 
“I think in terms of reducing risk of cardiovascular 
disease and retinopathy and peripheral neuropathy, all 
those sorts of secondary complications of diabetes, it’s 
predominantly the blood sugar that is important to keep 
at a managed level. The longer that people have blood 
sugar above recommended then the more likely they 
are to have secondary complications.” GP4 
Furthermore, HCPs described many interacting factors which influenced their 
decisions about when to initiate GLM in patients. In the following sections, I 
will describe the construction of themes, categories and sub-categories, and 
discuss the main influencing factors which emerged from my analysis.  
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5.4  Findings: themes, categories, and sub-categories 
As indicated in chapter 3, this strand was informed by the NPT and the SEM 
theories. While the NPT informed the development of the topic guide, the 
SEM levels were the basis for the construction of initial themes and 
categories which were used as an aid in the initial process of data analysis. 
These categories, however, were not rigid and changed during the analysis 
of the interviews by the introduction of inductively constructed ones. 
Table 34 provides the list of the final themes, categories and sub-categories 
that will be presented in the following main findings sections. As the table 
shows, several factors at all levels of the SEM influenced HCPs’ decisions 
about when to initiate GLM. While these factors are reported separately, in 
many cases, they overlapped and were interwoven.  
Table 34. List of final themes, categories and sub-categories 
describing factors that influence HCPs decisions about when to 
initiate GLM in people with newly diagnosed T2DM. 
Theme Categories Sub-categories 
1. Individual patient-
related considerations 
Physiological Hba1c  
Development and presence of symptoms 
Age  
Comorbidities  
Psychological Mental health 
Motivation/psychological readiness 
Expectations  








Historical contact with patients 





Assessment of patients’ readiness 
Discussion of complications/ GLMs side effects  
3. Contextual factors Practice Resources: time and workforce 
Division of tasks/HCPs’ role 
HCPs Keeping updated  
Perception of role within the healthcare team 
NHS Primary care workload 
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Clinical guidelines 
Frameworks: QOF / House of care 
 
As previously indicated, the SEM was intended to be used as a framework 
for reporting the main themes. However, this was not fully accomplished as 
the order and presentation of the themes were chosen according to what 
HCPs reported as determinant factors. In this manner, the first theme 
presented in this chapter relates to individual patient-related factors, this 
decision was made due to that most of the factors that influenced HCPs’ 
decisions on when to start GLM were attributed to aspects related to patients.  
Thus, patients’ individual characteristics and conditions were described as a 
major determinant and are described first. The second theme is healthcare 
professional-patient related factors, this refers to the interaction between 
HCPs and their patients, which had the potential to shape HCPs decision-
making about the initiation of GLM. The third theme is contextual factors 
which includes organisational and community aspects, in other words, the 
context in which HCPs relationship with peers and patients are embedded 
and can influence HCPs clinical decision-making about GLM initiation.  
5.5 Theme 1: Individual patient-related 
considerations 
In accordance with what was found in the quantitative analysis, individual 
patient characteristics were described as having a central influence on 
decisions about when to initiate medication, which included the patient’s age 
and HbA1c. Moreover, in the interviews, additional aspects such as whether 
patients were perceived to be motivated to change their diet and lifestyles, 
and the existence of other health problems were also considered important. 
Because of their paramount importance, these individual patient-related 
considerations will be reported first. 
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5.5.1 Physiological aspects 
In the previous chapter, quantitative data showed that some physiological 
aspects such as HbA1c and age were related to GLM initiation. In keeping 
with these findings, HCPs described a patient’s HbA1c, age and 
comorbidities to be among the main aspects related to GLM initiation.  
According to the HCPs who were interviewed, at diagnosis, all patients have 
raised levels that place them in the T2DM diagnosis category; however, 
some have levels that are considerably above the cut-off points. It was 
reported that the higher the patient’s HbA1c at diagnosis, the more likely it 
was that pharmacological treatment would be prescribed, especially if the 
patient had other health conditions such as hypertension and 
hypercholesterolemia, which increased their cardiovascular risk. 
“If you had, as I said, a very high haemoglobin A1C you 
are not going to achieve that straight away, so you are 
not going to achieve a satisfactory level [HbA1c] on diet 
alone, so you might start medication sooner.” GP1 
“If I was kind of thinking this is a patient who probably 
needs prescription, probably because they got a high 
initial HbA1c, in which I am thinking that diet and 
lifestyle interventions may be insufficient.” GP2 
Furthermore, a patient’s HbA1c was also seen as a proxy measure of their 
ability to succeed with lifestyle and diet interventions. Generally, HCPs 
suggested that a high HbA1c reflected a patient’s unhealthy habits, which 
were viewed as difficult to modify. Some HCPs suggested that not all patients 
should be prescribed GLM straight after diagnosis unless their HbA1c was 
very high. As exemplified below by GP1, some were worried that attaining 
good control of HbA1c with medication would discourage patients from 
attempting to manage their diabetes through lifestyle changes. Thus, if 
patients were given medication immediately, GPs were concerned that they 
might not see any point in changing their diet and lifestyle. 
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“For all patients, it is terribly important that we address 
the lifestyle straight away. And for the majority of 
patients, if their HbA1c is not too high, then that’s all we 
can do in the first instance. Now we would know that if 
your HbA1c was sky-high is unlikely that you are going 
to achieve that without some medication, but the 
dilemma, because if we bring all the control excellent 
with drugs straight away, then you’ll be less inclined to 
do your bit of lifestyle.” GP1 
Moreover, participants reported that a factor that is commonly associated 
with increased HbA1c is the presence of symptoms. They suggested that the 
higher the HbA1c, the higher the chances of patients experiencing symptoms 
such as polyuria and polydipsia. For some HCPs, the presence of symptoms 
influenced their decisions about whether the patient was prescribed GLM. 
The following extracts are interesting examples of how the presence of 
symptoms, in general, may play a pivotal role in the time to initiation of GLM: 
“The main factor that makes you decide whether to start 
medication as soon after diagnosis is whether they 
have symptoms or not in terms of osmotic symptoms. 
For instance, thirst and passing a lot of urine as a result 
of having a high sugar level. So, polyuria, polydipsia, 
you are much more likely to start medication for those 
patients than those who don’t have thirst and passing a 
lot of urine.” GP6 
“Symptoms would be if they are very thirsty or they’re 
passing a lot of urine, or they have a thrush-type 
infection or something like that. So these people’s 
symptoms suggest that sugar level’s up, particularly 
higher, and early medication for them might be a good 
idea to get on top of their symptoms.” GP9 
However, as illustrated in the excerpts below, the decision about when to 
start pharmacological treatment was not solely based on raised blood 
glucose levels and associated symptoms; it was also affected by other 
factors, including the patient’s age and comorbidities. Elderly patients were 
often seen as more frail, and HCPs were often concerned about the risk of 
hypoglycaemic events in these patients. Therefore, the HbA1c cut-off used to 
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start pharmacological treatment for glucose control in these patients was 
reported as being less rigid than in younger patients. 
“If they were very frail then all we would worry about is 
whether or not they were having symptoms. But say 
they were a fit 80-year-old then I would certainly maybe 
not have their diabetic control as tight as a 30-year-old 
but at the same time, if they were a fit 80-year-old, the 
main thing I would be concerned about, apart from them 
not having symptoms, was not having hypos.” GP 5 
“Elderly people we don’t want to start really heavily 
treating them because you can always lead to more 
problems. You don’t want them to get hypoglycaemic if 
they are elderly if they are frail if they live by themselves 
because you can put them at further risk of falls or them 
really becoming unwell and nobody being aware of that. 
So you would set different targets for different cohorts 
of patients, really.” PN1 
These findings suggest that although high HbA1c is a major factor, HCPs 
consider a large number of other factors related to each patient when making 
their decisions. For instance, as reported in the quote above by PN1, they 
would weigh the estimated life expectancy of a patient against their quality of 
life. Furthermore, as illustrated below in the quote by GP1, elderly patients 
were more likely to be treated using flexible targets and were started on 
medication at a higher HbA1c than younger patients. Likewise, the estimated 
life expectancy was taken into account when making their decisions; HCPs 
believed people with a longer life expectancy would benefit the most from 
receiving GLM. Conversely, for people who were thought to have a shorter 
life expectancy, reaching a low blood glucose level or establishing a tight 
glucose control was not seen as critical as these patients commonly had 
other diseases, and are frailer and seen as less likely to benefit from GLM. 
“The decision to start medication would be based 
largely on what HbA1c is; it would be affected by age, 
with younger patients we might be more aggressive to 
try and improve to get good control earlier than we 
would with somebody who is 80. Because if you are 80 
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you are going to live for less time … maybe we would 
let your blood sugar be slightly higher than if you were 
34 when your life expectancy is more and we want you 
to get good control to reduce the risks of complications.” 
GP1 
“Lowering HbA1c has the benefit of reducing diabetes 
complications over the course of many years. So, if you 
don’t have a life expectancy that is too long … don’t 
have enough years to kind of benefit from lower HbA1c, 
so there’s no point in starting medication. That is unless 
… they have a very high sugar level and they get some 
symptoms, thirst, passing lot of urine, then they have 
some benefit from starting medication in terms of 
symptoms relief.” GP6 
HCPs described mental health conditions such as depression as being 
common among people with T2DM. These conditions were described as 
potentially increasing the likelihood of receiving GLM because patients with 
mental health issues were seen as having difficulties implementing lifestyle 
changes.  
“Other people have other comorbidities, so particularly 
mental health; I think that can be quite challenging for 
people because they’re not really necessarily able to 
want to prioritise physical illness and so it just doesn’t 
come into their minds in the same way because they’re 
just battling with a mental illness.” GP4 
HCPs’ considerations and perceptions of mental health will be further 
considered in the following section. 
5.5.2 Psychological aspects  
Regarding psychological aspects, HCPs’ views surfaced mainly in relation to 
patients’ motivation to adopt and adhere to a healthy diet and lifestyle. 
Moreover, psychological aspects also included HCPs’ assessment of 
patients’ willingness to start GLM. As described in the previous section, 
HCPs considered changes in diet and lifestyle as being necessary for all 
patients who are diagnosed with T2DM, and therefore, all patients were 
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encouraged to make these changes, including the initiation of physical 
activity. While it was noted that it could be very challenging for patients to 
make these kinds of changes, some HCPs observed that diagnosis provided 
an important opportunity to motivate patients and provide them with 
information about healthy lifestyles. Several suggested that in the period 
directly after diagnosis, some patients are more likely to be motivated to 
make lifestyle changes than others. 
“The point of diagnosis it’s quite a powerful time 
because people are usually a bit shocked about the fact 
they have diabetes so that can be quite an important 
time, I think, to move people and discuss lifestyle 
changes.” GP4 
“Some patients do want, when they are first diagnosed, 
the opportunity to try and adjust their lifestyle, some 
patients say they’re not gonna take any medication.” 
PN4 
As the quote above by PN4 suggests, initiation of GLM was sometimes 
delayed in situations where patients expressed a wish to be given an 
opportunity to change their lifestyle. Thus, the decision to start 
pharmacological treatment and the recommendations provided by HCPs 
varied on an individual basis. 
HCPs considered the patient’s motivation to be a crucial factor in 
implementing and maintaining diet and lifestyle changes. They suggested 
that sometimes it was possible to gauge a patient’s engagement with their 
health and their willingness to make lifestyle changes based on previous 
interactions (e.g. previous consultations to discuss diabetes-related issues or 
for other health conditions); aspects related to HCP-patient previous 
interaction will be further discussed further in section 5.5.1. 
As previously stated, mental health conditions were among the factors that 
HCPs took into consideration when prescribing GLM. As illustrated in the 
excerpts below, patients who were perceived to be less motivated due to 
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depression or other mental health conditions were often seen as being in a 
vicious circle of unhealthy habits and were thus more likely to be started on 
GLM sooner: 
“Sometimes I don’t know, they can be a bit depressed, 
and maybe that’s sort of the cause they’re getting 
diabetes. Maybe they are depressed and not motivated 
to do much exercise… quite isolated … eating a lot … 
feeling rubbish … it could be that they’re depressed and 
it’s causing them to put on weight in the first place. 
These people tend not to be overly motivated, so it is up 
to us to try and encourage them to lose weight.” PN2 
“There’s also an element of how motivated the 
individual is, if … they aren’t that motivated to change 
their lifestyle, or … unable to change their lifestyle very 
much. Then, you think, you’ve given them lots of advice 
but they are unlikely to be able to achieve that, and then 
they’re more likely to start medication.” GP6  
As suggested in the quote below by GP2, patients’ wider situation and 
context were also seen by HCPs as influencing their motivation to manage 
their glucose levels. For instance, people who had interacted with other 
people with T2DM or who had knowledge of the complications of T2DM were 
sometimes perceived as more motivated to tightly manage their glucose 
levels as they were more aware of the consequences of sub-optimal glucose 
control.  
“There are the patients who because of experiences; 
family members have diabetes or patients who know of 
the diabetes complications. Who are very aware of 
things like stroke, heart attacks and amputations, who 
are the patients who’ll say no, I want lifestyle 
interventions and I want medication, and I want to have 
my HbA1c checked in 3 months’ time, not 6 months’ 
time or whatever, I have it checked every 3 months to 
make sure we are making progress. But again, I think 
those patients are the minority.” GP2 
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Furthermore, HCPs considered that aspects such as health literacy, and 
patients’ knowledge about diabetes promoted discussion on the initiation of 
GLM and fostered a more productive conversation with them. Some HCPs 
perceived people from low socio-economic groups and those with poor health 
literacy as being less engaged with their healthcare.  
“Sometimes, the sort of lower socioeconomic groups 
can be a little bit less motivated. They want a quick fix, 
they just want tablets, and they want it to all be made 
better, which is not really the attitude that we want to 
promote.” PN1 
 “Some patients want a lot of involvement…depending 
on their health literacy and the education level or their 
motivation, some people will understand a lot about the 
medications and be very pleased when you try to, you 
know, to discuss the medication and give them the 
choice… I think the media has quite a role in terms of 
scaring people about medication and their side effects. 
So the patients will read in newspapers or read on the 
internet that things that kind of make them scared of the 
medication.” GP6 
Furthermore, as reported above by GP6, some patients were exposed to 
information that was not always reliable or correct. However, the availability 
of information and exposure to media was also regarded as something that 
generated discussion and increased patients’ engagement with their 
condition. 
5.5.2.1 Patients’ needs and observed expectations 
HCPs described that the patient had to be the focus of the consultation and 
thus that patients’ opinions were central to decisions as to when to start 
medication to lower glucose levels. However, participants observed that a 
significant proportion of their time during consultation was taken up by 
assessing patients’ needs and expectations. As described in the literature 
review, a typical consultation length in primary care is very limited; this 
aspect will be further discussed in section 5.6.1.1.  
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HCPs shared their views that before prescribing GLM, patients needed to be 
asked about their priorities and goals in the management of their diabetes, a 
patient’s priorities and readiness to start medication were two aspects that 
were viewed as central to starting pharmacological treatment for glucose-
control. Some participants suggested that there was often a discrepancy 
between HCPs’ and patients’ health priorities, which could affect the timing of 
the initiation of GLM. In the quotes below, PN1 and GP10 explained that 
sometimes controlling their blood glucose was not a priority for patients, 
especially if they lived with other health conditions. Furthermore, as the first 
quote exemplifies, conversations with patients had the potential to uncover 
aspects that could affect treatment for glucose control, such as low mood or 
lack of motivation.  
“I ask them what matters to them the most: if they want 
to improve their diabetes or if they want to improve their 
breathing or sometimes the discussion would lead to 
finding out they’ve got low mood. So if they’ve got low 
mood then they’re not compliant with their tablets 
because they can’t be bothered, they’ve lost motivation. 
So generally sort of just having that discussion you can 
find out a lot about what their aims are, which is really 
interesting actually.” PN1 
“I suppose the main thing is to let the patient talk first to 
get an idea of what’s they’re concerned about so you 
can build on that rather than it all being about what the 
clinician think needs to be the focus of the consultation.” 
GP10 
The development of a relationship with the patient appeared to influence 
decisions as to when to initiate GLM as it facilitated discussion about patient-
related aspects. HCPs mentioned that physiological aspects, such as HbA1c 
were central when setting goals. However, HCPs noted that realistic goals 
were necessary in order to avoid demoralising the patient. The comments 
below illustrate the perceived importance of establishing a HCP-patient 
relationship where both individuals felt able and confident to discuss 
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decisions about diabetes management, and presumably decisions about 
when to start medications for glucose control. 
“Type 2 diabetes by nature is a progressive disease 
that’s important to say to patients, to not be alarmed by 
the fact that sometimes control can worsen over time in 
despite of their best efforts because we know that it’s 
the very nature of it. And that’s important, so we don’t 
get disillusion with what’s going on, they are trying their 
best, but yeah, their HbA1c is not getting much better, 
and that’s important but also to make them aware that 
we could have to add therapy should things no 
improve.” GP2 
“It’s … a step at a time because if they’re gonna be 
overly tight with their diet, they are gonna feel fully 
miserable. And that has happened, so that’s why I have 
to be careful, they get depressed because there’s 
nothing that they feel they can eat if they want to keep 
their HbA1c spot on. It’s looking at the person, as an 
individual very much so, and keep it around their needs, 
realistic goals and expectations… You always remind 
patients that is a progressive illness, and for some 
patient, it will progress faster than others despite them 
being as good as they can with their diet and their 
lifestyle…They can do just the best they can do, and 
you obviously have to support them in that, but make 
sure they don’t get disheartened if they don’t achieve it 
as quickly as they would like.” PN5 
Overall, the initiation of GLM involved discussion with the patient and HCPs 
were keen to consider the patient’s readiness to start on pharmacological 
treatment for glucose control. However, HCPs also noted that it was 
imperative not to delay pharmacological treatment any longer than 
necessary. 
“It varies from person to person [the time a patient is on 
diet and lifestyle only]. As long as you don’t end up 
colluding with the patient and just continuing, and 
before you know, one year, two years elapsed into 
diagnosis. For some patients we will try a few months, 
other patients want to try up to six months as long as 
they are trying to change their behaviour and they are 
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maybe showing some improvement in their HbA1c or 
reduction in weight or some other parameters, showing 
that they’re engaging with the diabetes management 
and care. Then, I am happy to continue with that.” GP9 
“I could be persuaded by someone saying I am gonna 
lose 2 or 3 stone, if they’re gonna do that, that’s very 
effective treatment, it is a negotiation, is not, I don’t 
make the decision on my own. We make a decision 
together, that’s the way we would do about times.” 
GP11 
The development of a HCP-patient relationship and negotiation with patients 
will be further addressed in section 5.5. 
5.5.3 Patients’ cultural and religious backgrounds 
With regard to the patient’s background and wider context, cultural 
differences were deemed a factor that might influence the decision about 
when to initiate medication for glucose control. Some patients from ethnic 
and religious minority groups were perceived as being less likely to exercise 
or to engage in physical activity and, therefore, these patients might be 
prescribed GLM sooner as they were viewed as more likely to struggle to 
implement lifestyle changes.  
“I find for my Asian patients, Asian women going to the 
gym is completely unacceptable because there are men 
there and, you know, wearing skimpy shorts or skimpy 
tops, and you know we have to understand the cultural 
differences.” GP8 
As reported below, HCPs’ also described other cultural aspects, such as the 
affinity to certain kind of sports like football, which they considered and took 
into account to provide tailored advice on lifestyle modifications, particularly 
to incentivise their patients to engage in physical activity.  
“You know, particularly in this place, men particularly 
like football. So, again is encouraging people to say well 
can you seek a football team? So, people have a 
passion for football for example and is actually relatively 
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easy for them to find a place to play football once a 
week... we know once a week is not enough but it's just 
a start.” GP8 
Moreover, GP8 reported that in order to provide such advice, HCPs’ need to 
know about their patients’ history, interests and preferences. However, it is 
important to note that GP8 was the GP in charge of all people with T2DM in 
their practice and had the opportunity to see the same patients over time. 
In this section, I have described individual patient-related considerations 
which HCPs described as the most important aspects to consider for initiating 
GLM. As discussed above, HCPs took a set of interwoven individual 
physiological and psychological factors into consideration before prescribing 
GLM. However, HCPs’ decisions about when to initiate GLM were not solely 
based on the assessment and recognition of individual-patient related 
factors, they were also influenced by other issues such as the HCP-patient 
relationship and contextual factors. The next section addresses aspects 
related to the relationship between the HCP and the patient, and how this 
relationship affected prescription practices. 
5.6 Theme 2: Healthcare professional-patient related 
factors 
The section below describes HCP-patient related factors that influenced the 
initiation of GLM. These factors included previous interaction with patients, and 
negotiation with patients. 
5.6.1 Interaction with patients and the development of a HCP-
patient relationship  
Participants described the importance of building a relationship that 
strengthens cooperative diabetes management. A number of participants 
were of the opinion that knowing patients by having seen them historically for 
other health conditions made consultations easier and facilitated discussion 
regarding the initiation of GLM. Similarly, the constant interaction with 
patients by virtue of seeing them for other health conditions helped HCPs to 
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use their consultation time efficiently, as previous interaction with the patient 
was seen to reduce the time that HCPs spent gathering information about 
them. GP10 describes in the quote below, their opinion about how the lack of 
continuity of care can lead to a situation where their patients have to explain 
their health problems or other issues to clinicians every time they visit their 
practice, which was viewed as quite draining for patients. 
“We all probably consult slightly different, and our 
advice might be slightly different, but if you see the 
same person, you get consistent messages and 
probably build a relationship with that person. Certainly, 
a lot of our patients prefer that, which you can 
understand, it’s better that you build a relationship with 
a particular clinician, and then they know you and you 
know them, and you can achieve more in your 
consultation when you know the background. I think 
patients don’t like having to explain their whole story 
every time they come in. And, if you got someone who’s 
got a lot of issues with their health, particularly mental 
health, then that can take time to get someone to get to 
know you, and you maybe don’t achieve much in the 
consultation because half of the consultation is around 
information gathering rather than providing information 
to the patient.” GP10 
Conversely, continuous contact with patients was described as helping to 
build a cooperative relationship that supported tailored diabetes management 
and enhanced discussion and negotiation between HCPs and their patients 
about their treatment. Some HCPs described having the opportunity to see 
patients over time, either to manage their diabetes or other health issues. 
Historical contact with patients was seen as placing HCPs in a position where 
they might be able to assess people’s readiness to change their lifestyle or 
start GLM. However, the increased demand for health services and the 
reduced number of HCPs was described as making this kind of ongoing 
healthcare management more challenging.  
“I think the benefit of being a GP is you get to know 
your patients and, so you’ll see the same people 
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several times over the course of their life and often 
you’d had seen that patient about something else over 
the precedent years. So, you might have established 
rapport with them and got to know them and know a bit 
about their life, what is important to them. And, at the 
end of the day you cannot, you know, you can’t force 
people to take medication. It’s just about having a good 
conversation, but unfortunately, these outcomes take 
time, and we are very short of time in general practice.” 
GP6 
Moreover, a number of participants also suggested that historical contact with 
patients helped them to gauge patients’ motivation and their likelihood to 
succeed with diet and lifestyle changes. In the following quotes, HCPs give 
their accounts of the importance of the HCP-patient relationship and its 
limitations. In the first quote PN5, who is a specialist in diabetes and was in 
charge of conducting check-ups and reviews of people with T2DM, described 
how knowing patients by virtue of having seen them in previous consultations 
influenced their decisions about when to initiate GLM.  
“We are looking at the patient as an individual; you are 
looking at what their HbA1c is, whether they would 
prefer to try the diet before any medication. Again, it 
would depend, if that is what they ask, then that’s 
obviously what you have to do. It’s the patient’s choice, 
you have to let them be aware what the goals are, what 
are we aiming for, and it might not be fully achievable, 
but you certainly have to support it 100%.” PN5  
5.6.2 Negotiation with patients 
The initiation of GLM was described as always implying negotiation, which 
HCPs described as usually being triggered by different aspects previously 
discussed such as high HbA1c levels, or the presence of symptoms, which 
were addressed in the previous section. This sub-section seeks to bring 
insights from the interaction between HCPs and their patients in pursuing 
shared-decision making about GLM initiation. 
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In the quotes below some HCPs give an account of shared-decision making. 
Commonly, the suggestion to initiate GLM by the HCP was determined by 
individual-patient considerations. Once the recommendation was made, the 
patient had to be willing to accept the medication. However, some HCPs saw 
it as part of their responsibilities to advise patients to accept medication when 
they considered it necessary from a medical point of view.  
“You’re going to be much more persuasive if their 
situation is more serious and HbA1c levels are much 
higher or they’re symptomatic, those are the things for 
me that would push you towards it being a shared 
decision, but the doctors are taking a lot more of a 
burden for all the decision-making.” GP4 
“It’s a negotiation, is not, I don’t make the decision on 
my own, we make a decision together, that’s the way 
that we would do about times. Guiding people, if 
someone has HbA1c in the hundreds with significant 
osmotic symptoms, who has never succeeded in any 
diet in their lives, then we would have a conversation 
about the likelihood of them succeeding.”GP11 
HCPs reported that during the negotiations, diet, lifestyle and consequences 
of poor glucose control were discussed. As exemplified in the quotes below, 
GP6 and PN3 described using these consultations to enable their patients to 
make choices about their health, including about when to start medication to 
lower blood glucose.  
“I think if you have a good discussion with the patient, 
with the person, and they make an informed decision to 
start medication, they’re much more likely to comply 
with the medication, to continue with it cause, you 
know, comply with the medication means agreement.” 
GP6 
“Well, I would probably be honest with them saying, you 
know, your HbA1c is at this level, you’ve tried to get it 
down over the last few months without success in 
changing your lifestyle, what are your thoughts about 
starting medication? Then some of them will say well 
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actually, that’s fine; I want to start medication if it’s 
going to help me. Others would say, well actually I’ve 
not been very good over the last few months what if I 
want to try and change my diet and then come back. 
So, it’s variable; everybody is different. Some patients 
are just willing to straightaway accept medication; 
others are not.” PN3 
Additionally, as described by GP6, shared decision-making was frequently 
sought by HCPs. There are various reasons as to why HCPs tried to ensure 
shared decision-making about when to start on GLM. HCPs described that 
one of the main reasons to pursue shared decision-making was related to 
adherence to treatment. Involving patients in the decisions to start 
pharmacological treatment was believed to increase adherence and to save 
on NHS resources. 
“You know, it’s one thing to prescribe a medicine, it’s 
quite another for somebody to take it. So certainly I’ve 
been persuaded by the idea of shared decision-making 
and just understanding where an individual is at, what 
they feel is the benefit of taking the medicine.” GP4 
“They have to be completely involved in it because it’s a 
waste of time and money to prescribe them something 
they’re not interested in taking, or they don’t understand 
about taking, they don’t understand how it’s going to 
help them. It’s, yeah, a complete waste of resources.” 
PN1 
For most HCPs, the decision to start patients on GLM also included a 
discussion about the potential side-effects and benefits of medicines. As 
described in the quote below by GP4, informing patients about the potential 
side effects of the medication was also perceived to promote dialogue and 
enable shared-decision making:  
“I think that’s crucial to recognise that medicines have 
effects that aren’t wanted and so that’s important to let 
them know about. And it’s about being able to inform 
them so that they can make a decision about whether 
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they want to go ahead with that medicine. So that’s a 
big part of shared decision-making” GP4 
Having described aspects related to patients and the HCP-patient 
relationship, the next section of this chapter moves on to consider contextual 
factors that informed HCPs’ decisions about when to start GLM. 
5.7 Theme 3: Contextual Factors 
The contextual factors described in this section related to the healthcare 
system, the location and other characteristics of the practice, HCPs’ 
backgrounds, the existence of clinical guidelines (including the recent 
decommissioning of QOF), and HCPs’ perceptions of their roles, and also 
their roles in relation to the roles of other colleagues in their practice. These 
factors appeared to have a considerable influence on HCPs’ decision-making 
because, as I will consider further below, they could facilitate or hinder their 
focus on individual patient-related factors.  
5.7.1 Practice-related  
As described at the beginning of this chapter, the characteristics of the 
practices where participants worked varied considerably. Similarly, 
differences were seen in relation to the length of consultation and the number 
of HCPs working at practices, which was often related to the size and 
location of the practice. In addition, while some practices had a GP diabetes 
specialist working at the practice, others did not, in which case the nurses 
performed most of the diabetes-related care, including monitoring and 
reviewing patients annually; consequently, the division of tasks was diverse 
across practices.  
5.7.1.1 Resources 
A practice’s resources are used here to refer to the time available for 
consultations and human resources. In most cases, HCPs reported an 
increase in their practice size over the years, which had led to a rise in the 
number of HCPs working within their practice. The number of GPs in each 
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practice ranged from 6 to 11, while the number of nurses ranged from 1 to 5. 
Some participants reported having lead GPs for different clinical specialisms, 
including diabetes care.  
The majority of participants emphasised that in practices without a lead GP 
for diabetes, most of the day-to-day diabetes care was carried out by nurses. 
Many GPs commented that one of the main reasons for this was the short 
length of consultation times to which they were expected to adhere. Usually, 
GPs specialists had longer appointment times for diabetes care; some of 
them indicated that they spent between 15 to 30 minutes with each patient in 
diabetes-related consultations. However, for the majority of GPs, the 
standard consultation time was just 10 minutes. In contrast, diabetes-related 
consultation times with nurses were longer (20 to 40 minutes). As exemplified 
in the quotes below, short consultations were frequently described as a 
challenge when delivering diabetes-related care: 
“The appointment is only 10 minutes long… You go into 
that consultation knowing that’s impossible to go 
through every single thing, to have the opportunity to 
run through diabetes, the causes, lifestyle factors, 
lifestyle interventions, medication options, 
microvascular risk, macrovascular risk. Technically, 
when you think about all that’s involved in a diagnosis 
and explanation revise you could easily add up to an 
hour of work, we have 10 minutes.” GP2 
As the quote above indicates, time restrictions during consultation could limit 
HCPs’ ability to provide information and assess a patient’s motivation and 
needs to achieve optimal glucose levels, which as described in section 
5.4.2.1 could influence their decisions about when to start GLM. Similarly, 
some HCPs discussed their experiences of the scarcity of time and human 
resources and the implications of these on diabetes care, such as being 
inclined to prescribe at an early stage and focus more on patients’ HbA1c 
levels instead of looking at their patients’ life circumstances. This realisation 
arose from challenges they faced having short consultation times, as time 
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constraints did not always permit a productive discussion to take place and 
that this could potentially result in patients being put onto medication faster. 
“Each patient is entitled to a personalised plan, but also 
each patient needs resources, but they all require GP 
time.” GP7 
“I think that short consultation times in primary care is 
part of the reason we prescribe too much probably. You 
are focusing very much on that because that’s what you 
feel you need to get done in the time, if there isn’t 
medication then that’s probably where you focus…I 
suppose, the doctors, we tend to be more focus on the 
medication, looking whether we need to put them on 
medication straight away or lifestyle changes is going to 
be enough… I suppose partly because our times are 
quite short we tend to leave a lot of the education to the 
nurses who have longer appointments and who have 
more access to the resources.” GP10 
The excerpt above by GP10 provides an interesting example of how factors 
such as professional role (e.g. Nurse, GP) and consultation length could 
influence decisions about when to start GLM. Here, GP10 who works in a 
practice where the practice nurses are specialists in T2DM, suggested that 
nurses and GPs might approach diabetes management differently due to 
different consultation lengths. This is an issue which is explored further in 
sub-section 5.6.2.1.  
“In an ideal scenario, as GPs, we would have longer 
availability for new diabetic patients…you could 
probably go through things in more detail, give the 
patients more opportunity for questions and answers. 
We know when doing that, and getting them more 
involved than having to do information-delivery focused 
on time, is probably likely to have better outcomes.” 
GP2 
Moreover, HCPs suggested that short consultation times could influence the 
assessment of patient’s needs and expectations and the amount of 
information that could be provided to patients, which in turn could hinder a 
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patient’s ability to make an informed decision about starting GLM. In the 
quote below, GP6 gives an account of the importance of providing and 
reinforcing information about diabetes. 
“That often can take several meetings with the patient 
before they actually, they’d accept the need to start 
medication. At the end of the day is just a negotiation 
with the patient, and if you put them in a position to 
make an informed decision, you know, and they don’t 
want to take the medication then I am very happy with 
that” GP6 
The workforce in primary care was also a factor which, according to some 
HCPs, can influence the care provided to patients with diabetes. Some 
practices relied on employing temporary personnel; only one participant 
suggested that this might lead to a lack of standard in diabetes management. 
However, as discussed later on, standardisation of care can be enhanced by 
the use of clinical guidelines, which are of great importance to HCPs. 
5.7.1.2 Division of tasks 
The short length of consultations and the increased workload burden in 
practices, which was seen as being caused by lack of personnel or increased 
demand, were regarded as affecting both GPs’ and nurses’ professional roles 
in terms of the tasks they performed. In the example below and in 
accordance with the information above, a GP gives an account of how the 
shortage of HCPs in their practice had forced them to diversify their roles 
when providing diabetes care: 
“Basically I [after the removal of dietician and podiatrist 
in their practice] had to start a dietary history from the 
patient, but to me was actually very revealing and it had 
a significant impact in changing patient management… 
with podiatry, I then happen to do all the foot checks 
myself. So, therefore, my workload in the appointment 
changed quite significantly, and I am having to put a lot 
more work into the appointment.” GP8 
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Although in the quote above the GP refers to the performance of a task that 
did not used to be part of their role as something ‘revealing’, it could impact 
on the service provided to people with T2DM as their workload is increased. 
Likewise, nurses also described the diversification of their roles over time, 
with several participants describing an increasing responsibility and authority 
in decisions about when to initiate a course of GLM.  
Although nurses are often viewed as having an educational role within 
diabetes care, many HCPs described nurses conducting follow-up 
consultations and annual check-ups. Nurses who had completed a diploma in 
diabetes were additionally in charge of initiating, managing and modifying 
pharmacological treatment. However, the HCP in charge of prescribing 
varied depending on the practice’s characteristics. As it will be discussed in 
the next sub-section, aspects related to HCPs role (i.e. GP or nurse) could 
influence decisions about why and when to initiate GLM. 
5.7.2 HCP-related  
Diabetes care is a dynamic field, and new knowledge is available frequently; 
therefore, HCPs are continually required to update their knowledge about 
current medications and guidelines. For HCPs with a special interest in 
diabetes, keeping up to date with guidelines was described as ‘no problem’ 
(GP8). Conversely, for many HCPs without a special interest in diabetes, 
keeping up to date represented a challenge: 
“As GPs, you are in a position whereby you have to 
keep up to date with every single speciality, with every 
single speciality… that is a herculean task.” GP2 
As described in the quote below, decisions about when to start GLM were 
influenced by HCPs’ knowledge of current drugs. These findings suggest that 
in general, if they do not feel confident about their knowledge, initiation of 
GLM might be a challenge to GPs who are non-specialists in diabetes. 
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“It’s sometimes quite hard to keep up to date with the 
new medications, you know, and the guidance, yes, 
they all have complicated names, and they are using 
quite specific situations so try and remember which 
drug to use and which specific situation is very difficult. 
When you’re not initiating these drugs that often you do 
tend to need to look it up just to remind yourself 
because it might not be that often that you are seeing 
someone that you need to initiate a drug. Obviously, if 
you are a specialist in diabetes or work in a specialist 
clinic, then it would be more often”. GP10 
“I hope to keep reasonably up to date with diagnosis 
and management. Up to probably second-line treatment 
of diabetes, beyond that, I guess many people struggle 
with it, even specialists”. GP11 
5.7.2.1 Healthcare professionals’ perceptions of their roles 
Here, I consider how HCPs’ perceptions of their professional role (e.g. GP, 
nurse) may play a role in diabetes management. Some HCPs perceived that 
the decision of when to initiate GLM sometimes differ between themselves 
and other colleagues. Thus, their thoughts and accounts on these 
discrepancies are presented in this sub-section. 
Given the substantial and increasing role of nurses in chronic disease 
management; their oversight of annual reviews and in some instances their 
ability to prescribe GLM, aspects that inform their decisions could help 
understand differences in prescription patterns. In the quote below, GP10 
gives an account of the increasing participation of nurses in chronic disease 
management such as T2DM. 
“The practice nurse mostly run the diabetic reviews and 
one of them is a prescriber, another one is nearly 
finishing her prescribing course, and they are very 
experienced in chronic disease management, the 
practice nurses. They’ve taken on the majority of the 
type 2 diabetes. I mean, obviously, they also do a lot of 
other long-term conditions review.” GP10 
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Moreover, some participants suggested that aspects related to HCPs’ 
interest in diabetes might lead to variations in prescription patterns. As 
previously described, keeping up to date with diabetes was sometimes seen 
as a challenging and overwhelming task for those without a particular interest 
in the area, whereas specialists seemed to be more confident about their 
knowledge. However, this opinion was not shared by all participants, 
especially by HCPs without a special interest in diabetes. These contrasting 
views are exemplified in the following quotes from GP9 who has a special 
interest in diabetes and GP3 who does not. In the excerpt, GP3 suggests that 
non-specialists could be more likely to inform their practices by the use of 
guidelines.   
“My colleagues who don’t have a special interest, a lot 
of them just feel overwhelmed by all the changes, the 
new drug classes, the new guidelines and how to 
manage.” GP9 
 “Well I’m sure some GPs may have some more of a 
special interest in diabetes, but because we have 
guidelines I’m sure 90% of us will do the same thing.” 
GP3 
Furthermore, some HCPs highlighted the importance of having colleagues 
with a special interest in diabetes as it gave them more confidence and 
provided them with a sense of support. For instance, in the quotes below, 
GP8 perceived that his workload increased due to the absence of an old 
colleague who was interested in T2DM. Likewise, PN4 described the sense 
of confidence provided by having a specialist in the practice to whom they 
can inquire about specific aspects related to T2DM management:  
“My nurse, previous nurse was replaced with a very 
good nurse, but she didn’t have the same training in 
diabetes as my previous nurse did. So again, I dare to 
say that more work has fallen on my shoulders because 
of that, in diabetes…the prescribing and the initiation 
and changes on treatment is all on me, all the time. The 
present nurse just does all the tick boxing.” GP8 
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“We don’t have any GPs here who have a special 
interest in diabetes; I know some surgeries will have a 
diabetes lead or an asthma lead. I know, in my last 
surgery we did, it was easy, if you had a query you 
knew there was someone who had an interest, whereas 
here there is not. Sometimes it can be quite difficult if 
you need to actually go and ask the GP because they 
don’t know a great deal about some of the stuff.” PN4 
Therefore, by PN4’s narrative, it would seem that HCPs also inform their 
practices through discussion and interaction with other HCPs. In general, 
HCPs’ roles at their practices were a factor that influenced the perceived 
need to keep up to date; overall, knowledge about diabetes was described as 
part of their responsibility. However, specialists allowed themselves more 
time to stay up to date while non-specialists mentioned that keeping up to 
date with the essentials was acceptable.  
Taken together, these findings suggest that differences in prescription 
patterns between practices could be related to the HCPs in charge of 
prescribing and whether they have a special interest in diabetes care. This 
finding suggested the inclusion of a new variable to the quantitative strand. 
The variable planned to analysed was in relation to the HCP prescribing (i.e. 
GP or nurse) and/or whether they have a special interest in diabetes; 
however, as it will be explained in the next chapter, this was not possible. 
5.7.3 Healthcare system related  
A number of factors relating to the organisation of resources and people 
within the NHS also appeared to influence prescription practices with regards 
to diabetes care. As described in earlier chapters, in the past diabetes care 
was routinely provided within secondary care. However, it was reported by 
HCPs that the increased prevalence of chronic diseases and the rising 
burden on the Scottish healthcare system resulted in the need for more 
diabetes care to be provided in primary care. With this shift came the need 
for further training and specialisation of HCPs working in primary care: 
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“You have to remember we are just talking about 
diabetes today. I also have to look after everyone with 
heart disease, with asthma, COPD, atrial fibrillation, and 
all of these areas have their own drug classes, their 
own guidelines development. We live and work in very 
challenging times in primary care.” GP9 
Furthermore, as it has been pointed out previously, GPs working within 
primary care also had to deal with short appointment lengths. The increased 
workload and short-consultation times might be particularly challenging for 
GPs without a particular interest in diabetes. As a result, the availability of 
tools such as guidelines and structured education programmes was seen as 
crucial. 
5.7.3.1 Clinical Guidelines  
Participants were aware of national guidelines such as SIGN and NICE and 
reported using them as a general framework for providing diabetes care and 
prescribing GLM. The majority of HCPs reported that SIGN guidelines were 
the ones followed in their practices.  
The perceived value of guidelines varied depending on HCPs’ training, 
experiences and background. In most cases, early-career HCPs and those 
without a particular interest in diabetes considered guidelines to be useful 
resources that facilitated their job in terms of making decisions regarding 
treatment initiation. This is of particular importance since these HCPs could 
be more inclined to decide to initiate pharmacological treatment based on 
guidelines. In the quotes below, a practice nurse without a special interest in 
diabetes, and a GP also without special interest in diabetes highlight the 
usefulness of guidelines to them. 
“It could be a few months since I’ve done a newly 
diagnosed diabetic so you want to have something 
written down so you can say well I have to cover ABCD 
today and then I’ll cover the rest next day.” PN2 
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“I think for the new diabetic drugs I do find the 
guidelines helpful because, partly is difficult to 
remember and you want to look it up, and to have it laid 
out in a clear fashion, is very helpful.” GP10 
Although the guidelines’ usefulness was recognised, some of the HCPs with 
a particular interest in diabetes described guidelines as something to be used 
with caution, presenting them as an aid to prescribing that should not 
override the need to take into account patients’ individual needs and 
circumstances. In the quotes below, two GPs with a special interest in 
diabetes, and with a decade of experience each, give their accounts on the 
utility of guidelines: 
“A lot of the guidelines are very explicit about tailoring 
the treatment to the individual patient, so there is, you 
know, sometimes treatments are useful for some 
patients and not for others.” GP6 
“Guidelines are important because they help promote 
consistency of care; they help promote beneficial 
recommendations but can also be a disadvantage 
because guidelines don’t often take into account the 
patient’s individualised circumstances… We need to 
look at it as handrails rather than train tracks, we as 
doctors and nurses should have the confidence to 
deviate from guidelines when they benefit that patient 
that is in front of us.” GP9 
Hence, individual-patient related factors were indicated once more as the 
most important aspects such HCPs considered when starting GLM. 
Furthermore, both nurses and GPs indicated the importance of establishing 
goals and starting medication in agreement with patients. However, there 
were perceived differences between them about when to initiate oral GLM. 
For instance, GPs considered nurses to be more likely to adhere to protocols 
and guidelines, while nurses perceived their actions to be more consistent 
with the guidelines: 
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“In my experience nurses are much better following 
protocols, so maybe they’re more likely to stick for three 
months before start metformin, and the doctors tend to 
not stick to that quite so in like sort of black and white 
fashion.” GP6 
“I think, as practice nurses, we are probably more 
consistent. I think, even when I look at all the GPs, what 
the GPs do, everybody tend to do things differently. So, 
I don’t think we’ve always got a great deal of 
consistency [within their practice]. Some GPs will start 
people on metformin, and their HbA1c is 49, others 
could be 60, and they don’t bother. I think there is a lot 
of inconsistency out there…and I think as well because 
nurses, I suppose, have to work more to guidelines that 
we’re probably more consistent, whereas a GP 
obviously have the flexibility to elude sometimes.” PN4 
The quote above by PN4, suggests that nurses might prioritise physiological 
aspects such as a patients’ HbA1c when making decisions about when to 
initiate GLM, as they seemed to be more likely to use guidelines to inform 
their practice. This is an interesting finding given that nurses tend to spend 
more time with patients and most likely get to know them better than GPs. 
In 2016, the QOF, which rewarded practices for registering patients and 
maintaining them under specific targets for chronic diseases, was 
decommissioned in Scotland. The QOF included diabetes management in its 
remit and established specific goals for glucose control. HCPs frequently 
reported QOF’s implementation as positive for T2DM management since it 
raised awareness and helped standardise diabetes care and treatment.  
“I think it [QOF] probably raised the standard; I think it 
probably standardised, almost, the treatment of 
diabetes and probably raised the awareness of it.” GP5 
“I think QOF was a useful thing when it first came out. A 
lot of practices had a good quality care for diabetes, but 
there was a lot of practices that were kind of behind the 
curve of chronic diseases management by the year of 
2000 to 2004, that was four years before QOF came in. 
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QOF came in 2004 and forced a lot of practices to 
improve their chronic disease management, which 
improved diabetes care. But I also think QOF had a lot 
of downsides, was very prescriptive so, you know, 
trying to get everybody’s blood pressure to a certain 
target that wasn’t clinical appropriate.” GP6 
However, as exemplified in the preceding quote by GP6, HCPs’ opinions of 
QOF targets varied, and some considered this to be one of QOF’s main 
downsides, since the incentive to reach certain targets was not considered 
appropriate for some patients, especially the elderly and those with multi-
morbidities. Therefore, the existence of QOF was described as hindering 
their ability to focus on patient-related factors. Overall, participants believed 
that the decommissioning of the QOF would not negatively influence diabetes 
care and GLM prescribing practices. This view was shared by many HCPs 
who considered that QOF guidelines were still adhered to indirectly. 
 “We work through that QOF template even though it’s 
not there anymore; we still keep the template, we still 
do all the things that they wanted us to do and just 
because is good practice” PN2 
“People are not paid as of QOF, but they’re probably 
still carrying on clinically as per QOF because that’s 
what’s done for the past ten years and there’s nothing 
that actually replaces it. They’re probably still using 
QOF as a guideline because that’s what they used for 
the past ten years”. GP8 
5.7.3.2 House of Care 
Some of the HCPs interviewed worked at practices where the House of Care 
framework was followed. This patient-centred framework was described as a 
useful tool that gives patients the opportunity to take control of their health. 
“Is more about getting the patient to be involved in the 
decision making rather than just about data collection, it 
is a good idea” GP1 
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“I think it’s far more patient-centred, far more patient-
specific. So, we meet the individual concerns of the 
patient rather than doing a sort of tick-box exercise for a 
review” PN1 
The House of Care framework was described as influencing decisions 
regarding diabetes care, such as when to initiate medication for glucose 
control, as it encourages patients to be active agents in their care and to be 
involved in establishing treatment goals. HCPs commonly described it as a 
facilitator for goal setting, primarily due to its person-centred approach, which 
forced HCPs to take a step back and allowed patients to take control of their 
health. 
“With the house of care, the idea is that the patients 
decide. They get a copy of all their results; the idea is 
that they’ll have a read, and then they’ll come in, and 
you’d discuss what they, is there is any concern, what 
they want to do. Is kind of not meant to us telling them 
anymore, is meant them saying, you know, my weight’s 
gone up a wee bit I want to focus on that, or I am quite 
happy with how things are. Some people come in and, 
I’ve got a lady who recently lost her husband so at the 
moment her diabetes is, you know, for her is not a great 
issue because she’s still grieving. It is really meant to 
be what the patient decides, just sometimes is difficult 
for us healthcare professionals to take a step back” 
PN4 
5.8 Summary  
A variety of intertwined factors and considerations influenced HCPs’ 
decision-making about initiating GLM. These fell into three main categories: 
individual-patient related considerations, HCP-patient related factors, and 
contextual factors.  
Individual patient-related considerations included patients’ ages, HbA1c, 
whether they were perceived to be motivated to change, their lifestyle and 
other health problems. HCP-patient related factors included historical contact 
with patients. The final category, contextual factors, included HCPs’ training, 
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division of labour within their practices, clinical guidelines (including the 
recent decommissioning of the QOF), and HCPs’ perceptions of how their 
own roles fitted in with those of other colleagues involved in delivering 
diabetes care.  
Individual-patient related aspects were of the utmost importance to HCPs 
when making the decision of initiating GLM. This was also shown in chapter 
4 were aspects such as age, HbA1c and other metabolic aspects showed to 
play a crucial role. However, other factors relating to the other categories 
hindered or facilitated HCPs ability to focus on individual factors. For 
instance, GPs reported having limited consultation times which made difficult 
for them to assess patients’ motivation and needs. Historical contact with 
patients was often described as facilitating the provision of tailored advice 
about lifestyle changes. 
This chapter has described the set of intertwined and dynamic factors that 
influenced clinical decision-making in relation to initiation of pharmacological 
treatment for glucose control in people with T2DM. The chapter that follows 
moves on to integrate and discuss the findings of both strands of this study, 
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Chapter 6 Discussion 
6.1 Introduction  
This study, based in Scotland, aimed to identify factors associated with GLM 
initiation, and to explore and describe the views and experiences of HCPs 
working in primary care about the initiation of GLM. In this chapter, I begin by 
providing a summary of the main results from each strand of the study. Next, 
I provide a side-by-side comparison of the main findings where is possible to 
do so. Then, I discuss the overall study findings in the context of the existing 
literature on the topic. I address the limitations and strengths of the study and 
finish by describing the implications of my findings and recommending 
potential directions for future research. 
6.2 Summary of main findings 
The mixed-methods design allowed me to combine quantitative and 
qualitative methods in one study. Overall, the dataset analyses and the 
interviews with HCPs showed that patient related aspects, particularly clinical 
factors such as HbA1c, were fundamental when HCPs were deciding when 
to initiate GLM. However, the findings that emerged from the interviews 
revealed that clinical decision-making on GLM initiation in people with newly 
diagnosed T2DM is much more complex than being based only on HbA1c 
and encompasses a set of interwoven aspects. 
The retrospective cohort study that formed the quantitative strand of the work 
included data from 154,660 people with T2DM diagnosed in Scotland 
between 2004 and 2012 and who survived for at least two years. Overall, 
people who received GLM prescription within two years of diagnosis of T2DM 
had higher BMI, HbA1c, and cholesterol than those who did not. Of the 
54.9% (n=84,997) receiving prescriptions within two years after diagnosis of 
T2DM, 56.8% received them in the first three months after diagnosis. The 
proportions of people receiving a prescription for GLM increased over time, 
particularly for the proportion of people that received a prescription within 
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three months of diagnosis. This period reflects the period during which 
guidelines recommend that lifestyle changes should be attempted in order to 
control glucose levels. Factors that were independently associated with 
longer time to drug treatment initiation were increasing age, other/unknown 
ethnicity, lower deprivation, receiving antihypertensive medication, HbA1c 
<53 mmol/mol, and BMI <30 Kg/m2. Moreover, the stratified analysis by age 
groups showed no significant association between sexes for the oldest 
groups (60 to74 years, and >75 years). However, in the group of people aged 
30 to 44 years females had shorter time to GLM initiation, and in those aged 
45 to 59 years, males had shorter time to GLM initiation. 
The interviews showed that HCPs’ decision-making about when to initiate 
GLM in people recently diagnosed with T2DM is a complex process. Hence, 
their decision-making entails the formal assessment of metabolic factors 
such as HbA1c, and the informal assessment, during their interactions with 
patients, of the patient’s motivation, lifestyle and the consideration of other 
aspects such as perceived life expectancy and quality of life. HCPs’ indicated 
that, although HbA1c is the main aspect to consider, patients’ wider 
circumstances influence and inform their decisions on whether and when to 
initiate GLM.  
In general, HCPs’ suggested that older people with T2DM are often frail 
and/or have other health problems, and a short life expectancy. Thus, for 
these patients, the benefits of GLM were judged against the individual 
patient’s quality of life, overall health condition and projected life expectancy. 
Younger people with T2DM were considered by most HCPs to obtain more 
benefits from attaining and maintaining their HbA1c at optimal levels than 
older people. The adoption of a healthy lifestyle by following an appropriate 
diet and performing or increasing physical activity was reported as important, 
however, most HCPs considered that for some people, such as less 
motivated patients and some older patients, changing their lifestyle is 
particularly difficult to achieve.  
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Some HCPs indicated that the moment of diagnosis can be an important 
trigger for lifestyle changes. However, HCPs emphasised the importance of 
considering the patient’s motivation, mental health and own priorities when 
assessing whether lifestyle change is likely to be feasible. Historical contact 
with patients was deemed to facilitate the provision of information and shared 
decision-making, but HCPs acknowledged that their increased workload 
combined with lack of personnel and restricted consultation length 
sometimes limited their ability to provide patient-centred care.  
6.3 Convergence of findings 
The findings from each strand enhanced each other, a joint display using a 
table, and a narrative comparison and interpretation of the combined findings 
are presented through this chapter. In mixed-methods research, joint displays 
are means to bring the data together in a visual way through figures, tables, 
graphs or matrix. The narrative approach to the integration of findings implies 
that findings from each strand are weaved whenever possible to report a 
topic or area (Fetters et al., 2013). 
Table 35 below summarises the main findings. To facilitate comparison, the 
table includes a side-by-side topic comparison. In this chapter, a topic does 
not necessarily relate to the themes presented in chapter 5 but to areas or 
themes identified in the overall analysis of both strands. Although the findings 
from each strand cannot be compared on every component or topic, they 
converged to a certain extent. Hence, the findings from the qualitative strand 
enhance the understanding of the quantitative results by providing a 
comprehensive perspective from the HCPs and include themes that could not 
been assessed quantitatively in the available data but that can help 
understand some of the associations reported.  
As indicated in chapter 3, results from the quantitative analysis informed the 
qualitative interviews and vice versa. However, the two sets of findings 
converged only in two, intertwined, broad topics. The first topic relates to time 
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to prescription for GLM and HCPs’ rationale for starting pharmacological 
treatment in particular individuals. The second theme is concerned with how 
the characteristics of people with newly diagnosed T2DM played a role in the 
initiation of GLM. 
Furthermore, two additional broad themes that were identified only in the 
qualitative strand will be discussed: HCP-patient relationship and contextual 
factors. These themes could not be assessed in the available quantitative 
data to understand in what ways the two sets of data related to each other, 
for the following reasons: 
a) HCP-patient relationship and HCPs’ perceptions. These subjective 
aspects included those concerned with the development of a HCP-
patient relationship and the potential differences according to their 
professional role (e.g. nurse, GP) and/or special interest in diabetes. 
Information on the professional role of the prescriber was not included 
in the available dataset so could not be investigated in the quantitative 
analysis. 
b) Contextual factors. These factors included guidelines and frameworks, 
consultation length and continuity of care. HCPs discussed and 
provided their perspectives on clinical guidelines, particularly focusing 
on QOF and its recent decommission in Scotland. However, since the 
cohort study covered the period from 2004 to 2012, I could not test the 
potential impact on QOF’s decommissioning on GLM prescription in 
the quantitative data. Furthermore, HCPs’ historical contact with 
patients and the limitations imposed by the wider healthcare system 
such as short consultation length were not possible to analyse 
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Table 35. Summary of main findings 
QUANTITATIVE STRAND QUALITATIVE STRAND 
PRESCRIPTION OF GLUCOSE-LOWERING MEDICATION 
 55% of the cohort received GLM 
prescription within 2 years of 
diagnosis. 
 Metformin was the most frequent 
initial prescription. However, its use 
decreased with increasing age. 
 GLM initiation was seen by HCPs as 
something that would be necessary for 
almost all patients.  
 Diagnosis was considered an important 
time-point to assess patients’ motivation 
and encourage a healthy lifestyle. 
PATIENTS’ CHARACTERISTICS 
 79.5% of people with HbA1c >53 
mmol/mol received GLM prescription 
within 2 years of diagnosis. 
 The fully adjusted Cox regression 
model showed that longer time to 
GLM prescription initiation was 
associated with being older, male 
sex6, other/unknown ethnicity 
(compared with British), least 
deprived SIMD quintiles, HbA1c <53 
mmol/mol, BMI <30 Kg/m2, not 
being on lipid-lowering medication. 
 Patient’s HbA1c was seen as the most 
important factor when deciding when to 
prescribe GLM.  
 HbA1c was seen by HCPs as a proxy 
measure of a patient’s ability to succeed 
with lifestyle and diet interventions. 
 Some HCPs perceived that people from low 
socioeconomic groups and those with poor 
health literacy were less engaged with their 
healthcare.  
 Tight glucose control was not seen as 
critical in people who were thought to have 
a shorter life expectancy. 
HCP-PATIENT RELATIONSHIP 
  Historical contact with patients was deemed 
as a positive aspect. 
 HCPs considered that enabling their 
patients to make choices about their health 
could increase adherence to treatment. 
CONTEXTUAL FACTORS 
  Guidelines were seen as very useful. 
 The decommissioning of the QOF was not 
perceived as affecting diabetes care. 
 Consultation times were seen as a 
challenge to patient-centred care.  
 Prescription patterns could differ between 
nurses and GPs, and between HCPs with 
and without a special interest in diabetes. 
                                            
6 The stratified analysis by age groups showed that amongst people aged 30 to 44 years females had 
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Having presented the convergence of topics in a side-by-side comparison 
table, in the following sections I will address each topic by discussing how 
they compare and can be interpreted in light of the existing literature. 
6.4 Prescription of glucose-lowering medication 
I explored the prescription of GLM objectively and subjectively by using 
patients’ clinical and demographic data and interviewing HCPs. In general, 
HCPs considered that the initiation of GLM is something that most patients 
will need at some point due to the progressive nature of T2DM and that the 
main goal of prescribing GLM is to reduce the risk of complications resulting 
from increased levels of glucose. This view of preventing complications 
instead of managing them is supported by the literature. For instance, Bain et 
al. (2016) conducted a review which sought to evaluate contemporary 
diabetes care in the UK, particularly for glycaemic and BMI control. The 
authors claimed that preventing complications rather than managing them 
would bring greater health and economic outcomes.  
In this cohort of 154,660 people diagnosed with T2DM between 2004 and 
2012 in Scotland, the majority of the population were white Scottish/British 
(70.2%), 9.8% had other ethnic background and 20% of the cohort’s ethnicity 
was unknown. This is broadly in accordance with the population structure in 
Scotland where, although proportions are slightly different, most of the 
population is white Scottish/British. The proportion of white Scottish and 
British was >80% while other ethnic groups represented <10% of the 
population in the 2011 Scottish census (National Records of Scotland, 2011). 
6.4.1 Time to glucose-lowering medication initiation 
In the analysis of time to medication initiation, I found that among other 
factors, in the analyses using age in years as well as in binary categories 
(<65 years and >65 years) being male was independently associated with 
longer time to glucose-lowering prescription in adjusted regression models. 
However, this finding was not corroborated in the qualitative strand as HCPs 
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did not report to manage their patients differently depending on whether they 
were male or female. Moreover, studies that have looked at time to treatment 
initiation have included sex as part of the patient’s demographic variables but 
not in their analysis (Sinclair et al., 2012, Zhang et al., 2012, Sun et al., 
2013), or the analysis did not show a statistically significant difference 
between male and female patients (Spoelstra et al., 2004).  
Recently, a qualitative study conducted in Scotland by Dimova et al. (2019) 
looked at differences according to patients’ gender. People with T2DM and 
relatives of people with T2DM were interviewed. The authors suggested that 
depending on their gender, people with T2DM may manage their diet 
differently; indicating that women often took a more active role in the 
management of their diabetes than men. Although the study did not focus on 
GLM initiation, it further suggests that T2DM management may differ 
according to patients’ gender and emphasises the need for studying these 
possible differences. 
Overall, 55% of the cohort received a GLM prescription within two years from 
diagnosis. Similar proportions of people receiving prescription of glucose-
lowering treatment were reported from a UK cohort that included patients 
with diabetes diagnosed between 2003 and 2005. After two years from 
diagnosis, 51% of the cohort had initiated GLM therapy (Sinclair et al., 2012). 
In the current study, metformin was the most frequent initial prescription 
(82.3%) as either mono- or combined therapy, but its use decreased with 
increasing age. The SIGN guideline for the pharmacological management for 
diabetes recommends using metformin with caution in people with moderate 
renal impairment and with declining kidney function and to avoid its use in 
people with severe renal impairment (Scottish Intercollegiate Guidelines 
Network (SIGN), 2017b). Although a variable related to kidney disease was 
not included in the cohort analyses, kidney disease is more common in older 
than younger people, thus this may help explain the decreased use of 
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metformin in older people with T2DM in this study (National Kidney 
Federation, 2019).  
In accordance with the present results, previous studies in the UK that have 
looked at prescribing in people with T2DM have reported that metformin was 
the drug most commonly prescribed overall (Whyte et al., 2019), and as first-
line treatment (Curtis et al., 2018, Wilkinson et al., 2018). Whyte et al. (2019) 
reported metformin prescription in 79.2% of their cohort in England, which 
included all people with T2DM between 2012 and 2016. Curtis et al. (2018) 
reported that in England, for the period 1998-2016, metformin was the drug 
most commonly prescribed as first-line treatment. Similarly, Wilkinson et al. 
(2018) who described drug choices for people with T2DM in primary care in 
England, Wales, Scotland, and Northern Ireland reported that, overall, 73% 
of people’s treatment was initiated with metformin. Moreover, the use of 
metformin as first-line GLM is consistent with national guidelines (Scottish 
Intercollegiate Guidelines Network (SIGN), 2017b) and contemporary 
research on GLM patterns in the UK (Filion et al., 2009, Sharma et al., 2016, 
Heald et al., 2018, Sinclair et al., 2012). 
Overall, of those who received a prescription (n=84,997), 56.8% received it 
within three months (90 days) after diagnosis, 25.1% between three and 12 
months after diagnosis, and 18.1% within 12 to 24 months after diagnosis. A 
stratified analysis (chapter 4, figure 7) showed that the proportions of people 
receiving GLM prescription within three months after diagnosis increased 
from 25.6% in 2004 to 36.1% in 2012. This pattern could be related to an 
approach to tight glycaemic control sooner rather than later when treating 
T2DM. A tight glycaemic target at diagnosis is supported by clinical 
guidelines which suggest that a target of 48 mmol/mol instead of 53 
mmol/mol may be appropriate for some individuals at diagnosis (Scottish 
Intercollegiate Guidelines Network (SIGN), 2017a). However, this 
recommendation became available after the period of this study. Moreover, 
the increased proportions of people who received GLM prescription within 
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three months may suggest the need for looking at ways to support lifestyle 
changes. 
Some HCPs expressed their willingness to start medication soon after 
diagnosis if the patients have symptoms of hyperglycaemia or if their HbA1c 
were considered too high. However, some HCPs believed that attaining good 
control of HbA1c with tablets would hinder patients’ attempt to improve their 
lifestyle. Unfortunately, data on patients’ symptoms are not available in the 
dataset. However, studies that have looked at patients’ perceptions, have 
shown that some people with T2DM prefer to receive a prescription rather 
than changing their lifestyle. For instance, Elliott et al. (2016) who conducted 
a sequential explanatory mixed-methods study (questionnaire  focus 
groups) in the UK, reported that people with T2DM described that, although 
they did not like taking them, medicines were sometimes a way to avoid 
lifestyle changes, as they perceived that their medication did what it takes to 
improve their HbA1c. However, results from this study may not be fully 
comparable since it included people with all types of diabetes and excluded 
people whose English was not their first language. 
6.5 Patients’ characteristics 
6.5.1 HbA1c 
Comparison of the two strands of this study showed corroboration of the 
importance of HbA1c in the timing of GLM initiation. The quantitative strand 
showed that the majority (79.5%) of people with HbA1c >53 mmol/mol 
received GLM prescription within 2 years of diagnosis as compared to 25.8% 
in people with HbA1c <53 mmol/mol. This finding was in line with findings 
from the qualitative strand where HCPs’ described that the main aspect they 
took into account when prescribing was the patients’ HbA1c. Although 
patients’ wider circumstances were also considered, HbA1c was seen as a 
proxy measure of patients’ ability to engage with a healthy lifestyle. Hence, if 
a patient’s HbA1c was considered too high their likelihood to succeed with 
lifestyle changes was considered low. Moreover, HCPs reported that the 
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higher the HbA1c the likelihood of developing symptoms increased. This 
helps to better understand why people with high HbA1c may receive GLM 
sooner. Furthermore, the high proportion of people with HbA1c >53 
mmol/mol who received a prescription are in line with those of previous 
quantitative studies presented in chapter 2 which found a higher likelihood of 
receiving drug therapy the higher the HbA1c (Mor et al., 2015, Sinclair et al., 
2012). 
Currently, either plasma glucose concentration or HbA1c can be used to 
diagnose T2DM; however, it was not until 2011 that the WHO recommended 
the use of HbA1c as a diagnostic test for T2DM (Scottish Intercollegiate 
Guidelines Network (SIGN), 2017a, World Health Organization, 2011). This 
aspect may explain the fact that the quantitative analysis on glycaemic 
control and GLM prescription showed that sometimes HbA1c was below the 
cut-off point for diagnosis of diabetes (chapter 4, table 25), which presumably 
had been based on glucose rather than HbA1c.  
6.5.2 Other metabolic indicators 
The crude comparison of baseline characteristics of people who received and 
did not receive pharmacological prescription showed interesting results. For 
instance, there were small but statistically significant differences in the 
proportions of people with high blood pressure. Those who did not receive 
medication prescription included a higher proportion of people with higher 
systolic blood pressure. However, this may be related to the age difference 
between groups; people who did not receive prescription were older than 
those who did (63.5 vs 59.9 years). It has been recognised that hypertension 
is a common issue among elderly, and it is caused by the age-related 
stiffening of the major arteries (National Institute on Aging, 2019, Tan JL and 
Thakur K., 2019, Ferri et al., 2017).  
In this study, people with baseline HbA1c >53 mmol/mol, compared to those 
with baseline HbA1c <53 mmol/mol, tended to have higher proportions of 
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people with cholesterol >5mmol/L (41.1% vs 49.4%), and higher proportions 
of people with BMI >30 Kg/m2 (57.0% vs 59.8%). The WHO have reported 
risk factor clustering for CVD in which T2DM is included alongside increased 
BMI, hypertension and dyslipidaemia (World Health Organization, 2018c). 
Studies conducted with people with T2DM have reported similar risk factor 
clustering. For instance, Bays et al. (2007) who conducted a national 
representative survey in the US and performed further analysis comparing 
their results with those from the National Health and Nutrition Examination 
Survey (NHANES), reported that the prevalence of T2DM and hypertension 
increased linearly as BMI increased. The findings of this study are therefore 
consistent with the clustering of CVD risk factors and the important role of 
age in terms of CVD risk observed in previous research. However, the study 
conducted by Bays et al. (2007) investigated the relationship of body mass 
index with diabetes mellitus, hypertension and dyslipidaemia rather than 
GLM initiation. Some of the studies on clinical inertia and time to GLM 
initiation, which were presented in chapter 2, have failed to report the risk 
factor clustering and mainly focused their analysis on HbA1c levels (Khunti et 
al., 2013, Sinclair et al., 2012, Spoelstra et al., 2004, Sun et al., 2013, Mata-
Cases et al., 2016). 
These results reflect those of the qualitative strand in which HCPs reported 
that patients with high HbA1c and other health conditions, such as 
hypertension and hypercholesterolemia, were more likely to receive GLM 
sooner. It can thus be suggested that the clustering of CVD risk factors is one 
important aspect that HCPs consider when deciding when to initiate GLM in 
people with recently diagnosed T2DM. 
6.5.3 Patient’s age and overall health 
As previously described, I found that older age was associated with longer 
time to GLM initiation. This was consistent with findings from the qualitative 
strand in which HCPs described elderly patients as often being frail and 
having other medical conditions; therefore, tight glucose control was reported 
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as being less important for them. In these patients, HCPs gauged aspects 
such as the presence of symptoms, quality of life and life expectancy. HCPs 
believed people with a longer life expectancy would benefit the most from 
receiving GLM which helps explain some findings from the cohort study. 
There are, however, other possible explanations. Further studies have 
suggested that older people with T2DM have difficulties in changing their 
lifestyle. For instance, a study conducted in people with T2DM (n=20) 
attending primary care in England, reported that older adults were the most 
reluctant to follow dietary advice and change their diet in order to support the 
management of their diabetes (Arana et al., 2019). However, this should not 
be generalised and decisions on treatment to control glucose levels should 
be based on individual circumstances. 
As mentioned above, the results from the quantitative strand showed that 
older age was associated with longer time to drug treatment initiation. These 
results are consistent with those reported by Sinclair et al. (2012) in a UK 
cohort that included newly diagnosed patients during the index period of 
2003-2005 where older age (in years) was negatively associated with drug 
treatment initiation within two years of diagnosis (HR: 0.98, CI: 0.97-0.99). 
However, HbA1c > 7.5% and its interaction with age showed a positive 
association with drug treatment initiation. Hence, the negative effect of age 
on time to GLM medication was reduced in people with high HbA1c at 
baseline. (Sinclair et al., 2012). 
Moreover, after formally testing for an interaction between age and HbA1c, 
the stratified analysis by age groups in the current study showed that across 
all age groups, people with HbA1c >53 mmol/mol have shorter time to GLM 
initiation. Moreover, after adjusting by demographic (sex, ethnicity, SIMD) 
and metabolic characteristics (BMI, CVD) and other variables, the analysis 
with age as binary categories (<65 years and >65 years), showed that 
increasing age (>65 years) was associated with longer time to GLM initiation 
(HR:0.78; CI: 0.77–0.80) compared with people <65 years old. Similar results 
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were reported in the literature review. For instance, by Zhang et al. (2012) 
from a US cohort of patients diagnosed between the period of 2003-2005 and 
followed for two years after diagnosis. In this study, after adjusting for HbA1c, 
BMI and other clinical covariates, increasing age (>65 years) was associated 
with longer time to drug treatment initiation than among people <65 years of 
age (HR: 0.82; CI: 0.75-0.90) (Zhang et al., 2012).  
A possible explanation for these findings, in which older people with T2DM 
were less likely to receive GLM even after adjusting for HbA1c, could be due 
to their individual health circumstances which demand an individualised 
approach (International Diabetes Federation, 2013). In 2013, the IDF 
recommended changing glycaemic goals for older people with T2DM, which 
included relaxation of glycaemic goals depending on the frailty and degree of 
independence of the individual with T2DM (International Diabetes Federation, 
2013). Currently, the Scottish guidelines for diabetes have no specific 
glycaemic control target set for the elderly, however, an individualised 
approach is recommended when setting glycaemic targets (Scottish 
Intercollegiate Guidelines Network (SIGN), 2017a, Scottish Intercollegiate 
Guidelines Network (SIGN), 2017b).  
One unanticipated finding was that among the youngest group of patients (30 
to 44 years), although at baseline 80.3% had HbA1c >53 mmol/mol, after two 
years of diagnosis only 69.3% had received GLM prescription. Zhang et al. 
(2011) reported that among young patients, one of the main reasons for non-
treatment was patients’ fear of weight gain (Zhang et al., 2011). In the 
qualitative strand of the current study, although HCPs’ reported to have tight 
HbA1c targets for younger patients, they reported to be willing to delay the 
initiation of GLM if the patient requested more time to attempt to improve 
their glucose levels by lifestyle changes. 
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6.5.4 Healthy lifestyle: diet and physical activity 
The comparison of this topic between strands offered complementary 
information rather than a corroboration of findings. The quantitative strand 
showed that a higher proportion of people (61.5%) who received GLM had 
BMI >30 Kg/m2 than those who did not (54.9%), however, it is important to 
note that in both groups more than half were obese by the WHO criteria 
(World Health Organization, 2019a). In people with T2DM and overweight or 
obesity, a hypocaloric diet and regular exercise have shown to improve 
HbA1c and reduce risk factors for CVD such as cholesterol and blood 
pressure (Tay et al., 2015, Boniol et al., 2017). I assumed that people who 
did not receive medication were managed by lifestyle only, however, because 
it was beyond the scope of the study, changes in HbA1c during follow-up 
according to the type of treatment (lifestyle only or GLM) were not analysed. 
It is also possible that effectiveness of lifestyle interventions differed by age. 
Before, moving onto discussing the qualitative findings on a healthy lifestyle, I 
would like to briefly return to chapter 2 where I highlighted the importance of 
reducing weight in people with T2DM. In particular, I described a study 
conducted in the UK, the DiRECT trial, which showed that 36% of people 
who had been diagnosed with T2DM (no longer than six years before 
recruitment), and who followed a weight-management programme 
(intervention group) achieved T2DM remission defined as HbA1c in the 
normal range in the absence of glucose-lowering treatment and sustained 
normoglycaemia at 24 months (Lean et al., 2019). However, is important to 
note that people in the intervention group were provided a liquid formula diet 
to replace their meals (Leslie et al., 2016). This intervention is currently being 
introduced in clinical practice and may affect treatment choices, at least in 
some people. A systematic analysis and meta-analysis reported that 
changing dietary environment rather than diet behaviour in the treatment in 
people with T2DM has shown greater improvement in the reduction of 
HbA1c. In this context, a changed environment was considered when all or 
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most of the food was provided to participants instead of changing dietary 
behaviour by instruction or education about a healthy diet (Cradock et al., 
2017). Thus, the findings from the DiRECT are not unexpected. Although 
they provide important insights on glycaemic control and diabetes remission, 
it is not clear whether the results will be widely applicable in a real-world 
context. 
In the current study, HCPs reported that all their patients with T2DM were 
encouraged to adopt a healthy lifestyle that included advice on diet and 
physical activity. However, Lawton et al. (2008) who interviewed 32 Pakistani 
and Indians with T2DM in Edinburgh reported that, although most people 
described having received advice about a healthy diet during the initial 
stages of their diabetes, some participants considered that they received 
limited information. Similarly, Peel et al. (2010) interviewed 20 people with 
new diagnoses (within six months) of T2DM in the Lothian region of Scotland. 
Participants reported to have received vague and non-specific guidance 
about physical activity from HCPs. These discrepancies between HCPs’ and 
patients’ perceptions of the advice provided is an aspect that needs further 
research consideration. However, one likely cause of patients’ perceptions of 
insufficient information from their HCPs may be due to the limited 
consultation length and HCPs’ perceptions of patients’ motivation to engage 
in a healthy lifestyle. 
Some HCPs suggested that engaging in physical activity was very difficult for 
some patients. These findings reflect to some extent those by Khairnar et al. 
(2019) who surveyed HCPs (n=21) in primary care in the US. The majority 
(95%) of HCPs considered exercise and healthy diet as very important 
activities for self-care, however, 85.7% and 80.9% considered moderate 
exercise and following the recommended diet, respectively, as difficult for 
their patients; some HCPs considered that their patients were not motivated 
or interested. However, the reasons were assessed by an open-ended 
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question as part of a survey; hence, answers lacked a nuance that could 
have been obtained by interviewing them.  
In accordance with the current study findings, Lawton et al. (2005) 
interviewed Indian and Pakistani people with T2DM in Edinburgh. The 
authors reported that in general people were aware that they should perform 
physical activity as part of the management of T2DM. However, few reported 
to put the advice they received from HCPs into practice. The reasons 
included lack of time, the presence of other health conditions, such as 
arthritis or knee pain that made it difficult to perform physical activity, and 
climatic conditions (participants reported to dislike going out in rain, wind and 
cold conditions). Moreover, participants raised some cultural/ethnic aspects; 
these included a generalised belief that diabetes was caused by factors out 
of their control and that that they could do little to prevent the deterioration of 
their health. Women reported additional reasons for not performing physical 
activity, these included: the lack of single-sex facilities in which they would 
not have to “expose” their bodies to men, and fear that something would 
happen to them while going out such as fainting or falling. Additionally, Peel 
et al. (2010) reported that amongst people with recently diagnosed T2DM in 
Lothian, only a few considered that physical activity was important for their 
blood glucose control. However, the authors reported that among patients 
who implemented and maintained physical activity levels, walking dogs 
played a substantial role. This finding emphasises the need for asking 
patients about their personal interests that may promote physical activity. 
Moreover, results from focus groups conducted by Vinter-Repalust et al. 
(2004) to explore attitudes and problems that people with T2DM encountered 
while adhering to the therapeutic regimen provide further interesting insights 
from patients’ perspectives. The authors reported that, for most patients, 
having diabetes meant that they would need to change their lifestyle, 
particularly their diet and to increase their physical activity. However, for 
some people, it also meant that their family would need to change their 
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eating habits. Changes to their diets was particularly difficult during family 
celebrations and special celebrations, and at their work place. Most patients 
reported preferring taking pills to control their glucose levels than following a 
healthy diet. Furthermore, although all people with T2DM who participated 
were highly mobile, physical activity was perceived as being the most difficult 
to undertake; people reported lack of motivation, lack of willpower, laziness, 
and time pressures as they reasons. Hence, the views of HCPs that I found 
in the interviews might reflect patients’ expressed difficulty in changing their 
behaviours.  
This leads to another important finding; HCPs pointed out the need for 
patient-centred care. Certain aspects such as patients’ socioeconomic 
circumstances and occupation have been reported as influencing HCPs 
decisions. In this instance, Rushforth et al. (2016) conducted a qualitative 
systematic review of studies that described HCPs perceptions of T2DM 
management. The authors reported that, in some cases, patients’ 
socioeconomic and occupational circumstances were considered as 
sometimes limiting the patient’s ability to adopt a healthy lifestyle or take their 
medicines. Similarly, people with T2DM have reported different challenges to 
the ones reported above in adopting a healthy lifestyle, such as the 
availability and affordability of healthy food (Rendle et al., 2013, Landa-Anell 
et al., 2019).  
Furthermore, it has been reported that although HCPs perceive the provision 
of information to people with T2DM as part of their tasks, the adoption of a 
healthy lifestyle is seen as the patient’s responsibility, (Jallinoja et al., 2007, 
Gómez-Velasco et al., 2019). In this study, I found that HCPs described 
decision-making as something that is made in negotiation with the patient, as 
the final decision of whether to take medication or follow dietary advice is the 
patient’s. However, this kind of discussion with patients could be challenging 
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6.5.4.1 Diagnosis  
Earlier I described that HCPs would often prescribe GLM at diagnosis of 
T2DM if the patient described having symptoms caused by increased 
glucose levels. Moreover, some HCPs suggested that diagnosis of T2DM 
provides an important moment to foster the adoption of a healthy lifestyle 
because most patients are more motivated to make lifestyle changes. A 
possible explanation for this finding may be due to that some people with 
T2DM have expressed to experience such feelings at diagnosis, which raises 
the need for assessing patients’ understandings and needs at diagnosis of 
T2DM.  
Some studies have reported that patients’ experiences and reactions at 
diagnosis have important variations, which could influence the way in that 
patients perceive and assimilate the HCPs’ advice. For instance, participants 
in the study conducted by Elliott et al. (2016) mentioned that T2DM diagnosis 
was a moment of “shock”, however, with time their feeling changed and 
T2DM became more an inconvenience in their lives, time also diminished 
their motivation to change their lifestyle. This highlights the importance of 
reinforcing lifestyle advice at later stages of T2DM. 
Other studies that have further looked at diagnosis of T2DM have reported 
different ways in which people react, experience and perceive their diagnosis 
of T2DM. Peel et al. (2004) interviewed 40 people with newly diagnosed 
T2DM in Scotland and reported three ways in which patients described 
arriving at their diagnosis. First, suspected diabetes: people with this 
narrative presented symptoms they believed were related to T2DM, and by 
having the suspicion of possible T2DM they were able to prepare emotionally 
to diagnosis and reduced the “shock”. Second, illness: people in this group 
referred to experience symptoms that they did not relate to T2DM. 
Participants reported to feel astonished but relief at diagnosis, some 
mentioned they were relieved that it was not something “worse”. Third, 
routine: where people were diagnosed by a routine test when attending their 
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clinic or general practice for something else, for some, their diagnosis 
became something more to be added to their pattern of ill health while others 
reported a more emotional reaction and to feel scared or shocked. The 
identification of the way in which a patient arrives at diagnosis may help refer 
or facilitate tailored interventions. 
Similarly, Abreu et al. (2018) conducted interviews with 26 people with 
T2DM. The authors reported that people with T2DM generally experienced 
diagnosis in three different ways. First, disruption: people enacting this 
narrative recalled diagnosis a disruptive moment in where they became self-
aware of being at risk, which also caused anxiety, panic and uncertainty. 
These patients were described by the authors as being from good to 
excellent in understanding health information and being very independent; 
and reported as commonly search information and treatments outside the 
standard healthcare system. Second, empathy: these people usually 
adjusted their lives and habits strictly following medical recommendations 
and treatments. These people displayed some understanding of health 
information and had a more active participation in treatment, their main 
source of information were HCPs. Third, minimisation: some had a narrative 
of T2DM as having a low impact in their lives and daily routines. These 
people often had little understanding of their health condition and were not 
interested in the details of their condition.  
It is possible, therefore, that although HCPs in the current study reported 
perceiving some of the feelings experienced by their patients at diagnosis, 
insufficient attention has been paid to the way in which their patients’ deal 
with the diagnosis in order to understand the best approach to manage their 
diabetes and achieve patient-centred care. Moreover, HCPs’ point of view 
about consultation times should not be overlooked; limited consultation time 
was regarded by HCPs’ as a barrier to assessing patient’s motivation and 
needs. The need for longer consultation times is an aspect that has been 
recognised as a significant challenge in primary care, particularly for older 
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patients who are more likely to have multiple conditions (ISD Scotland, 
2018a, ICM Unlimited on behalf of the British Medical Association, 2015). 
Consultation length is an aspect that is discussed in section 6.7.2. 
It is important to mention that most HCPs in the current study reported 
referring people with newly diagnosed T2DM to DESMOND, which as 
described in chapter 2, is a structured group education programme available 
in some health boards in Scotland and in England. Winkley et al. (2018) 
interviewed HCPs working in primary care in the UK in order to determine 
their views about group structured education for people with newly diagnosed 
T2DM. HCPs considered that interaction with other people with T2DM was 
among the positive aspects of DESMOND; however, they reported believing 
that few patients attend. Some HCPs reported believing that people who 
need the information the most usually do not attend, these people were 
particularly those with mental health issues and non-English speakers. 
Hence, although structured education programmes are important tools which 
may relieve some of HCPs workload, consideration must be given to 
potential patients’ barriers to attend these programmes. 
6.5.5 Socioeconomic status  
Some HCPs perceived that people from low socioeconomic groups and poor 
health literacy were less engaged with their healthcare. This finding is 
consistent with the quantitative strand which showed that people in the more 
deprived SIMD quintiles received medication sooner than those in the less 
deprived quintiles. Some studies have looked at differences in T2DM care 
depending on socioeconomic status have shown the different perceptions 
that HCPs have about people from low socioeconomic groups. For instance, 
Havele et al. (2018) interviewed physicians working in Internal Medicine and 
Family Medicine departments in a hospital in the US. The authors reported 
that physicians modified their instructions and were less stringent with people 
of low socioeconomic status and/or poor literacy because HCPs perceive 
these people to face more challenges in their disease management.  
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Moreover, Dao et al. (2019) interviewed HCPs (GPs and nurses) and people 
with sub-optimal control of T2DM (HbA1c >53 mmol/mol, blood pressure 
>130/80mmHg, BMI >30 Kg/m2 and hyperlipidaemia) in a low socioeconomic 
area of Sydney, Australia. The authors reported that most HCPs reported 
that their patients were unmotivated or that they were initially motivated but 
their motivation decreased with time. Many HCPs’ considered that mental 
health conditions, such as depression, was a barrier to some patients and 
contributed to over-eating and not performing physical activity. Most patients 
reported to be motivated, however, they also described that their 
commitments at work or with their families allowed them little time to engage 
in physical activity or prepare healthy meals. Most patients reported that their 
main educational source about T2DM were the GP and dietician, and 
reported to struggle with their diets and to need more support from their GPs 
or to be referred to a dietician. These findings suggest that HCPs’ 
perceptions on people from low socioeconomic groups may not reflect their 
patients’ levels of motivation. Hence, tailored advice could improve patients 
engagement with lifestyle changes. 
6.5.6 Ethnicity, health literacy and minority groups 
In the current study, some HCPs observed that people from some ethnic and 
religious minority groups, people with depression, and frail patients were less 
likely to engage with physical activity or exercise. These results reflect those 
of Ross et al. (2019), who reported that HCPs in the UK believed that some 
patients such as people with mental health problems, low literacy and non-
English speakers require more support. HCPs also considered that these 
patients were not suitable to attend self-education for diabetes.  
The ethnicity of people with T2DM was included in the cohort analysis; 
however, outcomes were not stratified by ethnic background because of the 
large proportion of missing data and the small proportion of people of non-
white ethnicity in Scotland. However, differences in T2DM care and 
management, and disease perception by ethnicity have been studied 
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previously. Ledford et al. (2019) surveyed people with T2DM in the US and 
reported significant differences between people according to their ethnicity. 
Compared to Asian Americans, White Americans were reported as having 
better understanding of the disease process. Likewise, compared with Asian 
Americans and Black Americans, White Americans perceived a significantly 
greater longevity of diabetes. However, a note of caution is due here since 
other characteristics of patients, such as duration of T2DM and the presence 
of complications or other diseases were not analysed. Moreover, Staff et al. 
(2017) reported that in Sweden, there was no difference between BMI or 
reaching targets for blood pressure, LDL, albuminuria or smoking between 
native Nordics and non-Nordic people with T2DM. However, there was a 
difference in HbA1c, where few non-Nordic reached HbA1c targets. These 
results suggest that people from certain ethnic backgrounds may need 
additional support from their HCPs to achieve and maintain optimal glucose 
control because they may have different perceptions of T2DM and barriers to 
optimal management. 
6.5.7 Mental health 
Variables related to mental health conditions were not included in the cohort, 
thus, these data cannot be compared between strands. However, the 
findings of the qualitative strand in which HCPs saw people with mental 
health conditions as struggling with the implementation of lifestyle changes, 
are of particular importance since it has been reported that people with T2DM 
have an increased risk of developing depression (Nouwen et al., 2010). The 
relationship between depression and T2DM has been reported to be 
bidirectional. Hence, depression negatively affects T2DM outcomes including 
glycaemic control, and T2DM complications increase the risk of, and 
worsening the course of depression (Semenkovich et al., 2015). 
Even in people with T2DM without a reported diagnosis of depression, some 
see their disease as a source of distress and consider treatment for T2DM, 
either lifestyle changes or medication, as a source of emotional burden 
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(Stoop et al., 2019). Mental health could also affect the frequency in which 
people with T2DM seek medical help. In a recent study, people with a lifetime 
history of depression, with current depressive symptoms and T2DM, were 
reported to use fewer treatment services to treat their T2DM (Lee et al., 
2020). However, the study was conducted in Korea and the findings may not 
be extrapolated to the Scottish context, although both provide universal 
access to healthcare (Kwon et al., 2015, Steel and Cylus, 2012), cultural 
differences might play a role. Nevertheless, these studies underline the 
importance of taking into account patients’ mental health. In particular, these 
patients may be prescribed GLM sooner if they are seen as lacking 
motivation to implement lifestyle changes.  
Similarly, comorbid depression may lead to HCPs to prescribe GLM sooner 
as patients with comorbid depression are often reported as lacking 
motivation. This finding is supported by Ciechanowski et al. (2000) who 
reported that severity of depression in people with T2DM is associated with 
significantly worse adherence to diet, which includes the type of diet followed 
and the amount of food consumed. The severity of depression has also been 
associated with the use of oral GLM (Ciechanowski et al., 2000). These 
findings might help explain why in the current study the perceived reduced 
likelihood to implement lifestyle changes seemed to be an aspect influencing 
HCPs’ decisions about starting patients on GLM sooner.  
6.6 HCP-patient relationship  
Overall, HCPs reported that aspects such as previous interaction with 
patients were reported as facilitating shared decision-making and cooperative 
healthcare management. HCPs emphasised that the initiation of GLM implied 
negotiation with patients, which included a discussion about patients’ 
lifestyle. Moreover, all HCPs reported seeking and encouraging shared 
decision-making, however, some HCPs suggested that the approach to 
diabetes care differs between HCPs according to their clinical role (nurse, 
GP) and special interest in T2DM. 
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6.6.1 Negotiation with patients  
The suggestion to initiate GLM by the HCP to their patients was determined 
by individual-patient considerations. HCPs suggested that shared decision-
making increased treatment adherence and saved NHS resources. The 
discussion with patients was reported as including disclosure about potential 
side-effects of the medication. As reported in chapter 2, Milos et al. (2014) 
conducted focus groups with GPs in primary care in Sweden and reported 
that they would seek to create a dialogue with their patients about the 
treatment approach. HCPs’ considered that written evidence-based 
information, such as in a leaflet, was a good way to provide information to 
patients and foster discussion. This finding suggests that people with T2DM 
may benefit from receiving written information about GLM to inform their 
decisions. 
Moreover, I found that HCPs’ often reported that patients’ and HCPs’ 
priorities had to be in alignment. Hence, patients need to be “ready” to accept 
and take GLM. A possible explanation for this may be the fact that people 
with T2DM and other health conditions, sometimes prioritise the condition 
that they consider to have a greater impact in their social and physical lives 
(Boyle et al., 2016). Furthermore, not taking into account the patient’s 
opinions might be disadvantageous. Stoop et al. (2019) reported from their 
interviews with people with T2DM that for some patients, diabetes care was a 
source of distress, particularly when they felt not being supported by their 
HCP and when they perceive the advice that was provided to them was 
unrealistic and unattainable or that their personal context was not taken into 
consideration. Discrepancies between HCPs’ and patient’s perceptions have 
been previously reported (Woodcock and Kinmonth, 2001, Linmans et al., 
2015). Therefore, asking patients about their health priorities can provide 
important information to HCPs when deciding to prescribe GLM. 
In this study, some of the practices where HCPs worked followed the “house 
of care” model. The house of care model promotes patient-centred care 
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achieved by care-planning conversations between people and HCPs, 
promoting shared decision-making. The purpose is to enable patients to 
express their needs and decide according to their priorities (Health and 
Social Care Alliance Scotland (the ALLIANCE), 2019, Mathers and Paynton, 
2016). The combination of findings so far suggests the adoption of 
frameworks that support patient-centred care, which are discussed in section 
6.7.1.  
6.7 Contextual factors 
This theme cannot be directly compared with the quantitative strand because 
variables related to the practices and HCPs were not available in the cohort. 
However, these findings provide relevant information to understand some of 
the results previously reported.  
6.7.1 Guidelines and frameworks  
Thus far, discrepancies in the prescription of GLM seem to be rooted in the 
evaluation performed by HCPs of their patient’s needs and discussion of the 
patient’s preferences. In Scotland, SIGN guidelines are available to HCPs. 
These guidelines have been developed to provide recommendations, based 
on evidence, for best practice in the management of diabetes (Scottish 
Intercollegiate Guidelines Network (SIGN), 2017a). Currently, there is an 
additional stand-alone guideline, SIGN 154, which covers pharmacological 
treatment for glucose-control (Scottish Intercollegiate Guidelines Network 
(SIGN), 2017b). 
In this study, HCPs expressed that guidelines are very useful, and many 
reported consulting them before initiating GLM. However, a need for flexibility 
depending on the individual was recognised. These findings broadly support 
the studies presented in chapter 2. For instance, Alexander et al. (2016) 
conducted a study with physicians in Canada about clinical guidelines for 
diabetes; physicians’ reported taking into account patients’ particular life 
contexts and sought shared decision-making. Similarly, other studies that 
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have explored HCPs’ perceptions of and attitudes towards clinical guidelines 
in a more general way, have concluded that guidelines are often seen as 
useful tools that help support evidence-based decision-making (Hunt et al., 
2012, Ingemansson et al., 2014).  
Moreover, quantitative research conducted by Thepwongsa et al. (2014) who 
surveyed GPs practising in rural and remote Australia, showed that GPs 
reported that the main aspects that influence and inform their decision-
making were clinical guidelines, consultation with specialists, and 
professional training. While only 59.1% responded being up to date on new 
technologies and treatment for T2DM, 85.9% referred finding clinical 
guidelines useful when providing diabetes care. The findings reported by 
Thepwongsa et al. (2014) highlight that guidelines are not the only resource 
used by HCPs which is consistent with findings from the current study. In the 
qualitative strand, I found that HCPs’ reported trying to keep themselves up 
to date by different means such as attending conferences, meeting and 
discussing new information with peers; this appeared to be more common 
among those with a special interest in diabetes. 
For the present study, while data for the quantitative strand was drawn from 
people diagnosed from 2004 to 2012, a period in which the QOF was in 
force, the interviews with HCPs were conducted two years after it was 
decommissioned. HCPs perceived that the QOF decommissioning would not 
negatively affect diabetes care because its guidelines were still adhered to 
indirectly. Furthermore, some HCPs considered that without incentives to 
reach targets, they were able to focus more on patient-related factors. Thus, 
HCPs’ views in this study reflect what has been previously reported in the 
introduction and literature review about the criticism of QOF as hindering 
person-centred care because it focused on clinical targets (Gillam, 2010, 




Discussion  251 
6.7.2 Consultation length and continuity of care 
GPs reported that their consultation times in primary care are really 
challenging, especially for new patients as delivering information becomes 
quite difficult with the 10-minute slot they usually have. In accordance with 
the present findings, the National Survey of GPs conducted in 2015 by the 
British Medical Association reported that in Scotland, 63% of GPs reported 
that there should be longer consultations for certain groups such as those 
with long term conditions. Overall, 93% of GPs in Scotland considered that 
consultation lengths were inadequate (ICM Unlimited on behalf of the British 
Medical Association, 2015). Likewise, as reported in chapter 2, previous 
studies have reported time constraints as a barrier to deliver patient-centred 
consultations (Pooley et al., 2001, Noor Abdulhadi et al., 2013, Daniels et al., 
2001, Ingemansson et al., 2014). However, a review conducted by Wilson et 
al. (2016) reported that, although there is some evidence that increased 
consultation times led to greater patients’ satisfaction, currently there is no 
strong evidence which supports the alteration of consultation length. 
Furthermore, HCPs often reported that historical contact with patients was a 
positive aspect that helped them reduce the time spent in gathering 
information about the patient. HCPs described how knowing patients by 
having seen them previously for other health conditions made consultations 
easier and facilitated discussion regarding the initiation of GLM and lifestyle 
change. Previous studies in the UK have reported similar findings about 
considering continuity of care as a positive aspect. For instance, Alazri et al. 
(2007) explored GPs’ and nurses’ experiences of continuity of care for people 
with T2DM in primary care by interviewing 16 GPs and 18 nurses who 
managed T2DM. HCPs considered that the care provided for a patient by a 
named HCP, which could last for a few years to a whole lifetime, helped to 
encourage patients to follow their advice and provided an opportunity to 
reinforce such advice. However, HCPs acknowledged that the higher the 
number of patients registered in a practice the more difficult it was to achieve 
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continuity in care. In general, HCPs considered that for long-term conditions, 
such as T2DM, continuity of care was crucial.  
Continuity of care might be of particular importance for older patients. 
Greaves et al. (2003) interviewed 25 nurses in the UK who reported that 
continuity of care facilitated treatment modifications in elderly patients. 
However, this finding must be interpreted with caution, not only because the 
study was conducted more than fifteen years ago, but also due to the authors 
having focused on views about converting people with diabetes from oral 
hyperglycaemic agents to injected insulin within primary care. Nevertheless, 
receiving care from the same HCP has not always been reported as 
essential, Boyle et al. (2016) reported that people with T2DM in Australia did 
not consider continuity of care as completely necessary, particularly if they 
considered that the HCP would mainly be conducting clinical tests and 
check-ups. It can thus be suggested that, although HCPs’ in the current study 
reported it as a positive aspect, continuity of care is needed only for some 
people and thus, the patient must be the one who decides whether they 
desire to see the same HCP over time. 
6.7.3 HCPs’ perceptions of their roles 
The interviews with HCPs revealed potential differences in prescription 
patterns between nurses and GPs, and between HCPs with a special interest 
in diabetes and without special interest. However, with a small sample of 
HCPs, caution must be applied, as the findings may not reflect real practice. 
Quantitative studies have reported differences in prescription depending on 
HCPs’ characteristics. For instance, Grant et al. (2007) who surveyed 
physicians reported that compared to specialists, general physicians tended 
to avoid insulin and prescribed glitazones instead. Likewise, Escalada et al. 
(2016) reported that GPs, compared to endocrinologists, often delay insulin 
initiation. However, these studies focused on insulin initiation instead of first-
line GLM.  
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Nurses had increasing participation in diabetes care, and their decisions on 
when to start drug treatment might be guided more by patients’ HbA1c levels 
and although they also consider individual factors, they might be more likely 
to try to persuade patients to start at an early stage if the guidelines indicate 
so. The increasing role of nurses in diabetes care in the UK has been 
reported in the literature review (National Statistics Scotland, 2013). 
However, differences in prescription patterns by HCPs role, in the context of 
newly diagnosed T2DM, has not been reported.  
6.8 Reflections on the research 
Before addressing the limitations and strengths of this study, I would like to 
provide a reflection on conducting this research. Mixed-methods studies 
provide valuable insights into a topic; however, to engage in such endeavour 
there are some aspects that should not be overlooked.  
First, it is essential to consider critically the time element. I initially 
underestimated the time that I would need for conducting both strands, 
fortunately, this was pointed out during the first-year review and I made the 
practical decision to change the sequential design to a convergent parallel 
design. Although the study design made it feasible for me to obtain 
experience of both types of research and to switch from one strand to the 
other whenever it was necessary, this study challenged my time 
management skills and capability to swap from quantitative to qualitative 
methods and at the same time to bear in mind that they should form coherent 
strands of the same study. 
Second, since this study had limited funding, incentives to participate were 
not offered to HCPs to participate in the interviews. In retrospect, considering 
their busy schedules, there is a possibility that more HCPs might have 
participated if I had been able to offer an economic incentive. This could have 
helped by allowing me to have more time with participants to discuss some 
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aspects in more depth, such as HCPs’ approach to management depending 
on patients’ sex and HCPs’ perceptions of their role. 
6.9  Limitations and strengths 
6.9.1 Limitations  
This study has limitations, which I will now address. It is important to consider 
that, due to differences in guidelines and policies between countries, this 
research may only apply to the Scottish context. Moreover, as described 
earlier, I would like to acknowledge the differences between years from the 
patient’s data (2004-2012) and the interviews with HCPs (2018). The main 
change occurred during these years was QOF decommissioning, and 
although the interviews made evident that there is still a legacy of QOF, 
differences in prescription patterns in patients diagnosed with T2DM after 
2012 may have taken place.  
In chapter 2, the systematic search and reviews are subject to inherent 
limitations of the type of review. Although this type of review incorporates 
different study types to provide a holistic view of the topic, and the initial 
search process met the requirements of a systematic review, the consequent 
steps are not subject to a clearly defined process of synthesis which may 
result in some subjective selection of evidence (Grant and Booth, 2009). 
Moreover, since the search, selection process and synthesis were done only 
by me, and not by two people working independently, the possibility that the 
selection of articles was influenced by personal bias cannot be discarded. 
However, some best practice recommendations for systematic reviews were 
followed where possible. For instance, the development of criteria used to 
decide which studies were included; although explicit inclusion and exclusion 
criteria are not required for systematic search and reviews, the Cochrane 
handbook advises the use of eligibility criteria to help readers understand the 
scope of the review and provide an argument of why some studies they are 
aware of were not included. Moreover, an account of the results of the search 
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was provided in a PRISMA-type flow diagram which summarised the 
selection process. Similarly, tables were created to summarise the 
information for each study included as well as tables with information for full-
text studies which were excluded (included in appendices) (Page Matthew J 
et al., 2019, Lefebvre C et al., 2019).  
In relation to the cohort dataset, it is not possible to know whether data in the 
SCI-Diabetes dataset is entirely accurate in terms of emigration as changes 
depend on practices maintaining accurate lists of active patients. However, 
updated demographic details are routinely collected and, before recording a 
new diagnosis onto the system, GPs are encouraged to do a patient search 
to ascertain their presence on the system (INPS, 2013, Cunningham et al., 
2011). Accuracy of other variables in SCI-diabetes is also difficult to assess. 
However, as described in chapter 3, a search and deletion of implausible 
data were conducted prior to the analysis of missing data.  
The potential inclusion of people with T1DM in the cohort was reduced by 
selecting those recorded as having T2DM, who were or at least 30 years of 
age and had no record of GLM prescription before the date of diagnosis of 
diabetes. However, 1.2% of those who received GLM (0.67% of the whole 
cohort) were prescribed insulin as first GLM (alone or in combination with 
another drug) with a mean of 161 days from diagnosis to prescription 
suggesting that a small proportion of the cohort may have had T1DM. 
Another important aspect that needs to be taken into consideration is the fact 
that only people with recently diagnosed T2DM who survived for at least two 
years of follow-up were included in the cohort. The rationale for this decision 
was to provide equal lengths of follow-up for all participants and to reduce the 
influence of potential terminal illness on treatment decisions and HbA1c. 
Moreover, there was an important proportion of missing data in the cohort, 
only 56.7% of the population had data available for all variables of interest. I 
used multiple imputation, which is considered an appropriate method for 
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handling missing data, and utilised 45 imputed datasets as recommended by 
the literature. Furthermore, the comparison of the imputed dataset and the 
CCA suggested that the use of complete cases may provide biased results 
because of the differences in characteristics between people with and without 
missing data. BMI was the variable with the largest proportion of missing 
values, and the Cox regression for the CCA showed no statistically significant 
association between BMI and receipt of prescription within two years for BMI 
whereas the association was statistically significant in the imputed dataset. 
However, as discussed in the quantitative results section, this discrepancy 
may be related to power (i.e. chance) rather than bias, since apart from this 
finding, the results of the imputed dataset were largely consistent with those 
of the CCA suggesting that there is little evidence of bias in the CCA. 
As reported in the literature review, sometimes HbA1c is less reliable in some 
non-white ethnic groups. While this is not a major limitation of the study since 
I did not look at the differences between HbA1c across ethnic groups, and 
the focus was not related to describing ethnic differences, I must observe that 
the ethnicity of 20% of the cohort was unknown. However, as mentioned 
previously, the Scottish census of 2011 reported that non-white 
Scottish/British represented <10% of the population (National Records of 
Scotland, 2011). Hence, is likely that an important proportion of those whose 
ethnicity was unknown was indeed white Scottish/British. Another important 
limitation lies in the dichotomisation of ethnicity into Scottish/British and 
other/unknown for the Cox regression in the quantitative strand. By utilising 
these two categories it was not possible to fully compare findings from the 
cohort analyses with those of the interviews in which some HCPs considered 
that patients from some minority ethnic groups were less likely to engage in 
physical activity and so were more likely to be prescribed GLM earlier than 
the majority white population. Although the univariate regression indicated 
shorter time to GLM for people of other/unknown ethnicity, the fully adjusted 
model showed that people from other/unknown ethnicity had longer time to 
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GLM initiation than Scottish/British. The relationship of other ethnicities in 
clinical decision-making about when to initiate GLM is still an aspect that 
needs further exploration. The study has limited power to investigate the 
association between non-white ethnicity and time to GLM but increasing 
completeness of recording of ethnicity may make it feasible in the future.  
Unfortunately, for the quantitative strand, no data were included about 
chronic kidney disease, which was reported to be a factor influencing 
decisions about when to initiate GLM, particularly amongst older patients. It 
would have been desirable to add this variable to the dataset. 
Further limitations arise from the use of HbA1c, as data and changes in 
HbA1c after initiation of GLM were not included. Baseline HbA1c was defined 
broadly in terms of the time-frame used to define the variable, which as 
reported in chapter 3, as the average value between 180 days before and 
after diagnosis in order to minimise missingness. In relation to this, a study in 
the UK showed that people with T2DM (mean duration 6 years) who were not 
taking insulin and were initiating or changing their type or dose of GLM, their 
HbA1c decreased by 7.1+1.3 mmol/mol on average after 12 weeks of 
initiating their new GLM or dose (Hirst et al., 2014). This finding shows that 
HbA1c values can be quickly reduced by using GLMs. Thus, for people who 
started GLM soon after diagnosis in the current study and who did not have 
an HbA1c value recorded prior to treatment, the reported baseline HbA1c 
values could potentially have been lower than the real HbA1c values at 
diagnosis. 
Although the sensitivity analysis presented in chapter 4 showed that 
proportions of people who received a GLM prescription increased at higher 
HbA1c levels, these were not addressed in the analyses. For the Cox 
regression analysis, HbA1c was dichotomised in either <53 mmol/mol or >53 
mmol/mol. However, while the inclusion of additional categories may have 
had an impact on the results, the results showed that shorter time to GLM 
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was strongly associated with HbA1c >53 mmol/mol. In the current study, cut-
offs points were based on targets in clinical guidelines rather than the curve 
points or ‘bumps’ found in the Martingale residuals plots. However, for BMI 
and HbA1c conventional clinical definitions and bumps in the data were 
similar.  
Lastly, recruiting HCPs for the interviews was rather challenging, particularly 
since no incentive to take part in the study was offered. HCPs often reported 
that they were very busy and had no time to participate. Although I obtained 
enough data to answer the research questions, recruiting more participants, 
as initially planned may have provided richer and more extensive findings. 
Moreover, I interviewed relatively few nurses and did not have the 
opportunity to interview HCPs from across a diversity of areas, for instance 
remote rural areas. 
6.9.2 Strengths  
This study has a number of strengths which I will now describe. First, the 
convergent parallel mixed-methods design, although challenging to carry out, 
allowed the comparison of two different sets of data to provide greater insight 
into the timing of GLM prescription in people with newly diagnosed T2DM.  
Second, the cohort of patients was drawn from SCI-diabetes which contains 
patients’ records from all health boards in Scotland. Overall, 154,660 people 
were included in the cohort. Thus, the analyses of a large dataset which is 
nationally representative provide more accurate estimates about people with 
newly diagnosed T2DM in Scotland.  
Third, the interviews and their analysis commenced simultaneously, this 
allowed me to use preliminary findings in the subsequent interviews by 
improving my topic guide. Moreover, by keeping the questions as open as 
possible HCPs were able to guide the conversation to what they considered 
more important when deciding when to initiate people with newly diagnosed 
T2DM on GLM. 
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Fourth, to my knowledge, this is the first study which has looked at GLM 
initiation in people with newly diagnosed T2DM using a mixed-methods 
design. Although some limitations need to be taken into consideration, this 
study provides important knowledge about the topic and highlights the 
complex set of factors that play a role when prescribing GLM. 
6.10 Implications and directions for future research 
Through this study, I sought to determine what factors were associated with 
GLM initiation, and what were the views and experiences of healthcare 
professionals working in primary care about when to initiate GLM. The 
convergent parallel mixed-methods design enabled me to answer this 
question by using quantitative and qualitative data in a way that would not 
have been possible with other study design.  
The study has identified that in Scotland, older age, living in less deprived 
areas, being male, having lower BMI and HbA1c were independently 
associated with longer time to GLM initiation. However, it also showed that 
clinical decision-making encompasses not only clinical aspects related to the 
patient but also to the patients’ perceived or expressed motivation and 
readiness to make lifestyle changes, the healthcare system and the HCPs’ 
characteristics. Thus, in line with realistic medicine which encourages HCPs 
to have an open and honest dialogue with people about their needs, patient-
centred care is essential (Realistic Medicine, 2019). 
Moreover, the present study raises the possibility that HCPs without a special 
interest in diabetes might feel less confident in managing people with 
diabetes, which emphasises the importance of providing them with the 
opportunity to keep up to date with and to be able to critically appraise and 
attempt to apply clinical guidelines appropriately to individual patients. The 
interviews yielded an important implication for current practice. HCPs 
expressed the need for guidelines with separate goals, particularly for elderly 
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patients, which now are available in the ADA standards of care but did not 
exist when this research started.  
Hence, this study has added important knowledge to the study of GLM 
initiation in people with newly diagnosed T2DM. This study provides evidence 
of the patterns and factors associated with drug initiation in Scotland in the 
QOF period, which are valuable to compare, once there is sufficient data 
gathered, with the period after the decommissioning of QOF. After the 
decommissioning of the QOF, there may be changes to the patterns in GLM 
prescription partly due to changes to the GP contract and also due to other 
factors such as increasing interest in the potential for remission of T2DM. 
Therefore, further analyses are recommended in order to describe treatment 
patterns in the years after QOF termination.  
In the quantitative component of this study, clinical and metabolic variables 
were included, however, cardiovascular risk scores were not calculated, 
which may be important to consider in the future. Newer drugs for treating 
diabetes such as GLP-1 agonists may have a protective effect against 
cardiovascular disease but are currently only recommended for treating 
people with existing CVD and hyperglycaemia that has not responded to 
lifestyle modification and metformin monotherapy (American Diabetes 
Association, 2019d). Furthermore, during the analysis of both quantitative 
and qualitative findings further queries related to differences by patient’s sex 
and ethnicity were raised. For future research, it would be valuable to include 
stratified analyses to identify differences and to examine HCPs’ views and 
perceptions of the role of these aspects in more depth. For the quantitative 
analysis, it would be interesting to extend this work to include repeated 
measures of HbA1c and to investigate whether time to glucose-lowering 
treatment influenced subsequent risk of complications of diabetes. 
Likewise, further understanding and review of prescription patterns for certain 
groups of clinical interest such as elderly and people with comorbidities are 
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needed given the increasing recognition of the challenges in providing care to 
people with multimorbidity. In particular, the role of mental health conditions 
in T2DM management and outcomes emphasises the importance of 
comprehensive individualised care for people with T2DM. 
In addition, it would be interesting to study patterns of prescribing second- and 
third-line drugs given the introduction of new drug classes in recent years, 
including GLP-1 agonists and DPP-4 inhibitors that are likely to displace some 
insulin prescribing. However, such pharmaco-epidemiological analysis would 
benefit from including repeated, time updated HbA1c measurements and not 
only baseline measures. 
6.11 Conclusion  
This study provided novel insights into clinical decision-making, particularly 
on HCPs’ experiences, views and factors they consider when deciding when 
to prescribe GLM in people with recently diagnosed T2DM. In addition, the 
qualitative strand showed how decision-making between people with recently 
diagnosed T2DM and HCPs working in primary care contributes to the timing 
of initiation of GLM. Both strands identified that there continues to be scope 
to improve support for people to make beneficial lifestyle changes following a 
diagnosis of T2DM. Recent RCT results indicating the potential for T2DM 
remission in people who achieve major weight loss have resulted in extended 
weight management services (Lean et al., 2018, Lean et al., 2019, Leslie et 
al., 2016). However, at population level it is important also to identify ways to 
change the wider environment to make it easier for people to live healthy 
lifestyles.  
By using a mixed-methods approach, I have provided insights on the factors 
and considerations that influence prescription of GLM in people with recently 
diagnosed T2DM. I have provided evidence that although HCPs’ considered 
HbA1c as fundamental to informing decisions to prescribe medication to 
lower glucose levels, their decision was not solely based on this indicator. 
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HCPs considered the wider context and patient’s other circumstances in 
seeking to provide patient-centred care. 
However, some important queries such as potential differences between 
HCPs according to their role (nurse, GP) or interest in diabetes needs to be 
addressed in further research. Likewise, future work needs to include sex- 
and ethnic-specific analysis of prescription patterns in order to identify 
potential clinically relevant inequities in the management of people with newly 
diagnosed T2DM. Finally, these findings help to understand why HCPs did 
not always prescribe glucose-lowering treatment when HbA1c levels might 
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Appendix 1 – Search strategies 
1A – Search strategy for quantitative studies 
a) PubMed  
"diabetes mellitus" OR "non insulin diabetes mellitus" OR "type 2 diabetes" OR 
"diabetic patient*" OR "glycemic control" 
 AND  
"general practic*" OR "physician" OR "primary care" OR "Clinical practice" OR 
"health practic*" 
 AND  
"Drug therapy" OR "treatment trend" OR prescription OR monotherapy OR "time 
to treatment" OR "treatment initiation" OR "drug utilization" OR "antidiabetic 
agent" OR therapy OR "medical decision making" OR "clinical decision making" 
OR "drug indication" OR "drug initiation" OR "treatment planning" OR "clinical 
inertia" OR "therapeutic inertia" OR "physician inertia" 
 
b) SCOPUS  
(TITLE-ABS-KEY ("type 2 diabetes mellitus" OR "glyc?emic control" OR "people 
with diabetes" OR "diabetic patient*") ) AND (TITLE-ABS-KEY ("general practic*" 
OR "physician*" OR "primary care" OR "medical practice*" OR "health care 
professional*" OR "health care personnel") ) AND ( (TITLE-ABS-KEY ("drug 
choice*" OR "drug indication" OR "treatment trend*" OR "treatment pattern*" OR 
prescription* OR monotherapy OR "time to treatment" OR "treatment initiation" 
OR "drug utili#ation") OR TITLE-ABS-KEY ("therapy delay" OR "drug initiation"  
OR inertia OR "treatment planning"  OR  "drug indication") ) ) 
 
c) EMBASE  
1. non insulin dependent diabetes mellitus/  
2. diabetes mellitus.tw.  
3. type 2 diabetes.tw.  
4. glyc?emic control.tw.  
5. people with diabetes.tw.  
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6. (non insulin adj2 diabetes).mp. [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword, floating subheading word]  
7. diabetic patient/  
8. professional practice/ or general practice/ or group practice/ or health care 
practice/ or medical practice/ or private practice/  
9. primary health care/  
10. health care personnel/  
11. general practic*.tw.  
12. physician*.tw.  
13. (primary adj2 care).tw.  
14. drug choice/ or drug indication/ or monotherapy/ or pharmaceutical care/  
15. time to treatment/ or therapy delay/ or treatment planning/  
16. treatment trend*.tw.  
17. treatment pattern*.tw.  
18. (time adj2 treatment).tw.  
19. treatment initiation.tw.  
20. drug utili#ation.tw.  
21. (reason* adj3 treat*).tw.  
22. drug initiation.tw.  
23. ((clinical or therapeutic or physician) adj2 inertia).mp. [mp=title, abstract, 
heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword, floating subheading word]  
24. drug indication.tw.  
25. treatment planning.tw.  
26. 1 or 2 or 3 or 4 or 5 or 6 or 7  
27. 8 or 9 or 10 or 11 or 12 or 13  
28. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25  





1B – Search strategy for qualitative studies 
a) EMBASE 
1 non insulin dependent diabetes mellitus/ 
2 diabetes type 2.mp. 
3 1 or 2 
4 Health care professionals.mp. or health care personnel/ 
5 GPs.mp. 
6 physician/ 
7 nurses.mp. or nurse/ 
8 doctors.mp. 
9 or 5 or 6 or 7 or 8 
10 primary care.mp. or primary medical care/ 
11 general practice.mp. or general practice/ 
12 10 or 11 
13 experience/ or experiences.mp. 
14 views.mp. 
15 attitudes.mp. or attitude/ 
16 13 or 14 or 15 
17 3 AND 9 AND 12 AND 16 
 
b) SCOPUS 
(TITLE-ABS-KEY ("non insulin diabetes mellitus" OR "type 2 diabetes") AND 
TITLE-ABS-KEY ("healthcare professional" OR "health care professional" OR gp 
OR nurse OR physician) AND TITLE-ABS-KEY ("primary care" OR "general 
practice" OR "family medicine" ) AND TITLE-ABS-KEY (experiences OR views 
OR attitudes) ) 
 
c) PubMed 
((((diabetes OR "type 2 diabetes" OR "clinical inertia" OR guidelines OR 
"decision-making")) AND ("primary care" OR "general practice" OR "primary 
health care")) AND (GP OR nurse OR physician OR "health personnel" OR 
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Appendix 2 – Full-text articles excluded  
2A – Section 1: Quantitative full-text articles excluded 
 Author(s) Title Year  Reason 
1 Armendáriz Cuñado, M., 
Giménez Robredo, A. I., 
Jaio Atela, N. 
Oral antidiabetics 
prescription in primary 
care 
2006 No full-text available 
2 Bala, M. M., Placzkiewicz-
Jankowska, E., Topor-
Madry, R., Lesniak, W., 
Jaeschke, R., Sieradzki, J., 
Grzeszczak, W., Banasiak, 
W. 
Is newly diagnosed type 
2 diabetes treated 
according to the 
guidelines? Results of 
the Polish ARETAEUS1 
study 
2011 Focused in assessing the 
proportion of patients achieving 
diabetic control goals, and 
described current medication 
not initial treatment (I.e. only 
4.2% were not receiving GLM) 
3 Benford, M., Milligan, G., 
Pike, J., Anderson, P., 





prescribing choices and 
relationship with patient 
satisfaction and 
compliance 
2012 Not newly diagnosed nor 
patterns over time.  
4 Boudreau, D., Swain, B., 
O'Connor, P., Nichols, G. 
A., Raebel, M., Nakasato, 
C., Newton, K., Selby, J. 
 
Early initiation of 
metformin in new-onset 
type 2 diabetes 
2011 Conference poster – abstract 
only. 
5 Bramlage, P., Binz, C., 
Gitt, A. K., Krekler, M., 
Plate, T., Deeg, E., 
Tschope, D. 
Diabetes treatment 
patterns and goal 
achievement in primary 
diabetes care (DiaRegis) 
- study protocol and 
patient characteristics at 
baseline 
2010 Aim was to evaluate the 
specific characteristics, 
treatment patterns, quality of 
life and diabetes related events 
of T2DM patients who failed 
oral therapy. 
6 Calvert, M. J., McManus, 
R. J., Freemantle, N. 
The management of 
people with type 2 
diabetes with 
hypoglycaemic agents in 
primary care: 







7 Chu, W. M., Ho, H. E., 
Huang, K. H., Tsan, Y. T., 
Liou, Y. S., Wang, Y. H., 
Lee, M. C., Li, Y. C. 
The prescribing trend of 
oral antidiabetic agents 
for type 2 diabetes in 
Taiwan 
2017 Not newly diagnosed, elderly 
not UK 
8 Conthe, P., Mata, M., 
Orozco, D., Pajuelo, F., 
Barreto, C. S., Anaya, S. 
F., Gomis, R. 
Degree of control and 
delayed intensification of 
antihyperglycaemic 
treatment in type 2 
diabetes mellitus 
patients in primary care 
in Spain 
2011 Patients were selected if were 
already receiving medication or 
second line combination 
treatment initiation at 
least one year prior to study 
entry 
9 Deed, G., Barlow, J., Kuo, 
I. 
Early and tight glycaemic 
control: The key to 
managing type 2 
diabetes 
2012 Review – Australia  
10 Dennis, J. M., Henley, W. 
E., McGovern, A. P., 
Farmer, A. J., Sattar, N. 
Holman, R. R., Pearson, E. 
R., Hattersley, A. T., 
Shields, B. M., Jones, A. 
G., on behalf of the, 
Mastermind consortium 
Time trends in 
prescribing of type 2 
diabetes drugs, 
glycaemic response and 
risk factors: A 
retrospective analysis of 
primary care data, 2010–
2017 
2019 The primary unit of analysis 
was line of therapy. Patients 
who started more than one new 
therapy contributed to the 
analysis more than once with 
different lines of therapy. 
11 Ekstrom, N., Svensson, A. 
M., Miftaraj, M., Sundell, K. 
A., Cederholm, J., 
Zethelius, B., Eliasson, B., 
Gudbjornsdottir, S. 
Durability of oral 
hypoglycemic agents in 
drug naive patients with 
type 2 diabetes: Report 
from the Swedish 
national diabetes register 
(NDR) 
2015 Durability – 
continuation/discontinuation of 
GLMs only. 
12 Eliasson, B., Eeg-
Olofsson, K., Cederholm, 
J., Nilsson, P. M., 
Gudbjornsdottir, S. 
Antihyperglycaemic 
treatment of type 2 
diabetes: results from a 
national diabetes register 
2007 The aim was to analyse the 
clinical characteristics and 
pharmacological treatment. 
Therapy only classified as OHA 
and/or insulin. 
13 Gallagher, N., Cardwell, C. 
Hughes, C., O'Reilly, D. 
 
Increase in the 
pharmacological 
management of Type 2 
2015 Only proportions of people who 
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diabetes with pay-for-
performance in primary 
care in the UK 
14 Gearhart, J. G., Forbes, R. 
C. 
 
Initial management of 
the patient with newly 
diagnosed diabetes 
1995 No full-text available. 
15 Gelhorn H. L., Stringer S. 
M., Brooks A., Thompson 
C., Monz B. U., Boye K. S., 
Hach T., Lund S. S., 




with type 2 diabetes 
mellitus in the UK 
2013 Hypothetical situation 
16 Geier, A. S., Wellmann, I., 
Wellmann, J., Kajüter, H., 
Heidinger, O., Hempel, G., 
Hense, H. W. 
Patterns and 
determinants of new 
first-line 
antihyperglycaemic drug 
use in patients with type 
2 diabetes mellitus 
2014 Not clear whether people were 
newly diagnosed and only 
included those who were not 
prescribed during the first 6 
months from registration to a 
database. 
17 Göktaş, O., Öz Gül, Ö., 
Ertürk, E. 
Changes in the 
management of type 2 
diabetic patients in family 
medicine practices in the 
Bursa region 
2017 Not newly diagnosed and not 
EU/US 
18 Grant, R. W., Wexler, D. J. 
Watson, A. J., Lester, W. 
T., Cagliero, E., Campbell, 
E. G., Nathan, D. M. 
How doctors choose 
medications to treat type 
2 diabetes: A national 
survey of specialists and 
academic generalists 
2007 Survey/hypothetical  
19 Halimi, S., Balkau, B., 
Attali, C., Detournay, B., 
Amelineau, E., Blickle, J. 
F. 
Therapeutic 
management of orally 
treated type 2 diabetic 
patients, by French 
general practitioners in 
2010: the DIAttitude 
Study 
2012 Treatment intensification in 
France 
20 Higgins, V., Piercy, J., 
Roughley, A., Milligan, G., 
Leith, A., Siddall, J., 
Benford, M. 
Trends in medication use 
in patients with type 2 
diabetes mellitus: A long-
term view of real-world 
treatment between 2000 
and 2015 




21 Lang, V. B., Markovic, B. 
B., Kranjcevic, K. 
 
Family physician clinical 
inertia in glycemic 
control among patients 
with type 2 diabetes 
2015 Clinical inertia – not UK 
22 Machado-Duque, M. E., 
Ramírez-Riveros, A. C., 
Machado-Alba, J. E. 
Effectiveness and clinical 
inertia in patients with 
antidiabetic therapy 
2017 Clinical inertia – not UK 
23 Maguire, A., Mitchell, B. 
 
Characteristics of 
patients initiating oral 
antidiabetic therapy in 
the UK: Evidence of 
delayed treatment? 
2012 Abstract only  
24 Maguire, A., Mitchell, B. 




control and determinants 
of treatment change 
among patients with type 
2 diabetes in the United 
Kingdom primary care: A 
retrospective cohort 
study 
2014 No data on duration of T2DM or 
whether these were newly 
diagnosed.  
25 Mahabaleshwarkar, R., 
Gohs, F., Mulder, H., 
Wilkins, N., DeSantis, A., 
Anderson, W. E., 
Ejzykowicz, F., Rajpathak, 
S., Norton, H. J. 
Patient and Provider 
Factors Affecting Clinical 
Inertia in Patients With 
Type 2 Diabetes on 
Metformin Monotherapy 
2017 Focused only on metformin 
26 Marrett, E., Jameson, K., 
Zhang, Q., Meiler, S., 
Radican, L., Sinclair, A. 
 
Reasons for non-
treatment of newly 
diagnosed type 2 
diabetes mellitus (T2DM) 
in the United Kingdom 
2010 Conference publication – 
abstract only 
27 Marrett, E., Zhang, Q., 
Narayanan, S., Radican, L. 
Why are some older 
patients with newly-
diagnosed type 2 
diabetes not treated? 
2009 Conference publication – 
abstract only 
28 Mata-Cases, M., Benito-
Badorrey, B., Roura-
Olmeda, P., Franch-Nadal, 
Clinical inertia in the 
treatment of 
hyperglycemia in type 2 
2013 Clinical inertia – Spain  
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J., Pepio-Vilaubi, J. M., 
Saez, M., Coll-De-Tuero, 
G. 
diabetes patients in 
primary care 
29 Mata-Cases, M., Franch-
Nadal, J., Real, J., 
Mauricio, D. 
Glycaemic control and 
antidiabetic treatment 
trends in primary care 
centres in patients with 
type 2 diabetes mellitus 
during 2007-2013 in 
Catalonia: A population-
based study 
2016 Not newly diagnosed 
30 McEwan, P., Prettyjohns, 
M., Ketsetzis, G., Evans, L. 
M., Bergenheim, K. 
The impact of clinical 
inertia in the treatment of 
type 2 diabetes 
2011 Conference publication – 
abstract only 
31 McEwen L., Bilik D., 
Johnson S., Halter J., 
Karter A., Mangione C., 
Subramanian U., 
Waitzfelder B., Crosson J., 
Herman W. 
Predictors and Impact of 
Intensification of 
Antihyperglycemic 







Clinical inertia – not UK 
32 McGovern, A., Hinton, W. 
Calderara, S., Munro, N. 
Whyte, M., de Lusignan, S. 
A Class Comparison of 
Medication Persistence 




2018 Persistence of certain 
medications 
33 Morita, Y., Murayama, H., 
Odawara, M., Bauer, M. 
Treatment patterns of 
drug-naive patients with 
type 2 diabetes mellitus 
2019 the study was conducted in 
Japan  
34 Muralidharan, R. Approach to a person 
recently diagnosed with 
diabetes 
2007 No full-text available 
35 Pantalone, K. M., Hobbs, 
T. M., Wells, B. J., Kong, 
S. X., Kattan, M. W., 
Bouchard, J., Yu, C., 
Sakurada, B., Milinovich, 
A., Weng, W., Bauman, J., 




among patients with 
new-onset type 2 
diabetes in a large 
integrated health system 





36 Patel N., Stone M., 
Chauhan A., Davies M., 
Khunti K. 
Insulin initiation and 
management in people 
with Type 2 diabetes in 




2012 Clinical inertia – qualitative 
study. 
37 Plat, A., Penning-Van 
Beest, F., Kessabi, S., 
Groot, M., Herings, R. 
Change of initial oral 
antidiabetic therapy in 
type 2 diabetic patients 
2009 New users rather than newly 
diagnosed 
38 Qiu Y., Qiong L., Tang J., 
Fan C.,Li Z., Apecechea 
M., Hegar R., Shankar R., 
Kurtyka K., Engel S. 
Why physicians do not 
initiate dual therapy as 
recommended by AACE 
guidelines: A survey of 
clinicians in the United 
States 
2015 Guidelines adherence – US  
39 Ruiz-Negron N., Wander 
C., McAdam C., Pesa J., 
Bailey R., Bellows B. 
Factors Associated with 
Diabetes-Related 
Clinical Inertia in a 
Managed Care 
Population and Its Effect 
on Hemoglobin A1c 
Goal Attainment: A 
Claims-Based Analysis 
2019 Clinical inertia – not UK  
40 Sabale, U., Bodegard, J., 
Sundstrom, J., Ostgren, C. 
J., Nilsson, P., Johansson, 
G., Svennblad, B., 
Henriksson, M. 
Healthcare utilization 
and costs following 
newly diagnosed type-2 
diabetes in Sweden: A 
follow-up of 38,956 
patients in a clinical 
practice setting 
2015 Conference publication – 
abstract only 







2017 Not EU/US and focused on 
persistence between 
medication. 
42 Shaya, F. T., Chirikov, V. 
V., Bron, M., Howard, D. 
Comparison of physician 
practice patterns for 
older adults compared to 
NHANES diabetes 
2013 Not newly diagnosed 
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Foster, C., Yan, X., 
Khanna, N., Warrington, V. 
O. 
cohort on oral/other 
therapy 
43 Truter, I. 
 
An investigation into 
antidiabetic medication 
prescribing in South 
Africa 
1998 Not newly diagnosed – not 
EU/US 
44 Tschope, D., Bramlage, P., 
Binz, C., Krekler, M., Plate, 




hypoglycemia in a large 
cohort of type 2 diabetic 
patients - an analysis of 
the DiaRegis registry 
2011 Focused on hypoglycaemia – 
not newly diagnosed – only 
patients already on medication 
were selected 
45 Walley, T., Hughes, D., 
Kendall, H. 
Trends and influences 
on use of antidiabetic 
drugs in England, 1992-
2003 
2005 Proportions of use, not data on 
patients’ duration of T2D 
46 Whyte, M. B., Hinton, W., 
McGovern, A., van 
Vlymen, J., Ferreira, F., 
Calderara, S., Mount, J., 
Munro, N., de Lusignan, S. 
Disparities in glycaemic 
control, monitoring, and 
treatment of type 2 
diabetes in England: A 
retrospective cohort 
analysis 
2019 Not newly diagnosed 
47 Wiley, J. F. Blood glucose levels and 
glycaemic burden in 
76,341 patients 
attending primary care: 
Bittersweet findings from 
a 9-year cohort study 
2017 Trends in blood glucose levels 
and glycaemic control – 
Australia. 
48 Wilkinson, S., Douglas, I., 
Stirnadel-Farrant, H., 
Fogarty, D., Pokrajac, A., 
Smeeth, L., Tomlinson, L. 
Changing use of 
antidiabetic drugs in the 
UK: Trends in 
prescribing 2000-2017 
2018 People were included if they 
had already been prescribed, 
and this was considered the 
diagnosis but no further data. 
Focus primarily on escalation 
49 Yurgin, N., Secnik, K., 
Lage, M. J. 
 
Antidiabetic prescriptions 
and glycemic control in 
German patients with 
type 2 diabetes mellitus: 





A retrospective database 
study 
50 Zafar, A., Davies, M., 
Azhar, A., Khunti, K. 
Clinical inertia in 
management of T2DM 
2010 Review  
51 Ziemer, D. C., Miller, C. D., 
Rhee, M. K., Doyle, J. P., 
Watkins Jr, C., Cook, C. 
B., Gallina, D. L., El-Kebbi, 
I. M., Barnes, C. S., 
Dunbar, V. G., Branch Jr, 
W. T., Phillips, L. S. 
Clinical inertia 
contributes to poor 
diabetes control in a 
primary care setting 
2005 Clinical inertia – not UK 
 
2B – Section 2: Qualitative full-text articles excluded 
 Author(s) Title Year  Reason 
1 Austad B., Hetlevik I., 
Mjolstad B., Helvik AS. 
Applying clinical 
guidelines in general 
practice: a qualitative 
study of potential 
complications 
2016 Focused on complications of 
using guidelines rather than 
general views and experiences. 
2 Boivin, A., Legare, F., 
Gagnon, M. P. 
 
Competing norms: 
Canadian rural family 
physicians' perceptions 
of clinical practice 
guidelines and shared 
decision-making 
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Appendix 3 – Quality assessment checklists 
3A – Section 1: Quantitative appraisal7. 
NEWCASTLE - OTTAWA QUALITY 
ASSESSMENT SCALE COHORT STUDIES 
THE JOANNA BRIGGS INSTITUTE 
CHECKLIST FOR ANALYTICAL CROSS-
SECTIONAL STUDIES 
A study can be awarded a maximum of one star for 
each numbered item, except item 5 were two stars 
can be given. 
Selection  
1) Representativeness of the exposed cohort  
a. truly representative of the average people 
with T2DM in the community * 
b. somewhat representative of the average 
people with T2DM in the community * 
c. selected group of users. 
d. no description of the derivation of the cohort  
2) Selection of the non-exposed cohort  
a. drawn from the same community as the 
exposed cohort * 
b. drawn from a different source  
c. no description of the derivation of the non-
exposed cohort  
3) Ascertainment of exposure  
a. secure record (e.g. surgical records) *  
b. structured interview *  
c. written self-report  
d. no description  
4) Demonstration that outcome of interest was 
not present at start of study  
a. yes *  
b. no  
Comparability  
5) Comparability of cohorts on the basis of the 
design or analysis 
a. study controls for HbA1c/age/duration of 
T2DM * 
b. study controls for any additional factor * 
Outcome  
6) Assessment of outcome  
a. independent blind assessment *  
b. record linkage *  
c. self-report  
d. no description  
7) Was follow-up long enough for outcomes to 
occur  
a. yes (at least one year) *  
b. no  
8) Adequacy of follow up of cohorts  
A study will be awarded maximum one start 
per question.  
1) Were the criteria for inclusion in the 
sample clearly defined?  
a. Yes * 
b. No 
c. Unclear  
d. Not applicable * 
2) Were the study subjects and the setting 
described in detail?  
a. Yes * 
b. No 
c. Unclear  
d. Not applicable * 
3) Was the exposure measured in a valid 
and reliable way?  
a. Yes * 
b. No 
c. Unclear  
d. Not applicable * 
4) Were objective, standard criteria used for 
measurement of the condition?  
a. Yes * 
b. No 
c. Unclear  
d. Not applicable * 
5) Were confounding factors identified?  
a. Yes * 
b. No 
c. Unclear  
d. Not applicable * 
6) Were strategies to deal with confounding 
factors stated?  
a. Yes * 
b. No 
c. Unclear  
d. Not applicable * 
7) Were the outcomes measured in a valid 
and reliable way?  
a. Yes * 
b. No 
c. Unclear  
d. Not applicable * 
                                            
7 WELLS, G., SHEA, B., O'CONNELL, D., PETERSON, J., WELCH, V., LOSOS, M. & TUGWELL, P. The 
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Online]. 
Available: http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf [Accessed], MOOLA, S., MUNN, 
Z., TUFANARU, C., AROMATARIS, E., SEARS, K., SFETCU, R., CURRIE, M., QURESHI, R., MATTIS, 
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a. complete follow up - all subjects accounted 
for *  
b. subjects lost to follow up unlikely to 
introduce bias *  
c. no description of those lost  
d. no statement 
9 is the maximum number of stars that can be awarded to 
each article assessed using this scale. 
8) Was appropriate statistical analysis 
used? 
a. Yes * 
b. No 
c. Unclear  
d. Not applicable * 
8 is the maximum number of stars that can be 
awarded to each article assessed using this scale. 
 
3B – Section 2: Qualitative appraisal8. 
Section Question Answer 
A. Are the results 
valid? 




c. Can’t tell 
2. Is a qualitative methodology appropriate? a. Yes 
b. No 
c. Can’t tell 
3. Was the research design appropriate to 
address the aims of the research? 
a. Yes 
b. No 
c. Can’t tell 
4. Was the recruitment strategy appropriate to 
the aims of the research? 
a. Yes 
b. No 
c. Can’t tell 
5. Was the data collected in a way that 
addressed the research issue? 
a. Yes 
b. No 
c. Can’t tell 
6. Has the relationship between researcher 




c. Can’t tell 
B. What are the 
results? 




c. Can’t tell 
8. Was the data analysis sufficiently rigorous? a. Yes 
b. No 
c. Can’t tell 
9. Is there a clear statement of findings? a. Yes 
b. No 
c. Can’t tell 
C. Will the results help 
locally 
10. Is there a discussion of the contribution to 
existing knowledge or understanding? 
Identify new areas where research is 
necessary? Discussion if whether or how 
findings can be transferred to other 
populations or a consideration of other 
ways the research may be used? 
a. Yes 
b. No 
c. Can’t tell 
  
                                            




Appendix 4 – Complete case analysis 
Results of the complete case analysis 
The CCA dataset was built with information for people with T2DM who had complete 
data available for the variables of interest, which were BMI, SBP, DBP, HbA1c, and 
cholesterol. After the exclusion of patients who did not have complete data on the 
variables of interest, the CCA resulted in a dataset including 87,770 patients; people 
with more than one variable missing were excluded. Thus 66,890 cases were 
excluded (43.3%). Figure 12 presents in detail, the process followed to build the 
CCA dataset.  





Complete cases vs incomplete cases 
In table 36 the baseline characteristics for patients with complete data and those with 
incomplete data are described; the latter group is the one that was used for the CCA. 
As can be seen from the table, patients included in the CCA dataset were 
significantly older with a mean age of 61.3 years compared to a mean of 60.6 years 
for patients with incomplete data. Additionally, distributions of patients’ sex, ethnicity 
and SIMD were statistically significantly different between groups. The differences 
between the complete and incomplete cases suggest that results from the CCA 







 59,810 incomplete data for BMI 
 797 incomplete data for SBP- 
 8 incomplete data for DBP 
 4,366 incomplete data for HbA1c 
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Table 36. Baseline characteristics for patients with complete and 
incomplete data 





Age, years (mean + SD) 61.3 + 12.2 60.6 + 12.9 <0.0001 
Gender, male (%, n) 56.5 (49,589) 55.1 (36,832) <0.0001 























Characteristics of the population  
Having presented the differences between the CCA dataset and the incomplete 
cases, I will move on to compare the characteristics of the CCA dataset with the 
imputed dataset. It can be seen from the data in table 37 that both datasets were 
comprised of a majority of males and that the average age was about 61 years of 
age. Furthermore, other demographic characteristics such as ethnicity and SIMD 
showed similar proportions for both datasets. The majority of the people were 
identified as white Scottish/British, 71.0% (62,341), and 70.2% (108,602) for the 
CCA dataset and the imputed dataset, respectively. In relation to SIMD quintiles, 
both datasets presented decreasing proportions of people in each quintile. Hence, 
the majority of the population were in the most deprived quintiles.  
Table 37. Comparison of baseline characteristics of people in the CCA 
dataset and the Imputed Dataset 
Variable CCA Dataset 
(n= 87,770) 
Imputed Dataset 
(n = 154,660) 
Age, years (mean + SD) 61.3 + 12.2 61.0 + 12.5 
Age ranges, %                                               30 – 44  
45 – 59  













Gender, male (%, n) 56.5 (49,589) 55.9 (86,421) 





















Proportions of people with T2DM with and without GLM prescription and their 
characteristics 
Differences by year of diagnosis 
As shown in figure 13, from 2004 to 2012, more than half of the patients received a 
GLM prescription within two years from the diagnosis of T2DM. Proportions of 
people who received a prescription ranged from 52.6% in 2012 to 56.4% in 2011. 
The majority of the patients who received treatment within 24 months after diagnosis 
had received GLM by 12 months after diagnosis. Proportions of people receiving 
GLM prescription within the three first months after T2DM diagnosis increased by 
index year from 28% in 2004 to 37.3% in 2012). In contrast, a lower proportion of 
patients were prescribed their first drug within 12 to 24 months after diagnosis. 
Figure 13. Proportions of patients in the CCA dataset cohort who received drug 
treatment, stratified by period of prescription. 
 
2004 2005 2006 2007 2008 2009 2010 2011 2012
12 to 24 months 10.9% 10.1% 10.2% 9.8% 10.5% 8.6% 8.5% 8.9% 4.3%
3 to 12 months 16.5% 15.5% 14.6% 13.4% 12.6% 12.6% 12.1% 12.2% 11.0%
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Baseline characteristics of people with T2DM who received GLM prescription vs 
people with T2DM who did not. 
As observed in table 38, GLM-2Y (59.1 years) patients were significantly younger 
than NM-2Y (64.1 years). Overall, distributions of demographic characteristics such 
as SIMD significantly differed, a higher proportion of GLM-2Y patients were from the 
most deprived quintiles. 
Mean BMI was significantly higher for the GLM-2Y group than for the NM-2Y. 
Similarly, GLM-2Y had significantly higher mean HbA1c and mean cholesterol than 
NM-2Y. Similar results were found when stratified by BMI and HbA1c categories. As 
shown in table 38, 62.2% GLM-2Y had a BMI >30 Kg/m2, and 77.6% had an HbA1c 
> 53 mmol/mol. Likewise, a higher proportion of GLM-2Y had cholesterol levels > 5 
mmol/L. Moreover, GLM-2Y had a significant lower prevalence of pre-existing CVD. 
Similarly, proportions of people who were actively receiving lipid-lowering and 
antihypertensive medication were significantly lower among GLM-2Y than NM-2Y. 
Table 38. Characteristics of patients in the CCA dataset classified whether 
they received pharmacological treatment by two years after diagnosis  
Variable Received medication prescription P values 
Yes (48,468) No (39,302) 
Age, years (mean + SD) 59.1 + 12.1 64.1 + 11.7 < 0.0001 
Gender, male (%, n) 58.0 (28,132) 54.6 (21,457) < 0.0001 























BMI Mean Kg/m2 + SD 32.7 + 6.5 31.5 + 6.0 < 0.0001 
> 30 Kg/m2 (%, n) 62.2 (30,139) 55.6 (21,845) < 0.0001 
Systolic Blood Pressure  Mean mmHg + SD 137.4 + 14.6 138.5 + 14.4 < 0.0001 
> 130 mmHg (%, n) 68.1 (33,013) 71.6 (28,147) < 0.0001 
Diastolic Blood Pressure  Mean mmHg + SD 80.6 + 8.7 79.3 + 8.6 < 0.0001 
> 80 mmHg (%, n) 49.5 (23,990) 43.9 (17,247) < 0.0001 
HbA1c Mean mmol/mol + SD 68.3 + 18.4 48.6 + 9.3 < 0.0001 
> 53 mmol/mol(%, n) 77.6 (37,624) 19.6 (7,693) < 0.0001 
Cholesterol Mean mmol/L + SD 5.0 + 1.1 4.8 + 1.0 < 0.0001 




Pre-existing CVD (%, n) 17.5 (8,496) 22.5 (8,842) < 0.0001 
Receiving lipid-lowering medication (%, n) 32.5 (15,761) 43.0 (16,890) < 0.0001 
Receiving antihypertensive medication (%, n) 50.7 (24,578) 66.2 (26,031) < 0.0001 
Analysis by age groups 
Overall, in table 39 shows a negative association with between BMI. Thus, people 
between 30 to 44 years of age had the highest mean BMI, and those of 75 years of 
age and older had the lowest mean BMI. Similar results were found for baseline 
HbA1c and cholesterol. Conversely, a positive relationship was observed between 
age and mean SBP, prevalence of pre-existing CVD and proportions on lipid-
lowering medication and anti-hypertensive medication.  
For the 30-44 years old group, table 39 shows that although mean BMI was not 
significantly different by treatment group, the proportion of obese people (BMI > 30 
Kg/m2) was significantly higher for NM-2Y. Concerning HbA1c, mean levels and 
proportion of people with HbA1c > 53 mmol/mol were higher among GLM-2Y.  
Among people of 45 to 59 years the GLM-2Y group had higher mean BMI and also a 
higher proportion of people in the obese category. Moreover, mean HbA1c and the 
proportion of people with HbA1c > 53 mmol/mol were higher GLM-2Y. In contrast 
GLM-2Y had lower mean SBP, lower proportions pre-existing CVD, receiving lipid-
lowering medication and anti-hypertensive medication.  
For the 60 to 74 years old group, GLM-2Y patients had significantly higher mean 
BMI, mean HbA1c, mean DBP, and mean cholesterol. The GLM-2Y group also had 
a significantly lower proportion of pre-existing CVD and also lower proportions of 
people receiving lipid-lowering medication and anti-hypertensive medication. 
Among people > 75 years, GLM-2Y patients had significantly higher mean BMI, 
mean HbA1c, mean DBP, and mean cholesterol.. Conversely, GLM-2Y included a 
significantly lower proportion with pre-existing CVD and proportions of people 
receiving lipid-lowering medication and anti-hypertensive medication.  
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Glycaemic control and GLM prescription initiation 
Baseline HbA1c by age groups 
Overall, it can be seen that people from the CCA dataset displayed a mean HbA1c of 
59.5 mmol/mol, which was slightly lower than the one for the imputed dataset. 
Furthermore, the table shows that, the 30 to 44 years and 45 to 59 years-age groups 
presented a higher mean HbA1c than people from the 60 to 74 years and > 75 years 
age groups. 




30 to 44 
n= 8,809 
45 to 59 
n= 30,433 




Mean (SD), mmol/mol 59.5 (18.0) 65.5 (19.4) 61.7 (18.6) 57.5 (17.0) 55.5 (15.9) 
Median (IQR), mmol/mol 54 (46.5–68.5) 62 (50.3–78) 56.5 (48–73) 52 (46–64.5) 51 (45–60.7) 
Differences between people with optimal and sub-optimal HbA1c 
As shown in table 41, people with sub-optimal HbA1c consisted of 59.3% (26,878) 
men. Overall, there was a larger proportion of white Scottish/British and people from 
the most deprived SIMD quintiles than among people in the optimal HbA1c group. 
However, ethnicity proportions were not different from people with optimal and sub-
optimal HbA1c. Moreover, people with sub-optimal HbA1c were significantly younger 
than those with optimal HbA1c, mean age of 59.4 years and 63.4 years, respectively.  
Furthermore, people with sub-optimal HbA1c Had significantly higher mean BMI and 
proportion with BMI >=30kg/m2 than people with optimal HbA1c. Likewise, mean 
cholesterol and mean DBP were higher for people with sub-optimal HbA1c. In 
contrast, people with optimal HbA1c had a significantly larger proportions of people 
with SBP > 130 mmHg, pre-existing CVD, people receiving lipid-lowering medication, 
and people receiving anti-hypertensive medication. Similar results were found in the 






Table 41. Characteristics of people with recently diagnosed T2DM stratified 
by baseline optimal and sub-optimal HbA1c levels  
Variable Sub-optimal HbA1c P values 
Yes (45,317) No (42,453) 
Age, years (mean + SD) 59.4 (12.2) 63.4 (11.7) <0.0001 
Gender, male (%, n) 59.3 (26,878) 53.5 (22,711) <0.0001 
Ethnicity, White Scottish/British (%, n) 71.0 (32,170) 71.1 (30,171 0.739 
















BMI Mean Kg/m2 + SD 32.4 (6.3) 31.9 (6.2) <0.0001 
> 30 Kg/m2 (%, n) 60.5 (27,406) 57.9 (24,578) <0.0001 
Systolic Blood Pressure  Mean mmHg + SD 137.8 (14.8) 137.9 (14.2) 0.256 
> 130 mmHg (%, n) 69.0 (31,249) 70.5 (29,911) <0.0001 
Diastolic Blood Pressure  Mean mmHg + SD 80.7 (8.7) 79.3 (8.5) <0.0001 
> 80 mmHg (%, n) 50.1 (22,686) 43.7 (18,551) <0.0001 
Cholesterol Mean mmol/L + SD 5.1 (1.1) 4.8 (1.0) <0.0001 
> 5 mmol/L (%, n) 47.9 (21,706) 39.3 (16,696) <0.0001 
Pre-existing CVD (%, n) 16.8 (7,594) 23.0 (9,744) <0.0001 
Receiving lipid-lowering medication (%, n) 30.4 (13,767) 44.5 (18,884) <0.0001 
Receiving antihypertensive medication (%, n) 48.8 (22,099) 67.2 (28,510) <0.0001 
GLM prescription among people with optimal and sub-optimal HbA1c 
Approximately one-third of people (25.5%) with optimal HbA1c received medication 
prescription by two years after diagnosis. Conversely, for those with sub-optimal 
HbA1c, the majority in the CCA dataset (74.5%) received a pharmacological 
prescription for glucose control within two years after T2DM diagnosis. 
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Figure 14. Proportions of people with T2DM in the CCA, with optimal and sub-
optimal HbA1c with and without prescription for pharmacological treatment 
within 2 years of diagnosis of diabetes. 
 
Proportions of people who received and did not receive GLM prescription stratified 
by different ranges of sub-optimal HbA1c 
Figure 15 below illustrates the breakdown of people with and without GLM 
prescription stratified by different groups of sub-optimal HbA1c. In general, the 
majority of people with HbA1c > 53 mmol/mol received medication prescription, 
ranging from 69.1% (12,859) for those with an HbA1c of 53 – 63 mmol/mol to 96.1% 
(8,154) for the people with an HbA1c > 85 mmol/mol.  
In the figure, it can be observed a clear trend of decreasing proportions of people 
without medication prescription. Thus, the higher the HbA1c group, the larger the 
proportion of people who received GLM prescription by two years after diagnosis. 
Overall, proportions were similar to the ones found for the imputed dataset. 























Figure 15. Proportions of people with T2DM in the CCA dataset with optimal and 
sub-optimal HbA1c with and without pharmacological treatment, stratified 
by ranges of sub-optimal HbA1c 
 
Sub-optimal HbA1c by age groups 
Table 42 shows that across all age groups there was a decreasing trend of people 
without medication prescription the higher HbA1c, which is in accordance to data 
previously shown in figure 15. It is also shown that the 30 to 44 years group had a 
high proportion of people with HbA1c >63 mmol/mol. Conversely, people >75 years 
had the lowest proportions of people with HbA1c in the highest categories. 
Table 42. Proportions of patients in the CCA with sub-optimal glucose 
control who did not receive pharmacological treatment by two years after 
diagnosis, stratified by age groups and HbA1c sub-optimal ranges.  
Variable All 
N= 7,693 
Age group (years) 
30 to 44 
n= 715 
45 to 59 
n= 2,532 




53 – 63 mmol/mol (%, n) 74.9 (5,763) 58.6 (419) 67.9 (1,719) 80.0 (2,511) 85.3 (1,114) 
64 – 74 mmol/mol (%, n) 14.4 (1,108) 21.4 (153) 17.6 (445) 12.1 (381) 9.9 (129) 
75 – 85 mmol/mol (%, n) 6.3 (488) 11.2 (80) 8.6 (219) 4.9 (153) 2.8 (36) 











No 31609 5763 1108 488 334
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Time to GLM prescription 
Time to GLM initiation by age group  
Kaplan Meier 
The results of the Kaplan-Meier survival analysis are presented in figure 16. For the 
CCA dataset cohort, 32.9%, 46.2%, and 55.2% of the cohort initiated drug treatment 
within 30 days, 1 year, and 2 years of diagnosis, respectively. Furthermore, figure 16 
shows that the proportion of patients who had received drug treatment for T2DM 
within two years of diagnosis decreased with increasing age, proportions of people 
who received GLM prescription by two years after diagnosis were 72.7%, 62.3%, 
50.1%, and 40.2% for patients in the 30 to 44, 45 to 59, 60 to 74, and > 75 age 
groups, respectively (p<0.0001). 
Figure 16. Kaplan-Meier curves for the CCA for time to glucose-lowering treatment 





Table 43 below presents the comparison of proportions of people who received GLM 
prescription by two years after the diagnosis of T2DM and the median time to 




after stratifying by age groups. Overall, mean and median days were higher for the 
older age group and lower for the youngest group. 
Table 43. Time to pharmacological treatment initiation by age group among 
patients over 30 years of age in Scotland 2004-2013 with complete data 




Age group (years) 
30 to 44 
n= 8,809 
45 to 59 
n=30,433 




Patients with drug treatment within  











Median days to time to treatment 
initiation (IQR) 
46 (7 – 210) 31 (6 – 159) 43 (7 – 201.2) 53 (7 – 233) 55 (7 – 235) 
Mean days to time to treatment 
initiation  
143.3 121.8 140.7 151.9 149.7 
Factors associated with time to drug treatment initiation  
In this section, the results of the Cox regression analysis, the univariate and the four 
adjusted models are presented. As explained in the results section, the first column 
“Univariate model” indicates the results from the one variable to the left side of the 
table. The following column “Adjusted model 1” presents the results the model 
adjusted by demographic characteristics of the patients, variables included in the 
model were age, sex, ethnicity, and SIMD. Next, the column “Adjusted model 2” 
provides the results from the model, which adjusted for the demographic 
characteristics included in the previous model plus baseline HbA1c. Then, the 
column “Adjusted model 3” presents results from the model included the ones in 
model 2 plus other metabolic factors such as BMI, SBP, DBP, cholesterol and pre-
existing CVD. Finally, the last column “Adjusted model 4” provides the results of the 
model, including demographics, HbA1c, BMI, pre-existing CVD and the use of other 
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CCA dataset: Hazard ratios for GLM prescription 
Table 44 provides the results obtained from the Cox regression analysis. In general, 
increased age was associated with longer time to drug treatment initiation. Moreover, 
HbA1c >53 mmol/mol was associated with shorter time to drug prescription.  
The adjusted model 1 shows an association between increased age and longer time 
to medication prescription. Likewise, being female compared to male, identified as 
having other/unknown ethnicity compared to white ethnicity and from the least 
compared to the most deprived SIMD quintiles were associated with longer time to 
medication prescription. In the adjusted model 2, where HbA1c was taken into 
account, age, other/unknown ethnicity and the least deprived SIMD quintiles were 
associated with increased prescription time. However, being female compared to 
male and having HbA1c >53 vs <53 mmol/mol were associated with shorter times to 
treatment. 
Furthermore, in the fully adjusted models 3 and 4, it can be seen that from the 
demographic factors, increased age, other/unknown ethnicity, and the least deprived 
SIMD quintiles were associated with longer time to GLM prescription. Moreover, 
HbA1c >53 mmol/mol was associated with shorter times to pharmacological 
prescription. However, no significant association was found for BMI >30 Kg/m2. 
In relation to other metabolic factors, model 3 indicates that raised blood pressure; 
SBP >130 mmHg and DBP >80 mmHg; was associated with longer time to drug 
treatment prescription. Likewise, cholesterol >5 mmol/L and pre-existing CVD were 
associated with longer time to GLM prescription. Moreover, the adjusted model 4 
shows that receiving antihypertensive medication was associated with longer time to 
medication prescription. However, receiving lipid-lowering medication was 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   














   
   
   
   





















   
   
   
   





















   
   
   
   
   
   




















   
   
   
   
   
   
   


















   
   
   
   
   
   
   



















   
   
   
   
   
   
   






















   
   
   
   
   
















   
   
   
   
   
   
   
   
   
   
   
   



















































Appendices  321 
Appendix 5 – Interview topic guide  
Introduction  
- Thank participant and explain the PhD study 
- Remind them that their participation is voluntary  
- Ask if there is any question and inform about the consent form. 
Topic guide 
1. I would like to start by asking you about your practice. Could you tell me 
more about your work please?  
o Compared to other practices in the area, how big is this practice? 
o What kind of area is the practice in? 
o What kind of patients does the practice serve? 
 Are there a lot of people from ethnic minority groups? 
o How the practice has change in the last years? 
o How is the practice structured? How many GPs and nurses work in 
the practice? 
o How is the workload divided within the healthcare team? 
o How is diabetes care organised in the practice? Is there anyone else 
responsible for care of people with diabetes? How do you divide the 
workload? 
2. I would like to know more about you role in the practice. Could you tell me 
a little bit about yourself and your role in your practice? 
o What is your job title? 
o How long have you been practising? Do you usually get to see the 
same patients? 
o How long have you been working in this practice? 
o How long have you been working in this position? 
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o Do you feel you have received appropriate training for the role? Do 
you have the opportunity to keep up to date? If so, how do you do 
this? 
o How hard/easy is to keep updated with new policies/guidelines? 
4. What is a typical patient pathway when a patient is diagnosed with type 2 
diabetes? 
o  Is it possible for all or some newly diagnosed patients to be referred 
to a structured diabetes education course? Where? What sort of 
education? Who is in charge of this? Are there any alternatives – for 
example can you refer people to a dietician? 
o How long does it take to be seen? 
o What happens if the patient is not motivated or is reluctant to go? Are 
they put on medications?  
o Does education affect their motivation? How useful have you found 
this programme/course? What patients say about this 
programme/course? Do they find it useful?  
o Do you think it is possible to predict who will do well using 
lifestyle/dietary management? What makes you decide how long to let 
people attempt lifestyle change. How patient’s motivation is assessed? 
o How frequently do you review patients? In the first year after the 
diagnosis of diabetes in your practice?  
o How frequently do you review people in terms of their diabetes in the 
second and subsequent years after a diagnosis of diabetes? 
o Does it help to reduce hba1c if the patient is motivated?  
5. How do you decide when is appropriate or necessary to prescribe 
pharmacological treatment for glucose control? 
o What kinds of factors and considerations influence your decision? Can 
you talk me through some examples? 
 Is patient’s age important? Is patient’s history of weight 
management important?  
 Are there differences between genders?  
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o How much are patients usually involved in the decisions about when 
to initiate pharmacological treatment? How continuity of care is related 
to these decisions?  
o The side effects of the medications are usually discussed with the 
patient?  
o What kind of patients tend to be reluctant or resistant to starting 
pharmacological treatment? What kind of patients tend to push for 
pharmacological treatment? 
o What medications, other than for glucose control, are typically 
provided to newly diagnosed patients? What are the most common 
types of treatment? 
o Are there any reasons about why your decisions about when to initiate 
pharma treatment might have changed over time? 
o Do you think you manage patients differently?  
6. Does the guidelines and targets influence your practice? 
o Have past and present guidelines been useful?  
o Is there anything that can be done different to better help and enable 
support for people with T2DM? 
o Do you think the decommissioning of QOF has had any impact on the 
treatment and care given to patients with T2DM? In particular do you 
think it might affect decisions about when to initiate treatment 
7. Is there anything else you would like to talk about today which would help 
us to understand when and why people with T2DM in your practice are 
prescribed pharmacological treatment? 
 
Thank participant for their time. Explain dissemination activities and how and 
when they can access the findings from the study. Ask participants if they 
can pass on an invitation pack to potentially interested colleagues and 
explain processes for doing so.  
